

**AUSTRALIAN NSP SURVEY
NATIONAL DATA REPORT**

2004 - 2008

**PREVALENCE OF HIV, HCV AND
INJECTING AND SEXUAL BEHAVIOUR
AMONG IDUs AT NEEDLE AND SYRINGE PROGRAMS**



National Centre in HIV
Epidemiology and Clinical Research
The University of New South Wales

May 2009

The National Centre in HIV Epidemiology and
Clinical Research is funded by the Australian
Government Department of Health and Ageing,
and is affiliated with the Faculty of Medicine,
The University of New South Wales

© National Centre in HIV Epidemiology and Clinical Research 2009

ISSN 1448-5915

This publication is available at: <http://www.nchechr.unsw.edu.au>

Suggested citation:

National Centre in HIV Epidemiology and Clinical Research.
Australian NSP Survey National Data Report 2004-2008.
National Centre in HIV Epidemiology and Clinical Research,
The University of New South Wales, Sydney, NSW. 2009.

National Centre in HIV Epidemiology and Clinical Research
Level 2, 376 Victoria Street, Darlinghurst NSW 2010 Australia

Telephone: **02 9385 0900** Facsimilie: **02 9385 0920** International prefix: **612** Email: recept@nchechr.unsw.edu.au

AUSTRALIAN NSP SURVEY

Prevalence of HIV, HCV and injecting and sexual behaviour
among IDUs at Needle and Syringe Programs

NATIONAL DATA REPORT
2004 - 2008

Report prepared by Jenny Iversen, Rachel Deacon, Kerri Shying and Lisa Maher

National Centre in HIV Epidemiology and Clinical Research
The University of New South Wales

May 2009

The National Centre in HIV Epidemiology and Clinical Research is funded by the Australian Government Department of Health and Ageing, and is affiliated with the Faculty of Medicine, The University of New South Wales.

Acknowledgements

We would like to acknowledge everyone who assisted in the development and conduct of the 2008 Australian NSP Survey, including NSP clients, managers and staff at participating NSP survey sites, laboratory staff at the Centre for Immunology, in particular Philip Cunningham, Irati Garaizar Uribe and Celine Yan, the project investigators and the original steering committee responsible for developing the survey methodology. Special thanks are also due to everyone in the VHEPP team at NCHECR, The Wrigley Company for supplying sugar free gum to survey participants and Greg Smith and Melissa Lennon at Educational Assessment Australia, for scanning and validating completed surveys.

We acknowledge the support and input of the following members of the Australian NSP Survey advisory group during 2008: Ms Tracey Dobie (ACT); Mr Owen Westcott (NSW); Mr Shayne Kilford (NT); Mr Robert Kemp/Mr Gregory Perry (QLD); Mr Stephen Lymb/Ms Danielle Bament (SA); Ms Tania Hunt/Ms Francine Smith (TAS); Mr Roland Jauering (VIC); Ms Jude Bevan (WA); Ms Fiona Poeder (Australian Injecting and Illicit Drug Users League); Mr John Ryan (ANEX), Dr Libby Topp (Centre for Health Research in Criminal Justice) and Dr Tony Butler (National Drug Research Institute). We are particularly grateful to Dr. Alex Wodak (Drug & Alcohol Services, St Vincent's Hospital) for chairing the group.

Ethical approvals for the survey were obtained from Institutional Ethics Committees associated with the investigators and participating NSP sites. The National Centre in HIV Epidemiology and Clinical Research is funded by the Australian Government Department of Health and Ageing, and is affiliated with the Faculty of Medicine, The University of New South Wales.

While the survey is the result of collaboration between many organisations and individuals, its success is due to the dedication and vision of the late Dr. Margaret MacDonald, who was responsible for its development and conduct from 1994 to 2003.

Table of contents

Summary

Key Points	1
Introduction.....	2
Injecting behaviour.....	3
Sexual behaviour.....	4
HIV antibody prevalence	5
HCV antibody prevalence	6
2008 module: Needle and syringe use, re-use and cleaning.....	8

Tables

National.....	9
Australian Capital Territory	32
New South Wales	45
Northern Territory.....	68
Queensland.....	87
South Australia	110
Tasmania	133
Victoria	146
Western Australia.....	169

Methodological Notes	186
-----------------------------------	-----

NSP Survey Questionnaire	188
---------------------------------------	-----

Participating NSP sites	192
--------------------------------------	-----

List of Tables	194
-----------------------------	-----

Summary

Key Points

HIV and HCV antibody prevalence:

- HIV antibody prevalence remained low, nationally, at less than two percent, with the exception of participants reporting male homosexual identity (37% in 2008).
- HCV antibody prevalence has remained high, but stable, at 62% over the past three years.
- HCV antibody prevalence was lowest among those participants aged less than 20 years and those injecting for less than 3 years.
- HCV antibody prevalence was higher among both male and female participants reporting an Indigenous background compared to non-Indigenous participants in all of the past five years.
- HCV antibody prevalence was also higher among those reporting incarceration in the year prior to survey completion compared to those that did not report recent incarceration.
- HCV antibody prevalence was lower among participants reporting meth/amphetamine as the last drug injected compared to those last injecting heroin. Conversely, HIV antibody prevalence was higher among participants reporting meth/amphetamine as the last drug injected compared to those reporting last injecting heroin.

Demographic characteristics:

- The median age of survey participants continued to increase, from 32 years in 2004 to 36 years in 2008.
- The proportion of participants aged less than 25 years has declined annually, from 19% in 2004 to 9% in 2008. Participants reporting less than three years duration of drug injection also declined over this period, from 7% in 2004 to 5% in 2008.

Injecting behaviour:

- The proportion of participants reporting daily or more frequent injection in the month prior to the survey remained stable at between 47% and 49%.
- The proportion of participants reporting heroin as the drug last injected has been relatively stable at around one third of participants (range 26% to 36%). The proportion reporting meth/amphetamine as the drug last injected has also been relatively stable at around one third of participants (range 28% to 38%).
- The proportion of participants reporting morphine or other opioids (such as MS Contin, OxyContin, Endone or homebake) as the last drug injected increased from 8% in 2004 to 15% in 2008.
- Receptive sharing in the month prior to survey completion was relatively low and stable between 2004 and 2008 (range 13% to 18%).
- Almost half the survey participants reported re-use of a needle, syringe or winged vein infusion set (butterfly) in the month prior to survey completion in 2008.
- Of those that reported re-use of a needle, syringe or winged vein infusion set, the majority (84%) also reported cleaning of these items.

Introduction

This report presents national, state and territory data from the annual Australian Needle and Syringe Program (NSP) Survey for the period 2004 to 2008. The Australian NSP Survey monitors human immunodeficiency virus (HIV) and hepatitis C antibody prevalence among injecting drug users (IDUs) in Australia. The survey also monitors behavioural indices of risk and provides important information for planning prevention, treatment and support policies and services. Each year, all clients attending selected NSPs during the designated survey period are invited to complete a brief, anonymous questionnaire and to provide a capillary blood sample for HIV and hepatitis C virus (HCV) antibody testing.

In 2008, 52 NSP sites participated in the survey, and of these, 32 (62%) had also participated in each of the last five years. The number of survey participants ranged from 1800 in 2005 to 2270 in 2008, while the annual response rate varied from 36% to 50% (Table 2).

Two thirds of survey participants were male in all survey years, with one third female and less than one percent identifying as transgender. The proportion of Indigenous participants has been stable at 10% to 11% over the last four years, up from 8% in 2004. The proportion of participants born in Australia was also stable over the past four years at between 84% and 86%, up from 79% in 2004, while the proportion of participants from a non-English speaking background decreased from 15% in 2005 to 5% in 2007 and 2008. The proportion of participants reporting incarceration in the 12 months prior to survey completion has been stable at 13% over the last three years, down from 18% in 2005. Of those that were incarcerated in the preceding year, the proportion reporting injection in prison declined from 53% in 2004 to 33% in 2008 (Table 2).

Participants reported high rates of both HIV and HCV testing in all survey years. In 2008, 86% of participants reported a previous HIV test, while 50% reported a HIV test in the last 12 months. There were slightly higher rates of HCV testing, with 89% of participants reporting a previous HCV test and 55% reporting a HCV test in the last 12 months (Table 8).

Survey participants also reported high rates of engagement with drug treatment services, with 79% of participants reporting current or previous drug treatment in 2008. The proportion of participants reporting methadone maintenance treatment at the time of survey participation remained stable at between 31% and 33% over the last five years. Survey participants were asked to report buprenorphine and buprenorphine-naloxone treatment for the first time in 2008. Just over one in ten participants (N=290, 13%) reported current buprenorphine treatment and six percent (N=142) reported current buprenorphine-naloxone treatment at the time of survey completion (Table 4).


In contrast, rates of engagement with hepatitis C treatment services are low among survey respondents. Despite increased efficacy of interferon based treatment for hepatitis C, uptake among survey participants remains very low, with less than 1% of survey respondents reporting previous or current interferon based hepatitis C treatment in all years 2004 to 2008 (Table 8).

Injecting behaviour

The median age of first drug injection remained stable at 18 years for all survey years, however the median age at the time of the survey increased from 32 years in 2004 to 36 years in 2008. This was accompanied by an increase in the median duration of injecting, which rose from 11 years in 2004 to 15 years in 2008. The proportion of new injectors (injecting for less than 3 years) declined from 7% in 2004 to 5% in 2008 (Table 2).


Reporting of heroin as the last drug injected remained relatively stable at around one third of survey participants over the period 2004 to 2008 (range 26% to 36%). Meth/amphetamine was also commonly reported, with between 28% and 38% of respondents reporting meth/amphetamine as the drug last injected (Figure 1). The proportion of participants reporting methadone as the drug last injected was relatively stable at 10% or less over the period 2004 to 2008, however reports of morphine and other pharmaceutical opioids as the last drug injected increased from 8% in 2004 to 15% in 2008. Relatively small proportions of survey respondents (5% or less) reported the last drug injected as anabolic steroids, cocaine or buprenorphine in all of the past five years (Table 3).

Figure 1 Participants reporting heroin, meth/amphetamine, and morphine/other opioids as the drug last injected by state and territory, 2004 - 2008



The proportion of participants reporting re-use of someone else's used needle and syringe in the previous month (receptive sharing) remained relatively stable at between 13% and 18% during the last five years. Recent receptive sharing was more commonly reported by participants aged less than 25 years, compared to older age groups in all of the past five years (Figure 2, $p=0.07$ in 2008). Among those who reported receptive sharing of a needle and syringe, re-use after only one person was most commonly reported, typically a regular sex partner or close friend.

Figure 2 Participants reporting receptive sharing of a needle and syringe in the month prior to the survey by age group, 2004 - 2008



During the period 2004 to 2008, the proportion of participants reporting at least one public injection was stable at between 45% and 48%. Participants that reported heroin as the drug last injected were significantly more likely to report recent public injecting than those that had last injected meth/amphetamine in all of the past five years (Figure 3, $p<0.001$ in 2008).

Figure 3 Participants reporting at least one public injection* in the month preceding the survey by drug last injected, 2004 - 2008



Sexual behaviour

Of the participants that reported sex with a regular sex partner in the month prior to survey completion (N=1190), around a quarter reported condom use in all of the past four years (range 23% to 25%). Reports of condom use with non regular sex partners were higher, with around two thirds of those that reported sex with a non regular partner reporting condom use (range 63% to 72%). The proportion of respondents reporting commercial sex work in the month prior to the survey was low and stable at 6% over the past four years, while use of condoms at last commercial sex was high at between 83% and 95% in all years from 2004 to 2008 (Table 7).

HIV antibody prevalence

Over the past five years, HIV antibody prevalence has remained low at 1.5% or less nationally and less than 2.5% in all states and territories (Table 9, Figure 4). There were no HIV antibody positive participants in Tasmania or the ACT in the period 2004 to 2008. HIV prevalence was consistently higher among homosexual male participants than among bisexual or heterosexual male participants or female participants in all survey years (Figure 5). HIV prevalence was also higher among those reporting meth/amphetamine as last drug injected compared to those reporting heroin as last drug injected (Figure 6).

Figure 4 HIV antibody prevalence by state and territory, 2004 - 2008




Figure 5 HIV antibody prevalence by gender and sexual identity, 2004 - 2008




Figure 6 HIV antibody prevalence by drug last injected, 2004 - 2008



HCV antibody prevalence


Nationally, HCV antibody prevalence has been stable at 62% for each of the past three years (Table 22), up from 60% in 2004. There is some variation among state and territories however, with HCV antibody prevalence consistently higher than national prevalence in the ACT, NSW and Victoria, and HCV antibody prevalence consistently lower than national prevalence in Western Australia, South Australia, Queensland and the Northern Territory in each of the past five years (Figure 7).

Figure 7 HCV antibody prevalence by age group, 2004 – 2008



HCV antibody prevalence continues to be highest among participants aged over 30 years and among those with a longer history of injecting (Tables 24 and 25). As can be seen in Figure 8, in 2008, HCV antibody prevalence was 20% among those that had been for less than one year, 50% among those injecting for 8 or 9 years and 75% or more among those injecting for 20 years or longer.

Figure 8 HCV antibody prevalence by duration of injecting in 2008



HCV antibody prevalence was higher among participants reporting heroin as last drug injected compared to those reporting meth/amphetamine as last drug injected in all years for both males and females (Figure 9). HCV antibody prevalence was also higher among participants reporting imprisonment in the year prior to survey completion compared to those not reporting recent imprisonment (Figure 10), and among Indigenous background participants, compared to those from a non-Indigenous background (Figure 11).

Figure 9 HCV antibody prevalence by drug last injected and gender, 2004 – 2008




Figure 10 HCV antibody prevalence by recent imprisonment and gender, 2004 - 2008





Figure 11 HCV antibody prevalence by indigenous status and gender, 2004 - 2008



2008 module: Needle and syringe use, re-use and cleaning

In 2008, the questionnaire component of the NSP Survey included a set of one-off questions that asked respondents to identify their use, re-use and cleaning of a range of items used for injecting in the month prior to survey completion (see survey instrument on page 188). Of those that reported injecting in the month prior to the survey, three quarters (N=1535) reported use of a 1ml needle and syringe. Forty one percent (N=824) reported use of a non-1ml needle and/or syringe (ie a 3, 5, 10 or 20ml syringe, detachable needle and/or a winged vein infusion set) and a quarter of respondents (N=497) reported use of both a 1ml and non-1ml needle or syringe.

Table 1 Number (percentage) of respondents by use, re-use and cleaning of injecting equipment in the month prior to survey completion


	Used*	Re-used*	Cleaned*
Number surveyed	N=2018	N=2018	N=2018
1ml needle/syringe	1535 (76%)	646 (32%)	601 (30%)
Non-1ml needle/syringe**	824 (41%)	388 (19%)	370 (18%)
Any needle/syringe	1862 (92%)	926 (46%)	863 (43%)
Wheel filter	229 (11%)	83 (4%)	61 (3%)
Any item	1864 (92%)	964 (48%)	891 (44%)

* More than one item could be selected

** 3, 5, 10 or 20 ml syringe, detachable needle and/or winged vein infusion set

Reuse of injecting equipment was relatively common with almost half of the respondents (N=964, 48%) reporting recent re-use of a needle, syringe, winged vein infusion set or wheel filter. Reuse of a 1ml needle and syringe was most commonly reported, with almost a third of survey respondents (N=646, 32%) reporting reuse of this item in the month prior to survey completion. Recent reuse of a non-1ml needle and syringe was reported by 19% of respondents (N=388), although use of these items was also less common. Of those that had used a non 1ml needle, syringe or winged vein infusion set, almost half reported reuse of one or more of these items. A small number of respondents (N=38, 2%) reported reuse of a wheel filter but did not report recent reuse of any needles or syringes. Of those that reported recent reuse of any needle, syringe or winged vein infusion set (N=926), reports of cleaning were high, with 84% of respondents (N=774) reporting recent cleaning one or more of these injecting items. It should be noted that a small number of respondents reported cleaning, but not re-use of some injecting items. It is therefore assumed that in some instances, items were cleaned for later use, or items were cleaned for use by others.

Figure 12 Participants reporting use, re-use and cleaning of needles and syringes in the month preceding the survey, by state and territory in 2008



National
2004 – 2008

Table 2 Number (percentage) of respondents by demographic characteristics and year of survey

Demographic characteristics	2004	2005	2006	2007	2008
Number of sites	43	52	45	52	52
N° surveyed	N=2035	N=1800	N=1961	N=1912	N=2270
Response (%)	50	42	36	36	36
Gender (%)					
Male	1360 (67)	1149 (64)	1265 (65)	1241 (65)	1456 (64)
Female	659 (32)	642 (36)	683 (35)	660 (35)	803 (35)
Transgender	7 (< 1)	8 (< 1)	10 (< 1)	9 (< 1)	6 (< 1)
Not reported	9 (< 1)	1 (< 1)	3 (< 1)	2 (< 1)	5 (< 1)
Sexual identity (%)					
Heterosexual	1669 (82)	1464 (81)	1611 (82)	1570 (82)	1843 (81)
Bisexual	173 (9)	150 (8)	176 (9)	177 (9)	219 (10)
Homosexual	84 (4)	99 (6)	109 (6)	116 (6)	115 (5)
Not reported	109 (5)	87 (5)	65 (3)	49 (3)	93 (4)
Age and duration of injection (years)					
<i>Median age</i>	32	34	34	35	36
<i>Age range</i>	16-65	15-66	13-68	14-69	16-70
<i>Age group (%)</i>					
<25 years	389 (19)	258 (14)	237 (12)	183 (10)	208 (9)
25+ years	1637 (80)	1542 (86)	1717 (88)	1726 (90)	2056 (91)
Not reported	9 (< 1)	--	7 (< 1)	3 (< 1)	6 (< 1)
<i>Median age 1st IDU</i>	18	18	18	18	18
<i>Age range</i>	5-56	9-55	10-52	10-56	10-60
<i>N° not reported</i>	53	67	71	51	46
<i>Median years IDU</i>	11	13	14	15	15
<i>Range</i>	< 1-71	< 1-46	< 1-45	< 1-49	< 1-48
<i>Duration of drug injection (%)</i>					
<3 years	154 (7)	161 (9)	108 (6)	102 (5)	113 (5)
3+ years	1827 (90)	1559 (87)	1779 (91)	1759 (92)	2110 (93)
Not reported	54 (3)	80 (4)	74 (4)	51 (3)	47 (2)
Aboriginal and Torres Strait Islander origin (%)					
No	1813 (89)	1563 (87)	1695 (86)	1663 (87)	1934 (85)
Yes	165 (8)	185 (10)	203 (10)	203 (11)	250 (11)
Not reported	57 (3)	51 (3)	63 (3)	46 (2)	86 (4)
Region/Country of birth					
Australia	1613 (79)	1551 (86)	1668 (85)	1649 (86)	1918 (84)
Other Oceania	63 (3)	54 (3)	62 (3)	46 (2)	83 (4)
Asia	145 (7)	14 (1)	17 (< 1)	22 (1)	32 (1)
UK & Ireland	91 (5)	95 (5)	105 (5)	85 (4)	125 (6)
Other	83 (4)	72 (4)	73 (4)	72 (4)	68 (3)
Not reported	40 (2)	14 (1)	36 (2)	38 (2)	44 (2)
Main language spoke at home by parents					
English speaking	1354 (67)	1534 (85)	1735 (88)	1778 (93)	2128 (94)
Non-English speaking	228 (11)	266 (15)	121 (6)	102 (5)	109 (5)
Not reported	453 (22)	--	105 (5)	32 (2)	33 (1)
Imprisonment last year (%)					
No	1631 (80)	1477 (82)	1622 (83)	1569 (82)	1812 (80)
Yes	373 (18)	252 (14)	247 (13)	254 (13)	287 (13)
Not reported	31 (2)	71 (4)	92 (5)	89 (5)	171 (8)
Injected in prison last year (%)	N = 373	N=252	N=247	N=254	N=287
Yes	198 (53)	87 (35)	90 (36)	95 (37)	96 (33)
Frequency of injection last month (%)					
Not last month	145 (7)	160 (9)	182 (9)	155 (8)	230 (10)
Less than weekly	348 (17)	297 (17)	368 (19)	337 (18)	343 (15)
Weekly not daily	530 (26)	458 (25)	476 (24)	484 (25)	576 (25)
Daily or more	982 (48)	879 (49)	919 (47)	900 (47)	1099 (48)
Not reported	30 (2)	6 (< 1)	16 (< 1)	36 (2)	22 (1)

National

Table 3 Number (percentage) of respondents by last drug injected, injecting behaviour in the month prior to survey and year of survey

Injecting behaviour	2004	2005	2006	2007	2008
Last drug injected (%)	N=2035	N=1800	N=1961	N=1912	N=2270
Anabolic steroids	25 (1)	29 (1)	36 (2)	20 (1)	35 (2)
Cocaine	52 (2)	53 (3)	44 (2)	33 (2)	53 (2)
Heroin	738 (36)	618 (34)	510 (26)	593 (31)	781 (34)
Methadone	135 (7)	166 (9)	180 (9)	187 (10)	192 (8)
Meth/Amphetamine	665 (33)	573 (32)	737 (38)	574 (30)	645 (28)
Morphine/Other Opioids	164 (8)	158 (9)	236 (12)	268 (14)	345 (15)
Subutex/Buprenorphine	42 (2)	56 (3)	101 (5)	99 (5)	104 (5)
More than one	136 (7)	40 (2)	36 (2)	53 (3)	53 (2)
Other	27 (2)	39 (2)	32 (2)	51 (3)	21 (1)
Not reported	51 (2)	68 (4)	49 (3)	34 (2)	41 (2)
N° Injected last month	N = 1860	N=1634	N=1763	N=1721	N=2018
Places injected last month (%)*					
Own home	1508 (81)	1319 (81)	1498 (90)	1488 (89)	1780 (89)
Friend's home	756 (41)	618 (38)	703 (42)	714 (43)	825 (41)
Dealer's home	319 (17)	233 (14)	279 (17)	278 (17)	362 (18)
Street, park, beach	431 (23)	351 (21)	352 (21)	385 (23)	441 (22)
Car	586 (32)	487 (30)	548 (33)	561 (33)	606 (30)
Public toilet	413 (22)	344 (21)	363 (22)	389 (23)	451 (23)
Commercial injecting room	36 (2)	47 (3)	43 (3)	47 (3)	50 (3)
Squat	117 (6)	74 (5)	104 (6)	102 (6)	120 (6)
Use of sterile needles & syringes last month (%)					
All injections	1328 (71)	1184 (72)	1262 (72)	1234 (72)	1429 (71)
Most of the time	411 (22)	371 (23)	371 (21)	374 (22)	475 (24)
Half of the time	39 (2)	36 (2)	47 (3)	41 (2)	48 (2)
Some of the time	36 (2)	18 (1)	24 (1)	25 (1)	28 (1)
Not last month	11 (1)	4 (0)	17 (<1)	3 (<1)	13 (<1)
Not reported	35 (2)	21 (1)	42 (2)	44 (3)	25 (1)
Re-used someone else's used needle & syringe last month (%)					
None	1473 (79)	1345 (83)	1432 (81)	1381 (80)	1640 (81)
Once	113 (6)	60 (4)	88 (5)	104 (6)	108 (5)
Twice	92 (5)	57 (4)	64 (4)	53 (3)	101 (5)
3-5 times	83 (5)	55 (3)	62 (4)	70 (4)	70 (3)
>5 times	45 (2)	37 (2)	47 (3)	36 (2)	55 (3)
Not reported	54 (3)	73 (4)	70 (4)	77 (4)	44 (2)
Number of people needle & syringe was re-used after last month (%)					
None	1473 (79)	1277 (78)	1432 (81)	1381 (80)	1640 (81)
One	168 (9)	147 (9)	129 (7)	125 (7)	169 (8)
Two	31 (2)	13 (1)	19 (1)	22 (1)	19 (<1)
Three to five	14 (1)	13 (1)	8 (<1)	14 (<1)	17 (<1)
More than five	9 (1)	10 (1)	11 (<1)	8 (<1)	7 (<1)
Don't know	44 (2)	67 (4)	46 (3)	43 (3)	71 (4)
Not reported	121 (6)	107 (7)	118 (7)	128 (7)	95 (5)
Relationship to people needle & syringe was re-used after last month (%)*					
Regular sex partner	122 (7)	137 (8)	104 (6)	119 (7)	136 (7)
Casual sex partner	17 (1)	6 (<1)	14 (<1)	12 (<1)	12 (<1)
Close friend	81 (4)	66 (4)	57 (3)	64 (4)	84 (4)
Acquaintance	36 (2)	31 (2)	26 (1)	23 (1)	29 (1)
Other	16 (1)	13 (1)	10 (<1)	16 (1)	21 (1)
Equipment used after someone else last month (%)*					
Spoon	507 (27)	365 (22)	351 (20)	379 (24)	436 (24)
Water	400 (22)	293 (18)	255 (15)	274 (17)	314 (17)
Filter	299 (16)	201 (12)	173 (10)	208 (13)	219 (12)
Drug mix	224 (12)	193 (12)	140 (8)	136 (9)	155 (8)
Tourniquet	216 (12)	192 (12)	166 (10)	168 (11)	195 (11)
None**	---	---	1064 (62)	1024 (65)	1181 (64)
Injected by someone after that person injected themselves or others last month (%)					
No	1538 (83)	1321 (81)	1451 (82)	1402 (81)	1673 (83)
Yes	258 (14)	217 (13)	240 (14)	235 (14)	281 (14)
Not reported	64 (3)	96 (6)	72 (4)	84 (5)	64 (3)

* More than one option could be selected

** New variable in 2006

Table 4 Number (percentage) of respondents by treatment for drug use and year of survey

Treatment for drug use	2004	2005	2006	2007	2008
N° surveyed	N=2035	N=1800	N=1961	N=1912	N=2270
Any treatment/therapy for drug use (%)					
No	421 (21)	406 (23)	414 (21)	370 (19)	444 (20)
Yes	1552 (76)	1374 (76)	1495 (76)	1504 (79)	1785 (79)
Not reported	62 (3)	20 (1)	51 (3)	38 (2)	41 (2)
History of methadone maintenance treatment (%)					
Currently	621 (31)	600 (33)	575 (29)	605 (32)	696 (31)
Previously	467 (23)	426 (24)	519 (26)	539 (28)	587 (26)
Never	842 (41)	753 (42)	821 (42)	740 (39)	938 (41)
Not reported	105 (5)	21 (1)	46 (2)	28 (1)	49 (2)
History of buprenorphine (Subutex®) treatment (%)*					
Currently	--	--	--	--	290 (13)
Previously	--	--	--	--	566 (25)
Never	--	--	--	--	1355 (60)
Not reported	--	--	--	--	49 (2)
History of buprenorphine-naloxone (Suboxone®) treatment (%)*					
Currently	--	--	--	--	142 (6)
Previously	--	--	--	--	270 (12)
Never	--	--	--	--	1787 (79)
Not reported	--	--	--	--	71 (3)

* New variable in 2008

Table 5 Number (percentage) of respondents by source of needle and syringe acquisition last month and year of survey

Needle & Syringe acquisition	2004	2005	2006	2007*	2008
N° surveyed	N=2035	N=1800	N=1961	N=1912	N=2270
From an NSP last month (%)					
Daily or almost daily	226 (11)	227 (13)	220 (11)	--	244 (11)
A couple of times each week	571 (28)	473 (26)	596 (30)	--	576 (25)
Less than weekly	580 (29)	472 (26)	468 (24)	--	605 (27)
Once last month	353 (17)	387 (22)	373 (19)	--	454 (20)
Not in the last month	257 (13)	220 (12)	267 (14)	--	340 (15)
Not reported	48 (2)	20 (1)	37 (2)	--	51 (2)
From a chemist last month (%)					
Daily or almost daily	83 (4)	57 (3)	66 (3)	--	62 (3)
A couple of times each week	194 (10)	133 (7)	168 (9)	--	185 (8)
Less than weekly	293 (14)	191 (11)	256 (13)	--	229 (10)
Once last month	365 (18)	310 (17)	360 (18)	--	400 (18)
Not in the last month	1306 (51)	1060 (59)	1033 (53)	--	1321 (58)
Not reported	64 (3)	49 (3)	78 (4)	--	73 (3)

* Not asked in this form in 2007.

Table 6 Number (percentage) of respondents by injecting equipment use, re-use and cleaning last month

Use, re-use and cleaning of any item*	Used	Re-used	Cleaned**
N° surveyed***	N=2018	N=2018	N=2018
Yes	1864 (92)	964 (48)	891 (44)
No	45 (2)	868 (43)	947 (47)
Not reported	109 (5)	186 (9)	180 (9)
Use, re-use and cleaning by item type#			
1ml	1535 (76)	646 (32)	601 (30)
3 ml	441 (22)	148 (7)	156 (8)
5 ml	334 (17)	122 (6)	124 (6)
10 ml	173 (9)	77 (4)	79 (4)
20 ml	126 (6)	62 (3)	62 (3)
Detachable needle (tip)	386 (19)	84 (4)	93 (5)
Winged vein infusion set (butterfly)	241 (12)	98 (5)	89 (4)
Wheel filter	229 (11)	83 (4)	61 (3)

* New question in 2008

** Includes 70 respondents that reported cleaning but not re-use in the last month

More than one item could be selected

*** Excludes respondents that did not inject in the last month

National

Table 7 Number (percentage) of respondents by sexual behaviour in the month prior to survey and year of survey

Sexual behaviour	2004	2005	2006	2007	2008
N ^o surveyed	N=2035	N=1800	N=1961	N=1912	N=2270
Sex with a regular partner last month (%) **					
No	--	800 (44)	831 (42)	813 (43)	1015 (45)
Yes	--	966 (54)	1074 (55)	1026 (54)	1190 (52)
Not reported	--	34 (2)	56 (3)	73 (4)	65 (3)
Condom used with regular partner last month (%)**					
N ^o surveyed		N=966	N=1074	N=1026	N=1190
Never	--	686 (71)	750 (70)	756 (74)	828 (70)
Sometimes	--	133 (14)	150 (14)	131 (13)	144 (12)
Every time	--	103 (11)	96 (9)	103 (10)	154 (13)
Not reported	--	44 (5)	78 (7)	36 (4)	64 (5)
Sex with other partner/s last month (%)**					
No	--	1461 (81)	1569 (80)	1562 (82)	1838 (81)
Yes	--	296 (16)	296 (15)	279 (15)	345 (15)
Not reported	--	43 (2)	96 (5)	71 (4)	87 (4)
Condom used with other partner/s last month (%)**					
N ^o surveyed		N=296	N=296	N=279	N=345
Never	--	74 (25)	77 (26)	91 (33)	85 (25)
Sometimes	--	76 (26)	74 (25)	69 (25)	101 (29)
Every time	--	135 (46)	127 (43)	105 (38)	143 (41)
Not reported	--	11 (4)	18 (6)	14 (5)	16 (5)
Sex work last month (%)					
No	1808 (89)	1653 (92)	1736 (89)	1721 (90)	1991 (88)
Yes	172 (8)	108 (6)	125 (6)	115 (6)	139 (6)
Not reported	55 (3)	39 (2)	100 (5)	76 (4)	140 (6)
Condom used at last sex work last month (%)*					
Yes	149 (90)	204 (95)	101 (86)	92 (87)	105 (83)

* Percentages exclude missing data

** New variable format commenced in 2005

Table 8 Number (percentage) of respondents reporting previous testing for HIV and HCV infection and HCV treatment by year of survey

	2004	2005	2006	2007	2008
N ^o surveyed	N=2035	N=1800	N=1961	N=1912	N=2270
Previous HIV test (%)					
Yes, last year	1223 (60)	1035 (58)	1117 (57)	1077 (56)	1124 (50)
> 1 year ago	560 (28)	564 (31)	618 (32)	617 (32)	818 (36)
Never tested	214 (10)	191 (11)	187 (10)	187 (10)	215 (9)
Not reported	38 (2)	10 (1)	39 (2)	31 (2)	113 (5)
Previous HCV test (%)					
Yes, last year	1287 (63)	1089 (61)	1176 (60)	1147 (60)	1257 (55)
> 1 year ago	527 (26)	521 (29)	579 (30)	596 (31)	769 (34)
Never tested	191 (9)	179 (10)	166 (8)	141 (7)	154 (7)
Not reported	30 (2)	11 (1)	40 (2)	28 (1)	90 (4)
Any treatment for HCV (%)	N = 931	N=826	N=894	N=848	N=1203
Interferon	32 (3)	26 (3)	25 (3)	20 (2)	51 (4)
Interferon+Ribavirin	19 (2)	13 (2)	25 (3)	23 (3)	56 (5)
Other	27 (3)	20 (2)	18 (2)	17 (2)	21 (2)
No treatment	824 (89)	759 (92)	791 (88)	747 (88)	1039 (86)
Not reported	29 (3)	8 (1)	35 (4)	41 (5)	36 (3)
Current treatment for HCV	N = 21	N=20	N=21	N=15	N=27
Interferon/Interferon+Ribavirin	12	11	11	6	18
Other		9	9	10	9

HIV antibody prevalence

Table 9 HIV antibody prevalence by gender and year of survey

Year of survey	Male		Female		Total *	
	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)
2004	1216	17 (1.4)	595	3 (0.5)	1825	20 (1.1)
2005	1072	15 (1.4)	611	0 (0.0)	1692	15 (0.9)
2006	1223	26 (2.1)	661	2 (0.3)	1897	29 (1.5)
2007	1195	25 (2.1)	639	2 (0.3)	1845	28 (1.5)
2008	1396	29 (2.1)	764	3 (0.4)	2170	33 (1.5)
χ^2 trend p value		0.096		0.845		0.081

* Total includes people whose gender was not reported or reported as transgender

Table 10 HIV antibody prevalence by sexual identity, gender and year of survey

Sexual identity	Male		Female		Total *	
	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)
2004						
Heterosexual	1058	1 (0.1)	435	2 (0.5)	1496	3 (0.2)
Bisexual	45	1 (2.2)	108	1 (0.9)	155	2 (1.3)
Homosexual	45	13 (28.9)	30	0 (0.0)	75	13 (17.3)
p value		<0.001		0.6		<0.001
2005						
Heterosexual	939	4 (0.4)	439	0 (0.0)	1379	4 (0.3)
Bisexual	37	0 (0.0)	106	0 (0.0)	144	0 (0.0)
Homosexual	53	11 (20.8)	32	0 (0.0)	90	11 (12.2)
p value		<0.001		<0.001		<0.001
2006						
Heterosexual	1070	3 (0.3)	484	1 (0.2)	1557	4 (0.3)
Bisexual	55	4 (7.3)	110	1 (0.9)	171	6 (3.5)
Homosexual	59	19 (32.2)	46	0 (0.0)	107	19 (17.8)
p value		<0.001		0.428		<0.001
2007						
Heterosexual	1055	5 (0.5)	458	2 (0.4)	1514	7 (0.5)
Bisexual	47	2 (4.3)	119	0 (0.0)	170	3 (1.8)
Homosexual	69	18 (26.1)	42	0 (0.0)	114	18 (15.8)
p value		<0.001		1.000		<0.001
2008						
Heterosexual	1228	3 (0.2)	537	1 (0.2)	1767	4 (0.2)
Bisexual	56	3 (5.4)	152	2 (1.3)	209	6 (2.9)
Homosexual	62	23 (37.1)	48	0 (0.0)	112	23 (20.6)
p value		<0.001		0.181		<0.001

* Total includes people whose gender was not reported or reported as transgender

National

Table 11 HIV antibody prevalence by age group, gender and year of survey

Age group	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2004						
< 20 years	30	0 (0.0)	33	0 (0.0)	64	0 (0.0)
20 – 24	176	2 (1.1)	103	1 (1.0)	279	3 (1.1)
25 – 29	239	1 (0.4)	125	0 (0.0)	366	1 (0.3)
30 + years	768	13 (1.7)	334	2 (0.6)	1108	15 (1.4)
p value		0.6		0.6		0.4
2005						
< 20 years	17	0 (0.0)	22	0 (0.0)	39	0 (0.0)
20 – 24	109	1 (0.9)	90	0 (0.0)	199	1 (0.5)
25 – 29	177	0 (0.0)	137	0 (0.0)	315	0 (0.0)
30 + years	769	14 (1.8)	362	0 (0.0)	1,139	14 (1.2)
p value		0.3		---		0.2
2006						
< 20 years	19	0 (0.0)	24	0 (0.0)	43	0 (0.0)
20 – 24	101	2 (2.0)	81	0 (0.0)	182	2 (1.1)
25 – 29	230	0 (0.0)	124	0 (0.0)	357	1 (0.3)
30 + years	868	24 (2.8)	430	2 (0.5)	1308	26 (2.0)
p value		0.032		1.000		0.095
2007						
< 20 years	18	0 (0.0)	15	0 (0.0)	33	0 (0.0)
20 – 24	72	0 (0.0)	69	0 (0.0)	142	0 (0.0)
25 – 29	202	3 (1.5)	131	0 (0.0)	334	3 (0.9)
30 + years	901	22 (2.4)	423	2 (0.5)	1333	25 (1.9)
p value		0.649		1.000		0.281
2008						
< 20 years	21	0 (0.0)	16	0 (0.0)	37	0 (0.0)
20 – 24	86	0 (0.0)	73	0 (0.0)	159	0 (0.0)
25 – 29	187	1 (0.5)	142	2 (1.4)	331	4 (1.2)
30 + years	1097	28 (2.6)	532	1 (1.2)	1637	29 (1.8)
p value		0.191		0.175		0.361

* Total includes people whose gender was not reported or reported as transgender

Table 12 HIV antibody prevalence by duration of drug injection, gender and year of survey

Duration of drug injection	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2004						
<3 years	84	2 (2.4)	51	0 (0.0)	135	2 (1.5)
3 to 5 years	138	2 (1.5)	84	0 (0.0)	224	2 (0.9)
6 to 10 years	312	3 (1.0)	161	0 (0.0)	474	3 (0.6)
10 + years	656	9 (1.4)	290	3 (1.0)	949	12 (1.3)
p value		0.7		0.8		0.6
2005						
<3 years	54	2 (3.7)	29	0 (0.0)	84	2 (2.4)
3 to 5 years	100	2 (2.0)	74	0 (0.0)	175	2 (1.1)
6 to 10 years	97	0 (0.0)	106	0 (0.0)	204	0 (0.0)
10 + years	775	9 (1.2)	372	0 (0.0)	1,153	9 (0.8)
p value		0.2		---		0.2
2006						
<3 years	59	1 (1.7)	42	0 (0.0)	102	1 (1.0)
3 to 5 years	81	2 (2.5)	67	0 (0.0)	148	2 (1.4)
6 to 10 years	227	4 (1.8)	159	1 (.6)	390	6 (1.5)
10 + years	799	18 (2.3)	378	1 (.3)	1185	19 (1.6)
p value		0.936		0.658		1.000
2007						
<3 years	61	1 (1.6)	37	0 (0.0)	98	1 (1.0)
3 to 5 years	67	2 (3.0)	58	0 (0.0)	126	2 (1.6)
6 to 10 years	210	2 (1.0)	132	0 (0.0)	345	2 (0.6)
10 + years	826	19 (2.4)	394	2 (0.5)	1227	22 (1.8)
p value		0.537		1.000		0.411
2008						
<3 years	68	5 (7.4)	44	0 (0.0)	112	5 (4.5)
3 to 5 years	114	3 (2.6)	50	0 (0.0)	164	3 (1.8)
6 to 10 years	194	1 (0.5)	152	0 (0.0)	347	1 (0.3)
10 + years	986	19 (1.9)	508	3 (0.6)	1502	23 (1.5)
p value		0.014		1.000		0.016

* Total includes people whose gender was not reported or reported as transgender

National

Table 13 HIV antibody prevalence by last drug injected, gender and year of survey

Last drug injected	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2004						
Heroin	464	4 (0.9)	207	1 (0.5)	676	5 (0.7)
Meth/Amphetamine	360	9 (2.5)	221	1 (0.5)	581	10 (1.7)
More than one	75	2 (2.7)	45	1 (2.2)	120	3 (2.5)
Other/Not reported	317	2 (0.6)	122	0 (0.0)	448	2 (0.5)
p value		0.08		0.4		0.06
2005						
Heroin	353	3 (0.8)	235	0 (0.0)	590	3 (0.5)
Meth/Amphetamine	333	5 (1.5)	196	0 (0.0)	534	5 (0.9)
More than one	24	1 (4)	15	0 (0.0)	39	1 (2.5)
Other/Not reported	355	6 (1.7)	168	0 (0.0)	525	6 (1.1)
p value		0.362		---		0.3
2006						
Heroin	303	4 (1.3)	187	0 (0.0)	495	4 (0.8)
Meth/Amphetamine	448	17 (3.8)	261	1 (0.4)	713	19 (2.7)
More than one	26	1 (3.9)	9	0 (0.0)	35	1 (2.9)
Other/Not reported	446	4 (0.9)	204	1 (0.5)	654	5 (0.8)
p value		0.012		1.000		0.012
2007						
Heroin	348	4 (1.2)	222	0 (0.0)	574	4 (0.7)
Meth/Amphetamine	348	10 (2.9)	204	1 (0.5)	552	11 (2.0)
More than one	31	0 (0.0)	18	0 (0.0)	49	0 (0.0)
Other/Not reported	468	11 (2.4)	195	1 (0.5)	670	13 (1.9)
p value		0.384		0.565		0.183
2008						
Heroin	494	3 (0.6)	253	1 (0.4)	749	4 (0.5)
Meth/Amphetamine	362	17 (4.7)	238	1 (0.4)	604	19 (3.2)
More than one	39	1 (2.6)	12	1 (8.3)	51	2 (3.9)
Other/Not reported	501	8 (1.6)	261	0 (0.0)	766	8 (1.0)
p value		0.001		0.026		<0.001

* Total includes people whose gender was not reported or reported as transgender

Table 14 HIV antibody prevalence by frequency of drug injection last month, gender and year of survey

Frequency of drug injection last month	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2004						
Not last month	80	0 (0.0)	47	0 (0.0)	129	0 (0.0)
Less than weekly	198	1 (0.5)	113	1 (0.9)	311	2 (0.6)
Weekly not daily	313	12 (3.8)	158	1 (0.6)	471	13 (2.8)
Daily or more	611	3 (0.5)	274	1 (0.4)	891	4 (0.5)
p value		0.001		0.8		0.001
2005						
Not last month	93	1 (1.1)	56	0 (0.0)	150	1 (0.7)
Less than weekly	166	5 (3.0)	101	0 (0.0)	270	5 (1.9)
Weekly not daily	294	7 (2.4)	142	0 (0.0)	439	7 (1.6)
Daily or more	517	2 (0.4)	308	0 (0.0)	827	2 (0.2)
p value		0.3		---		0.3
2006						
Not last month	109	1 (0.9)	66	1 (1.5)	178	2 (1.1)
Less than weekly	222	8 (3.6)	134	0 (0.0)	357	8 (2.2)
Weekly not daily	309	10 (3.2)	149	1 (0.7)	461	11 (2.4)
Daily or more	572	7 (1.2)	308	0 (0.0)	886	8 (0.9)
p value		0.062		0.138		0.103
2007						
Not last month	89	5 (5.6)	59	0 (0.0)	149	5 (3.4)
Less than weekly	220	5 (2.3)	111	1 (0.9)	332	6 (1.8)
Weekly not daily	293	6 (2.1)	165	0 (0.0)	462	7 (1.5)
Daily or more	572	8 (1.4)	292	1 (0.3)	869	9 (1.0)
p value		0.086		0.538		0.156
2008						
Not last month	136	4 (2.9)	83	1 (1.2)	220	5 (2.3)
Less than weekly	222	8 (3.6)	105	0 (0.0)	330	8 (2.4)
Weekly not daily	347	9 (2.6)	204	1 (0.5)	552	10 (1.8)
Daily or more	679	8 (1.2)	363	1 (0.3)	1047	10 (1.0)
p value		0.068		0.391		0.116

* Total includes people whose gender was not reported or reported as transgender

National

Table 15 HIV antibody prevalence by re-use of someone else's used needle and syringe last month, gender and year of survey

Re-used someone else's used needle & syringe last month	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2004						
No	872	13 (1.5)	446	3 (0.7)	1322	16 (1.2)
Yes	217	2 (0.9)	85	0 (0.0)	304	2 (0.7)
p value		0.7		1.0		0.6
2005						
No	800	13 (1.6)	456	0 (0.0)	1,262	13 (1.0)
Yes	130	1 (0.8)	68	0 (0.0)	200	1 (0.5)
p value		0.5		---		0.5
2006						
No	896	20 (2.2)	485	0 (0.0)	1387	20 (1.4)
Yes	161	4 (2.5)	86	0 (0.0)	249	5 (2.0)
p value		0.776		---		0.571
2007						
No	869	15 (1.7)	467	2 (0.4)	1343	18 (1.3)
Yes	162	4 (2.5)	79	0 (0.0)	244	4 (1.6)
p value		0.522		1.000		0.764
2008						
No	1024	23 (2.3)	544	2 (0.4)	1576	26 (1.7)
Yes	193	2 (1.0)	118	0 (0.0)	312	2 (0.6)
p value		0.408		1.000		0.300

* Total includes people whose gender was not reported or reported as transgender

Table 16 HIV antibody prevalence by imprisonment last year, gender and year of survey

Imprisonment last year	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2004						
No	927	15 (1.6)	522	2 (0.4)	1456	17 (1.2)
Yes	270	2 (0.7)	68	1 (1.5)	340	3 (0.9)
p value		0.4		0.3		1.0
2005						
No	845	15 (1.8)	533	0 (0.0)	1386	15 (1.1)
Yes	179	0 (0.0)	59	0 (0.0)	239	0 (0.0)
p value		0.07		---		0.1
2006						
No	971	25 (2.6)	583	2 (0.3)	1566	28 (1.8)
Yes	181	1 (0.6)	61	0 (0.0)	243	1 (0.4)
p value		0.106		1.000		0.165
2007						
No	946	23 (2.4)	560	2 (0.4)	1514	25 (1.7)
Yes	190	2 (1.0)	59	0 (0.0)	249	2 (0.8)
p value		0.412		1.000		0.413
2008						
No	1079	26 (2.4)	648	0 (0.0)	1735	27 (1.6)
Yes	208	2 (1.0)	65	2 (3.1)	274	4 (1.5)
p value		0.296		0.008		1.000

* Total includes people whose gender was not reported or reported as transgender

Table 17 HIV antibody prevalence by condom use at last sex with regular partner, gender and year of survey

Condom use at last sex	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2004						
No	805	11 (1.4)	422	2 (0.5)	1235	13 (1.1)
Yes	385	6 (1.6)	157	1 (0.6)	543	7 (1.3)
p value		0.8		1.0		0.6
2005**						
No	389	1 (0.3)	300	0 (0.0)	690	1 (0.1)
Yes	177	4 (2.3)	88	0 (0.0)	267	4 (1.5)
p value		0.02		---		0.009
2006						
No	533	6 (1.1)	339	1 (0.3)	880	8 (0.9)
Yes	57	3 (5.3)	35	0 (0.0)	92	3 (3.3)
p value		0.047		1.000		0.077
2007						
No	506	4 (0.8)	344	2 (0.6)	856	7 (0.8)
Yes	66	1 (1.5)	31	0 (0.0)	98	1 (1.0)
p value		0.460		1.000		0.581
2008						
No	547	4 (0.7)	380	0 (0.0)	930	4 (0.4)
Yes	93	3 (3.2)	52	1 (1.9)	147	5 (3.4)
p value		0.067		0.120		0.004

* Total includes people whose gender was not reported or reported as transgender

**Question changed to "condom use with regular partner in last month" in 2005.

Table 18 HIV antibody prevalence by sex work last month, gender and year of survey

Sex work last month	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2004						
No	1123	14 (1.3)	487	2 (0.4)	1615	16 (1.0)
Yes	64	2 (3.1)	93	1 (1.1)	161	3 (1.9)
p value		0.2		0.4		0.2
2005						
No	1021	14 (1.4)	525	(0.0)	1553	14 (0.9)
Yes	27	1 (3.7)	73	(0.0)	102	1 (1.0)
p value		0.3		---		0.9
2006						
No	1123	24 (2.1)	548	2 (0.4)	1678	26 (1.6)
Yes	34	2 (5.9)	81	0 (0.0)	121	3 (2.5)
p value		0.176		1.000		0.440
2007						
No	1108	23 (2.1)	541	2 (0.4)	1656	25 (1.5)
Yes	34	1 (2.9)	76	0 (0.0)	114	2 (1.8)
p value		0.519		1.000		0.691
2008						
No	1264	27 (2.1)	633	3 (0.5)	1905	30 (1.6)
Yes	39	2 (5.1)	91	0 (0.0)	131	3 (2.3)
p value		0.214		1.000		0.467

* Total includes people whose gender was not reported or reported as transgender

National

Table 19 HIV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and year of survey

Aboriginal and Torres Strait Islander origin	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2004						
No	1097	15 (1.4)	522	2 (0.4)	1631	17 (1.0)
Yes	87	1 (1.2)	56	1 (1.8)	145	2 (1.4)
p value		1.0		0.3		0.7
2005						
No	946	15 (1.6)	521	0 (0.0)	1,475	15 (1.0)
Yes	95	0 (0.0)	74	0 (0.0)	170	0 (0.0)
p value		0.2		---		0.2
2006						
No	1074	24 (2.2)	556	2 (0.4)	1639	27 (1.7)
Yes	109	2 (1.8)	89	0 (0.0)	199	2 (1.0)
p value		1.000		1.000		0.763
2007						
No	1045	21 (2.0)	548	2 (0.4)	1602	23 (1.4)
Yes	118	3 (2.5)	80	0 (0.0)	200	4 (2.0)
p value		0.728		1.000		0.532
2008						
No	1214	26 (2.1)	631	1 (0.2)	1853	28 (1.5)
Yes	130	2 (1.5)	105	2 (1.9)	237	4 (1.7)
p value		1.000		0.055		0.778

* Total includes people whose gender was not reported or reported as transgender

Table 20 HIV antibody prevalence by region/country of birth, gender and year of survey

	Male		Female		Total *	
2004						
Australia	941	14 (1.5)	498	3 (0.6)	1450	17 (1.2)
Other Oceania	29	0 (0.0)	27	0 (0.0)	56	0 (0.0)
Asia	119	0 (0.0)	19	0 (0.0)	138	0 (0.0)
UK & Ireland	58	2 (3.5)	23	0 (0.0)	81	2 (2.5)
Other	46	0 (0.0)	21	0 (0.0)	69	0 (0.0)
p value		0.4		1.0		0.4
2005						
Australia	911	13 (1.4)	541	0 (0.0)	1,459	13 (0.9)
Other Oceania	31	1 (3.2)	14	0 (0.0)	47	1 (2.1)
Asia	10	0 (0.0)	4	0 (0.0)	14	0 (0.0)
UK & Ireland	61	1 (1.6)	32	0 (0.0)	93	1 (1.1)
Other	52	0 (0.0)	15	0 (0.0)	67	0 (0.0)
p value		0.8		---		0.8
2006						
Australia	1026	22 (2.1)	577	2 (0.4)	1611	24 (1.5)
Other Oceania	38	1 (2.6)	23	0 (0.0)	62	2 (3.2)
Asia	11	0 (0.0)	4	0 (0.0)	15	0 (0.0)
UK & Ireland	73	2 (2.7)	30	0 (0.0)	104	2 (1.9)
Other	49	1 (2.0)	21	0 (0.0)	71	1 (1.4)
p value		0.824		1.000		0.535
2007						
Australia	1023	22 (2.2)	557	2 (0.4)	1590	25 (1.6)
Other Oceania	25	1 (4.0)	19	0 (0.0)	45	1 (2.2)
Asia	13	0 (0.0)	9	0 (0.0)	22	0 (0.0)
UK & Ireland	56	2 (3.6)	28	0 (0.0)	84	2 (2.4)
Other	51	0 (0.0)	19	0 (0.0)	70	0 (0.0)
p value		0.506		1.000		0.640
2008						
Australia	1181	24 (2.0)	650	3 (0.5)	1836	27 (1.5)
Other Oceania	34	3 (8.8)	27	0 (0.0)	63	4 (6.4)
Asia	21	1 (4.8)	7	0 (0.0)	28	1 (3.6)
UK & Ireland	68	0 (0.0)	43	0 (0.0)	113	0 (0.0)
Other	71	1 (1.4)	25	0 (0.0)	96	1 (1.0)
p value		0.063		1.000		0.033

* Total includes people whose gender was not reported or reported as transgender

National

Table 21 HIV antibody prevalence by main language spoken at home by parents, gender and year of survey

Main language spoken at home by parents	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2004	755	11 (1.5)	454	2 (0.4)	1219	13 (1.1)
English speaking	162	0 (0.0)	43	0 (0.0)	205	0 (0.0)
Non-English speaking		0.2		1.0		0.2
p value						
2005	888	15 (1.7)	546	0 (0.0)	1,441	15 (1.0)
English speaking	184	0 (0.0)	65	0 (0.0)	251	0 (0.0)
Non-English speaking		0.1		---		0.1
p value						
2006						
English speaking	1063	24 (2.3)	610	2 (0.3)	1683	27 (1.6)
Non-English speaking	84	2 (2.4)	28	0 (0.0)	114	2 (1.8)
p value		0.715		1.000		0.706
2007						
English speaking	1100	24 (2.2)	609	2 (0.3)	1719	27 (1.6)
Non-English speaking	70	1 (1.4)	27	0 (0.0)	98	1 (1.0)
p value		1.000		1.000		1.000
2008						
English speaking	1299	28 (2.2)	728	3 (0.4)	2037	32 (1.6)
Non-English speaking	73	1 (1.4)	28	0 (0.0)	101	1 (1.0)
p value		1.000		1.000		1.000

* Total includes people whose gender was not reported or reported as transgender

HCV antibody prevalence

Table 22 HCV antibody prevalence by gender and year of survey

Year of survey	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004	1223	715 (58)	599	371 (62)	1836	1093 (60)
2005	1076	657 (61)	609	377 (62)	1694	1040 (61)
2006	1217	736 (60)	656	419 (64)	1886	1162 (62)
2007	1140	695 (61)	605	388 (64)	1756	1091 (62)
2008	1352	852 (63)	737	453 (61)	2099	1311 (62)
χ^2 trend p value		0.033		0.906		0.062

* Total includes people whose gender was not reported or reported as transgender

Table 23 HCV antibody prevalence by sexual identity, gender and year of survey

Sexual identity	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Heterosexual	1065	619 (58)	439	272 (62)	1507	892 (59)
Bisexual	45	28 (62)	108	66 (61)	155	95 (61)
Homosexual	45	25 (56)	30	19 (63)	75	44 (59)
p value		0.8		0.9		0.9
2005						
Heterosexual	943	578 (61)	437	267 (61)	1381	845 (61)
Bisexual	37	20 (54)	106	64 (60)	144	85 (59)
Homosexual	54	31 (57)	32	24 (75)	91	59 (65)
p value		0.6		0.3		0.7
2006						
Heterosexual	1065	669 (63)	481	308 (64)	1549	979 (63)
Bisexual	55	25 (45)	109	76 (70)	170	102 (60)
Homosexual	59	26 (44)	45	23 (51)	106	51 (48)
p value		0.001		0.094		0.008
2007						
Heterosexual	1009	627 (62)	431	278 (65)	1441	906 (63)
Bisexual	45	25 (56)	116	77 (66)	165	105 (64)
Homosexual	63	30 (48)	41	21 (51)	107	53 (50)
p value		0.053		0.200		0.023
2008						
Heterosexual	1192	760 (64)	517	317 (61)	1711	1078 (63)
Bisexual	51	30 (59)	147	93 (63)	199	123 (62)
Homosexual	60	26 (43)	47	29 (62)	109	56 (51)
p value		0.006		0.901		0.054

* Total includes people whose gender was not reported or reported as transgender

National

Table 24 HCV antibody prevalence by age group, gender and year of survey

Age group	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
< 20 years	30	6 (20)	33	12 (36)	64	18 (28)
20 – 24	178	65 (37)	104	56 (54)	282	121 (43)
25 – 29	240	120 (50)	125	57 (46)	367	179 (49)
30 + years	772	522 (68)	337	246 (73)	1115	772 (69)
p value		<0.001		<0.001		<0.001
2005						
< 20 years	22	10 (45)	17	3 (18)	39	13 (33)
20 – 24	90	46 (51)	110	34 (31)	200	80 (40)
25 – 29	137	74 (54)	177	92 (52)	315	167 (53)
30 + years	772	528 (68)	360	247 (69)	1140	780 (68)
p value		<0.001		<0.001		<0.001
2006						
< 20 years	18	1 (6)	23	6 (26)	41	7 (17)
20 – 24	100	42 (42)	81	44 (54)	181	86 (48)
25 – 29	230	118 (51)	124	77 (62)	357	196 (55)
30 + years	864	571 (66)	426	290 (68)	1300	867 (67)
p value		<0.001		<0.001		<0.001
2007						
< 20 years	18	4 (22)	14	5 (36)	32	9 (28)
20 – 24	67	23 (34)	63	32 (51)	131	56 (43)
25 – 29	190	97 (51)	126	75 (60)	317	173 (55)
30 + years	863	569 (66)	401	276 (69)	1273	851 (67)
p value		<0.001		0.002		<0.001
2008						
< 20 years	21	6 (29)	16	7 (43)	37	13 (35)
20 – 24	84	25 (30)	73	34 (47)	157	59 (38)
25 – 29	176	93 (53)	140	81 (58)	318	175 (55)
30 + years	1066	725 (68)	507	331 (65)	1581	1061 (67)
p value		<0.001		0.005		<0.001

* Total includes people whose gender was not reported or reported as transgender

Table 25 HCV antibody prevalence by duration of drug injection, gender and year of survey

Duration of drug injection	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
<3 years	84	23 (27)	51	11 (22)	135	34 (25)
3 to 5 years	140	43 (31)	84	32 (38)	226	75 (33)
6 to 10 years	313	167 (53)	163	97 (60)	477	265 (56)
10 + years	660	468 (71)	292	225 (77)	955	696 (73)
p value		<0.001		<0.001		<0.001
2005						
<3 years	96	22 (23)	46	22 (48)	144	45 (31)
3 to 5 years	100	32 (32)	74	25 (34)	175	58 (33)
6 to 10 years	97	46 (47)	106	58 (55)	204	105 (51)
10 + years	736	529 (72)	353	253 (72)	1094	785 (72)
p value		<0.001		<0.001		<0.001
2006						
<3 years	58	9 (16)	41	9 (22)	100	18 (18)
3 to 5 years	79	25 (32)	67	19 (28)	146	44 (30)
6 to 10 years	227	111 (49)	158	102 (65)	389	214 (55)
10 + years	797	558 (70)	375	280 (75)	1180	844 (72)
p value		<0.001		<0.001		<0.001
2007						
<3 years	59	8 (14)	37	11 (30)	96	19 (20)
3 to 5 years	67	22 (33)	55	29 (53)	123	52 (42)
6 to 10 years	197	85 (43)	124	68 (55)	324	154 (48)
10 + years	786	558 (71)	372	267 (72)	1165	831 (71)
p value		<0.001		<0.001		<0.001
2008						
<3 years	67	13 (19)	43	17 (40)	110	30 (27)
3 to 5 years	112	32 (29)	50	19 (38)	162	51 (31)
6 to 10 years	181	90 (50)	150	79 (53)	332	169 (51)
10 + years	960	699 (73)	485	336 (69)	1453	1040 (72)
p value		<0.001		<0.001		<0.001

* Total includes people whose gender was not reported or reported as transgender

National

Table 26 HCV antibody prevalence by last drug injected, duration of drug injection and year of survey

Last drug injected	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Heroin	35	12 (34)	639	449 (70)	681	468 (69)
Meth/Amphetamine	62	14 (23)	515	229 (44)	584	248 (42)
More than one	6	2 (33)	109	70 (64)	121	75 (62)
Other/Not reported	32	6 (19)	395	288 (73)	450	302 (67)
p value		0.4		<0.001		<0.001
2005						
Heroin	30	14 (47)	563	389 (69)	593	403 (68)
Meth/Amphetamine	58	9 (16)	482	241 (50)	540	250 (46)
More than one	1	1 (100)	39	32 (82)	40	33 (83)
Other/Not reported	55	19 (35)	477	343 (72)	532	362 (68)
p value		0.003		<0.001		<0.001
2006						
Heroin	12	3 (25)	464	349 (75)	493	364 (74)
Meth/Amphetamine	53	4 (8)	635	305 (48)	710	319 (45)
More than one	0	(0)	33	23 (70)	34	24 (71)
Other/Not reported	35	11 (31)	583	425 (73)	649	455 (70)
p value		0.010		<0.001		<0.001
2007						
Heroin	21	6 (29)	517	359 (69)	545	371 (68)
Meth/Amphetamine	52	10 (19)	460	244 (53)	524	265 (51)
More than one	2	0 (0.0)	37	19 (51)	48	22 (46)
Other/Not reported	21	3 (14)	598	415 (69)	639	433 (68)
p value		0.706		<0.001		<0.001
2008						
Heroin	22	9 (41)	688	507 (74)	721	524 (73)
Meth/Amphetamine	43	8 (19)	538	256 (48)	587	265 (45)
More than one	2	2 (100)	43	35 (81)	46	37 (80)
Other/Not reported	43	11 (26)	678	462 (68)	745	485 (65)
p value		0.034		<0.001		<0.001

* Total includes people who did not report duration of drug injection

Table 27 HCV antibody prevalence by frequency of injection last month, duration of drug injection and year of survey

Frequency of drug injection last month	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Less than daily	55	15 (27)	718	425 (59)	785	447 (57)
Daily or more	67	18 (27)	819	550 (67)	897	578 (64)
p value		0.9		0.001		0.002
2005						
Less than daily	77	20 (26)	626	384 (61)	732	421 (58)
Daily or more	48	23 (48)	734	491 (67)	824	542 (66)
p value		0.01		0.03		0.001
2006						
Less than daily	51	4 (8)	740	463 (63)	812	476 (59)
Daily or more	39	11 (28)	801	526 (66)	881	566 (64)
p value		0.611		<0.001		<0.001
2007						
Less than daily	54	8 (15)	687	443 (64)	753	463 (61)
Daily or more	36	8 (22)	768	499 (65)	826	525 (64)
p value		0.408		0.869		0.405
2008						
Less than daily	53	10 (19)	792	490 (62)	855	505 (59)
Daily or more	36	15 (42)	951	650 (68)	1010	679 (67)
p value		0.030		0.005		<0.001

* Total includes people who did not report duration of drug injection

Table 28 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and year of survey

Re-used someone else's used needle & syringe last month	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
No	92	21 (23)	1218	755 (62)	1331	791 (59)
Yes	26	11 (42)	276	189 (68)	304	202 (66)
p value		0.05		0.04		0.02
2005						
No	94	32 (34)	1111	700 (63)	1265	769 (61)
Yes	16	7 (44)	173	124 (72)	198	137 (69)
p value		0.5		0.03		0.02
2006						
No	77	13 (17)	1262	791 (63)	1378	824 (60)
Yes	10	1 (10)	220	156 (71)	248	171 (69)
p value		1.000		0.019		0.007
2007						
No	73	12 (16)	1176	754 (64)	1271	785 (62)
Yes	13	4 (31)	215	145 (67)	235	156 (66)
p value		0.405		0.394		0.187
2008						
No	71	17 (24)	1428	918 (64)	1529	952 (62)
Yes	16	8 (50)	278	196 (71)	296	206 (70)
p value		0.063		0.046		0.018

* Total includes people who did not report duration of drug injection

National

Table 29 HCV antibody prevalence by imprisonment last year, duration of drug injection and year of survey

Imprisonment last year	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
No	116	29 (25)	1323	774 (59)	1465	815 (56)
Yes	16	5 (31)	317	250 (79)	342	264 (77)
p value		0.6		<0.001		<0.001
2005						
No	124	33 (27)	1205	743 (62)	1386	805 (58)
Yes	13	9 (69)	210	162 (77)	241	187 (78)
p value		<0.001		0.002		<0.001
2006						
No	90	16 (18)	1412	860 (61)	1558	906 (58)
Yes	7	2 (29)	224	176 (79)	240	184 (77)
2007						
No	88	16 (18)	1315	816 (62)	1439	855 (59)
Yes	3	2 (67)	226	170 (75)	238	181 (76)
p value		0.099		0 (0.0)		0 (0.0)
2008						
No	96	24 (25)	1555	959 (62)	1680	998 (59)
Yes	7	4 (57)	250	196 (78)	264	204 (77)
p value		0.085		<0.001		<0.001

* Total includes people who did not report duration of drug injection

Table 30 HCV antibody prevalence by sex work last month, duration of drug injection and year of survey

Sex work last month	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
No	124	30 (24)	1466	900 (61)	1625	949 (58)
Yes	7	4 (57)	153	111 (73)	161	116 (72)
p value		0.07		0.007		0.001
2005						
No	140	43 (31)	1345	856 (64)	1555	941 (61)
Yes	2	2 (100)	93	69 (74)	102	76 (75)
p value		0.04		0.04		0.005
2006						
No	90	17 (19)	1515	964 (64)	1699	1017 (61)
Yes	5	1 (20)	114	75 (66)	121	77 (64)
p value		1.000		0.687		0.629
2007						
No	82	16 (20)	1452	938 (65)	1573	983 (62)
Yes	7	2 (29)	98	63 (64)	110	68 (62)
p value		0.626		1.000		0.919
2008						
No	99	26 (26)	1715	1104 (64)	1850	1149 (62)
Yes	4	3 (75)	117	80 (68)	123	83 (67)
p value		0.067		0.424		0.250

* Total includes people who did not report duration of drug injection

Table 31 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and year of survey

Aboriginal and Torres Strait Islander origin	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
No	1103	640 (58)	524	320 (61)	1639	966 (59)
Yes	88	58 (66)	58	41 (71)	148	100 (68)
p value		0.1		0.2		0.04
2005						
No	950	576 (61)	521	313 (60)	1479	894 (60)
Yes	95	63 (66)	72	56 (78)	168	120 (71)
p value		0.3		0.003		0.006
2006						
No	1069	639 (60)	553	339 (61)	1631	981 (60)
Yes	108	69 (64)	87	68 (78)	196	138 (70)
p value		0.471		0.003		0.003
2007						
No	998	599 (60)	523	333 (64)	1530	939 (61)
Yes	112	80 (71)	73	48 (66)	187	129 (69)
p value		0.019		0.795		0.046
2008						
No	1177	732 (62)	614	372 (61)	1799	1108 (62)
Yes	125	82 (66)	98	67 (68)	225	151 (67)
p value		0.497		0.148		0.109

* Total includes people whose gender was not reported or reported as transgender

National

Table 32 HCV antibody prevalence by region/country of birth, gender and year of survey

Region/Country of birth	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Australia	946	532 (56)	501	309 (62)	1458	846 (58)
Other Oceania	29	16 (55)	27	18 (67)	56	34 (61)
Asia	120	88 (73)	19	10 (53)	139	98 (71)
UK & Ireland	59	37 (63)	23	15 (65)	82	52 (63)
Other	46	26 (57)	22	15 (68)	70	42 (60)
p value		0.009		0.8		0.07
2005						
Australia	914	551 (60)	539	331 (61)	1460	887 (61)
Other Oceania	31	14 (45)	14	9 (64)	47	24 (51)
Asia	10	4 (40)	4	1 (25)	14	5 (36)
UK & Ireland	61	46 (75)	32	22 (69)	93	68 (73)
Other	53	37 (70)	15	10 (67)	68	47 (69)
p value		0.01		0.5		0.01
2006						
Australia	1021	613 (60)	573	366 (64)	1602	984 (61)
Other Oceania	38	20 (53)	23	17 (74)	62	37 (60)
Asia	11	6 (55)	4	2 (50)	15	8 (53)
UK & Ireland	73	49 (67)	30	19 (63)	104	68 (65)
Other	48	28 (58)	20	9 (45)	69	37 (54)
p value		0.651		0.336		0.559
2007						
Australia	975	592 (61)	526	334 (64)	1511	934 (62)
Other Oceania	24	16 (67)	17	9 (53)	42	25 (60)
Asia	12	9 (75)	8	6 (75)	20	15 (75)
UK & Ireland	53	33 (62)	28	20 (71)	81	53 (65)
Other	50	31 (62)	19	14 (74)	69	45 (65)
p value		0.880		0.631		0.715
2008						
Australia	1145	721 (63)	626	378 (60)	1776	1103 (62)
Other Oceania	34	14 (41)	26	13 (50)	62	27 (44)
Asia	19	17 (89)	6	3 (50)	25	20 (80)
UK & Ireland	66	40 (61)	43	31 (72)	111	72 (65)
Other	68	46 (68)	25	18 (72)	93	64 (69)
p value		0.008		0.259		0.006

* Total includes people whose gender was not reported or reported as transgender

Table 33 HCV antibody prevalence by main language spoken at home by parents, gender and year of survey

Main language spoken at home by parents	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
English speaking	758	431 (57)	456	281 (62)	1224	715 (58)
Non-English speaking	163	109 (67)	44	25 (57)	207	134 (65)
p value		0.02		0.5		0.09
2005						
English speaking	892	546 (61)	544	333 (61)	1443	884 (61)
Non-English speaking	184	111 (60)	65	44 (68)	251	156 (62)
p value		0.8		0.3		0.8
2006						
English speaking	1058	643 (61)	607	391 (64)	1675	1039 (62)
Non-English speaking	83	45 (54)	27	14 (52)	112	60 (54)
p value		0.246		0.219		0.088
2007						
English speaking	1048	642 (61)	576	369 (64)	1634	1018 (62)
Non-English speaking	68	41 (60)	26	17 (65)	95	59 (62)
p value		0.898		1.000		1.000
2008						
English speaking	1262	788 (62)	704	433 (62)	1976	1227 (62)
Non-English speaking	68	51 (75)	26	14 (54)	94	65 (69)
p value		0.039		0.422		0.191

* Total includes people whose gender was not reported or reported as transgender

Australian Capital Territory 2004 – 2008

Table 34 Number (percentage) of respondents by demographic characteristics and year of survey

Demographic characteristics	2004	2005	2006	2007	2008
Number of sites	1	1	1	1	1
N° surveyed	N=28	N=39	N=52	N=22	N=31
Response (%)	---	70	---	---	---
Gender (%)					
Male	23 (82)	30 (77)	31 (60)	12 (55)	22 (71)
Female	5 (18)	9 (23)	20 (39)	10 (45)	9 (29)
Transgender	---	---	1 (2)	---	---
Not reported	---	---	---	---	---
Sexual identity (%)					
Heterosexual	23 (82)	33 (85)	44 (85)	19 (86)	22 (71)
Bisexual	1 (4)	2 (5)	7 (13)	1 (5)	3 (10)
Homosexual	2 (7)	1 (3)	1 (2)	2 (9)	3 (10)
Not reported	2 (7)	3 (8)	---	---	3 (10)
Age and duration of injection (years)					
<i>Median age</i>	34	36	33	29.5	36
Age range	17-50	15-57	15-60	17-61	22-56
<i>Age group (%)</i>					
<25 years	5 (18)	6 (15)	7 (13)	5 (23)	3 (10)
25+ years	23 (82)	33 (85)	44 (85)	17 (77)	28 (90)
Not reported	---	--	1 (2)	---	---
<i>Median age 1st IDU</i>	18	17	17	16	18
Age range	14-45	11-28	12-39	12-33	11-40
Not reported	1	9	2	1	---
<i>Median years IDU</i>	14	18	13	11	16
Range	<1-35	<1-32	<1-45	2-47	2-38
<i>Duration of drug injection (%)</i>					
<3 years	3 (11)	1 (3)	2 (4)	1 (5)	1 (3)
3+ years	24 (86)	38 (97)	48 (92)	20 (91)	30 (97)
Not reported	1 (3)	--	2 (4)	1 (5)	---
Aboriginal and Torres Strait Islander origin (%)					
No	23 (82)	31 (79)	49 (94)	21 (95)	25 (81)
Yes	3 (11)	7 (18)	3 (6)	---	4 (13)
Not reported	2 (7)	1 (3)	---	1 (5)	2 (6)
Region/Country of birth (%)					
Australia	26 (92)	32 (82)	43 (83)	18 (82)	25 (81)
Other Oceania	---	1 (3)	2 (4)	---	---
Asia	1 (4)	1 (3)	1 (2)	1 (5)	2 (6)
UK & Ireland	1 (4)	2 (5)	1 (2)	2 (9)	1 (3)
Other	---	3 (8)	4 (8)	1 (5)	2 (6)
Not reported	---	---	1 (2)	---	1 (3)
Main language spoken at home by parents (%)					
English speaking	23 (82)	30 (77)	42 (81)	20 (91)	30 (97)
Non-English speaking	---	9 (23)	7 (13)	2 (9)	1 (3)
Not reported	5 (18)	---	3 (6)	---	---
Imprisonment last year (%)					
No	22 (79)	33 (85)	44 (85)	19 (86)	26 (84)
Yes	6 (21)	4 (10)	7 (13)	2 (9)	2 (6)
Not reported	---	2 (5)	1 (2)	1 (5)	3 (10)
Injected in prison (%)	N=6	N=4	N=7	N=2	N=2
Yes	2 (33)	2 (50)	4 (57)	1 (50)	0 (0)
Frequency of injection last month (%)					
Not last month	1 (3)	8 (21)	7 (13)	3 (14)	0 (0)
Less than weekly	8 (29)	4 (10)	13 (25)	1 (5)	3 (10)
Weekly not daily	5 (18)	15 (38)	19 (37)	9 (41)	15 (48)
Daily or more	12 (43)	12 (31)	13 (25)	8 (36)	13 (42)
Not reported	2 (7)	---	---	1 (5)	---

Table 35 Number (percentage) of respondents by last drug injected, injecting behaviour in the month prior to survey and year of survey

Injecting behaviour	2004	2005	2006	2007	2008
Last drug injected (%)	N=28	N=39	N=52	N=22	N=31
Anabolic steroids	---	---	---	---	---
Cocaine	---	---	---	---	---
Heroin	14 (50)	14 (36)	20 (38)	9 (41)	14 (45)
Methadone	4 (14)	3 (8)	6 (12)	---	2 (6)
Meth/Amphetamine	9 (32)	10 (26)	21 (40)	9 (41)	9 (29)
Morphine/Other Opioids	---	2 (5)	1 (2)	1 (5)	2 (6)
Subutex/Buprenorphine	---	---	3 (6)	2 (9)	3 (10)
More than one	---	2 (5)	---	1 (5)	---
Other drug	1 (4)	---	1 (2)	---	---
Not reported	---	8 (20)	---	---	1 (3)
N° Injected last month	N = 25	N=31	N=45	N=18	N=31
Places injected last month (%)*					
Own home	17 (68)	20 (65)	35 (81)	16 (94)	27 (87)
Friend's home	13 (52)	11 (35)	20 (47)	11 (65)	11 (35)
Dealer's home	7 (28)	6 (19)	14 (33)	8 (47)	5 (16)
Street, park, beach	6 (24)	9 (29)	11 (26)	8 (47)	12 (39)
Car	8 (32)	11 (35)	20 (47)	8 (47)	12 (39)
Public toilet	12 (48)	11 (35)	16 (37)	9 (53)	12 (39)
Commercial injecting room	---	2 (6)	1 (2)	1 (6)	2 (6)
Squat	4 (16)	6 (19)	8 (19)	2 (12)	3 (10)
Use of new sterile needles & syringes last month (%)					
All injections	17 (68)	19 (61)	32 (71)	9 (50)	24 (77)
Most of the time	8 (32)	11 (35)	12 (27)	6 (33)	6 (19)
Half of the time	---	---	1 (2)	1 (6)	1 (3)
Some of the time	---	1 (3)	---	1 (6)	---
Not last month	---	---	---	---	---
Not reported	---	---	---	1 (6)	---
Re-used another's used needle & syringe last month (%)					
None	20 (80)	25 (81)	35 (78)	9 (50)	25 (81)
Once	2 (8)	1 (3)	3 (7)	3 (17)	2 (6)
Twice	1 (4)	---	---	1 (6)	2 (6)
3-5 times	1 (4)	---	3 (7)	2 (11)	1 (3)
>5 times	---	---	3 (7)	2 (11)	1 (3)
Not reported	1 (4)	5 (16)	1 (2)	1 (6)	---
Number of people needle & syringe was re-used after last month (%)					
None	20 (80)	21 (68)	35 (78)	9 (50)	25 (81)
One	1 (4)	4 (13)	3 (7)	2 (11)	3 (10)
Two	---	---	2 (4)	3 (17)	---
Three to five	---	---	1 (2)	---	---
More than five	---	---	1 (2)	---	---
Don't know	1 (4)	2 (6)	1 (2)	2 (11)	1 (3)
Not reported	3 (12)	4 (13)	2 (4)	2 (11)	2 (6)
Relationship to people needle & syringe was re-used after last month (%)*					
Regular sex partner	1 (4)	3 (10)	4 (9)	2 (11)	2 (6)
Casual sex partner	---	---	1 (2)	---	1 (3)
Close friend	1 (4)	2 (6)	3 (7)	3 (17)	---
Acquaintance	---	1 (3)	3 (7)	2 (11)	---
Other	---	---	---	1 (6)	1 (3)
Equipment used after someone else last month (%)*					
Spoon	11 (44)	10 (32)	17 (40)	6 (35)	11 (37)
Water	7 (28)	9 (29)	12 (28)	9 (53)	8 (27)
Filter	7 (28)	5 (16)	7 (16)	4 (24)	6 (20)
Drug mix	5 (20)	7 (23)	7 (16)	4 (24)	7 (23)
Tourniquet	1 (4)	2 (6)	9 (21)	4 (24)	1 (3)
None**	---	---	21 (49)	5 (30)	19 (63)
Injected by someone after that person injected themselves or others last month (%)					
No	18 (72)	21 (68)	37 (82)	10 (56)	28 (90)
Yes	7 (28)	4 (13)	7 (16)	6 (33)	3 (10)
Not reported	---	6 (19)	1 (2)	2 (11)	---

* More than one option could be selected

** New variable in 2006

ACT

Table 36 Number (percentage) of respondents by treatment for drug use and year of survey

Treatment for drug use	2004	2005	2006	2007	2008
N° surveyed	N=28	N=39	N=52	N=22	N=31
Any treatment/therapy for drug use (%)					
No	5 (18)	13 (33)	7 (13)	5 (23)	3 (10)
Yes	23 (82)	25 (64)	45 (87)	17 (77)	27 (87)
Not reported	---	1 (3)	---	---	1 (3)
History of methadone maintenance treatment (%)					
Currently	9 (32)	14 (36)	20 (38)	5 (23)	11 (35)
Previously	6 (21)	9 (23)	11 (21)	9 (41)	10 (32)
Never	12 (43)	15 (38)	21 (40)	8 (36)	9 (29)
Not reported	1 (4)	1 (3)	---	---	1 (3)
History of buprenorphine (Subutex®) treatment (%)*					
Currently	--	--	--	--	6 (19)
Previously	--	--	--	--	5 (16)
Never	--	--	--	--	19 (61)
Not reported	--	--	--	--	1 (3)
History of buprenorphine-naloxone (Suboxone®) treatment (%)*					
Currently	--	--	--	--	3 (10)
Previously	--	--	--	--	5 (16)
Never	--	--	--	--	22 (71)
Not reported	--	--	--	--	1 (3)

* New variable in 2008

Table 37 Number (percentage) of respondents by site of needle and syringe acquisition last month and year of survey

Syringe acquisition	2004	2005	2006	2007*	2008
N° surveyed	N=28	N=39	N=52	--	N=31
From an NSP last month (%)					
Daily or almost daily	6 (21)	8 (21)	8 (15)	--	5 (16)
A couple of times each week	11 (39)	7 (18)	23 (44)	--	13 (42)
Less than weekly	3 (11)	8 (21)	10 (19)	--	8 (26)
Once last month	4 (14)	1 (3)	3 (6)	--	3 (10)
Not in the last month	3 (11)	13 (33)	7 (13)	--	---
Not reported	1 (4)	2 (5)	1 (2)	--	2 (6)
From a chemist last month (%)					
Daily or almost daily	---	2 (5)	2 (4)	--	1 (3)
A couple of times each week	5 (18)	2 (5)	1 (2)	--	5 (16)
Less than weekly	4 (14)	5 (13)	11 (21)	--	6 (19)
Once last month	7 (25)	5 (13)	11 (21)	--	8 (26)
Not in the last month	11 (39)	23 (59)	23 (44)	--	9 (29)
Not reported	1 (4)	2 (5)	4 (2)	--	2 (6)

* Not asked in this form in 2007.

Table 38 Number (percentage) of respondents by injecting equipment use, re-use and cleaning last month

Use, re-use and cleaning of any item*	Used	Re-used	Cleaned**
N° surveyed	N=31	N=31	N=31
Yes	30 (97)	15 (48)	15 (48)
No	0 (0)	13 (42)	14 (45)
Not reported	1 (3)	3 (10)	2 (6)
Use, re-use and cleaning by item type#			
1ml	27 (87)	8 (26)	8 (26)
3 ml	6 (19)	3 (10)	4 (13)
5 ml	5 (16)	0 (0)	1 (3)
10 ml	11 (35)	3 (10)	3 (10)
20 ml	6 (19)	2 (6)	1 (3)
Detachable needle (tip)	4 (13)	0 (0)	0 (0)
Winged vein infusion set (butterfly)	9 (29)	2 (6)	2 (6)
Wheel filter	12 (39)	2 (6)	2 (6)

* New question in 2008

** Includes 1 respondent that reported cleaning but not re-use in the last month

More than one item could be selected

Table 39 Number (percentage) of respondents by sexual behaviour in the month prior to survey and year of survey

Sexual behaviour	2004	2005	2006	2007	2008
N° surveyed	N=28	N=39	N=52	N=22	N=31
Sex with a regular partner last month (%) **					
No	---	19 (49)	30 (58)	11 (50)	22 (71)
Yes	---	19 (49)	22 (42)	9 (41)	8 (26)
Not reported	---	1 (3)	---	2 (9)	1 (3)
Condom used with regular partner last month (%)**					
N° surveyed	---	N=19	N=22	N=9	N=8
Never	---	14 (74)	15 (68)	7 (78)	3 (38)
Sometimes	---	2 (11)	1 (5)	2 (22)	2 (25)
Every time	---	1 (5)	5 (23)	---	2 (25)
Not reported	---	2 (11)	1 (5)	---	1 (12)
Sex with other partner/s last month (%)**					
No	---	2 (40)	40 (77)	14 (64)	26 (84)
Yes	---	3 (60)	10 (19)	7 (32)	3 (10)
Not reported	---	---	2 (4)	1 (5)	2 (6)
Condom used with other partner/s last month (%)**					
N° surveyed	---	N=5	N=10	N=7	N=3
Never	---	6 (15)	4 (40)	3 (43)	2 (67)
Sometimes	---	3 (8)	1 (10)	2 (29)	1 (33)
Every time	---	1 (3)	4 (40)	2 (29)	---
Not reported	---	29 (74)	1 (10)	---	---
Sex work last month (%)					
No	26 (93)	38 (97)	47 (90)	20 (91)	29 (94)
Yes	2 (7)	1 (3)	3 (6)	1 (5)	2 (6)
Not reported	---	---	2 (4)	1 (5)	---
Condom used at last sex work last month (%)*					
Yes	2 (100)	1 (100)	2 (67)	1 (100)	---

* Percentages exclude missing data

** New variable format commenced in 2005

Table 40 Number (percentage) of respondents reporting previous testing for HIV and HCV infection and HCV treatment by year of survey

	2004	2005	2006	2007	2008
N° surveyed	N=28	N=39	N=52	N=22	N=31
Previous HIV test (%)					
Last year	19 (68)	20 (51)	39 (75)	13 (59)	8 (26)
> 1 year ago	3 (11)	14 (36)	12 (23)	9 (41)	21 (68)
Never tested	5 (18)	4 (10)	1 (2)	---	1 (3)
Not reported	1 (3)	1 (3)	---	---	1 (3)
Previous HCV test (%)					
Last year	17 (61)	24 (62)	38 (73)	12 (55)	11 (35)
> 1 year ago	6 (21)	11 (28)	12	10 (45)	18 (58)
Never tested	5 (18)	2 (5)	1	---	1 (3)
Not reported	---	2 (5)	1	---	1 (3)
Any treatment for HCV (%)	N = 17	N=21	N=34	N=12	N=18
Interferon	---	---	1 (3)	1 (8)	---
Interferon+Ribavirin	---	1 (5)	1 (3)	---	2 (11)
Other	---	17 (81)	---	---	1 (6)
No treatment	17 (100)	2 (10)	31 (91)	11 (92)	15 (83)
Not reported	---	1 (5)	1 (3)	---	---
Current treatment for HCV	N = 0	N=1	N=1	N=0	N=0
Interferon/Interferon+Ribavirin	---	1	---	---	---
Other	---	---	1	---	---

ACT

HIV antibody prevalence

Table 41 HIV antibody prevalence by gender and year of survey

Year of survey	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2004	18	0 (0.0)	5	0 (0.0)	23	0 (0.0)
2005	23	0 (0.0)	7	0 (0.0)	30	0 (0.0)
2006	30	0 (0.0)	18	0 (0.0)	49	0 (0.0)
2007	10	0 (0.0)	8	0 (0.0)	18	0 (0.0)
2008	18	0 (0.0)	8	0 (0.0)	26	0 (0.0)
χ^2 trend p value		---		---		---

* Total includes people whose gender was not reported or reported as transgender

HCV antibody prevalence

Table 42 HCV antibody prevalence by gender and year of survey

Year of survey	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004	18	12 (67)	5	4 (80)	23	16 (70)
2005	24	16 (67)	7	7 (100)	31	23 (74)
2006	29	23 (79)	16	10 (63)	46	33 (72)
2007	10	10 (100)	8	6 (75)	18	16 (89)
2008	18	12 (67)	8	6 (75)	26	18 (69)
χ^2 trend p value		0.459		0.522		0.755

* Total includes people whose gender was not reported or reported as transgender

Table 43 HCV antibody prevalence by sexual identity, gender and year of survey

Sexual identity	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Heterosexual	16	11(69)	3	2 (67)	19	13 (68)
Bisexual	1	0(0)	1	0 (100)	1	0 (0)
Homosexual	0	0	1	0(100)	1	1 (100)
p value		-		-		-
2005						
Heterosexual	20	14 (70)	6	6 (100)	26	20 (77)
Bisexual	1	0 (0)	1	1 (100)	2	1 (50)
Homosexual	1	1 (100)	0	0	1	1 (100)
p value		0.3		-		0.6
2006						
Heterosexual	28	22 (79)	10	7 (70)	38	29 (76)
Bisexual	---	---	6	3 (50)	7	3 (43)
Homosexual	1	1 (100)	---	---	1	1 (100)
p value		1.000		0.607		0.223
2007						
Heterosexual	9	9 (100)	7	5 (71)	16	14 (88)
Bisexual	---	---	1	0 (0)	2	0 (0)
Homosexual	1	1 (100)		1 (100)		1 (100)
p value		---		1.000		1.000
2008						
Heterosexual	13	8 (62)	6	4 (67)	19	12 (63)
Bisexual	2	1 (50)	---	---	2	1 (50)
Homosexual	1	1 (100)	1	1 (100)	2	2 (100)
p value		1.000		1.000		0.779

* Total includes people whose gender was not reported or reported as transgender

Table 44 HCV antibody prevalence by age group, gender and year of survey

Age group	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
< 20 years	--	--	1	1 (100)	1	1 (100)
20 – 24	2	1 (50)	2	2 (100)	4	3 (75)
25 – 29	2	1 (50)	--	--	2	1 (50)
30 + years	14	10 (71)	2	1 (50)	16	11 (69)
p value		0.7		0.4		0.8
2005						
< 20 years	1	0 (0)	--	---	1	0 (0)
20 – 24	2	0 (0)	1	1 (100)	3	1 (33)
25 – 29	2	2 (100)	3	3 (100)	5	5 (100)
30 + years	19	14 (74)	3	3 (100)	22	17 (77)
p value		0.5		0.06		0.6
2006						
< 20 years	---	---	1	0 (0)	1	0 (0)
20 – 24	3	1 (33)	2	1 (50)	5	2 (40)
25 – 29	6	5 (83)	5	3 (60)	11	8 (73)
30 + years	19	16 (85)	8	6 (75)	28	22 (79)
p value		0.144		0.685		0.107
2007						
< 20 years	1	1 (100)	1	1 (100)	2	2 (100)
20 – 24	---	---	3	3 (100)	3	3 (100)
25 – 29	4	4 (100)	2	1 (50)	6	5 (83)
30 + years	5	5 (100)	2	1 (50)	7	6 (86)
p value		---		0.571		1.000
2008						
< 20 years	---	---	---	---	---	---
20 – 24	1	0 (0.0)	1	1 (100)	2	1 (50)
25 – 29	1	0 (0.0)	2	2 (100)	3	2 (67)
30 + years	16	12 (75)	5	3 (60)	21	15 (71)
p value		0.098		1.000		0.777

* Total includes people whose gender was not reported or reported as transgender

Table 45 HCV antibody prevalence by duration of drug injection, gender and year of survey

Duration of drug injection	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
<3 years	2	1 (50)	1	1 (100)	3	2 (67)
3 to 5 years	-	-	1	0 (0)	1	0 (0)
6 to 10 years	2	1 (50)	2	2 (100)	4	3 (75)
10 + years	14	10 (71)	1	1 (100)	15	11 (73)
p value		<0.001		<0.001		<0.001
2005						
<3 years	8	1 (13)	-	-	8	1 (13)
3 to 5 years	-	-	-	-	-	-
6 to 10 years	-	-	1	1 (100)	1	1 (100)
10 + years	16	15 (94)	6	6(100)	22	21 (95)
p value						
2006						
<3 years	---	---	1	0 (0)	1	0 (0)
3 to 5 years	1	0 (0)	1	1 (100)	2	1 (50)
6 to 10 years	9	7 (78)	6	3 (50)	15	10 (67)
10 + years	17	14 (82)	8	6 (75)	26	20 (70)
p value		0.329		0.519		0.263
2007						
<3 years	1	1 (100)	---	---	1	1 (100)
3 to 5 years	---	---	2	2 (100)	2	2 (100)
6 to 10 years	3	3 (100)	2	2 (100)	5	5 (100)
10 + years	6	6 (100)	3	1 (33)	9	7 (78)
p value		---		0.238		0.669
2008						
<3 years	1	0 (0.0)	---	---	1	0 (0.0)
3 to 5 years	1	0 (0.0)	---	---	1	0 (0.0)
6 to 10 years	3	2 (67)	1	1 (100)	4	3 (75)
10 + years	13	10 (77)	7	5 (71)	20	15 (75)
p value		0.214		1.000		0.155

* Total includes people whose gender was not reported or reported as transgender

Table 46 HCV antibody prevalence by last drug injected, duration of drug injection and year of survey

Last drug injected	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Heroin	-	-	12	9 (75)	12	9 (75)
Meth/Amphetamine	2	1 (50)	4	2 (50)	6	3 (50)
More than one	-	-	-	-	-	-
Other/Not reported	1	1 (100)	4	3 (75)	5	4 (80)
p value		0.4		<0.001		<0.001
2005						
Meth/Amphetamine	2	0 (0)	8	7 (88)	10	7 (70)
Heroin	---	---	14	14 (100)	14	14 (100)
More than one	---	---	2	2 (100)	2	2 (100)
Other/Not reported	8	1 (13)	5	5 (100)	13	6 (46)
p value		1.000		0.517		0.005
2006						
Heroin	---	---	16	13 (81)	17	14 (82)
Meth/Amphetamine	1	0 (0)	18	10 (56)	20	11 (55)
More than one	---	---	---	---	---	---
Other/Not reported	---	---	9	8 (89)	9	8 (9)
p value		---		0.164		0.116
2007						
Heroin	---	---	7	5 (71)	7	5 (71)
Meth/Amphetamine	1	1 (100)	6	6 (100)	8	8 (100)
More than one	---	---	---	---	---	---
Other/Not reported	---	---	3	3 (100)	3	3 (100)
p value		---		0.650		0.294
2008						
Heroin	---	---	12	10 (83)	12	10 (83)
Meth/Amphetamine	1	0 (0.0)	7	4 (57)	8	4 (50)
More than one	---	---	---	---	---	---
Other/Not reported	---	---	6	4 (67)	6	4 (67)
p value		---		0.522		0.260

* Total includes people who did not report duration of drug injection

ACT

Table 47 HCV antibody prevalence by frequency of injection last month, duration of drug injection and year of survey

Frequency of drug injection last month	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Less than daily	---	---	10	7 (70)	10	7 (70)
Daily or more	2	1 (50)	9	6 (67)	11	7 (64)
p value		---		0.9		0.8
2005						
Less than daily	8	1 (13)	14	13 (93)	22	14 (64)
Daily or more	---	---	9	9 (100)	9	9 (100)
p value		---		0.4		0.04
2006						
Less than daily	---	---	28	22 (79)	30	24 (80)
Daily or more	1	0 (0)	9	4 (44)	10	4 (40)
p value		---		0.091		0.041
2007						
Less than daily	1	1 (100)	7	6 (86)	8	7 (88)
Daily or more	--	---	6	5 (83)	7	6 (86)
p value		---		1.000		1.000
2008						
Less than daily	---	---	14	10 (71)	14	10 (71)
Daily or more	1	0 (0.0)	11	8 (73)	12	8 (67)
p value		---		1.000		1.000

* Total includes people who did not report duration of drug injection

Table 48 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and year of survey

Re-used someone else's used needle & syringe last month	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
No	2	1 (50)	14	10 (71)	16	11 (69)
Yes	-	-	3	2 (67)	3	2 (67)
p value		-		0.9		0.9
2005						
No	-	-	18	17 (94)	18	17 (94)
Yes	-	-	1	1 (100)	1	1 (100)
p value		-		0.8		0.8
2006						
No	---	---	31	23 (74)	32	24 (75)
Yes	1	0 (0)	6	3 (50)	7	3 (43)
p value		---		0.335		0.172
2007						
No	1	1 (100)	7	5 (71)	8	6 (75)
Yes	---	---	5	5 (100)	6	6 (100)
p value		---		0.470		0.473
2008						
No	1	0 (0.0)	20	13 (65)	21	13 (62)
Yes	---	---	5	5 (100)	5	5 (100)
p value		---		0.274		0.281

* Total includes people who did not report duration of drug injection

Table 49 HCV antibody prevalence by imprisonment last year, duration of drug injection and year of survey

Imprisonment last year	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
No	3	2 (67)	14	9 (64)	17	11 (65)
Yes	-	-	6	5 (83)	6	5 (83)
p value				0.4		0.4
2005						
No	6	1 (17)	21	20 (95)	27	21 (78)
Yes	1	0 (0)	1	1 (100)	2	1 (50)
p value		0.7		0.8		0.4
2006						
No	1	0 (0)	37	26 (70)	39	27 (69)
Yes	---	---	6	5 (83)	6	5 (83)
p value		---		0.659		0.656
2007						
No	1	1 (100)	14	12 (86)	16	14 (88)
Yes	---	---	2	2 (100)	2	2 (100)
p value		---		1.000		1.000
2008						
No	1	0 (0.0)	20	15 (75)	21	15 (71)
Yes	---	---	2	1 (50)	2	1 (50)
p value		---		0.481		0.526

* Total includes people who did not report duration of drug injection

Table 50 HCV antibody prevalence by sex work last month, duration of drug injection and year of survey

Sex work last month	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
No	2	1 (50)	19	13 (68)	21	14 (67)
Yes	1	1 (100)	1	1 (100)	2	2 (100)
p value		0.4		0.5		0.3
2005						
No	8	1 (13)	23	22 (96)	31	23 (74)
Yes	-	-	-	-	-	-
p value						
2006						
No	1	0 (0)	39	31 (79)	41	32 (78)
Yes	---	---	3	0 (0)	3	3 (100)
p value		---		0.014		0.017
2007						
No	1	1 (100)	15	13 (87)	17	15 (88)
Yes	---	---	---	---	---	---
p value		---		---		---
2008						
No	1	0 (0.0)	23	16 (70)	24	16 (67)
Yes	---	---	---	---	---	---
p value		---		---		---

* Total includes people who did not report duration of drug injection

ACT

Table 51 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and year of survey

Aboriginal and Torres Strait Islander origin	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
No	16	10 (63)	3	2 (67)	19	12 (63)
Yes	1	1 (100)	2	2 (100)	3	3 (100)
p value		0.2		0.3		0.4
2005						
No	18	13 (72)	6	6 (100)	24	19 (79)
Yes	5	3 (60)	1	1 (100)	6	4 (67)
p value		0.3		0.003		0.006
2006						
No	27	21 (78)	15	9 (60)	43	30 (70)
Yes	2	2 (100)	1	1 (100)	3	3 (100)
p value		1.000		1.000		0.548
2007						
No	10	10 (100)	7	6 (86)	17	16 (94)
Yes	---	---	---	---	---	---
p value		---		---		---
2008						
No	13	8 (62)	7	5 (71)	20	13 (65)
Yes	4	3 (75)	---	---	4	3 (75)
p value		1.000		---		1.000

* Total includes people whose gender was not reported or reported as transgender

Table 52 HCV antibody prevalence by region/country of birth, gender and year of survey

Region/Country of birth	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Australia	16	11 (69)	5	4 (80)	21	15(71)
Other Oceania	---	---	---	---	---	---
Asia	---	---	---	---	---	---
UK & Ireland	---	---	---	---	---	---
Other	2	1 (50)	---	---	2	1 (50)
p value		0.009		---		---
2005						
Australia	20	14 (70)	6	6 (100)	26	20 (77)
Other Oceania	---	---	---	---	---	---
Asia	1	0 (0)	---	---	1	0 (0)
UK & Ireland	---	---	1	1 (100)	1	1 (100)
Other	3	2 (67)	---	---	3	2 (67)
p value		0.3		---		0.3
2006						
Australia	27	21 (78)	13	10 (77)	40	31 (78)
Other Oceania	1	1 (100)	1	0 (0)	2	1 (50)
Asia	---	---	---	---	---	---
UK & Ireland	---	---	1	0 (0)	1	1 (100)
Other	---	---	1	0 (0)	2	0 (0)
p value		1.000		0.036		0.020
2007						
Australia	10	10 (100)	6	5 (83)	16	15 (94)
Other Oceania	---	---	---	---	---	---
Asia	---	---	1	1 (100)	1	1 (100)
UK & Ireland	---	---	1	0 (0)	1	0 (0)
Other	---	---	---	---	---	---
p value		---		0.464		0.216
2008						
Australia	16	11 (69)	6	4 (67)	22	15 (68)
Other Oceania	---	---	---	---	---	---
Asia	1	0 (0.0)	---	---	1	0 (0.0)
UK & Ireland	1	1 (100)	---	---	1	1 (100)
Other	---	0 (0.0)	1	1(100)	1	1 (100)
p value		0.569		1.000		0.704

* Total includes people whose gender was not reported or reported as transgender

Table 53 HCV antibody prevalence by main language spoken at home by parents, gender and year of survey

Main language spoken at home by parents	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
English speaking	15	10 (67)	4	3 (75)	19	13 (68)
Non-English speaking	---	---	---	---	---	---
p value		---		---		---
2005						
English speaking	17	13 (76)	7	7 (100)	24	20 (83)
Non-English speaking	7	3 (43)	---	---	7	3 (43)
p value		0.1		---		0.03
2006						
English speaking	23	20 (87)	15	10 (67)	38	30 (79)
Non-English speaking	3	1 (33)	1	0 (0)	5	1 (20)
p value		0.085		0.375		0.017
2007						
English speaking	10	10 (100)	8	6 (75)	18	16 (89)
Non-English speaking	---	---	---	---	---	---
p value		---		---		---
2008						
English speaking	18	12 (67)	7	5 (71)	25	17 (68)
Non-English speaking	---	---	---	---	---	---
p value		---		---		---

* Total includes people whose gender was not reported or reported as transgender

**New South Wales
2004 – 2008**

Table 54 Number (percentage) of respondents by demographic characteristics and year of survey

Demographic characteristics	2004	2005	2006	2007	2008
Number of sites	17	23	21	21	22
N ^o surveyed	N=646	N=729	N=683	N=701	N=899
Response (%)	40	41	37	35	33
Gender (%)					
Male	436 (67)	464 (64)	434 (64)	450 (64)	582 (65)
Female	205 (32)	259 (36)	242 (35)	247 (35)	310 (34)
Transgender	2 (<1)	6 (1)	6 (<1)	3 (<1)	4 (<1)
Not reported	3 (<1)	---	1 (<1)	1 (<1)	3 (<1)
Sexual identity (%)					
Heterosexual	523 (81)	590 (81)	553 (81)	575 (82)	715 (80)
Bisexual	49 (8)	58 (8)	65 (10)	64 (9)	93 (10)
Homosexual	27 (4)	48 (7)	45 (7)	45 (6)	56 (6)
Not reported	47 (7)	33 (5)	20 (3)	17 (2)	35 (4)
Age and duration of injection (years)					
<i>Median age</i>	33	34	36	37	37
<i>Age range</i>	16 - 65	17-66	15-65	16-69	17-70
<i>Age group (%)</i>					
<25 years	106 (16)	89 (12)	61 (9)	59 (8)	81 (9)
25+ years	539 (83)	640 (88)	619 (91)	642 (92)	815 (91)
Not reported	1 (<1)	---	3 (<1)	---	3 (<1)
<i>Median age 1st IDU</i>	18	18	18	18	18
<i>Age range</i>	5 - 50	9-55	10-52	10-56	10-60
N ^o not reported	14	26	3	21	18
<i>Median years IDU</i>	12	13	15	16	17
<i>Range</i>	<1 - 45	<1-46	<1-43	<1-49	<1-48
<i>Duration of drug injection (%)</i>					
<3 years	47 (7)	60 (8)	31 (5)	23 (3)	46 (5)
>3+ years	585 (91)	642 (88)	625 (92)	657 (94)	835 (93)
Not reported	14 (2)	27 (4)	27 (4)	21 (3)	18 (2)
Aboriginal and Torres Strait Islander origin (%)					
No	546 (84)	590 (81)	571 (84)	575 (82)	736 (82)
Yes	81 (13)	115 (16)	87 (13)	105 (15)	131 (15)
Not reported	19 (3)	24 (3)	25 (4)	21 (3)	32 (4)
Region/Country of birth (%)					
Australia	454 (70)	628 (86)	575 (84)	592 (84)	781 (87)
Other Oceania	16 (2)	25 (3)	29 (4)	18 (3)	31 (3)
Asia	114 (18)	4 (1)	5 (<1)	10 (1)	8 (1)
UK & Ireland	17 (3)	31 (4)	35 (5)	26 (4)	38 (4)
Other	31 (5)	33 (5)	28 (4)	38 (5)	28 (3)
Not reported	14 (2)	8 (1)	11 (2)	17 (2)	13 (1)
Main language spoken at home by parents (%)					
English speaking	344 (53)	629 (86)	593 (87)	648 (92)	844 (94)
Non-English speaking	143 (22)	100 (14)	60 (9)	37 (5)	40 (4)
Not reported	159 (25)	0	30 (4)	16 (2)	15 (2)
Imprisonment last year (%)*					
No	493 (76)	568 (78)	556 (81)	566 (81)	687 (76)
Yes	148 (23)	130 (18)	94 (14)	103 (15)	137 (15)
Not reported	5 (1)	31 (4)	33 (5)	32 (5)	75 (8)
Injected in prison (%)	N=148	N=130	N=94	N=103	N=137
Yes	67 (45)	38 (29)	40 (43)	37 (36)	46 (34)
Frequency of injection last month (%)					
Not last month	40 (6)	71 (10)	88 (13)	81 (12)	126 (14)
Less than weekly	118 (18)	121 (17)	131 (19)	136 (19)	146 (16)
Weekly not daily	167 (26)	176 (24)	169 (25)	167 (24)	229 (25)
Daily or more	312 (48)	357 (49)	285 (42)	298 (43)	392 (44)
Not reported	9 (2)	4 (1)	10 (1)	19 (3)	6 (1)

Table 55 Number (percentage) of respondents by last drug injected, injecting behaviour in the month prior to survey and year of survey

Injecting behaviour	2004	2005	2006	2007	2008
Last drug injected (%)	N=646	N=729	N=683	N=701	N=899
Anabolic steroids	11 (2)	20 (3)	16 (2)	12 (2)	20 (2)
Cocaine	41 (6)	45 (6)	36 (5)	30 (4)	45 (5)
Heroin	320 (50)	296 (41)	231 (34)	254 (36)	346 (39)
Methadone	50 (8)	105 (14)	96 (14)	88 (13)	107 (12)
Meth/Amphetamine	148 (23)	183 (25)	197 (29)	185 (26)	230 (26)
Morphine/Other Opioids	21 (3)	24 (3)	49 (7)	57 (8)	80 (9)
Subutex/Buprenorphine	3 (<1)	2 (<1)	16 (2)	20 (3)	27 (3)
More than one	33 (5)	11 (2)	9 (<1)	26 (4)	21 (2)
Other	6 (1)	5 (<1)	4 (<1)	18 (3)	8 (1)
Not reported	7 (1)	25 (3)	20 (3)	11 (2)	15 (2)
N° Injected last month	N=597	N=654	N=585	N=601	N=767
Places injected last month (%)*					
Own home	474 (79)	520 (80)	506 (90)	517 (88)	673 (89)
Friend's home	201 (34)	228 (35)	219 (39)	226 (39)	316 (42)
Dealer's home	68 (11)	100 (15)	84 (15)	101 (17)	120 (16)
Street, park, beach	129 (22)	160 (24)	126 (22)	143 (24)	165 (22)
Car	136 (23)	157 (24)	144 (26)	159 (27)	181 (24)
Public toilet	110 (18)	134 (20)	110 (20)	137 (23)	163 (22)
Commercial injecting room	29 (5)	42 (6)	38 (7)	39 (7)	40 (5)
Squat	35 (6)	24 (4)	41 (7)	39 (7)	50 (7)
MSIC	43 (7)	42 (6)	59 (11)	62 (11)	64 (8)
Use of new sterile needles & syringes last month (%)					
All injections	416 (70)	472 (72)	407 (70)	431 (72)	544 (71)
Most of the time	137 (23)	146 (22)	129 (22)	130 (22)	174 (23)
Half of the time	10 (2)	15 (2)	12 (2)	17 (3)	22 (3)
Some of the time	18 (3)	6 (1)	10 (2)	9 (2)	11 (1)
Not last month	4 (<1)	1 (<1)	11 (2)	---	7 (1)
Not reported	12 (2)	14 (2)	16 (3)	14 (2)	9 (1)
Re-used another's used needle & syringe last month (%)					
None	473 (79)	532 (82)	477 (82)	485 (81)	604 (79)
Once	41 (7)	26 (4)	31 (5)	42 (7)	50 (7)
Twice	28 (5)	24 (4)	20 (3)	19 (3)	42 (5)
3-5 times	27 (4)	26 (4)	17 (3)	17 (3)	26 (3)
>5 times	10 (2)	16 (2)	14 (2)	6 (1)	22 (3)
Not reported	18 (3)	28 (4)	26 (4)	32 (5)	23 (3)
Number of people needle & syringe was re-used after last month (%)					
None	473 (79)	504 (77)	477 (82)	485 (81)	604 (79)
One	58 (10)	65 (10)	43 (7)	42 (7)	66 (9)
Two	10 (2)	5 (1)	7 (1)	7 (1)	11 (1)
Three to five	3 (<1)	5 (1)	2 (<1)	5 (<1)	10 (1)
More than five	3 (<1)	3 (<1)	2 (<1)	2 (<1)	3 (<1)
Don't know	13 (2)	28 (4)	16 (3)	12 (2)	30 (4)
Not reported	37 (6)	44 (7)	38 (7)	48 (8)	43 (6)
Relationship to people needle & syringe was re-used after last month (%)*					
Regular sex partner	43 (7)	60 (9)	30 (5)	36 (6)	56 (7)
Casual sex partner	4 (1)	3 (<1)	5 (<1)	2 (<1)	7 (1)
Close friend	24 (4)	29 (4)	15 (3)	27 (4)	39 (5)
Acquaintance	16 (3)	10 (2)	12 (2)	12 (2)	12 (2)
Other	6 (1)	4 (1)	4 (<1)	4 (<1)	8 (1)
Equipment used after someone else last month (%)*					
Spoon	181 (30)	152 (23)	114 (20)	134 (25)	160 (23)
Water	125 (21)	107 (16)	68 (12)	101 (19)	114 (16)
Filter	89 (15)	66 (10)	36 (6)	62 (11)	78 (11)
Drug mix	59 (10)	67 (10)	45 (8)	45 (8)	50 (7)
Tourniquet	67 (11)	71 (11)	47 (8)	58 (11)	74 (11)
None**	---	---	358 (62)	353 (65)	457 (66)
Injected by someone after that person injected themselves or others last month (%)					
No	502 (84)	528 (81)	497 (85)	494 (82)	631 (82)
Yes	72 (12)	87 (13)	60 (10)	77 (13)	110 (14)
Not reported	23 (4)	41 (6)	28 (5)	30 (5)	26 (3)

* More than one option could be selected

** New variable in 2006

Table 56 Number (percentage) of respondents by treatment for drug use and year of survey

Treatment for drug use	2004	2005	2006	2007	2008
N° surveyed	N=646	N=729	N=683	N=701	N=899
Any treatment/therapy for drug use (%)					
No	80 (12)	123 (17)	97 (14)	106 (15)	128 (14)
Yes	555 (86)	599 (82)	565 (82)	578 (82)	754 (84)
Not reported	11 (2)	7 (1)	21 (3)	17 (2)	17 (2)
History of methadone maintenance treatment (%)					
Currently	285 (44)	320 (44)	298 (44)	286 (41)	379 (42)
Previously	153 (24)	153 (21)	169 (25)	182 (26)	219 (24)
Never	198 (31)	250 (34)	201 (29)	218 (31)	281 (31)
Not reported	10 (1)	6 (1)	15 (2)	15 (2)	20 (2)
History of buprenorphine (Subutex®) treatment (%)*					
Currently	--	--	--	--	120 (13)
Previously	--	--	--	--	193 (21)
Never	--	--	--	--	564 (63)
Not reported	--	--	--	--	22 (2)
History of buprenorphine-naloxone (Suboxone®) treatment (%)*					
Currently	--	--	--	--	26 (3)
Previously	--	--	--	--	59 (7)
Never	--	--	--	--	782 (87)
Not reported	--	--	--	--	32 (4)

* New variable in 2008

Table 57 Number (percentage) of respondents by site of needle and syringe acquisition last month and year of survey

Needle & Syringe acquisition	2004	2005	2006	2007*	2008
N° surveyed	N = 646	N=729	N=683	--	N=899
From an NSP last month (%)					
Daily or almost daily	85 (13)	117 (16)	77 (11)	--	102 (11)
A couple of times each week	160 (25)	193 (26)	194 (28)	--	229 (25)
Less than weekly	174 (27)	159 (22)	164 (24)	--	227 (25)
Once last month	122 (19)	160 (22)	134 (20)	--	166 (18)
Not in the last month	87 (13)	95 (13)	98 (14)	--	160 (18)
Not reported	18 (3)	5 (1)	16 (2)	--	15 (2)
From a chemist last month (%)					
Daily or almost daily	41 (6)	28 (4)	21 (3)	--	32 (4)
A couple of times each week	59 (9)	61 (8)	57 (8)	--	83 (9)
Less than weekly	95 (15)	63 (9)	83 (12)	--	90 (10)
Once last month	87 (13)	127 (17)	122 (18)	--	143 (16)
Not in the last month	341 (53)	430 (59)	364 (53)	--	521 (58)
Not reported	23 (4)	20 (3)	36 (5)	--	30 (3)

* Not asked in this form in 2007

Table 58 Number (percentage) of respondents by injecting equipment use, re-use and cleaning last month

Use, re-use and cleaning of any item*	Used	Re-used	Cleaned**
N° surveyed***	N=767	N=767	N=767
Yes	700 (91)	369 (48)	358 (47)
No	16 (2)	331 (43)	347 (45)
Not reported	51 (7)	67 (9)	62 (8)
Use, re-use and cleaning by item type#			
1ml	586 (76)	240 (31)	235 (31)
3 ml	126 (16)	43 (6)	44 (6)
5 ml	173 (23)	72 (9)	80 (10)
10 ml	57 (7)	43 (6)	45 (6)
20 ml	36 (5)	26 (3)	32 (4)
Detachable needle (tip)	157 (20)	43 (6)	47 (6)
Winged vein infusion set (butterfly)	71 (9)	46 (6)	42 (5)
Wheel filter	48 (6)	13 (2)	11 (1)

* New question in 2008

** Includes 34 respondents that reported cleaning but not re-use in the last month

More than one item could be selected

*** Excludes respondents that did not inject in the last month

New South Wales

Table 59 Number (percentage) of respondents by sexual behaviour in the month prior to survey and year of survey

Sexual behaviour	2004	2005	2006	2007	2008
N ^o surveyed	N = 646	N=729	N=683	N=701	N=899
Sex with a regular partner last month (%)**					
No	--	314 (43)	288 (42)	300 (43)	392 (44)
Yes	--	397 (54)	376 (55)	375 (54)	481 (54)
Not reported	--	18 (2)	19 (3)	26 (4)	26 (3)
Condom used with regular partner last month (%)**					
N ^o surveyed		N=397	N=376	N=375	N=481
Never	--	277 (70)	259 (69)	275 (73)	330 (69)
Sometimes	--	59 (15)	51 (14)	38 (10)	61 (13)
Every time	--	46 (12)	28 (7)	49 (13)	69 (14)
Not reported	--	15 (4)	38 (10)	13 (3)	21 (4)
Sex with other partner/s last month (%)**					
No	--	583 (80)	525 (77)	570 (81)	705 (78)
Yes	--	125 (17)	124 (18)	100 (14)	165 (18)
Not reported	--	21 (3)	34 (5)	31 (4)	29 (3)
Condom used with other partner/s last month (%)**					
N ^o surveyed		N=125	N=124	N=100	N=165
Never	--	31 (25)	26 (21)	28 (28)	38 (23)
Sometimes	--	34 (27)	38 (31)	17 (17)	39 (24)
Every time	--	56 (45)	53 (43)	47 (47)	79 (48)
Not reported	--	4 (3)	7 (6)	8 (8)	9 (5)
Sex work last month (%)					
No	568 (88)	660 (91)	586 (86)	618 (88)	771 (86)
Yes	65 (10)	52 (7)	59 (9)	50 (7)	78 (9)
Not reported	13 (2)	17 (2)	38 (6)	33 (5)	50 (6)
Condom used at last sex work last month (%)*					
Yes	59 (94)	72 (94)	49 (88)	47 (98)	57 (84)

* Percentages exclude missing data

** New variable format commenced in 2005

Table 60 Number (percentage) of respondents reporting previous testing for HIV and HCV infection and HCV treatment by year of survey

	2004	2005	2006	2007	2008
N ^o surveyed	N = 646	N=729	N=683	N=701	N=899
Previous HIV test (%)					
Yes, last year	411 (64)	436 (60)	409 (60)	392 (56)	443 (49)
> 1 year ago	176 (27)	226 (31)	199 (29)	228 (33)	334 (37)
Never tested	54 (8)	64 (9)	60 (9)	65 (9)	73 (8)
Not reported	5 (1)	3 (0)	15 (2)	16 (2)	49 (5)
Previous HCV test (%)					
Yes, last year	429 (66)	452 (62)	420 (61)	420 (60)	494 (55)
> 1 year ago	165 (26)	211 (29)	203 (30)	215 (31)	327 (36)
Never tested	45 (7)	64 (9)	47 (7)	52 (7)	45 (5)
Not reported	7 (1)	2 (0)	13 (2)	14 (2)	33 (4)
Any treatment for HCV (%)					
Interferon	9 (3)	16 (4)	8 (2)	2 (<1)	24 (4)
Interferon+Ribarvarin	7 (2)	3 (1)	9 (2)	10 (3)	29 (5)
Other	13 (4)	4 (1)	8 (2)	4 (1)	5 (1)
No treatment	302 (88)	346 (93)	327 (90)	312 (91)	470 (86)
Not reported	10 (3)	3 (1)	11 (3)	16 (5)	18 (3)
Current treatment for HCV					
	N = 6	N=3	N=7	N=3	N=13
Interferon/Interferon+Ribarvirin	3	3	3	2	9
Other	3	---	4	1	4

HIV antibody prevalence

Table 61 HIV antibody prevalence by gender and year of survey

Year of survey	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2004	407	6 (1.5)	194	1 (0.5)	606	7 (1.2)
2005	436	6 (1.4)	243	0 (0.0)	685	6 (0.9)
2006	424	12 (2.8)	232	1 (0.4)	663	14 (2.1)
2007	439	12 (2.7)	240	2 (0.8)	683	15 (2.2)
2008	563	15 (2.7)	297	3 (1.0)	867	19 (2.2)
χ^2 trend p value		0.096		0.196		0.031

* Total includes people whose gender was not reported or reported as transgender

Table 62 HIV antibody prevalence by sexual identity, gender and year of survey

Sexual identity	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2004						
Heterosexual	345	0 (0.0)	141	1 (0.7)	487	1 (0.2)
Bisexual	15	0 (0.0)	33	0 (0.0)	48	0 (0.0)
Homosexual	14	6 (42.9)	11	0 (0.0)	25	6 (24.0)
p value		<0.001		1.0		<0.001
2005						
Heterosexual	386	1 (0.3)	171	0 (0.0)	557	1 (0.2)
Bisexual	10	0 (0.0)	44	0 (0.0)	55	0 (0.0)
Homosexual	24	5 (20.8)	16	0 (0.0)	44	5 (11.4)
p value		<0.001		---		<0.001
2006						
Heterosexual	366	2 (0.6)	170	1 (0.6)	537	3 (0.6)
Bisexual	23	3 (13.0)	38	0 (0)	64	4 (6.3)
Homosexual	27	7 (25.9)	16	0 (0)	44	7 (15.9)
p value		<0.001		1.000		<0.001
2007						
Heterosexual	383	4 (1.0)	174	2 (1.2)	558	6 (1.1)
Bisexual	21	0 (0.0)	42	0 (0.0)	64	1 (1.6)
Homosexual	25	8 (32.0)	19	0 (0.0)	44	8 (18.2)
p value		<0.001		1.000		<0.001
2008						
Heterosexual	488	2 (0.4)	202	1 (0.5)	691	3 (0.4)
Bisexual	25	0 (0.0)	63	2 (3.2)	89	3 (3.4)
Homosexual	31	13 (41.9)	21	0 (0.0)	54	13 (24.1)
p value		<0.001		0.207		<0.001

* Total includes people whose gender was not reported or reported as transgender

Table 63 HIV antibody prevalence by age group, gender and year of survey

Age group	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2004						
< 20 years	10	0 (0.0)	6	0 (0.0)	16	0 (0.0)
20 – 24	53	0 (0.0)	30	1 (3.3)	83	1 (1.2)
25 – 29	75	1 (1.3)	38	0 (0.0)	115	1 (0.9)
30 + years	268	5 (1.9)	120	0 (0.0)	391	5 (1.3)
p value		0.9		0.2		1.0
2005						
< 20 years	6	0 (0.0)	5	0 (0.0)	11	0 (0.0)
20 – 24	36	1 (2.8)	34	0 (0.0)	70	1 (1.4)
25 – 29	63	0 (0.0)	57	0 (0.0)	121	0 (0.0)
30 + years	331	5 (1.5)	147	0 (0.0)	483	5 (1.0)
p value		0.7		---		0.7
2006						
< 20 years	3	0 (0)	6	0 (0)	9	0 (0.0)
20 – 24	31	1 (3.2)	19	0 (0)	50	1 (2.0)
25 – 29	67	0 (0)	42	0 (0)	111	1 (0.9)
30 + years	322	11 (3.4)	163	1 (0.6)	490	12 (2.7)
p value		0.353		1.000		0.576
2007						
< 20 years	3	0 (0.0)	5	0 (0.0)	8	0 (0.0)
20 – 24	25	0 (0.0)	23	0 (0.0)	48	0 (0.0)
25 – 29	59	3 (5.1)	40	0 (0.0)	100	3 (3.0)
30 + years	352	9 (2.6)	172	2 (1.2)	527	12 (2.3)
p value		0.518		1.000		0.684
2008						
< 20 years	5	0 (0.0)	5	0 (0.0)	10	0 (0.0)
20 – 24	40	0 (0.0)	29	0 (0.0)	69	0 (0.0)
25 – 29	66	1 (1.5)	45	2 (4.4)	113	4 (3.5)
30 + years	449	14 (3.1)	218	1 (0.5)	672	15 (2.2)
p value		0.718		0.135		0.455

* Total includes people whose gender was not reported or reported as transgender

Table 64 HIV antibody prevalence by duration of drug injection, gender and year of survey

Duration of drug injection	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2004						
<3 years	26	2 (7.7)	17	0 (0.0)	43	2 (4.7)
3 to 5 years	44	0 (0.0)	18	0 (0.0)	62	0 (0.0)
6 to 10 years	106	0 (0.0)	50	0 (0.0)	157	0 (0.0)
10 + years	223	4 (1.8)	107	1 (0.9)	331	5 (1.5)
p value		0.06		1.0		0.07
2005						
<3 years	19	0 (0.0)	10	0 (0.0)	30	0 (0.0)
3 to 5 years	35	2 (5.7)	18	0 (0.0)	53	2 (3.8)
6 to 10 years	42	0 (0.0)	49	0 (0.0)	92	0 (0.0)
10 + years	324	2 (0.6)	157	0 (0.0)	485	2 (0.4)
p value		0.03		---		0.02
2006						
<3 years	19	1 (5.3)	11	0 (0)	30	1 (3.3)
3 to 5 years	27	1 (3.7)	18	0 (0)	45	1 (2.2)
6 to 10 years	67	2 (3.0)	47	1 (2.1)	118	4 (3.4)
10 + years	292	8 (2.7)	149	0 (0)	444	8 (1.8)
p value		0.576		0.338		0.437
2007						
<3 years	11	0 (0.0)	11	0 (0.0)	22	0 (0.0)
3 to 5 years	31	1 (3.2)	19	0 (0.0)	51	1 (1.0)
6 to 10 years	61	0 (0.0)	42	0 (0.0)	104	0 (0.0)
10 + years	326	11 (3.4)	158	2 (1.3)	486	14 (2.9)
p value		0.520		1.000		0.312
2008						
<3 years	33	3 (9.1)	15	0 (0.0)	48	3 (6.3)
3 to 5 years	44	2 (4.6)	15	0 (0.0)	59	2 (3.4)
6 to 10 years	70	0 (0.0)	49	0 (0.0)	120	0 (0.0)
10 + years	400	10 (2.5)	217	3 (1.4)	622	14 (2.3)
p value		0.049		1.000		0.047

* Total includes people whose gender was not reported or reported as transgender

Table 65 HIV antibody prevalence by last drug injected, gender and year of survey

Last drug injected	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2004						
Heroin	216	2 (0.9)	86	0 (0.0)	304	2 (0.7)
Meth/Amphetamine	82	3 (3.7)	54	1 (1.9)	136	4 (2.9)
More than one	21	1 (4.8)	10	0 (0.0)	31	1 (3.2)
Other/Not reported	88	0 (0.0)	44	0 (0.0)	135	0 (0.0)
p value		0.09		0.6		0.05
2005						
Heroin	183	2 (1.1)	109	0 (0.0)	286	2 (0.7)
Meth/Amphetamine	101	3 (3.0)	65	0 (0.0)	170	3 (1.8)
More than one	7	0 (0.0)	23	0 (0.0)	11	0 (0.0)
Other/Not reported	146	1 (0.7)	46	0 (0.0)	219	1 (0.5)
p value		0.392		---		0.6
2006						
Heroin	133	2 (1.5)	88	0 (0.0)	223	2 (0.9)
Meth/Amphetamine	124	8 (6.5)	64	0 (0.0)	192	9 (4.7)
More than one	5	0 (0.0)	4	0 (0.0)	9	0 (0.0)
Other/Not reported	162	2 (1.2)	76	1 (1.3)	239	3 (1.3)
p value		.057		0.621		0.055
2007						
Heroin	153	4 (2.6)	91	0 (0.0)	246	4 (1.6)
Meth/Amphetamine	109	4 (3.7)	71	1 (1.4)	180	5 (2.8)
More than one	13	0 (0.0)	5	0 (0.0)	18	0 (0.0)
Other/Not reported	164	4 (2.4)	73	1 (1.4)	239	6 (2.5)
p value		0.871		0.543		0.762
2008						
Heroin	218	1 (0.5)	116	1 (0.9)	335	2 (0.6)
Meth/Amphetamine	138	11 (8.0)	75	1 (1.3)	217	13 (6.0)
More than one	15	0 (0.0)	6	1 (16.7)	21	1 (4.8)
Other/Not reported	192	3 (1.6)	100	0 (0.0)	294	3 (1.0)
p value		0.001		0.043		<0.001

* Total includes people whose gender was not reported or reported as transgender

Table 66 HIV antibody prevalence by frequency of drug injection last month, gender and year of survey

Frequency of drug injection last month	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2004						
Not last month	22	0 (0.0)	14	0 (0.0)	38	0 (0.0)
Less than weekly	67	0 (0.0)	44	0 (0.0)	111	0 (0.0)
Weekly not daily	100	5 (5.0)	52	0 (0.0)	152	5 (3.3)
Daily or more	212	1 (0.5)	83	1 (1.2)	297	2 (0.7)
p value		0.02		1.0		0.07
2005						
Not last month	208	0 (0.0)	127	0 (0.0)	336	0 (0.0)
Less than weekly	116	3 (2.6)	53	0 (0.0)	171	3 (1.8)
Weekly not daily	68	3 (4.4)	38	0 (0.0)	108	3 (2.8)
Daily or more	43	0 (0.0)	22	0 (0.0)	66	0 (0.0)
p value		0.03		---		0.02
2006						
Not last month	49	1 (2.0)	36	1 (2.8)	86	2 (2.3)
Less than weekly	77	2 (2.6)	50	0 (0.0)	127	2 (1.6)
Weekly not daily	119	6 (5.0)	45	0 (0.0)	166	6 (3.6)
Daily or more	172	3 (1.7)	99	0 (0.0)	275	4 (1.5)
p value		0.433		0.157		0.483
2007						
Not last month	47	2 (4.3)	32	0 (0.0)	80	2 (2.5)
Less than weekly	87	1 (1.2)	47	1 (2.1)	134	2 (1.5)
Weekly not daily	99	3 (3.0)	59	0 (0.0)	161	4 (2.5)
Daily or more	196	6 (3.1)	96	1 (1.0)	292	7 (2.4)
p value		0.713		0.625		0.927
2008						
Not last month	77	3 (3.9)	45	1 (2.2)	123	4 (3.3)
Less than weekly	96	5 (5.2)	41	0 (0.0)	140	5 (3.6)
Weekly not daily	148	3 (2.0)	73	1 (1.4)	222	4 (1.8)
Daily or more	239	4 (1.7)	135	1 (0.7)	376	6 (1.6)
p value		0.252		0.842		0.396

* Total includes people whose gender was not reported or reported as transgender

New South Wales

Table 67 HIV antibody prevalence by re-use of someone else's used needle & syringe last month, gender and year of survey

Re-used someone else's used needle & syringe last month	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2004						
No	290	4 (1.4)	152	1 (0.7)	442	5 (1.1)
Yes	77	1 (1.3)	23	0 (0.0)	102	1 (1.0)
p value		1.0		1.0		1.0
2005						
No	321	6 (1.9)	176	0 (0.0)	501	6 (1.2)
Yes	54	0 (0.0)	34	0 (0.0)	89	0 (0.0)
p value		0.3		---		0.3
2006						
No	294	9 (3.1)	166	0 (0)	464	9 (1.9)
Yes	56	2 (3.6)	22	0 (0)	79	3 (3.8)
p value		0.691		---		0.396
2007						
No	306	6 (2.0)	165	2 (1.2)	474	9 (1.9)
Yes	56	4 (7.1)	26	0 (0.0)	82	4 (4.9)
p value		0.053		1.000		0.110
2008						
No	388	11 (2.8)	190	2 (1.1)	584	14 (2.4)
Yes	79	1 (1.3)	52	0 (0.0)	131	1 (0.8)
p value		0.700		1.000		0.328

* Total includes people whose gender was not reported or reported as transgender

Table 68 HIV antibody prevalence by imprisonment last year, gender and year of survey

Imprisonment last year	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2004						
No	287	5 (1.7)	167	0 (0.0)	458	5 (1.1)
Yes	117	1 (0.9)	25	1 (4.0)	143	2 (1.4)
p value		0.7		0.1		0.7
2005						
No	327	6 (1.8)	201	0 (0.0)	533	6 (1.1)
Yes	90	0 (0.0)	34	0 (0.0)	125	0 (0.0)
p value		0.2		---		0.2
2006						
No	331	12 (3.6)	200	1 (0.5)	538	14 (2.6)
Yes	66	0 (0.0)	27	0 (0.0)	93	0 (0.0)
p value		0.230		1.000		0.242
2007						
No	342	10 (2.9)	205	2 (1.0)	550	12 (2.2)
Yes	76	2 (2.6)	26	0 (0.0)	102	2 (2.0)
p value		1.000		1.000		1.000
2008						
No	416	14 (3.4)	240	0 (0.0)	662	15 (2.3)
Yes	98	1 (1.0)	32	2 (6.3)	131	3 (2.3)
p value		0.323		0.013		1.000

* Total includes people whose gender was not reported or reported as transgender

Table 69 HIV antibody prevalence by condom use at last sex, gender and year of survey

Condom use at last sex	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2004						
No	251	4 (1.6)	129	1 (0.8)	385	5 (1.3)
Yes	148	2 (1.4)	60	0 (0.0)	208	2 (1.0)
p value		1.0		1.0		1.0
2005**						
No	164	0 (0.0)	113	0 (0.0)	277	0 (0.0)
Yes	84	2 (2.4)	39	0 (0.0)	125	2 (1.6)
p value		0.05		---		0.04
2006						
No	190	2 (1.1)	113	0 (0.0)	306	3 (1.0)
Yes	15	1 (6.7)	12	0 (0.0)	27	1 (3.7)
p value		0.205		---		0.288
2007						
No	181	2 (1.1)	119	2 (1.7)	303	5 (1.7)
Yes	29	1 (3.5)	19	0 (0.0)	48	1 (2.1)
p value		0.361		1.000		0.589
2008						
No	226	1 (0.4)	150	0 (0.0)	378	1 (0.3)
Yes	43	1 (2.3)	22	1 (4.6)	67	3 (1.5)
p value		0.295		0.128		0.012

* Total includes people whose gender was not reported or reported as transgender

** Question changed to "condom use with regular partner in last month" in 2005.

Table 70 HIV antibody prevalence by sex work last month, gender and year of survey

Sex work last month	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2004						
No	376	5 (1.3)	151	1 (0.7)	531	6 (1.1)
Yes	25	1 (4.0)	37	0 (0.0)	63	1 (1.6)
p value		0.3		1.0		0.5
2005						
No	415	5 (1.2)	202	0 (0.0)	621	5 (0.8)
Yes	12	1 (8.3)	35	0 (0.0)	49	1 (2.0)
p value				---		0.4
2006						
No	383	10 (2.6)	182	1 (0.6)	568	11 (1.9)
Yes	18	2 (11.1)	36	0 (0.0)	58	3 (5.0)
p value		0.096		1.000		0.132
2007						
No	407	11 (2.7)	190	2 (1.1)	600	13 (2.2)
Yes	9	1 (11.1)	40	0 (0.0)	50	2 (4.0)
p value		0.234		1.000		0.323
2008						
No	511	13 (2.5)	229	3 (1.3)	745	16 (2.2)
Yes	23	2 (8.7)	49	0 (0.0)	73	3 (4.1)
p value		0.133		1.000		0.236

* Total includes people whose gender was not reported or reported as transgender

New South Wales

Table 71 HIV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and year of survey

Aboriginal and Torres Strait Islander origin	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2004						
No	353	5 (1.4)	160	0 (0.0)	516	5 (1.0)
Yes	42	1 (2.4)	29	1 (3.5)	73	2 (2.7)
p value		0.5		0.2		0.2
2005						
No	369	6 (1.6)	185	0 (0.0)	559	6 (1.1)
Yes	54	0 (0.0)	48	0 (0.0)	103	0 (0.0)
p value		0.4		---		0.3
2006						
No	372	12 (3.2)	176	1 (0.6)	554	14 (2.5)
Yes	39	0 (0.0)	47	0 (0.0)	86	0 (0.0)
p value		0.615		1.000		0.235
2007						
No	366	10 (2.8)	190	2 (1.1)	559	12 (2.2)
Yes	56	1 (1.8)	47	0 (0.0)	104	2 (1.9)
p value		1.000		1.000		1.000
2008						
No	469	13 (2.8)	234	1 (0.4)	709	15 (2.1)
Yes	71	1 (1.4)	54	2 (3.7)	126	3 (2.4)
p value		1.000		0.091		0.744

* Total includes people whose gender was not reported or reported as transgender

Table 72 HIV antibody prevalence by region/country of birth, gender and year of survey

Region/Country of birth	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2004						
Australia	259	6 (2.3)	158	1 (0.6)	420	7 (1.7)
Other Oceania	4	0 (0.0)	12	0 (0.0)	16	0 (0.0)
Asia	100	0 (0.0)	12	0 (0.0)	112	0 (0.0)
UK & Ireland	14	0 (0.0)	3	0 (0.0)	17	0 (0.0)
Other	21	0 (0.0)	6	0 (0.0)	28	0 (0.0)
p value		0.6		1.0		0.7
2005						
Australia	368	5 (1.4)	216	0 (0.0)	588	5 (0.9)
Other Oceania	13	1 (7.7)	8	0 (0.0)	23	1 (4.4)
Asia	4	0 (0.0)	---	---	4	0 (0.0)
UK & Ireland	21	0 (0.0)	10	0 (0.0)	31	0 (0.0)
Other	26	0 (0.0)	6	0 (0.0)	32	0 (0.0)
p value		0.3		---		0.4
2006						
Australia	347	11 (3.2)	208	1 (0.5)	559	12 (2.2)
Other Oceania	17	0 (0.0)	11	0 (0.0)	29	1 (3.5)
Asia	3	0 (0.0)	1	0 (0.0)	4	0 (0.0)
UK & Ireland	28	0 (0.0)	7	0 (0.0)	35	0 (0.0)
Other	23	1 (4.4)	3	0 (0.0)	26	1 (3.9)
p value		0.793		1.000		0.503
2007						
Australia	365	11 (3.0)	208	2 (1.0)	576	14 (2.4)
Other Oceania	9	1 (11.1)	8	0 (0.0)	18	1 (5.6)
Asia	5	0 (0.0)	5	0 (0.0)	10	0 (0.0)
UK & Ireland	19	0 (0.0)	7	0 (0.0)	26	0 (0.0)
Other	28	0 (0.0)	9	0 (0.0)	37	0 (0.0)
p value		0.461		1.000		0.643
2008						
Australia	485	12 (2.5)	266	3 (1.1)	755	15 (2.0)
Other Oceania	14	2 (14.3)	10	0 (0.0)	26	3 (11.2)
Asia	5	0 (0.0)	1	0 (0.0)	6	0 (0.0)
UK & Ireland	25	0 (0.0)	9	0 (0.0)	35	0 (0.0)
Other	27	1 (3.7)	7	0 (0.0)	34	1 (2.9)
p value		0.135		1.000		0.063

* Total includes people whose gender was not reported or reported as transgender

New South Wales

Table 73 HIV antibody prevalence by main language spoken at home by parents, gender and year of survey

Main language spoken at home by parents	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2004						
English speaking	183	2 (1.1)	134	1 (0.8)	319	3 (0.9)
Non-English speaking	114	0 (0.0)	24	0 (0.0)	138	0 (0.0)
p value		0.5		1.0		0.6
2005						
English speaking	366	6 (1.6)	218	0 (0.0)	589	6 (1.0)
Non-English speaking	70	0 (0.0)	25	0 (0.0)	96	0 (0.0)
p value		0.3		---		0.3
2006						
English speaking	361	11 (3.1)	214	1 (0.5)	581	13 (2.2)
Non-English speaking	42	1 (2.4)	12	0 (0.0)	54	1 (1.9)
p value		1.000		1.000		1.000
2007						
English speaking	403	12 (3.0)	225	2 (0.9)	632	15 (2.4)
Non-English speaking	23	0 (0.0)	14	0 (0.0)	37	0 (0.0)
p value		1.000		1.000		1.000
2007						
English speaking	525	15 (2.9)	284	3 (1.1)	816	19 (2.3)
Non-English speaking	28	0 (0.0)	8	0 (0.0)	36	0 (0.0)
p value		1.000		1.000		1.000

* Total includes people whose gender was not reported or reported as transgender

HCV antibody prevalence

Table 74 HCV antibody prevalence by gender and year of survey

Year of survey	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004	409	288 (70)	197	141 (72)	611	433 (71)
2005	439	302 (69)	243	168 (69)	688	474 (69)
2006	424	292 (69)	232	173 (75)	663	468 (71)
2007	428	289 (68)	231	169 (73)	663	460 (69)
2008	539	379 (70)	281	208 (74)	827	591 (71)
χ^2 trend p value		0.914		0.315		0.677

* Total includes people whose gender was not reported or reported as transgender

Table 75 HCV antibody prevalence by sexual identity, gender and year of survey

Sexual identity	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Heterosexual	347	242 (70)	144	104 (72)	492	346 (70)
Bisexual	15	8 (53)	33	25 (76)	48	33 (69)
Homosexual	14	10 (71)	11	7 (64)	25	17 (68)
p value		0.4		0.7		0.9
2005						
Heterosexual	389	270 (69)	171	112 (66)	560	382 (68)
Bisexual	10	7 (70)	44	34 (77)	55	42 (76)
Homosexual	24	15 (63)	16	13 (81)	44	31 (70)
p value		0.8		0.2		0.5
2006						
Heterosexual	366	263 (72)	170	130 (76)	537	393 (73)
Bisexual	23	14 (61)	38	27 (71)	64	41 (64)
Homosexual	27	11 (41)	16	9 (56)	44	21 (48)
p value		0.003		0.191		0.001
2007						
Heterosexual	374	264 (71)	166	121 (73)	541	386 (71)
Bisexual	20	11 (55)	41	34 (83)	62	45 (73)
Homosexual	24	8 (33)	19	9 (47)	43	17 (40)
p value		<0.001		0.020		<0.001
2008						
Heterosexual	468	337 (72)	191	144 (75)	660	481 (73)
Bisexual	24	17 (71)	59	45 (76)	84	62 (74)
Homosexual	29	12 (41)	20	13 (65)	51	26 (51)
p value		0.003		0.564		0.005

* Total includes people whose gender was not reported or reported as transgender

New South Wales

Table 76 HCV antibody prevalence by age group, gender and year of survey

Age group	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
< 20 years	10	4 (40)	6	1 (17)	16	5 (31)
20 – 24	53	26 (49)	31	20 (65)	84	46 (55)
25 – 29	76	48 (63)	38	22 (58)	116	72 (62)
30 + years	269	209 (78)	122	98 (80)	394	309 (78)
p value		<0.001		0.001		<0.001
2005						
< 20 years	6	1 (17)	5	2 (40)	11	3 (27)
20 – 24	36	12 (33)	34	24 (71)	70	36 (51)
25 – 29	63	39 (62)	57	34 (60)	121	74 (61)
30 + years	334	250 (75)	147	108 (73)	486	361 (74)
p value		<0.001		0.1		<0.001
2006						
< 20 years	3	1 (33)	6	4 (67)	9	5 (56)
20 – 24	31	16 (52)	19	14 (74)	50	30 (60)
25 – 29	67	39 (58)	42	30 (71)	111	69 (62)
30 + years	322	236 (73)	163	123 (75)	490	362 (74)
p value		0.004		0.868		0.015
2007						
< 20 years	3	0 (0.0)	5	3 (60)	8	3 (38)
20 – 24	22	6 (27)	22	13 (50)	44	19 (43)
25 – 29	56	27 (48)	39	25 (64)	96	53 (55)
30 + years	347	256 (74)	165	128 (78)	515	385 (75)
p value		<0.001		0.090		<0.001
2008						
< 20 years	5	2 (40)	5	3 (60)	10	5 (50)
20 – 24	38	13 (34)	29	19 (66)	67	32 (48)
25 – 29	60	37 (62)	44	29 (66)	106	67 (63)
30 + years	433	326 (75)	203	157 (77)	641	486 (76)
p value		<0.001		0.179		<0.001

* Total includes people whose gender was not reported or reported as transgender

Table 77 HCV antibody prevalence by duration of drug injection, gender and year of survey

Duration of drug injection	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
<3 years	26	8 (31)	17	4 (24)	43	12 (28)
3 to 5 years	44	23 (52)	18	6 (33)	62	29 (47)
6 to 10 years	107	74 (69)	51	36 (71)	159	111 (70)
10 + years	224	177 (79)	109	93 (85)	334	271 (81)
p value		<0.001		<0.001		<0.001
2005						
<3 years	33	10 (30)	19	12 (63)	53	22 (42)
3 to 5 years	35	13 (37)	18	7 (39)	53	20 (38)
6 to 10 years	42	22 (52)	49	33 (67)	92	56 (61)
10 + years	313	245 (78)	148	110 (74)	465	358 (77)
p value		<0.001		0.02		<0.001
2006						
<3 years	19	2 (11)	11	3 (27)	30	5 (17)
3 to 5 years	27	11 (41)	18	7 (39)	45	18 (40)
6 to 10 years	67	38 (57)	47	37 (79)	118	76 (64)
10 + years	292	231 (79)	149	121 (81)	444	354 (80)
p value		<<0.001		<<0.001		<<0.001
2007						
<3 years	11	1 (9)	11	4 (36)	22	5 (23)
3 to 5 years	31	11 (35)	18	15 (83)	50	27 (54)
6 to 10 years	57	24 (42)	40	24 (60)	98	48 (49)
10 + years	319	247 (77)	153	119 (78)	474	367 (77)
p value		<0.001		0.004		<0.001
2008						
<3 years	33	8 (24)	14	7 (50)	47	15 (32)
3 to 5 years	42	17 (40)	15	10 (67)	57	27 (47)
6 to 10 years	64	38 (59)	48	30 (63)	113	68 (60)
10 + years	386	309 (80)	203	161 (79)	594	473 (80)
p value		<0.001		0.011		<0.001

* Total includes people whose gender was not reported or reported as transgender

New South Wales

Table 78 HCV antibody prevalence by last drug injected, duration of drug injection and year of survey

Last drug injected	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Heroin	20	7 (35)	284	215 (76)	307	225 (73)
Meth/Amphetamine	12	2 (17)	123	80 (65)	137	84 (61)
More than one	1	1 (100)	29	23 (79)	32	26 (81)
Other/Not reported	10	2 (20)	119	93 (78)	135	98 (73)
p value		0.3		0.07		0.03
2005						
Heroin	14	5 (36)	272	202 (74)	286	207 (72)
Meth/Amphetamine	13	5 (38)	158	93 (59)	171	98 (57)
More than one	0	0 (0)	11	10 (91)	11	10 (91)
Other/Not reported	25	11 (44)	196	148 (76)	221	159 (72)
p value		0.934		0.001		0.001
2006						
Heroin	133	100 (75)	88	71 (81)	223	172 (77)
Meth/Amphetamine	124	72 (58)	64	39 (61)	192	112 (58)
More than one	5	5 (100)	4	4 (100)	9	9 (100)
Other/Not reported	162	115 (71)	76	59 (78)	239	175 (73)
p value		0.009		0.027		<<0.001
2007						
Heroin	10	2 (20)	229	163 (71)	241	167 (69)
Meth/Amphetamine	6	3 (50)	162	110 (68)	172	116 (67)
More than one	---	---	11	7 (64)	18	10 (56)
Other/Not reported	6	0 (0.0)	220	162 (74)	323	167 (72)
p value		0.119		0.594		0.430
2008						
Heroin	10	3 (30)	305	240 (79)	319	245 (77)
Meth/Amphetamine	11	3 (27)	195	123 (63)	209	126 (60)
More than one	---	---	18	17 (94)	18	17 (94)
Other/Not reported	26	9 (35)	246	188 (76)	281	203 (72)
p value		1.000		<0.001		<0.001

* Total includes people who did not report duration of drug injection

Table 79 HCV antibody prevalence by frequency of injection last month, duration of drug injection and year of survey

Frequency of drug injection last month	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Less than daily	13	3 (23)	248	177 (71)	265	184 (69)
Daily or more	24	9 (38)	271	205 (76)	299	218 (73)
p value		0.5		0.3		0.4
2005						
Less than daily	30	10 (33)	304	207 (68)	347	225 (65)
Daily or more	20	11 (55)	305	226 (74)	337	247 (73)
p value		0.1		0.1		0.02
2006						
Less than daily	16	0 (0)	269	199 (74)	293	201 (69)
Daily or more	11	3 (27)	251	183 (73)	275	197 (72)
p value		0.056		0.843		0.464
2007						
Less than daily	11	2 (18)	272	202 (74)	287	208 (72)
Daily or more	10	3 (30)	265	180 (68)	282	189 (67)
p value		0.635		0.107		0.171
2008						
Less than daily	23	3 (13)	318	224 (70)	344	229 (67)
Daily or more	15	8 (53)	332	263 (79)	357	277 (78)
p value		0.012		0.011		0.001

* Total includes people who did not report duration of drug injection

Table 80 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and year of survey

Re-used someone else's used needle & syringe last month	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
No	27	7 (26)	412	304 (74)	446	318 (71)
Yes	9	5 (56)	92	66 (72)	102	72 (71)
p value		0.1		0.7		0.9
2005						
No	33	12 (36)	452	316 (70)	503	342 (68)
Yes	9	6 (67)	77	63 (82)	89	71 (80)
p value		0.1		0.03		0.03
2006						
No	24	3 (13)	429	313 (73)	464	320 (69)
Yes	2	0 (0)	69	53 (77)	79	61 (77)
p value		1.000		0.559		0.146
2007						
No	14	4 (29)	439	309 (70)	460	320 (70)
Yes	5	1 (20)	72	53 (74)	79	56 (71)
p value		1.000		0.675		0.895
2008						
No	30	7 (23)	515	379 (74)	558	394 (71)
Yes	6	4 (67)	114	89 (78)	120	93 (78)
p value		0.057		0.345		0.146

* Total includes people who did not report duration of drug injection

New South Wales

Table 81 HCV antibody prevalence by imprisonment last year, duration of drug injection and year of survey

Imprisonment last year	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
No	31	7 (23)	424	299 (71)	462	310 (67)
Yes	11	5 (45)	127	110 (87)	144	121 (84)
p value		0.1		<0.001		<0.001
2005						
No	44	15 (34)	473	323 (68)	535	350 (65)
Yes	6	5 (83)	113	93 (82)	126	104 (83)
p value		0.02		0.003		<0.001
2006						
No	26	4 (15)	492	347 (71)	538	361 (67)
Yes	3	1 (33)	86	76 (88)	93	80 (86)
p value		0.446		<<0.001		<<0.001
2007						
No	20	5 (25)	499	350 (70)	533	363 (68)
Yes	---	---	95	72 (76)	99	76 (77)
p value		---		0.323		0.096
2008						
No	39	11 (28)	582	412 (71)	632	428 (68)
Yes	4	2 (50)	118	100 (85)	125	104 (83)
p value		0.572		0.001		<0.001

* Total includes people who did not report duration of drug injection

Table 82 HCV antibody prevalence by sex work last month, duration of drug injection and year of survey

Sex work last month	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
No	41	11 (27)	483	354 (73)	536	374 (70)
Yes	1	1 (100)	61	48 (79)	63	50 (79)
p value		0.3		0.4		0.1
2005						
No	52	21 (40)	549	387 (70)	624	424 (68)
Yes	1	1 (100)	46	37 (80)	49	40 (82)
p value		0.2		0.2		0.05
2006						
No	26	4 (15)	520	388 (75)	568	404 (71)
Yes	2	1 (50)	54	37 (69)	58	39 (67)
p value		0.331		0.331		0.546
2007						
No	19	5 (26)	548	393 (72)	581	408 (70)
Yes	1	0 (0.0)	45	32 (71)	49	33 (67)
p value		1.000		1.000		0.746
2008						
No	41	12 (29)	659	483 (73)	714	502 (70)
Yes	3	2 (67)	64	50 (78)	68	52 (76)
p value		0.234		0.459		0.330

* Total includes people who did not report duration of drug injection

Table 83 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and year of survey

Aboriginal and Torres Strait Islander origin	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
No	354	246 (69)	162	117 (72)	519	366 (71)
Yes	43	33 (77)	30	21 (70)	75	55 (73)
p value		0.3		0.8		0.7
2005						
No	372	258 (69)	185	124 (67)	562	385 (69)
Yes	54	38 (70)	48	39 (81)	103	78 (76)
p value		0.8		0.06		0.1
2006						
No	372	257 (69)	176	125 (71)	554	384 (69)
Yes	39	27 (69)	47	42 89)(86	69 (80)
p value		1.000		0.008		0.041
2007						
No	358	239 (67)	184	135 (73)	545	376 (69)
Yes	54	42 (78)	44	31 (70)	99	73 (74)
p value		0.118		0.708		0.405
2008						
No	449	314 (70)	225	163 (72)	680	480 (71)
Yes	67	50 (75)	48	40 (83)	116	91 (78)
p value		0.475		0.146		0.094

* Total includes people whose gender was not reported or reported as transgender

Table 84 HCV antibody prevalence by region/country of birth, gender and year of survey

Region/Country of birth	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Australia	260	174 (67)	160	117 (73)	423	293 (69)
Other Oceania	4	3 (75)	12	8 (67)	16	11 (69)
Asia	101	79 (78)	12	6 (50)	113	85 (75)
UK & Ireland	14	9 (64)	3	3 (100)	17	12 (71)
Other	21	14 (67)	7	5 (71)	29	20 (69)
p value		0.3		0.4		0.8
2005						
Australia	371	252 (68)	216	148 (69)	591	403 (68)
Other Oceania	13	8 (62)	8	7 (88)	23	16 (70)
Asia	4	2 (50)	---	---	4	2 (50)
UK & Ireland	21	18 (86)	10	7 (70)	31	25 (81)
Other	26	19 (73)	6	3 (50)	32	22 (69)
p value		0.4		0.5		0.6
2006						
Australia	347	241 (69)	208	155 (75)	559	397 (71)
Other Oceania	17	12 (71)	11	9 (82)	29	21 (72)
Asia	3	3 (100)	1	0 (0)	4	3 (75)
UK & Ireland	28	19 (68)	7	4 (57)	35	23 (66)
Other	23	13 (57)	3	3 (100)	26	16 (62)
p value		0.616		0.292		0.792
2007						
Australia	356	237 (67)	200	145 (73)	559	384 (69)
Other Oceania	9	7 (78)	7	5 (71)	17	12 (71)
Asia	5	3 (60)	5	3 (60)	10	6 (60)
UK & Ireland	17	14 (82)	7	7 (100)	24	21 (88)
Other	28	21 (75)	9	7 (78)	37	28 (76)
p value		0.568		0.516		0.273
2008						
Australia	464	324 (70)	251	187 (75)	719	514 (71)
Other Oceania	14	10 (71)	9	5 (56)	25	15 (60)
Asia	5	5 (100)	1	0 (0)	6	5 (83)
UK & Ireland	24	17 (71)	9	7 (78)	34	25 (74)
Other	25	18 (72)	7	5 (71)	32	23 (72)
p value		0.796		0.356		0.761

* Total includes people whose gender was not reported or reported as transgender

Table 85 HCV antibody prevalence by main language spoken at home by parents, gender and year of survey

Main language spoken at home by parents	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
English speaking	184	121 (66)	135	103 (76)	321	225 (70)
Non-English speaking	115	85 (74)	25	13 (52)	140	98 (70)
p value		0.1		0.01		1.0
2005						
English speaking	369	253 (69)	218	151 (69)	592	407 (69)
Non-English speaking	70	49 (70)	25	17 (68)	96	67 (70)
p value		0.8		0.9		0.8
2006						
English speaking	361	253 (70)	214	159 (74)	581	414 (71)
Non-English speaking	42	25 (60)	12	8 (67)	54	33 (61)
p value		0.163		0.517		0.122
2007						
English speaking	392	266 (68)	216	158 (73)	612	426 (70)
Non-English speaking	23	16 (70)	14	10 (71)	37	26 (70)
p value		1.000		1.000		1.000
2008						
English speaking	503	352 (70)	268	197 (74)	778	553 (71)
Non-English speaking	27	21 (78)	8	7 (88)	35	28 (80)
p value		0.517		0.685		0.339

* Total includes people whose gender was not reported or reported as transgender

**Northern Territory
2004 - 2008**

Table 86 Number (percentage) of respondents by graphic characteristics and year of survey

Demographic characteristics	2004	2005	2006	2007	2008
Number of sites	1	3	1	1	2
N° surveyed	N=23	N=29	N=20	N=31	N=75
Response (%)	16	36	---	29	40
Gender (%)					
Male	16 (70)	19 (66)	9 (45)	22 (71)	48 (64)
Female	6 (26)	10 (34)	11 (55)	9 (29)	27 (36)
Transgender	1 (4)	---	---	---	---
Not reported	---	---	---	---	---
Sexual identity (%)					
Heterosexual	19 (83)	26 (90)	13 (65)	28 (90)	62 (83)
Bisexual	4 (17)	2 (7)	4 (20)	1 (3)	4 (5)
Homosexual	---	1 (3)	3 (15)	2 (6)	5 (7)
Not reported	---	---	---	---	4 (5)
Age and duration of injection (years)					
<i>Median age</i>	38	35	33	38	39
<i>Age range</i>	21-50	19-56	24-52	25-59	17-66
<i>Age group (%)</i>					
<25 years	2 (9)	4 (14)	1 (5)	---	3 (4)
25+ years	21 (91)	25 (86)	19 (95)	31 (100)	72 (96)
Not reported	---	---	---	---	---
<i>Median age 1st IDU</i>	18	20	19.5	17	18
<i>Age range</i>	13-35	11-41	14-30	12-42	13-58
Not reported	---	2	---	1	2
<i>Median years IDU</i>	19	15	11.5	18	16
<i>Range</i>	3-32	1-36	5-36	3-36	<1-35
<i>Duration of drug injection (%)</i>					
<3 years	---	2 (7)	---	---	1 (1)
3+ years	23 (100)	26 (90)	20 (100)	30 (97)	72 (96)
Not reported	---	1 (3)	---	1 (3)	2 (3)
Aboriginal and Torres Strait Islander origin (%)					
No	21 (92)	27 (93)	17 (85)	---	61 (81)
Yes	1 (4)	1 (3)	3 (15)	30 (97)	13 (17)
Not reported	1 (4)	1 (3)	---	1 (3)	1 (1)
Region/Country of birth (%)					
Australia	20 (87)	28 (97)	19 (95)	28 (90)	65 (87)
Other Oceania	---	---	1 (5)	1 (3)	2 (3)
Asia	1 (4)	---	---	---	---
UK & Ireland	---	---	---	1 (3)	3 (4)
Other	1 (4)	---	---	---	2 (3)
Not reported	1 (4)	1 (3)	---	1 (3)	3 (4)
Main language spoken at home by parents (%)					
English speaking	17 (74)	25 (86)	18 (90)	29 (94)	75 (100)
Non-English speaking	---	4 (14)	---	1 (3)	---
Not reported	6 (26)	---	2 (10)	1 (3)	---
Imprisonment last year (%)					
No	17 (74)	26 (90)	19 (95)	29 (94)	69 (92)
Yes	5 (22)	2 (7)	1 (5)	1 (3)	3 (4)
Not reported	1 (4)	1 (3)	---	1 (3)	3 (4)
Injected in prison (%)	N=5	N=2	N=1	N=1	N=3
Yes	3 (60)	1 (50)	0 (0)	1 (100)	0 (0)
Frequency of injection last month (%)					
Not last month	---	---	---	2 (6)	4 (5)
Less than weekly	4 (18)	5 (17)	5 (25)	3 (10)	8 (11)
Weekly not daily	1 (4)	2 (7)	4 (20)	6 (19)	11 (15)
Daily or more	18 (78)	22 (76)	11 (55)	20 (65)	52 (69)
Not reported	---	---	---	---	---

Table 87 Number (percentage) of respondents by last drug injected, injecting behaviour in the month prior to survey and year of survey

Injecting behaviour	2004	2005	2006	2007	2008
Last drug injected (%)	N=23	N=29	N=20	N=31	N=75
Anabolic steroids	---	---	---	---	---
Cocaine	---	---	---	---	---
Heroin	---	---	---	---	2 (3)
Methadone	1 (4)	4 (14)	---	5 (16)	4 (5)
Meth/Amphetamine	7 (30)	8 (28)	7 (35)	5 (16)	13 (17)
Morphine/Other Opioids	13 (57)	14 (48)	12 (60)	16 (52)	47 (63)
Subutex/Buprenorphine	---	1 (3)	---	4 (13)	1 (1)
More than one	2 (9)	---	1 (5)	---	2 (3)
Other	---	1 (3)	---	---	4 (5)
Not reported	---	1 (3)	---	1 (3)	2 (3)
N° Injected last month	N = 23	N=29	N=17	N=29	N=71
Places injected last month (%)*					
Own home	22 (96)	24 (83)	16 (94)	26 (93)	67 (94)
Friend's home	12 (52)	9 (31)	9 (53)	8 (29)	27 (38)
Dealer's home	5 (22)	2 (7)	4 (24)	1 (4)	9 (13)
Street, park, beach	1 (4)	2 (7)	3 (18)	1 (4)	7 (10)
Car	4 (17)	3 (10)	4 (24)	3 (11)	8 (11)
Public toilet	3 (13)	1 (3)	2 (12)	6 (21)	9 (13)
Commercial injecting room	---	---	---	---	---
Squat	1 (4)	2 (7)	---	---	1 (1)
Use of new sterile needles & syringes last month (%)					
All injections	21 (92)	26 (90)	15 (75)	26 (90)	61 (86)
Most of the time	1 (4)	1 (3)	4 (20)	2 (7)	9 (13)
Half of the time	1 (4)	2 (7)	---	1 (3)	---
Some of the time	---	---	---	---	1 (1)
Not last month	---	---	---	---	---
Not reported	---	---	1 (5)	---	---
Re-used another's used needle & syringe last month (%)					
None	23 (100)	27 (93)	18 (90)	26 (90)	65 (92)
Once	---	---	---	---	1 (1)
Twice	---	---	---	---	2 (3)
3-5 times	---	1 (3)	---	1 (3)	3 (4)
>5 times	---	---	1 (5)	---	---
Not reported	---	1 (3)	1 (5)	2 (7)	---
Number of people needle & syringe was re-used after last month (%)					
None	23 (100)	27 (93)	18 (90)	26 (90)	65 (92)
One	---	---	---	---	2 (3)
Two	---	1 (3)	---	---	1 (1)
Three to five	---	---	1 (5)	---	1 (1)
More than five	---	---	---	---	1 (1)
Don't know	---	---	---	---	1 (1)
Not reported	---	1 (3)	1 (5)	3 (10)	---
Relationship to people needle & syringe was re-used after last month (%)*					
Regular sex partner	---	---	1 (5)	---	3 (4)
Casual sex partner	---	---	---	---	---
Close friend	---	1 (3)	---	---	2 (3)
Acquaintance	---	1 (3)	1 (5)	---	2 (3)
Other	---	---	---	---	---
Equipment used after someone else last month (%)*					
Spoon	7 (30)	8 (28)	3 (16)	4 (17)	18 (26)
Water	2 (9)	4 (14)	---	1 (4)	5 (7)
Filter	5 (22)	3 (10)	2 (11)	1 (4)	6 (9)
Drug mix	---	5 (17)	1 (5)	1 (4)	5 (7)
Tourniquet	2 (9)	7 (24)	1 (5)	1 (4)	14 (21)
None**	---	---	14 (74)	16 (67)	38 (56)
Injected by someone after that person injected themselves or others last month (%)					
No	21 (91)	26 (90)	18 (90)	22 (76)	59 (83)
Yes	2 (9)	2 (7)	---	4 (14)	11 (15)
Not reported	---	1 (3)	2 (10)	3 (10)	1 (1)

* More than one option could be selected

** New variable in 2006

Northern Territory

Table 88 Number (percentage) of respondents by treatment for drug use and year of survey

Treatment for drug use	2004	2005	2006	2007	2008
N° surveyed	N=23	N=29	N=20	N=31	N=75
Any treatment/therapy for drug use (%)					
No	9 (39)	13 (45)	12 (60)	13 (42)	22 (29)
Yes	14 (61)	16 (55)	8 (40)	17 (55)	53 (71)
Not reported	---	---	---	1 (3)	---
History of methadone maintenance treatment					
Currently	5 (22)	4 (14)	1 (5)	4 (13)	12 (16)
Previously	3 (13)	10 (34)	2 (10)	10 (32)	18 (24)
Never	15 (65)	15 (52)	17 (85)	16 (52)	45 (60)
Not reported	---	---	---	1 (3)	---
History of buprenorphine (Subutex®) treatment (%)*					
Currently	--	--	--	--	13 (17)
Previously	--	--	--	--	20 (27)
Never	--	--	--	--	42 (56)
Not reported	--	--	--	--	---
History of buprenorphine-naloxone (Suboxone®) treatment (%)*					
Currently	--	--	--	--	5 (7)
Previously	--	--	--	--	15 (20)
Never	--	--	--	--	54 (72)
Not reported	--	--	--	--	1 (1)

* New variable in 2008

Table 89 Number (percentage) of respondents by site of needle and syringe acquisition last month and year of survey

Needle & Syringe acquisition	2004	2005	2006	2007*	2008
N° surveyed	N=23	N=29	N=20	--	N=75
From an NSP last month (%)					
Daily or almost daily	1 (4)	4 (14)	1 (5)	--	5 (7)
A couple of times each week	3 (13)	7 (24)	3 (15)	--	5 (7)
Less than weekly	5 (22)	8 (28)	7 (35)	--	19 (25)
Once last month	13 (57)	9 (31)	8 (40)	--	31 (41)
Not in the last month	1 (4)	1 (3)	1 (5)	--	15 (20)
Not reported	---	---	---	--	---
From a chemist last month (%)					
Daily or almost daily	---	---	1 (5)	--	2 (3)
A couple of times each week	2 (9)	---	---	--	1 (1)
Less than weekly	---	---	3 (15)	--	1 (1)
Once last month	3 (13)	5 (17)	2 (10)	--	13 (17)
Not in the last month	18 (78)	22 (76)	13 (65)	--	55 (73)
Not reported	---	2 (7)	1 (5)	--	3 (4)

* Not asked in this form in 2007

Table 90 Number (percentage) of respondents by injecting equipment use, re-use and cleaning last month

Use, re-use and cleaning of any item*	Used	Re-used	Cleaned**
N° surveyed ^{†***}	N=71	N=71	N=71
Yes	69 (97)	25 (35)	20 (28)
No	2 (3)	45 (63)	49 (69)
Not reported	0 (0)	1 (1)	2 (3)
Use, re-use and cleaning by item type#			
1ml	24 (34)	8 (11)	4 (6)
3 ml	38 (54)	8 (11)	10 (14)
5 ml	37 (52)	8 (11)	6 (8)
10 ml	6 (8)	0 (0)	0 (0)
20 ml	4 (6)	1 (1)	1 (1)
Detachable needle (tip)	32 (45)	5 (7)	5 (7)
Winged vein infusion set (butterfly)	5 (7)	1 (1)	0 (0)
Wheel filter	10 (14)	4 (6)	3 (4)

* New question in 2008

More than one item could be selected

** Includes 2 respondents that reported cleaning but not re-use in the last month

*** Excludes respondents that did not inject in the last month

Table 91 Number (percentage) of respondents by sexual behaviour in the month prior to survey and year of survey

Sexual behaviour	2004	2005	2006	2007	2008
N° surveyed	N=23	N=29	N=20	N=31	N=75
Sex with a regular partner last month (%) **					
No	--	16 (55)	8 (40)	16 (52)	42 (56)
Yes	--	12 (41)	12 (60)	13 (42)	33 (44)
Not reported	--	1 (3)	---	2 (6)	---
Condom used with regular partner last month (%)**					
N° surveyed		N=12	N=12	N=13	N=33
Never	--	8 (67)	9 (75)	10 (77)	24 (73)
Sometimes	--	1 (8)	---	---	---
Every time	--	1 (8)	1 (8)	3 (23)	8 (24)
Not reported	--	2 (17)	2 (17)	---	1 (3)
Sex with other partner/s last month (%)**					
No	--	25 (86)	16 (80)	24 (77)	66 (88)
Yes	--	4 (14)	4 (20)	6 (19)	7 (9)
Not reported	--	---	---	1 (3)	2 (3)
Condom used with other partner/s last month (%)**					
N° surveyed	--	N=4	N=4	N=6	N=7
Never	--	3 (75)	1 (25)	2 (33)	2 (29)
Sometimes	--	---	1 (25)	---	3 (43)
Every time	--	1 (25)	2 (50)	4 (67)	2 (29)
Not reported	--	---	---	---	---
Sex work last month (%)					
No	23 (100)	28 (97)	15 (75)	28 (90)	69 (92)
Yes	---	---	4 (20)	1 (3)	4 (5)
Not reported	---	1 (3)	1 (5)	2 (6)	2 (3)
Condom used at last sex work last month (%)**					
Yes	---	---	4 (100)	1 (100)	4 (100)

* Percentages exclude missing data

** New variable format commenced in 2005

Table 92 Number (percentage) of respondents reporting previous testing for HIV and HCV infection and HCV treatment by year of survey

	2004	2005	2006	2007	2008
N° surveyed	N = 23	N=29	N=20	N=31	N=75
Previous HIV test (%)					
Yes, last year	13 (57)	15 (52)	15 (75)	16 (52)	36 (48)
> 1 year ago	7 (30)	12 (41)	4 (20)	12 (39)	25 (33)
Never tested	3 (13)	2 (7)	---	2 (6)	9 (12)
Not reported	---	---	1 (5)	1 (3)	5 (7)
Previous HCV test (%)					
Yes, last year	18 (78)	14 (48)	15 (75)	19 (61)	38 (51)
> 1 year ago	5 (22)	14 (48)	5 (25)	10 (32)	27 (36)
Never tested	---	1 (3)	---	1 (3)	5 (7)
Not reported	---	---	---	1 (3)	5 (7)
Any treatment for HCV (%)	N = 12	N=13	N=4	N=17	N=36
Interferon	---	---	---	---	2 (6)
Interferon+Ribarvarin	---	---	---	---	1 (3)
Other	1 (8)	1 (8)	---	2 (12)	2 (6)
No treatment	11 (92)	12 (92)	3 (75)	12 (71)	31 (86)
Not reported	---	---	1 (25)	3 (18)	---
Current treatment for HCV	N = 0	N = 0	N=0	N=1	N=2
Interferon/Interferon+Ribarvirin	---	---	---	1	1
Other	---	---	---	---	1

HIV antibody prevalence

Table 93 HIV antibody prevalence by gender and year of survey

Year of survey	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2004	11	0 (0.0)	4	0 (0.0)	16	0 (0.0)
2005	15	0 (0.0)	9	0 (0.0)	24	0 (0.0)
2006	9	0 (0.0)	11	0 (0.0)	20	0 (0.0)
2007	20	0 (0.0)	9	0 (0.0)	29	0 (0.0)
2008	46	1 (2.2)	27	0 (0.0)	73	1 (1.4)
χ^2 trend p value		0.378		---		0.368

* Total includes people whose gender was not reported or reported as transgender

Table 94 HIV antibody prevalence by sexual identity and year of survey

Sexual identity	N° tested	N° with HIV (%)
2004		
Heterosexual	12	0 (0.0)
Bisexual	4	0 (0.0)
Homosexual	---	0 (0.0)
2005		
Heterosexual	22	0 (0.0)
Bisexual	1	0 (0.0)
Homosexual	1	0 (0.0)
2006		
Heterosexual	13	0 (0.0)
Bisexual	4	0 (0.0)
Homosexual	3	0 (0.0)
2007		
Heterosexual	27	0 (0.0)
Bisexual	0	0 (0.0)
Homosexual	1	0 (0.0)
2008		
Heterosexual	60	1 (1.7)
Bisexual	4	0 (0.0)
Homosexual	5	0 (0.0)

Table 95 HIV antibody prevalence by age group and year of survey

Age group	N° tested	N° with HIV (%)
2004		
< 20 years	---	---
20 – 24	1	0 (0.0)
25 – 29	1	0 (0.0)
30 + years	14	0 (0.0)
2005		
< 20 years	---	---
20 – 24	2	0 (0.0)
25 – 29	1	0 (0.0)
30 + years	21	0 (0.0)
2006		
< 20 years	---	---
20 – 24	1	0 (0.0)
25 – 29	6	0 (0.0)
30 + years	13	0 (0.0)
2007		
< 20 years	---	---
20 – 24	---	---
25 – 29	6	0 (0.0)
30 + years	23	0 (0.0)
2008		
< 20 years	2	0 (0.0)
20 – 24	1	0 (0.0)
25 – 29	6	0 (0.0)
30 + years	64	1 (1.6)

Table 96 HIV antibody prevalence by duration of drug injection and year of survey

Duration of drug injection	N° tested	N° with HIV (%)
2004		
<3 years	---	---
3 to 5 years	3	0 (0.0)
6 to 10 years	---	---
10 + years	13	0 (0.0)
2005		
<3 years	2	0 (0.0)
3 to 5 years	2	0 (0.0)
6 to 10 years	2	0 (0.0)
10 + years	17	0 (0.0)
2006		
<3 years	---	0 (0.0)
3 to 5 years	1	0 (0.0)
6 to 10 years	5	0 (0.0)
10 + years	14	0 (0.0)
2007		
<3 years	---	---
3 to 5 years	3	0 (0.0)
6 to 10 years	3	0 (0.0)
10 + years	22	0 (0.0)
2008		
<3 years	1	0 (0.0)
3 to 5 years	3	0 (0.0)
6 to 10 years	12	0 (0.0)
10 + years	55	1 (1.8)

Table 97 HIV antibody prevalence by last drug injected and year of survey

Last drug injected	N° tested	N° with HIV (%)
2004		
Heroin	---	---
Meth/Amphetamine	6	0 (0.0)
Morphine/Other Opioids	9	0 (0.0)
Other/Not reported	1	0 (0.0)
2005		
Heroin	---	---
Meth/Amphetamine	6	0 (0.0)
Morphine/Other Opioids	11	0 (0.0)
Other/Not reported	7	0 (0.0)
2006		
Heroin	---	---
Meth/Amphetamine	7	0 (0.0)
Morphine/Other Opioids	12	0 (0.0)
Other/Not reported	1	0 (0.0)
2007		
Heroin	---	---
Meth/Amphetamine	5	0 (0.0)
Morphine/Other Opioids	15	0 (0.0)
Other/Not reported	9	0 (0.0)
2008		
Heroin	2	0 (0.0)
Meth/Amphetamine	12	0 (0.0)
Morphine/Other Opioids	2	0 (0.0)
Other/Not reported	57	1 (1.8)

Northern Territory

Table 98 HIV antibody prevalence by frequency of drug injection last month and year of survey

Frequency of drug injection	N° tested	N° with HIV (%)
2004		
Not injected last month	---	---
Less than daily	3	0 (0.0)
Daily or more	13	0 (0.0)
2005		
Not injected last month	---	---
Less than daily	5	0 (0.0)
Daily or more	19	0 (0.0)
2006		
Not injected last month	---	---
Less than daily	9	0 (0.0)
Daily or more	11	0 (0.0)
2007		
Not injected last month	2	0 (0.0)
Less than daily	9	0 (0.0)
Daily or more	18	0 (0.0)
2008		
Not injected last month	3	0 (0.0)
Less than daily	19	0 (0.0)
Daily or more	51	1 (2.0)

Table 99 HIV antibody prevalence by re-use of someone else's used needle and syringe last month and year of survey

Re-used someone else's used needle & syringe	N° tested	N° with HIV (%)
2004		
No	16	0 (0.0)
Yes	---	0 (0.0)
2005		
No	22	0 (0.0)
Yes	1	0 (0.0)
2006		
No	15	0 (0.0)
Yes	1	0 (0.0)
2007		
No	24	0 (0.0)
Yes	1	0 (0.0)
2008		
No	64	1 (1.6)
Yes	6	0 (0.0)

Table 100 HIV antibody prevalence by imprisonment last year and year of survey

Imprisonment last year	N° tested	N° with HIV (%)
2004		
No	12	0 (0.0)
Yes	4	0 (0.0)
2005		
No	6	0 (0.0)
Yes	1	0 (0.0)
2006		
No	16	0 (0.0)
Yes	1	0 (0.0)
2007		
No	28	0 (0.0)
Yes	0	0 (0.0)
2008		
No	67	1 (1.5)
Yes	3	0 (0.0)

Table 101 HIV antibody prevalence by condom use at last sex and year of survey

Condom use at last sex	N° tested	N° with HIV (%)
2004		
No	10	0 (0.0)
Yes	5	0 (0.0)
2005*		
No	6	0 (0.0)
Yes	1	0 (0.0)
2006		
No	9	0 (0.0)
Yes	1	0 (0.0)
2007		
No	10	0 (0.0)
Yes	2	0 (0.0)
2008		
No	45	1 (2.2)
Yes	1	0 (0.0)

*Question changed to "condom use with regular partner in last month" in 2005.

Northern Territory

Table 102 HIV antibody prevalence by sex work last month and year of survey

Sex work last month	N° tested	N° with HIV (%)
2004		
No	16	0 (0.0)
Yes	---	---
2005		
No	23	0 (0.0)
Yes	---	---
2006		
No	15	0 (0.0)
Yes	4	0 (0.0)
2007		
No	26	0 (0.0)
Yes	1	0 (0.0)
2008		
No	68	1 (1.5)
Yes	3	0 (0.0)

Table 103 HIV antibody prevalence by Aboriginal and Torres Strait Islander origin status and year of survey

Aboriginal and Torres Strait Islander origin	N° tested	N° with HIV (%)
2004		
No	15	0 (0.0)
Yes	1	0 (0.0)
2005		
No	23	0 (0.0)
Yes	1	0 (0.0)
2006		
No	17	0 (0.0)
Yes	3	0 (0.0)
2007		
No	28	0 (0.0)
Yes	---	---
2008		
No	60	1 (1.7)
Yes	13	0 (0.0)

Table 104 HIV antibody prevalence by region/country of birth and year of survey

Region/Country of birth	N° tested	N° with HIV (%)
2004		
Australia	15	0 (0.0)
Other Oceania	---	---
Asia	---	---
UK & Ireland	---	---
Other	1	0 (0.0)
2005		
Australia	24	0 (0.0)
Other Oceania	---	---
Asia	---	---
UK & Ireland	---	---
Other	---	---
2006		
Australia	19	0 (0.0)
Other Oceania	1	0 (0.0)
Asia	---	---
UK & Ireland	---	---
Other	---	---
2007		
Australia	26	0 (0.0)
Other Oceania	1	0 (0.0)
Asia	---	---
UK & Ireland	1	0 (0.0)
Other	---	---
2008		
Australia	63	1 (1.6)
Other Oceania	2	0 (0.0)
Asia	---	---
UK & Ireland	3	0 (0.0)
Other	4	0 (0.0)

Table 105 HIV antibody prevalence by main language spoken at home by parents and year of survey

Main language spoken at home by parents	N° tested	N° with HIV (%)
2004		
English speaking	11	0 (0.0)
Non-English speaking	---	---
2005		
English speaking	21	0 (0.0)
Non-English speaking	3	0 (0.0)
2006		
English speaking	18	0 (0.0)
Non-English speaking	---	---
2007		
English speaking	27	0 (0.0)
Non-English speaking	1	0 (0.0)
2008		
English speaking	73	1 (1.4)
Non-English speaking	---	---

HCV antibody prevalence

Table 106 HCV antibody prevalence by gender and year of survey

Year of survey	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004	11	6 (55)	4	3 (75)	16	9 (56)
2005	15	6 (40)	9	6 (67)	24	12 (50)
2006	7	4 (57)	10	1 (10)	17	5 (29)
2007	20	13 (65)	9	5 (56)	29	18 (62)
2008	46	23 (50)	26	15 (58)	72	38 (53)
χ^2 trend p value		0.823		0.315		0.677

* Total includes people whose gender was not reported or reported as transgender

Table 107 HCV antibody prevalence by sexual identity, gender and year of survey

Sexual identity	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Heterosexual	61	38 (62)	35	17 (49)	96	55 (57)
Bisexual	-	-	5	3 (60)	5	3 (60)
Homosexual	4	2 (50)	3	2 (67)	7	4 (57)
P value		0.6		0.8		1.0
2005						
Heterosexual	14	6 (43)	8	5 (63)	22	11 (50)
Bisexual	-	-	1	1 (100)	1	1 (100)
Homosexual	1	0 (0)	-	-	1	0 (0)
p value		0.4		0.5		0.6
2006						
Heterosexual	6	4 (67)	5	0 (0)	11	4 (36)
Bisexual	0	---	4	0 (0)	4	0 (0)
Homosexual	1	0 (0)	1	1 (100)	2	1 (50)
p value		0.429		0.100		0.413
2007						
Heterosexual	18	13 (72)	9	5 (56)	27	18 (67)
Bisexual	---	---	---	---	---	---
Homosexual	1	0 (0.0)	---	---	1	0 (0.0)
p value		0.316		---		0.357
2008						
Heterosexual	40	22 (55)	19	11 (58)	59	33 (56)
Bisexual	1	0 (0.0)	3	2 (67)	4	2 (50)
Homosexual	2	0 (0.0)	3	2 (67)	5	2 (40)
p value		0.108		1.000		0.867

* Total includes people whose gender was not reported or reported as transgender

Table 108 HCV antibody prevalence by age group, gender and year of survey

Age group	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
< 20 years	-	-	-	-	-	0 (0)
20 – 24	1	0 (0)	-	-	1	0 (0)
25 – 29	1	1 (100)	-	-	1	1 (100)
30 + years	9	5 (56)	4	3 (75)	14	8 (57)
p value		0.4		-		0.4
2005						
< 20 years	-	-	-	-	-	-
20 – 24	-	-	2	2 (100)	2	2 (100)
25 – 29	1	0 (0)	-	-	1	0 (0)
30 + years	14	6 (43)	7	4 (57)	21	10 (48)
p value		0.4		0.3		0.2
2006						
< 20 years	---	---	---	---	---	---
20 – 24	---	---	---	---	---	---
25 – 29	2	1 (50)	4	0 (0)	6	1 (17)
30 + years	5	3 (60)	6	1 (17)	11	4 (36)
p value		1.000		1.000		0.600
2007						
< 20 years	---	---	---	---	---	---
20 – 24	---	---	---	---	---	---
25 – 29	3	1 (33)	3	2 (67)	6	3 (50)
30 + years	17	12 (71)	6	3 (50)	23	15 (65)
p value		0.270		1.000		0.646
2008						
< 20 years	1	0 (0.0)	1	0 (0.0)	2	0 (0.0)
20 – 24	---	---	1	1 (100)	1	1 (100)
25 – 29	5	2 (40)	1	0 (0.0)	6	2 (33)
30 + years	40	21 (53)	23	14 (61)	63	35 (56)
p value		0.665		0.381		0.190

* Total includes people whose gender was not reported or reported as transgender

Northern Territory

Table 109 HCV antibody prevalence by duration of drug injection, gender and year of survey

Duration of drug injection	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
<3 years	-	-	-	-	-	-
3 to 5 years	1	0 (0)	2	1 (50)	3	0 (0)
6 to 10 years	-	-	-	-	-	-
10 + years	10	6 (60)	1	0 (0)	13	9 (69)
p value		<0.001		0.02		<0.001
2005						
<3 years	2	0 (0)	1	0 (0)	3	0 (0)
3 to 5 years	2	1 (50)	-	-	2	1 (50)
6 to 10 years	-	-	2	1 (50)	2	1 (50)
10 + years	10	5 (50)	6	5 (83)	16	10 (63)
p value		0.3		0.2		0.4
2006						
<3 years	---	---	---	---	---	---
3 to 5 years	---	---	---	---	---	---
6 to 10 years	1	1 (100)	4	0 (0)	5	1 (20)
10 + years	6	3 (50)	6	1 (17)	12	4 (33)
p value		1.000		1.000		1.000
2007						
<3 years	---	---	---	---	---	---
3 to 5 years	1	1 (100)	2	1 (50)	3	2 (67)
6 to 10 years	2	0 (0.0)	1	1 (100)	3	1 (33)
10 + years	16	11 (69)	6	3 (50)	22	14 (64)
p value		0.123		1.000		0.792
2008						
<3 years	---	---	1	0 (0.0)	1	0 (0.0)
3 to 5 years	3	1 (33)	---	---	3	1 (33)
6 to 10 years	7	0 (0.0)	5	4 (80)	12	4 (33)
10 + years	34	22 (65)	20	11 (55)	54	33 (61)
p value		0.002		0.337		0.183

* Total includes people whose gender was not reported or reported as transgender

Table 110 HCV antibody prevalence by last drug injected, duration of drug injection and year of survey

Last drug injected	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Meth/Amphetamine	---	---	6	4 (67)	6	4 (67)
Heroin	---	---	---	---	---	---
More than one	---	---	1	1 (100)	1	1 (100)
Other/Not reported	---	---	9	4 (44)	9	4 (44)
p value		---		0.5		0.5
2005						
Meth/Amphetamine	1	0 (0)	5	3 (60)	6	3 (50)
Heroin	---	---	---	---	---	---
More than one	---	---	---	---	---	---
Other/Not reported	2	0 (0)	16	9 (56)	18	9 (50)
p value		0.08		0.06		0.03
2006						
Meth/Amphetamine	---	---	6	1 (17)	6	1 (17)
Heroin	---	---	---	---	---	---
More than one	---	---	1	1 (100)	1	1 (100)
Other/Not reported	---	---	10	3 (30)	10	3 (30)
p value		---		0.360		0.360
2007						
Meth/Amphetamine	---	---	4	1 (25)	5	2 (40)
Heroin	---	---	---	---	---	---
More than one	---	---	---	---	---	---
Other/Not reported	---	---	24	16 (67)	24	16 (67)
p value		---		0.269		0.339
2008						
Meth/Amphetamine	1	0 (0.0)	2	1 (50)	2	1 (50)
Heroin	---	---	11	2 (18)	12	2 (17)
More than one	---	---	2	1 (50)	2	1 (50)
Other/Not reported	---	---	54	34 (63)	56	34 (61)
p value		---		0.016		0.015

* Total includes people who did not report duration of drug injection

Northern Territory

Table 111 HCV antibody prevalence by frequency of injection last month, duration of drug injection and year of survey

Frequency of drug injection last month	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Less than daily	---	---	3	1 (33)	3	1 (33)
Daily or more	---	---	13	8 (62)	13	8 (62)
p value		---		0.4		0.4
2005						
Less than daily	---	---	5	3 (60)	5	3 (60)
Daily or more	3	0 (0)	15	9 (60)	19	9 (47)
p value		---		>0.9		0.6
2006						
Less than daily	---	---	8	1 (13)	8	1 (13)
Daily or more	---	---	9	4 (44)	9	4 (44)
p value		---		0.294		0.294
2007						
Less than daily	---	---	9	5 (56)	9	5 (56)
Daily or more	---	---	17	11 (65)	18	12 (63)
p value		---		0.692		0.683
2008						
Less than daily	1	0 (0.0)	17	7 (41)	18	7 (39)
Daily or more	---	---	49	30 (61)	51	30 (59)
p value		---		0.169		0.176

* Total includes people who did not report duration of drug injection

Table 112 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and year of survey

Re-used someone else's used needle & syringe last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
No	-	-	16	9 (56)	16	9 (56)
Yes	-	-	-	-	-	-
p value						
2005						
No	3	0 (0)	18	10 (56)	22	10 (45)
Yes	-	-	1	1 (100)	1	1 (100)
p value		-		0.4		0.3
2006						
No	---	---	15	5 (33)	15	5 (33)
Yes	---	---	1	0 (0)	1	0 (0)
p value		---		1.000		1.000
2007						
No	---	---	23	14 (61)	24	15 (63)
Yes	---	---	1	1 (100)	1	1 (100)
p value		---		1.000		1.000
2008						
No	---	---	61	33 (54)	63	33 (52)
Yes	1	1 (100)	5	4 (80)	6	4 (67)
p value		---		0.375		0.679

* Total includes people who did not report duration of drug injection

Table 113 HCV antibody prevalence by imprisonment last year, duration of drug injection and year of survey

Imprisonment last year	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
No	-	-	12	5 (42)	12	5 (42)
Yes	-	-	4	4 (100)	4	4 (100)
p value				0.04		0.04
2005						
No	3	0(0)	18	10 (56)	22	10 (45)
Yes	-	-	1	1 (100)	1	1 (100)
p value				0.4		0.3
2006						
No	---	---	16	5 (31)	16	5 (31)
Yes	---	---	1	1 (0.0)	1	1 (0.0)
p value				1.000		1.000
2007						
No	---	---	27	17 (63)	27	17 (63)
Yes	---	---	---	---	---	---
p value				---		---
2008						
No	1	0 (0.0)	65	35 (54)	66	35 (53)
Yes	---	---	2	2 (100)	3	2 (67)
p value				0.498		1.000

* Total includes people who did not report duration of drug injection

Table 114 HCV antibody prevalence by sex work last month, duration of drug injection and year of survey

Sex work last month	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
No	-	-	16	9 (56)	16	9 (56)
Yes	-	-	-	-	-	-
p value						
2005						
No	3	0(0)	19	11 (58)	23	11 (48)
Yes	-	-	-	-	-	-
p value						
2006						
No	---	---	13	4 (31)	13	4 (31)
Yes	---	---	4	1 (25)	4	1 (25)
p value				1.000		1.000
2007						
No	---	---	25	17 (68)	26	18 (69)
Yes	---	---	1	0 (0.0)	1	0 (0.0)
p value				0.346		0.333
2008						
No	1	0 (0.0)	65	35 (54)	66	35 (53)
Yes	---	---	2	2 (100)	3	2 (67)
p value				0.498		1.000

* Total includes people who did not report duration of drug injection

Northern Territory

Table 115 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and year of survey

Aboriginal and Torres Strait Islander origin	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
No	11	6 (55)	3	2 (67)	15	8 (53)
Yes	-	-	1	1 (100)	1	1 (100)
p value		-		0.4		0.5
2005						
No	14	6 (43)	9	6 (67)	23	12 (52)
Yes	1	0 (0)	-	-	1	0 (0)
p value		0.4				0.4
2006						
No	7	4 (57)	7	1 (14)	14	5 (36)
Yes	---	---	3	0 (0)	3	0 (0)
p value		---		1.000		0.515
2007						
No	19	13 (68)	9	5 (56)	28	18 (64)
Yes	---	---	---	---	---	---
p value		---		---		---
2008						
No	39	21 (54)	20	12 (60)	59	33 (56)
Yes	7	2 (29)	6	3 (50)	13	5 (38)
p value		0.414		1.000		0.359

* Total includes people whose gender was not reported or reported as transgender

Table 116 HCV antibody prevalence by region/country of birth, gender and year of survey

Region/Country of birth	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Australia	10	6 (60)	4	3 (75)	15	9 (60)
Other Oceania	---	---	---	---	---	---
Asia	---	---	---	---	---	---
UK & Ireland	---	---	---	---	---	---
Other	1	0 (0)	---	---	1	0 (0)
p value		0.2		---		0.2
2005						
Australia	15	6 (40)	9	6 (67)	15	6 (67)
Other Oceania	---	---	---	---	---	---
Asia	---	---	---	---	---	---
UK & Ireland	---	---	---	---	---	---
Other	---	---	---	---	---	---
p value		---		---		---
2006						
Australia	6	3 (50)	10	1 (10)	16	4 (25)
Other Oceania	1	1 (100)	---	---	1	1 (100)
Asia	---	---	---	---	---	---
UK & Ireland	---	---	---	---	---	---
Other	---	---	---	---	---	---
p value		1.000		---		0.294
2007						
Australia	17	12 (71)	9	5 (56)	26	17 (65)
Other Oceania	1	1 (100)	---	---	1	1 (100)
Asia	---	---	---	---	---	---
UK & Ireland	1	0 (0.0)	---	---	1	0 (0.0)
Other	---	---	---	---	---	---
p value		0.544		---		0.595
2008						
Australia	39	20 (51)	23	13 (57)	62	33 (53)
Other Oceania	2	1 (50)	---	---	2	1 (50)
Asia	---	---	---	---	---	---
UK & Ireland	2	1 (50)	1	1 (100)	3	2 (67)
Other	3	1 (33)	1	0 (0.0)	4	1 (25)
p value		1.000		0.697		0.747

* Total includes people whose gender was not reported or reported as transgender

Northern Territory

Table 117 HCV antibody prevalence by main language spoken at home by parents, gender and year of survey

Main language spoken at home by parents	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
English speaking	6	4 (67)	4	3 (75)	11	7 (64)
Non-English speaking	---	---	---	---	---	---
p value		---		---		---
2005						
English speaking	12	6 (50)	9	6 (67)	21	12 (57)
Non-English speaking	3	0 (0)	---	---	3	0 (0)
p value		0.1		---		0.06
2006						
English speaking	6	4 (67)	9	1 (11)	15	5 (33)
Non-English speaking	---	---	---	---	---	---
p value		---		---		---
2007						
English speaking	18	12 (67)	9	5 (56)	27	17 (63)
Non-English speaking	1	1 (100)	---	---	1	1 (100)
p value		1.000		---		1.000
2008						
English speaking	46	23 (50)	26	15 (58)	72	38 (53)
Non-English speaking	---	---	---	---	---	---
p value		---		---		---

* Total includes people whose gender was not reported or reported as transgender

Queensland 2004 - 2008

Table 118 Number (percentage) of respondents by demographic characteristics and year of survey

Demographic characteristics	2004	2005	2006	2007	2008
Number of sites	7	7	7	7	8
N° surveyed	N=587	N=291	N=501	N=417	N=508
Response (%)	58	31	33	34	35
Gender (%)					
Male	407 (69)	198 (68)	353 (70)	282 (68)	341 (67)
Female	179 (30)	91 (31)	145 (29)	131 (31)	165 (32)
Transgender	1 (<1)	1 (0)	2 (<1)	3 (<1)	1 (<1)
Not reported	---	1 (0)	1 (<1)	1 (<1)	1 (<1)
Sexual identity (%)					
Heterosexual	492 (84)	236 (81)	411 (82)	350 (84)	436 (86)
Bisexual	46 (8)	23 (8)	37 (7)	32 (8)	40 (8)
Homosexual	27 (4)	19 (7)	39 (8)	25 (6)	21 (4)
Not reported	22 (4)	13 (4)	14 (3)	10 (2)	11 (2)
Age and duration of injection (years)					
<i>Median age</i>	31	32	33	35	34
<i>Age range</i>	16-61	16-63	13-57	17-60	16-60
Age group (%)					
<25 years	117 (20)	43 (15)	75 (15)	49 (12)	68 (13)
25+ years	468 (80)	248 (85)	425 (85)	367 (88)	438 (86)
Not reported	2 (<1)	--	1 (<1)	1 (<1)	2 (<1)
<i>Median age 1st IDU</i>	18	18	18	18	18
<i>Age range</i>	9-56	11-50	10-52	11-44	10-57
Not reported	11	9	1	12	7
<i>Median years IDU</i>	11	13	13	14	14
<i>Range</i>	<1-37	<1-37	<1-43	<1-38	<1-40
Duration of drug injection					
<3 years	45 (8)	18 (6)	39 (8)	32 (8)	29 (6)
3+ years	531 (90)	258 (89)	442 (88)	373 (89)	471 (93)
Not reported	11 (2)	15 (5)	20 (4)	12 (3)	8 (2)
Aboriginal and Torres Strait Islander origin (%)					
No	541 (92)	273 (94)	438 (87)	375 (90)	459 (90)
Yes	33 (6)	14 (5)	49 (10)	38 (10)	32 (6)
Not reported	13 (2)	4 (1)	14 (3)	4 (<1)	17 (3)
Region/Country of birth (%)					
Australia	492 (84)	259 (89)	436 (87)	374 (90)	431 (85)
Other Oceania	31 (5)	11 (4)	21 (4)	15 (4)	25 (5)
Asia	7 (1)	2 (1)	4 (<1)	1 (<1)	5 (1)
UK & Ireland	29 (5)	13 (4)	18 (4)	14 (3)	22 (4)
Other	16 (3)	5 (2)	12 (2)	10 (2)	14 (3)
Not reported	12 (2)	1 (<1)	10 (2)	3 (<1)	11 (2)
Main language spoken at home by parents (%)					
English speaking	453 (77)	259 (89)	465 (93)	395 (95)	489 (96)
Non-English speaking	12 (2)	32 (11)	17 (3)	17 (4)	13 (3)
Not reported	122 (21)	--	19 (4)	5 (1)	6 (1)
Imprisonment last year (%)					
No	499 (85)	250 (86)	412 (82)	363 (87)	418 (82)
Yes	83 (14)	34 (12)	67 (13)	43 (10)	56 (11)
Not reported	5 (1)	7 (2)	22 (4)	11 (3)	34 (7)
Injected in prison (%)					
Yes	N = 83 55 (66)	N=34 14 (41)	N=67 27 (40)	N=43 22 (51)	N=56 20 (36)
Frequency of injection last month (%)					
Not last month	59 (10)	35 (12)	61 (12)	32 (8)	50 (10)
Less than weekly	119 (20)	45 (15)	100 (20)	70 (17)	80 (16)
Weekly not daily	141 (24)	89 (31)	96 (19)	119 (29)	137 (27)
Daily or more	265 (45)	120 (41)	243 (49)	188 (45)	234 (46)
Not reported	3 (1)	2 (1)	1 (<1)	8 (2)	7 (1)

Queensland

Table 119 Number (percentage) of respondents by last drug injected, injecting behaviour in the month prior to survey and year of survey

Injecting behaviour	2004	2005	2006	2007	2008
Last drug injected (%)	N=587	N=291	N=501	N=417	N=508
Anabolic steroids	8 (1)	6 (2)	13 (3)	5 (1)	11 (2)
Cocaine	5 (1)	1 (<1)	2 (<1)	1 (<1)	2 (<1)
Heroin	165 (28)	85 (29)	115 (23)	106 (25)	124 (24)
Methadone	24 (4)	10 (3)	24 (5)	19 (5)	32 (6)
Meth/Amphetamine	256 (44)	116 (40)	197 (39)	145 (35)	171 (34)
Morphine/Other Opioids	67 (11)	43 (14)	94 (19)	96 (23)	120 (24)
Subutex/Buprenorphine	14 (2)	10 (3)	30 (6)	28 (7)	26 (5)
More than one	35 (6)	8 (3)	4 (<1)	2 (<1)	11 (2)
Other	5 (1)	2 (<1)	2 (<1)	6 (1)	6 (1)
Not reported	7 (1)	9 (3)	15 (3)	9 (2)	5 (1)
N^o Injected last month	N = 525	N=254	N=439	N=377	N=451
Places injected last month (%)*					
Own home	418 (80)	202 (80)	355 (85)	328 (88)	410 (91)
Friend's home	211 (40)	97 (38)	165 (40)	159 (43)	172 (38)
Dealer's home	99 (19)	38 (15)	65 (16)	53 (14)	66 (15)
Street, park, beach	117 (22)	57 (22)	88 (21)	65 (17)	73 (16)
Car	167 (32)	77 (30)	126 (30)	134 (36)	137 (31)
Public toilet	117 (22)	66 (26)	94 (23)	73 (20)	71 (16)
Commercial injecting room	4 (1)	2 (1)	1 (<1)	3 (<1)	2 (<1)
Squat	31 (6)	25 (10)	35 (8)	17 (5)	13 (3)
Use of new sterile needles & syringes last month (%)					
All injections	392 (75)	187 (74)	332 (76)	282 (75)	329 (73)
Most of the time	104 (20)	55 (22)	85 (19)	71 (19)	107 (24)
Half of the time	6 (1)	5 (2)	9 (2)	9 (2)	7 (2)
Some of the time	7 (1)	4 (2)	2 (<1)	2 (<1)	2 (<1)
Not last month	5 (1)	1 (<1)	1 (<1)	3 (<1)	2 (<1)
Not reported	11 (2)	2 (1)	10 (2)	10 (3)	4 (1)
Re-used another's used needle & syringe last month (%)					
None	417 (79)	206 (82)	349 (80)	316 (84)	388 (86)
Once	33 (6)	10 (4)	29 (7)	16 (4)	24 (5)
Twice	19 (4)	9 (4)	18 (4)	12 (3)	14 (3)
3-5 times	25 (5)	11 (4)	16 (4)	16 (4)	7 (2)
>5 times	12 (2)	8 (3)	9 (2)	9 (2)	13 (3)
Not reported	19 (4)	8 (3)	18 (4)	8 (2)	5 (1)
Number of people needle & syringe was re-used after last month (%)					
None	417 (79)	196 (77)	349 (80)	316 (84)	388 (86)
One	48 (9)	22 (9)	33 (8)	28 (7)	35 (8)
Two	9 (2)	1 (<1)	3 (<1)	5 (1)	---
Three to five	4 (1)	5 (2)	2 (<1)	2 (<1)	3 (1)
More than five	1 (<1)	1 (<1)	2 (<1)	1 (<1)	3 (1)
Don't know	10 (2)	14 (6)	12 (3)	8 (2)	9 (2)
Not reported	36 (7)	15 (6)	38 (9)	17 (5)	13 (3)
Relationship to people needle & syringe was re-used after last month (%)*					
Regular sex partner	34 (6)	21 (8)	29 (7)	26 (7)	26 (6)
Casual sex partner	4 (1)	---	4 (<1)	2 (<1)	1 (<1)
Close friend	20 (4)	8 (3)	12 (3)	13 (3)	13 (3)
Acquaintance	12 (2)	6 (2)	1 (<1)	---	7 (2)
Other	1 (<1)	3 (1)	2 (<1)	5 (1)	3 (1)
Equipment used after someone else last month (%)*					
Spoon	129 (25)	68 (27)	83 (20)	80 (23)	85 (21)
Water	109 (21)	45 (18)	67 (16)	50 (15)	61 (15)
Filter	76 (14)	38 (15)	51 (12)	53 (15)	48 (12)
Drug mix	56 (11)	32 (13)	35 (8)	33 (10)	32 (8)
Tourniquet	55 (10)	26 (10)	41 (10)	27 (8)	39 (9)
None**	---	---	268 (63)	239 (69)	280 (68)
Injected by someone after that person injected themselves or others last month (%)					
No	427 (81)	212 (83)	358 (82)	314 (83)	381 (84)
Yes	79 (15)	31 (12)	65 (15)	52 (14)	62 (14)
Not reported	19 (4)	11 (4)	16 (4)	11 (3)	8 (2)

* More than one option could be selected

** New variable in 2006

Table 120 Number (percentage) of respondents by treatment for drug use and year of survey

Treatment for drug use	2004	2005	2006	2007	2008
N° surveyed	N=587	N=291	N=501	N=417	N=508
Any treatment/therapy for drug use (%)					
No	174 (30)	73 (25)	115 (23)	86 (21)	124 (24)
Yes	407 (69)	215 (74)	374 (75)	323 (77)	374 (74)
Not reported	6 (1)	3 (1)	12 (2)	8 (2)	10 (2)
History of methadone maintenance treatment (%)					
Currently	141 (24)	62 (21)	91 (18)	94 (23)	92 (18)
Previously	120 (21)	87 (30)	140 (28)	132 (32)	129 (25)
Never	318 (54)	137 (47)	253 (51)	189 (45)	272 (54)
Not reported	8 (1)	5 (2)	17 (3)	2 (<1)	15 (3)
History of buprenorphine (Subutex®) treatment (%)*					
Currently	--	--	--	--	60 (12)
Previously	--	--	--	--	125 (25)
Never	--	--	--	--	309 (61)
Not reported	--	--	--	--	14 (3)
History of buprenorphine-naloxone (Suboxone®) treatment (%)*					
Currently	--	--	--	--	43 (8)
Previously	--	--	--	--	75 (15)
Never	--	--	--	--	376 (74)
Not reported	--	--	--	--	14 (3)

* New variable in 2008

Table 121 Number (percentage) of respondents by site of needle and syringe acquisition last month and year of survey

Needle & Syringe acquisition	2004	2005	2006	2007*	2008
N° surveyed	N=587	N=291	N=501	--	N=508
From an NSP last month (%)					
Daily or almost daily	53 (9)	25 (9)	52 (10)	--	19 (4)
A couple of times each week	168 (29)	79 (27)	162 (32)	--	133 (26)
Less than weekly	170 (29)	88 (30)	110 (22)	--	169 (33)
Once last month	94 (16)	55 (19)	84 (17)	--	107 (21)
Not in the last month	91 (15)	38 (13)	85 (17)	--	68 (13)
Not reported	11 (2)	6 (2)	8 (2)	--	12 (2)
From a chemist last month (%)					
Daily or almost daily	18 (3)	5 (2)	15 (3)	--	8 (2)
A couple of times each week	60 (10)	22 (8)	39 (8)	--	25 (5)
Less than weekly	98 (17)	41 (14)	71 (14)	--	60 (12)
Once last month	128 (22)	56 (19)	102 (20)	--	100 (20)
Not in the last month	270 (46)	159 (55)	258 (52)	--	298 (59)
Not reported	13 (2)	8 (3)	16 (3)	--	17 (3)

* Not asked in this form in 2007

Table 122 Number (percentage) of respondents by injecting equipment use, re-use and cleaning last month

Use, re-use and cleaning of any item*	Used	Re-used	Cleaned**
N° surveyed***	N=451	N=451	N=451
Yes	421 (93)	195 (43)	186 (41)
No	16 (4)	205 (45)	216 (48)
Not reported	14 (3)	51 (11)	49 (11)
Use, re-use and cleaning by item type#			
1ml	343 (76)	129 (29)	119 (26)
3 ml	132 (29)	42 (9)	48 (11)
5 ml	71 (16)	23 (5)	24 (5)
10 ml	41 (9)	10 (2)	9 (2)
20 ml	42 (9)	15 (3)	13 (3)
Detachable needle (tip)	98 (22)	17 (4)	18 (4)
Winged vein infusion set (butterfly)	73 (16)	12 (3)	14 (3)
Wheel filter	66 (15)	15 (3)	14 (3)

* New question in 2008

** Includes 15 respondents that reported cleaning but not re-use in the last month

More than one item could be selected

*** Excludes respondents that did not inject in the last month

Queensland

Table 123 Number (percentage) of respondents by sexual behaviour in the month prior to survey and year of survey

Sexual behaviour	2004	2005	2006	2007	2008
N ^o surveyed	N=587	N=291	N=501	N=417	N=508
Sex with a regular partner last month (%) **					
No	--	135 (46)	200 (40)	178 (43)	228 (45)
Yes	--	154 (53)	284 (57)	224 (54)	261 (51)
Not reported	--	2 (1)	17 (3)	15 (4)	19 (4)
Condom used with regular partner last month (%)**					
N ^o surveyed		N=154	N=284	N=224	N=261
Never	--	110 (71)	191 (67)	165 (74)	191 (73)
Sometimes	--	18 (12)	49 (17)	31 (14)	25 (10)
Every time	--	21 (14)	29 (10)	21 (9)	27 (10)
Not reported	--	5 (3)	15 (5)	7 (3)	18 (7)
Sex with other partner/s last month (%)**					
No	--	246 (85)	410 (82)	347 (83)	417 (82)
Yes	--	38 (13)	68 (14)	61 (15)	68 (13)
Not reported	--	7 (2)	23 (5)	9 (2)	23 (5)
Condom used with other partner/s last month (%)**					
N ^o surveyed		N=38	N=68	N=61	N=68
Never	--	9 (24)	17 (25)	20 (33)	21 (31)
Sometimes	--	9 (24)	15 (22)	22 (36)	16 (24)
Every time	--	18 (47)	32 (47)	16 (26)	28 (41)
Not reported	--	2 (5)	4 (6)	3 (5)	3 (4)
Sex work last month (%)					
No	535 (91)	275 (95)	458 (91)	387 (93)	455 (90)
Yes	35 (6)	9 (3)	20 (4)	20 (5)	14 (3)
Not reported	17 (3)	7 (2)	23 (5)	10 (2)	39 (8)
Condom used at last sex work last month (%)**					
Yes	31 (94)	32 (94)	17 (85)	11 (65)	12 (86)

* Percentages exclude missing data

** New variable format commenced in 2005

Table 124 Number (percentage) of respondents reporting previous testing for HIV and HCV infection and HCV treatment by year of survey

	2004	2005	2006	2007	2008
N ^o surveyed	N=587	N=291	N=501	N=417	N=508
Previous HIV test (%)					
Yes, last year	364 (62)	179 (62)	297 (59)	239 (57)	258 (51)
> 1 year ago	154 (26)	83 (29)	159 (32)	135 (32)	176 (35)
Never tested	58 (10)	29 (10)	37 (7)	40 (10)	49 (10)
Not reported	11 (2)	---	8 (2)	3 (<1)	25 (5)
Previous HCV test (%)					
Yes, last year	383 (65)	185 (64)	297 (59)	258 (62)	289 (57)
> 1 year ago	142 (24)	77 (26)	154 (31)	123 (30)	160 (32)
Never tested	54 (9)	28 (10)	38 (8)	32 (8)	36 (7)
Not reported	8 (2)	1 (<1)	12 (2)	4 (1)	23 (5)
Any treatment for HCV (%)					
	N = 248	N=129	N=207	N=188	N=238
Interferon	11 (4)	2 (2)	4 (2)	4 (2)	7 (3)
Interferon+Ribarvarin	4 (2)	5 (4)	8 (4)	8 (4)	11 (5)
Other	7 (3)	7 (5)	3 (1)	5 (3)	2 (1)
No treatment	217 (87)	112 (87)	187 (90)	163 (87)	211 (89)
Not reported	9 (4)	3 (2)	5 (2)	8 (4)	7 (3)
Current treatment for HCV					
	N=8	N=6	N=5	N=4	N=1
Interferon/Interferon+Ribarvirin	4	3	3	4	1
Other	4	3	2	---	---

HIV antibody prevalence

Table 125 HIV antibody prevalence by gender and year of survey

Year of survey	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2004	379	10 (2.6)	165	1 (0.6)	544	11 (2.0)
2005	188	4 (2.1)	88	0 (0.0)	278	4 (1.4)
2006	350	11 (3.1)	142	1 (0.7)	495	12 (2.4)
2007	279	10 (3.6)	130	0 (0.0)	413	10 (2.4)
2008	335	9 (2.7)	161	0 (0.0)	498	9 (1.8)
χ^2 trend p value		0.124		0.250		0.040

* Total includes people whose gender was not reported or reported as transgender

Table 126 HIV antibody prevalence by sexual identity, gender and year of survey

Sexual identity	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2004						
Heterosexual	335	1 (0.3)	121	0 (0.0)	456	1 (0.2)
Bisexual	13	1 (7.7)	30	1 (3.3)	43	2 (4.7)
Homosexual	16	7 (43.8)	8	0 (0.0)	24	7 (29.2)
p value		<0.001		0.2		<0.001
2005						
Heterosexual	159	1 (0.6)	67	0 (0.0)	227	1 (0.4)
Bisexual	8	0 (0.0)	14	0 (0.0)	22	0 (0.0)
Homosexual	12	3 (25.0)	5	0 (0.0)	17	3 (17.7)
p value		<0.001		---		<0.001
2006						
Heterosexual	303	0 (0.0)	104	0 (0.0)	408	0 (0.0)
Bisexual	11	0 (0.0)	22	1 (4.5)	34	1 (2.9)
Homosexual	26	11 (42.3)	12	0 (0.0)	39	11 (28.2)
p value		<0.001		0.246		<0.001
2007						
Heterosexual	249	1 (0.4)	98	0 (0.0)	347	1 (0.3)
Bisexual	7	1 (14.3)	22	0 (0.0)	31	1 (3.2)
Homosexual	18	8 (44.4)	6	0 (0.0)	25	8 (32.0)
p value		<0.001		---		<0.001
2008						
Heterosexual	302	0 (0.0)	127	0 (0.0)	430	0 (0.0)
Bisexual	10	2 (20)	27	0 (0.0)	37	2 (5.4)
Homosexual	17	7 (41)	4	0 (0.0)	21	7 (33)
p value		<0.001		---		<0.001

* Total includes people whose gender was not reported or reported as transgender

Queensland

Table 127 HIV antibody prevalence by age group, gender and year of survey

Age group	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2004						
< 20 years	12	0 (0.0)	9	0 (0.0)	21	0 (0.0)
20 – 24	56	1 (1.8)	33	0 (0.0)	89	1 (1.1)
25 – 29	78	0 (0.0)	39	0 (0.0)	117	0 (0.0)
30 + years	232	8 (3.5)	84	1 (1.2)	316	9 (2.9)
p value		0.4		1.0		0.3
2005						
< 20 years	3	0 (0.0)	4	0 (0.0)	7	0 (0.0)
20 – 24	26	0 (0.0)	10	0 (0.0)	36	0 (0.0)
25 – 29	41	0 (0.0)	22	0 (0.0)	63	0 (0.0)
30 + years	118	4 (3.4)	52	0 (0.0)	172	4 (2.3)
p value		0.5		---		0.5
2006						
< 20 years	11	0 (0)	6	0 (0)	17	0 (0)
20 – 24	35	1 (2.9)	22	0 (0)	57	1 (1.8)
25 – 29	68	0 (0)	27	0 (0)	96	0 (0)
30 + years	235	10 (4.3)	87	1 (1)	324	11 (3.4)
p value		0.356		1.000		0.267
2007						
< 20 years	6	0 (0.0)	1	0 (0.0)	7	0 (0.0)
20 – 24	2	0 (0.0)	14	0 (0.0)	42	0 (0.0)
25 – 29	48	0 (0.0)	19	0 (0.0)	67	0 (0.0)
30 + years	196	10 (5.1)	96	0 (0.0)	296	10 (3.4)
p value		0.397		---		0.365
2008						
< 20 years	11	0 (0.0)	5	0 (0.0)	16	0 (0.0)
20 – 24	27	0 (0.0)	21	0 (0.0)	48	0 (0.0)
25 – 29	55	0 (0.0)	29	0 (0.0)	84	0 (0.0)
30 + years	241	9 (3.7)	105	0 (0.0)	348	9 (2.6)
p value		0.507		---		0.452

* Total includes people whose gender was not reported or reported as transgender

Table 128 HIV antibody prevalence by duration of drug injection, gender and year of survey

Duration of drug injection	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2004						
<3 years	29	0 (0.0)	13	0 (0.0)	42	0 (0.0)
3 to 5 years	51	1 (2.0)	28	0 (0.0)	79	1 (1.3)
6 to 10 years	104	3 (2.9)	45	0 (0.0)	149	3 (2.0)
> 10 years	189	5 (2.7)	76	1 (1.3)	265	6 (2.3)
p value		1.0		1.0		1.0
2005						
<3 years	13	1 (7.7)	3	0 (0.0)	16	1 (6.3)
3 to 5 years	25	0 (0.0)	18	0 (0.0)	43	0 (0.0)
6 to 10 years	16	0 (0.0)	11	0 (0.0)	27	0 (0.0)
> 10 years	124	3 (2.4)	51	0 (0.0)	177	3 (1.7)
p value		0.4		---		0.3
2006						
<3 years	25	0 (0)	14	0 (0)	39	0 (0)
3 to 5 years	30	1 (3.3)	16	0 (0)	46	1 (2.2)
6 to 10 years	58	2 (3.5)	36	0 (0)	94	2 (2.1)
> 10 years	219	7 (3.2)	74	1 (1)	296	8 (2.7)
p value		1.000		1.000		0.953
2007						
<3 years	23	1 (4.4)	9	0 (0.0)	32	1 (3.1)
3 to 5 years	15	0 (0.0)	10	0 (0.0)	25	0 (0.0)
6 to 10 years	62	1 (1.6)	24	0 (0.0)	86	1 (1.2)
> 10 years	169	7 (4.1)	85	0 (0.0)	258	7 (2.7)
p value		0.791		---		0.799
2008						
<3 years	19	1 (5.3)	10	0 (0.0)	29	1 (3.5)
3 to 5 years	40	1 (2.5)	16	0 (0.0)	56	1 (1.8)
6 to 10 years	55	0 (0.0)	45	0 (0.0)	100	0 (0.0)
> 10 years	215	7 (3.3)	88	0 (0.0)	305	7 (2.3)
p value		0.363		---		0.287

* Total includes people whose gender was not reported or reported as transgender

Queensland

Table 129 HIV antibody prevalence by last drug injected, gender and year of survey

Last drug injected	Male		Female		Total *	
	N° tested	N° with	N° tested	N° with	N° tested	N° with
2004						
Heroin	109	2 (1.8)	45	0 (0.0)	154	2 (1.3)
Meth/Amphetamine	161	6 (3.7)	73	0 (0.0)	234	6 (2.6)
More than one	19	1 (5.3)	16	1 (6.3)	35	2 (5.7)
Other/Not reported	90	1 (1.1)	31	0 (0.0)	121	1 (0.8)
p value		0.4		0.1		0.2
2005						
Heroin	50	0 (0.0)	38	0 (0.0)	79	0 (0.0)
Meth/Amphetamine	74	1 (1.4)	30	0 (0.0)	114	1 (0.8)
More than one	6	1 (16.7)	1	0 (0.0)	8	1 (12.5)
Other/Not reported	58	2 (3.5)	13	0 (0.0)	77	2 (2.6)
p value		0.07		---		0.05
2006						
Heroin	71	1 (1.4)	41	0 (0)	113	1 (0.9)
Meth/Amphetamine	139	7 (5.0)	56	1 (1.8)	195	8 (4.1)
More than one	4	1 (25.0)	---	---	4	1 (25.0)
Other/Not reported	136	2 (1.5)	45	0 (0)	183	2 (1.1)
p value		0.043		1.000		0.022
2007						
Heroin	64	0 (0.0)	41	0 (0.0)	106	0 (0.0)
Meth/Amphetamine	97	4 (4.1)	46	0 (0.0)	143	4 (2.8)
More than one	4	0 (0.0)	2	0 (0.0)	6	0 (0.0)
Other/Not reported	114	6 (5.3)	41	0 (0.0)	158	6 (3.8)
p value		0.297		---		0.204
2008						
Heroin	83	1 (1.2)	41	0 (0.0)	124	1 (0.8)
Meth/Amphetamine	107	4 (3.7)	56	0 (0.0)	163	4 (2.5)
More than one	7	1 (14.3)	3	0 (0.0)	10	1 (10.0)
Other/Not reported	138	3 (2.2)	61	0 (0.0)	201	3 (1.5)
p value		0.186		---		0.184

* Total includes people whose gender was not reported or reported as transgender

Table 130 HIV antibody prevalence by frequency of drug injection last month, gender and year of survey

Frequency of drug injection last month	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2004						
Not last month	34	0 (0.0)	20	0 (0.0)	54	0 (0.0)
Less than weekly	78	1 (1.3)	35	0 (0.0)	113	1 (0.9)
Weekly not daily	87	6 (6.9)	41	1 (2.4)	128	7 (5.5)
Daily or more	177	2 (1.1)	69	0 (0.0)	246	2 (0.8)
p value		0.04		0.6		0.02
2005						
Not last month	74	0 (0.0)	40	0 (0.0)	114	0 (0.0)
Less than weekly	61	2 (3.3)	21	0 (0.0)	83	2 (2.4)
Weekly not daily	30	2 (6.7)	13	0 (0.0)	44	2 (4.6)
Daily or more	22	0 (0.0)	13	0 (0.0)	35	0 (0.0)
p value		0.1		---		0.1
2006						
Not last month	39	0 (0)	20	0 (0)	60	0 (0)
Less than weekly	71	6 (8.5)	27	0 (0)	99	6 (6.1)
Weekly not daily	70	2 (2.9)	24	1 (4.2)	94	3 (3.2)
Daily or more	169	3 (1.8)	71	0 (0)	241	3 (1.3)
p value		0.042		0.310		0.040
2007						
Not last month	24	2 (8.3)	8	0 (0.0)	32	2 (6.3)
Less than weekly	52	4 (7.7)	17	0 (0.0)	70	4 (5.7)
Weekly not daily	73	3 (4.1)	42	0 (0.0)	116	3 (2.6)
Daily or more	123	0 (0.0)	62	0 (0.0)	187	0 (0.0)
p value		0.005		---		0.003
2008						
Not last month	31	0 (0.0)	17	0 (0.0)	48	0 (0.0)
Less than weekly	53	2 (3.8)	25	0 (0.0)	78	2 (2.6)
Weekly not daily	92	5 (5.4)	44	0 (0.0)	136	5 (3.7)
Daily or more	154	2 (1.3)	73	0 (0.0)	229	2 (0.9)
p value		0.197		---		0.190

* Total includes people whose gender was not reported or reported as transgender

Queensland

Table 131 HIV antibody prevalence by re-use of someone else's used needle and syringe last month, gender and year of survey

Re-used someone else's used needle & syringe last month	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2004						
No	277	8 (2.9)	112	1 (0.9)	389	9 (2.3)
Yes	54	1 (1.9)	28	0 (0.0)	82	1 (1.2)
p value		1.0		1.0		1.0
2005						
No	136	4 (2.9)	57	0 (0.0)	194	4 (2.1)
Yes	25	0 (0.0)	11	0 (0.0)	37	0 (0.0)
p value		0.4		---		0.4
2006						
No	254	9 (3.5)	90	0 (0.0)	345	9 (2.6)
Yes	44	1 (2.3)	27	0 (0.0)	71	1 (1.4)
p value		1.000		---		1.000
2007						
No	207	7 (3.4)	104	0 (0.0)	314	7 (2.2)
Yes	34	0 (0.0)	16	0 (0.0)	51	0 (0.0)
p value		0.598		---		0.600
2008						
No	255	8 (3.1)	123	0 (0.0)	380	8 (2.1)
Yes	40	1 (2.5)	18	0 (0.0)	58	1 (1.7)
p value		1.000		---		1.000

* Total includes people whose gender was not reported or reported as transgender

Table 132 HIV antibody prevalence by imprisonment last year, gender and year of survey

Imprisonment last year	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2004						
No	311	9 (2.9)	149	1 (0.7)	460	10 (2.2)
Yes	63	1 (1.6)	16	0 (0.0)	79	1 (1.3)
p value		1.0		1.0		1.0
2005						
No	155	4 (2.6)	80	0 (0.0)	237	4 (1.7)
Yes	29	0 (0.0)	5	0 (0.0)	34	0 (0.0)
p value		0.4		---		0.5
2006						
No	273	10 (3.7)	130	1 (0.8)	406	11 (2.7)
Yes	57	1 (1.8)	10	0 (0.0)	67	1 (1.5)
p value		0.697		1.000		1.000
2007						
No	238	10 (4.2)	118	0 (0.0)	359	10 (2.8)
Yes	32	0 (0.0)	11	0 (0.0)	43	0 (0.0)
p value		0.613		---		0.609
2008						
No	276	7 (2.5)	134	0 (0.0)	411	7 (1.7)
Yes	36	1 (2.8)	47	0 (0.0)	53	1 (1.9)
p value		1.000		---		1.000

* Total includes people whose gender was not reported or reported as transgender

Table 133 HIV antibody prevalence by condom use at last sex, gender and year of survey

Condom use at last sex	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2004						
No	253	6 (2.4)	125	0 (0.0)	378	6 (1.6)
Yes	120	4 (3.3)	39	1 (2.6)	159	5 (3.1)
p value		0.7		0.2		0.2
2005**						
No	69	1 (1.5)	40	0 (0.0)	110	1 (0.9)
Yes	32	1 (3.1)	11	0 (0.0)	43	1 (2.3)
p value		0.6		---		0.5
2006						
No	156	3 (1.9)	77	1 (1.3)	236	4 (1.7)
Yes	21	1 (4.8)	8	0 (0.0)	29	1 (3.5)
p value		0.399		1.000		0.442
2007						
No	117	1 (0.9)	75	0 (0.0)	194	1 (0.5)
Yes	14	0 (0.0)	6	0 (0.0)	21	0 (0.0)
p value		1.000		---		1.000
2008						
No	133	2 (1.5)	78	0 (0.0)	212	2 (0.9)
Yes	15	0 (0.0)	9	0 (0.0)	24	0 (0.0)
p value		1.000		---		1.000

* Total includes people whose gender was not reported or reported as transgender

** Question changed to "condom use with regular partner in last month" in 2005 survey.

Table 134 HIV antibody prevalence by sex work last month, gender and year of survey

Sex work last month	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2004						
No	351	9 (2.6)	146	1 (0.7)	497	10 (2.0)
Yes	14	0 (0.0)	18	0 (0.0)	32	0 (0.0)
p value		1.0		1.0		1.0
2005						
No	177	4 (2.3)	83	0 (0.0)	262	4 (1.5)
Yes	5	0 (0.0)	4	0 (0.0)	9	0 (0.0)
p value		0.7		---		0.7
2006						
No	327	11 (3.7)	123	1 (0.8)	452	12 (2.7)
Yes	6	0 (0.0)	13	0 (0.0)	20	0 (0.0)
p value		1.000		1.000		1.000
2007						
No	263	10 (3.8)	118	0 (0.0)	383	10 (2.6)
Yes	8	0 (0.0)	10	0 (0.0)	20	0 (0.0)
p value				---		1.000
2008						
No	300	9 (3.0)	144	0 (0.0)	446	9 (2.0)
Yes	2	0 (0.0)	11	0 (0.0)	13	0 (0.0)
p value		1.000		---		1.000

* Total includes people whose gender was not reported or reported as transgender

Queensland

Table 135 HIV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and year of survey

Aboriginal and Torres Strait Islander origin	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2004						
No	347	9 (2.6)	156	1 (0.6)	503	10 (2.0)
Yes	23	0 (0.0)	5	0 (0.0)	28	0 (0.0)
p value		1.0		1.0		1.0
2005						
No	176	4 (2.3)	82	0 (0.0)	260	4 (1.5)
Yes	10	0 (0.0)	4	0 (0.0)	14	0 (0.0)
p value		0.6		---		0.6
2006						
No	306	9 (2.9)	128	1 (0.78)	434	10 (2.3)
Yes	34	2 (5.9)	13	0 (0.0)	48	2 (4.2)
p value		0.303		1.000		0.340
2007						
No	250	8 (3.2)	119	0 (0.0)	372	8 (2.2)
Yes	26	2 (7.7)	10	0 (0.0)	37	2 (5.4)
p value		0.240		---		0.226
2008						
No	316	9 (2.9)	136	0 (0.0)	453	9 (1.9)
Yes	7	0 (0.0)	20	0 (0.0)	28	0 (0.0)
p value		1.000		---		1.000

* Total includes people whose gender was not reported or reported as transgender

Table 136 HIV antibody prevalence by region/country of birth, gender and year of survey

Region/Country of birth	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2004						
Australia	322	7 (2.2)	138	1 (0.7)	460	8 (1.7)
Other Oceania	20	0 (0.0)	8	0 (0.0)	28	0 (0.0)
Asia	4	0 (0.0)	3	0 (0.0)	7	0 (0.0)
UK & Ireland	21	2 (9.5)	6	0 (0.0)	27	2 (7.4)
Other	6	0 (0.0)	6	0 (0.0)	12	0 (0.0)
p value		0.3		1.0		0.3
2005						
Australia	163	3 (1.8)	83	0 (0.0)	248	3 (1.2)
Other Oceania	9	0 (0.0)	---	0 (0.0)	9	0 (0.0)
Asia	1	0 (0.0)	1	0 (0.0)	2	0 (0.0)
UK & Ireland	9	1 (11.1)	4	0 (0.0)	13	1 (7.7)
Other	5	0 (0.0)	---	0 (0.0)	5	0 (0.0)
p value		0.4		---		0.4
2006						
Australia	302	8 (2.7)	125	1 (0.8)	430	9 (2.1)
Other Oceania	14	1 (7.1)	7	0 (0)	21	1 (4.8)
Asia	4	0 (0)	---	---	4	0 (0)
UK & Ireland	15	2 (13.3)	3	0 (0)	18	2 (11.1)
Other	6	0 (0)	6	0 (0)	12	0 (0)
p value		0.134		1.000		0.144
2007						
Australia	248	9 (3.6)	118	0 (0.0)	370	9 (2.4)
Other Oceania	9	0 (0.0)	6	0 (0.0)	15	0 (0.0)
Asia	--	---	1	0 (0.0)	1	0 (0.0)
UK & Ireland	11	1 (9.1)	3	0 (0.0)	14	1 (7.1)
Other	8	0 (0.0)	2	0 (0.0)	10	0 (0.0)
p value		0.663		---		0.499
2008						
Australia	283	8 (2.8)	138	0 (0.0)	422	8 (1.9)
Other Oceania	8	1 (12.5)	6	0 (0.0)	14	1 (7.1)
Asia	4	0 (0.0)	1	0 (0.0)	5	0 (0.0)
UK & Ireland	12	0 (0.0)	7	0 (0.0)	19	0 (0.0)
Other	21	0 (0.0)	6	0 (0.0)	27	0 (0.0)
p value		0.459		---		0.455

* Total includes people whose gender was not reported or reported as transgender

Queensland

Table 137 HIV antibody prevalence by main language spoken at home by parents, gender and year of survey

Main language spoken at home by parents	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2004						
English speaking	291	8 (2.8)	133	0 (0.0)	424	8 (1.9)
Non-English speaking	6	0 (0.0)	2	0 (0.0)	8	0 (0.0)
p value		1.0		---		1.0
2005						
English speaking	166	4 (2.4)	79	0 (0.0)	246	4 (1.6)
Non-English speaking	22	0 (0.0)	9	0 (0.0)	32	0 (0.0)
p value		0.5		---		0.5
2006						
English speaking	323	10 (3.1)	134	1 (0.8)	459	11 (2.4)
Non-English speaking	12	1 (8.3)	4	0 (0)	17	1 (5.9)
p value		0.335		1.000		0.357
2007						
English speaking	261	9 (3.5)	126	0 (0.0)	391	9 (2.3)
Non-English speaking	13	1 (7.7)	4	0 (0.0)	17	1 (5.9)
p value		0.390		---		0.351
2008						
English speaking	321	8 (2.5)	156	0 (0.0)	479	8 (1.7)
Non-English speaking	9	1 (11.1)	4	0 (0.0)	13	1 (7.7)
p value		0.223		---		0.216

* Total includes people whose gender was not reported or reported as transgender

HCV antibody prevalence

Table 138 HCV antibody prevalence by gender and year of survey

Year of survey	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004	381	188 (49)	166	94 (57)	547	282 (52)
2005	188	105 (56)	86	40 (47)	276	146 (53)
2006	349	185 (53)	142	88 (62)	494	276 (56)
2007	278	158 (57)	129	85 (66)	411	247 (60)
2008	333	182 (55)	159	91 (57)	494	275 (56)
χ^2 trend p value		0.685		0.318		0.911

* Total includes people whose gender was not reported or reported as transgender

Table 139 HCV antibody prevalence by sexual identity, gender and year of survey

Sexual identity	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Heterosexual	337	165 (49)	122	73 (60)	459	238 (52)
Bisexual	13	8 (62)	30	13 (43)	43	21 (49)
Homosexual	16	9 (56)	8	4 (50)	24	13 (54)
p value		0.6		0.3		0.9
2005						
Heterosexual	159	84 (53)	65	32 (49)	225	116 (52)
Bisexual	8	5 (63)	14	4 (29)	22	9 (41)
Homosexual	13	10 (77)	5	3 (60)	18	13 (72)
p value		0.2		0.3		0.1
2006						
Heterosexual	302	165 (55)	104	62 (59.6)	407	228 (56)
Bisexual	11	4 (36)	22	16 (73)	34	21 (62)
Homosexual	26	12 (46)	12	7 (58)	39	20 (51)
p value		0.345		0.521		0.669
2007						
Heterosexual	248	140 (56)	97	62 (64)	345	202 (59)
Bisexual	7	4 (57)	22	16 (73)	31	22 (71)
Homosexual	18	11 (61)	6	3 (50)	25	15 (60)
p value		0.943		0.553		0.414
2008						
Heterosexual	300	164 (55)	126	67 (53)	427	232 (54)
Bisexual	10	5 (50)	26	18 (69)	36	23 (64)
Homosexual	17	8 (47)	4	3 (75)	21	11 (52)
p value		0.819		0.292		0.556

* Total includes people whose gender was not reported or reported as transgender

Queensland

Table 140 HCV antibody prevalence by age group, gender and year of survey

Age group	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
< 20 years	12	2 (17)	9	4 (44)	21	6 (29)
20 – 24	57	15 (26)	33	15 (45)	90	30 (33)
25 – 29	78	22 (28)	39	11 (28)	117	33 (28)
30 + years	233	148 (64)	85	64 (75)	318	212 (67)
p value		<0.001		<0.001		<0.001
2005						
< 20 years	3	0 (0.0)	4	1 (25)	7	1 (14)
20 – 24	26	5 (19)	10	0 (0.0)	36	5 (14)
25 – 29	41	16 (39)	22	10 (45)	63	26 (41)
30 + years	118	84 (71)	50	29 (58)	170	114 (67)
p value		<0.001		0.007		<0.001
2006						
< 20 years	11	0 (0)	6	0 (0)	17	0 (0)
20 – 24	35	11 (31)	22	12 (55)	57	23 (40)
25 – 29	68	27 (40)	27	14 (52)	96	42 (44)
30 + years	234	146 (62)	87	62 (71)	323	210 (65)
p value		<0.001		0.002		<0.001
2007						
< 20 years	6	2 (33)	1	0 (0)	7	2 (29)
20 – 24	28	7 (25)	13	6 (46)	41	13 (32)
25 – 29	48	26 (54)	19	11 (58)	67	37 (55)
30 + years	195	122 (63)	96	68 (71)	295	194 (66)
p value		0.001		0.091		<0.001
2008						
< 20 years	11	4 (36)	5	4 (80)	16	8 (50)
20 – 24	27	6 (22)	21	9 (43)	48	15 (31)
25 – 29	54	23 (43)	28	16 (57)	82	39 (48)
30 + years	240	148 (62)	104	62 (60)	346	212 (61)
p value		<0.001		0.425		<0.001

* Total includes people whose gender was not reported or reported as transgender

Table 141 HCV antibody prevalence by duration of drug injection, gender and year of survey

Duration of drug injection	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
<3 years	29	10 (34)	13	2 (15)	42	12 (29)
3 to 5 years	52	10 (19)	28	10 (36)	80	20 (25)
6 to 10 years	104	41 (39)	46	23 (50)	150	64 (43)
> 10 years	190	125 (66)	76	57 (75)	266	182 (68)
p value		<0.001		<0.001		<0.001
2005						
<3 years	17	3 (18)	6	1 (17)	24	5 (21)
3 to 5 years	25	7 (28)	18	3 (17)	43	10 (23)
6 to 10 years	16	6 (38)	11	3 (27)	27	9 (33)
> 10 years	120	85 (71)	46	29 (63)	167	114 (68)
p value		<0.001		0.002		<0.001
2006						
<3 years	25	4 (16)	14	4 (29)	39	8 (21)
3 to 5 years	30	8 (27)	16	4 (25)	46	12 (26)
6 to 10 years	58	24 (41)	36	28 (78)	94	52 (55)
> 10 years	218	140 (64)	74	52 (70)	295	195 (66)
p value		<0.001		<0.001		<0.001
2007						
<3 years	23	4 (17)	9	2 (22)	32	6 (19)
3 to 5 years	15	4 (27)	10	5 (50)	25	9 (36)
6 to 10 years	62	26 (42)	23	11 (48)	85	37 (44)
> 10 years	168	117 (70)	85	66 (78)	257	187 (73)
p value		<0.001		<0.001		<0.001
2008						
<3 years	19	2 (11)	10	4 (40)	29	6 (21)
3 to 5 years	40	9 (23)	16	5 (31)	56	14 (25)
6 to 10 years	54	19 (35)	45	24 (53)	99	43 (43)
> 10 years	214	149 (70)	86	58 (67)	302	209 (69)
p value		<0.001		0.023		<0.001

* Total includes people whose gender was not reported or reported as transgender

Queensland

Table 142 HCV antibody prevalence by last drug injected, duration of drug injection and year of survey

Last drug injected	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Heroin	3	1 (33)	150	85 (57)	156	89 (57)
Meth/Amphetamine	24	9 (38)	210	84 (40)	235	94 (40)
More than one	1	0 (0)	32	18 (56)	35	18 (51)
Other/Not reported	14	2 (14)	104	79 (76)	121	81 (67)
p value		0.4		<0.001		<0.001
2005						
Heroin	4	2 (50)	74	42 (57)	78	44 (56)
Meth/Amphetamine	13	1 (7)	100	39 (39)	113	40 (36)
More than one	---	---	8	6 (75)	8	6 (75)
Other/Not reported	6	1 (17)	71	55 (77)	77	52 (73)
p value		0.3		<0.001		<0.001
2006						
Heroin	3	1 (33)	104	73 (70)	113	78 (69)
Meth/Amphetamine	22	2 (9)	165	70 (42)	195	73 (37)
More than one	---	---	4	3 (75)	4	3 (75)
Other/Not reported	14	5 (36)	162	113 (70)	182	122 (67)
p value		0.093		<0.001		<0.001
2007						
Heroin	4	0 (0.0)	100	66 (66)	106	67 (63)
Meth/Amphetamine	24	5 (21)	119	63 (53)	143	68 (48)
More than one	---	---	5	1 (20)	6	1 (17)
Other/Not reported	4	1 (25)	143	103 (72)	156	111 (71)
p value		1.000		0.002		<0.001
2008						
Heroin	2	1 (50)	120	82 (68)	123	84 (68)
Meth/Amphetamine	15	2 (13)	146	62 (42)	162	65 (40)
More than one	1	1 (100)	7	4 (57)	9	5 (56)
Other/Not reported	11	2 (18_)	184	118 (64)	200	121 (61)
p value		0.179		<0.001		<0.001

* Total includes people who did not report duration of drug injection

Table 143 HCV antibody prevalence by frequency of injection last month, duration of drug injection and year of survey

Frequency of drug injection last month	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Less than daily	23	8 (35)	216	108 (50)	241	117 (49)
Daily or more	14	3 (21)	233	142 (61)	249	146 (59)
p value		0.5		0.02		0.03
2005						
Less than daily	20	4 (20)	133	67 (50)	161	75 (47)
Daily or more	2	1 (50)	104	66 (63)	113	71 (63)
p value		0.3		0.04		0.01
2006						
Less than daily	17	1 (6)	169	93 (55)	192	95 (49)
Daily or more	17	6 (35)	212	137 (65)	241	150 (62)
p value		0.085		0.059		0.009
2007						
Less than daily	20	3 (15)	163	92 (56)	168	98 (53)
Daily or more	10	2 (20)	170	124 (73)	185	130 (70)
p value		1.000		0.002		0.001
2008						
Less than daily	14	4 (29)	199	106 (53)	214	110 (51)
Daily or more	9	2 (22)	213	140 (66)	225	143 (64)
p value		1.000		0.012		0.012

* Total includes people who did not report duration of drug injection

Table 144 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and year of survey

Re-used someone else's used needle & syringe last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
No	30	8 (27)	359	190 (53)	392	199 (51)
Yes	5	2 (40)	76	50 (66)	82	53 (65)
p value		0.6		0.04		0.02
2005						
No	15	4 (27)	168	90 (54)	194	100 (52)
Yes	1	0 (0)	32	20 (63)	35	21 (60)
p value		0.6		0.4		0.4
2006						
No	30	7 (23)	303	177 (58)	344	189 (55)
Yes	3	0 (0)	61	41 (67)	71	44 (62)
p value		1.000		0.252		0.296
2007						
No	27	4 (15)	280	175 (63)	313	184 (59)
Yes	3	1 (33)	46	37 (80)	50	39 (78)
p value		0.433		0.019		0.012
2008						
No	17	3 (18)	356	209 (59)	376	213 (57)
Yes	6	3 (50)	52	34 (65)	58	37 (64)
p value		0.279		0.450		0.322

* Total includes people who did not report duration of drug injection

Queensland

Table 145 HCV antibody prevalence by imprisonment last year, duration of drug injection and year of survey

Imprisonment last year	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
No	40	12 (30)	414	210 (51)	462	226 (49)
Yes	1	0 (0)	79	55 (70)	80	55 (69)
p value		1.0		0.002		0.001
2005						
No	22	4 (18)	199	108 (54)	235	119 (51)
Yes	2	1 (50)	31	20 (65)	34	22 (65)
p value		0.3		0.3		0.1
2006						
No	34	8 (24)	355	200 (56)	405	214 (53)
Yes	3	0 (0)	62	44 (71)	67	45 (67)
p value		1.000		0.036		0.034
2007						
No	31	5 (16)	317	188 (59)	358	199 (56)
Yes	1	1 (100)	39	34 (87)	42	37 (88)
p value		0.188		<0.001		<0.001
2008						
No	26	4 (15)	375	207 (55)	407	213 (52)
Yes	2	2 (100)	50	40 (80)	53	43 (81)
p value		0.040		0.001		<0.001

* Total includes people who did not report duration of drug injection

Table 146 HCV antibody prevalence by sex work last month, duration of drug injection and year of survey

Sex work last month	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
No	40	12 (30)	452	238 (53)	499	252 (51)
Yes	1	0 (0)	31	20 (65)	32	20 (63)
p value		1.0		0.2		0.2
2005						
No	24	5(21)	221	124 (56)	260	137 (53)
Yes	-	-	9	4 (44)	9	4 (44)
p value				0.5		0.6
2006						
No	37	8 (22)	394	229 (58)	451	246 (55)
Yes	---	---	20	14 (70)	20	14 (70)
p value		---		0.357		0.250
2007						
No	29	6 (21)	341	211 (62)	381	224 (59)
Yes	1	0 (0.0)	18	16 (89)	20	17 (85)
p value		1.000		0.023		0.020
2008						
No	27	5 (19)	408	238 (58)	442	246 (56)
Yes	1	1 (100)	12	6 (50)	13	7 (54)
p value		0.214		0.568		1.000

* Total includes people who did not report duration of drug injection

Table 147 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and year of survey

Aboriginal and Torres Strait Islander origin	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
No	349	173 (50)	156	86 (55)	505	259 (51)
Yes	23	11 (48)	6	5 (83)	29	16 (55)
p value		1.0		0.2		0.7
2005						
No	176	99 (56)	82	38 (46)	260	138 (53)
Yes	10	4 (40)	2	2 (100)	12	6 (50)
p value		0.3		0.1		0.8
2006						
No	305	161 (53)	128	74 (58)	433	235 (54)
Yes	34	16 (47)	13	13 (100)	48	30 (63)
p value		0.589		0.002		0.289
2007						
No	249	142 (57)	118	76 (64)	370	221 (60)
Yes	26	14 (54)	10	8 (80)	37	23 (62)
p value		0.836		0.492		0.861
2008						
No	314	168 (54)	135	72 (53)	450	241 (54)
Yes	7	3 (43)	20	16 (80)	28	20 (71)
p value		0.709		0.030		0.079

* Total includes people whose gender was not reported or reported as transgender

Queensland

Table 148 HCV antibody prevalence by region/country of birth, gender and year of survey

Region/Country of birth	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Australia	324	161 (50)	139	80 (58)	463	241 (52)
Other Oceania	20	10 (50)	8	4 (50)	28	14 (50)
Asia	4	2 (50)	3	1 (33)	7	3 (43)
UK & Ireland	21	11 (52)	6	4 (67)	27	15 (56)
Other	6	2 (33)	6	3 (50)	12	5 (42)
p value		0.9		0.9		0.9
2005						
Australia	163	92 (56)	81	38 (47)	246	131 (53)
Other Oceania	9	3 (33)			9	3 (33)
Asia	1	1 (100)	1	0 (0)	2	1 (50)
UK & Ireland	9	6 (67)	4	2 (50)	13	8 (62)
Other	5	2 (40)	---	---	5	2 (40)
p value		0.4		0.6		0.7
2006						
Australia	301	160 (53)	125	75 (60)	429	238 (55)
Other Oceania	14	4 (29)	7	7 (100)	21	11 (52)
Asia	4	2 (50)	---	---	4	2 (50)
UK & Ireland	15	10 (67)	3	2 (67)	18	12 (67)
Other	6	3 (50)	6	3 (50)	12	6 (50)
p value		0.332		0.135		0.875
2007						
Australia	247	141 (57)	117	77 (66)	368	222 (60)
Other Oceania	9	4 (44)	6	3 (50)	15	7 (47)
Asia	---	---	1	1 (100)	1	1 (100)
UK & Ireland	11	7 (64)	3	2 (67)	14	9 (64)
Other	8	4 (50)	2	2 (100)	10	6 (60)
p value		0.818		0.816		0.821
2008						
Australia	281	154 (55)	137	75 (55)	419	230 (55)
Other Oceania	8	1 (13)	6	5 (83)	14	6 (43)
Asia	4	4 (100)	1	0 (0.0)	5	4 (80)
UK & Ireland	12	6 (50)	7	3 (43)	19	9 (47)
Other	21	12 (57)	6	6 (100)	27	18 (67)
p value		0.054		0.053		0.425

* Total includes people whose gender was not reported or reported as transgender

Table 149 HCV antibody prevalence by main language spoken at home by parents, gender and year of survey

Main language spoken at home by parents	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
English speaking	292	147 (50)	134	72 (54)	426	219 (51)
Non-English speaking	6	4 (67)	2	1 (50)	8	5 (63)
p value		0.7		1.0		0.7
2005						
English speaking	166	95 (57)	77	34 (44)	244	130 (53)
Non-English speaking	22	10 (45)	9	6 (67)	32	16 (50)
p value		0.3		0.2		0.7
2006						
English speaking	322	169 (52)	134	83 (62)	458	254 (55)
Non-English speaking	12	7 (58)	4	2 (50)	17	10 (59)
p value		0.774		0.638		1.000
2007						
English speaking	260	150 (58)	125	83 (66)	389	237 (61)
Non-English speaking	13	6 (46)	4	2 (50)	17	8 (47)
p value		0.567		0.605		0.313
2008						
English speaking	319	174 (55)	155	89 (57)	476	265 (56)
Non-English speaking	9	5 (56)	4	2 (50)	13	7 (54)
p value		1.000		1.000		1.000

* Total includes people whose gender was not reported or reported as transgender

**South Australia
2004 - 2008**

Table 150 Number (percentage) of respondents by demographic characteristics and year of survey

Demographic characteristics	2004	2005	2006	2007	2008
Number of sites	6	7	6	7	7
N° surveyed	N = 255	N=211	N=200	N=220	N=196
Response (%)	42	47	36	39	45
Gender (%)					
Male	161 (63)	126 (60)	114 (57)	127 (58)	101 (52)
Female	89 (35)	84 (40)	86 (43)	91 (41)	93 (47)
Transgender	3 (1)	1 (<1)	---	2 (1)	1 (1)
Not reported	2 (1)	---	---	---	1 (1)
Sexual identity (%)					
Heterosexual	203 (80)	166 (79)	160 (80)	175 (80)	146 (74)
Bisexual	34 (13)	27 (13)	17 (9)	23 (10)	29 (15)
Homosexual	8 (3)	9 (4)	10 (5)	15 (7)	13 (7)
Not reported	10 (4)	9 (4)	13 (7)	7 (3)	8 (4)
Age and duration of injection (years)					
<i>Median age</i>	30	33	34	34	36
Age range	16 – 56	18-59	16-58	19-58	17-56
<i>Age group (%)</i>					
<25 years	65 (26)	30 (14)	27 (14)	25 (11)	19 (10)
25+ years	187 (73)	181 (86)	172 (86)	193 (88)	177 (90)
Not reported	3 (1)	---	1 (<1)	2 (1)	---
<i>Median age 1st IDU</i>	18	18	18	18	18
Age range	11 – 52	12-50	10-44	10-47	11-45
Not reported	13	4	1	5	4
<i>Median years IDU</i>	10	13	14	13	15
Range	<1 – 71	<1-38	<1-41	<1-41	1-41
<i>Duration of drug injection (%)</i>					
<3 years	24 (9)	16 (8)	15 (8)	16 (7)	13 (7)
3+ years	217 (85)	187 (89)	180 (90)	199 (90)	179 (91)
Not reported	14 (6)	8 (4)	5 (3)	5 (2)	4 (2)
Aboriginal and Torres Strait Islander origin (%)					
No	228 (90)	186 (88)	176 (88)	202 (92)	158 (81)
Yes	21 (8)	17 (8)	18 (9)	16 (7)	28 (14)
Not reported	6 (2)	8 (4)	6 (3)	2 (1)	10 (5)
Region/Country of birth (%)					
Australia	218 (85)	183 (87)	167 (84)	186 (85)	160 (82)
Other Oceania	3 (1)	2 (1)	1 (<1)	3 (1)	4 (2)
Asia	8 (3)	2 (1)	5 (3)	2 (<1)	5 (3)
UK & Ireland	13 (5)	16 (8)	18 (9)	18 (8)	17 (9)
Other	9 (4)	7 (3)	8 (4)	8 (4)	7 (4)
Not reported	4 (2)	1 (0)	1 (<1)	3 (1)	3 (2)
Main language spoken at home by parents (%)					
English speaking	179 (70)	174 (82)	166 (83)	195 (89)	179 (91)
Non-English speaking	24 (10)	37 (18)	19 (10)	23 (10)	12 (6)
Not reported	52 (20)	---	15 (8)	2 (1)	5 (3)
Imprisonment last year (%)					
No	197 (77)	179 (85)	174 (87)	173 (79)	158 (81)
Yes	43 (17)	24 (11)	18 (9)	32 (15)	21 (11)
Not reported	15 (6)	8 (4)	8 (4)	15 (7)	17 (9)
Injected in prison (%)	N = 43	N=24	N=18	N=32	N=21
Yes	22 (51)	8 (33)	4 (22)	8 (25)	7 (33)
Frequency of injection last month (%)					
Not last month	17 (7)	20 (9)	7 (4)	14 (6)	20 (10)
Less than weekly	34 (13)	42 (20)	37 (19)	40 (18)	30 (15)
Weekly not daily	68 (27)	51 (24)	58 (29)	54 (25)	51 (26)
Daily or more	129 (50)	98 (46)	96 (48)	112 (51)	93 (47)
Not reported	7 (3)	---	2 (1)	---	2 (1)

Table 151 Number (percentage) of respondents by last drug injected, injecting behaviour in the month prior to survey and year of survey

Injecting behaviour	2004	2005	2006	2007	2008
Last drug injected (%)	N=255	N=211	N=200	N=220	N=196
Anabolic steroids	1 (<1)	2 (1)	3 (2)	2 (1)	1 (1)
Cocaine	4 (2)	2 (1)	1 (<1)	2 (1)	4 (2)
Heroin	74 (29)	77 (36)	40 (20)	62 (28)	49 (25)
Methadone	12 (5)	5 (2)	7 (4)	11 (5)	10 (5)
Meth/Amphetamine	101 (40)	88 (42)	101 (51)	95 (43)	100 (51)
Morphine/Other Opioids	18 (7)	17 (8)	24 (12)	24 (11)	20 (10)
Subutex/Buprenorphine	2 (1)	4 (2)	14 (7)	10 (5)	7 (4)
More than one	16 (6)	6 (3)	3 (2)	6 (3)	2 (1)
Other	1 (<1)	1 (<1)	2 (1)	6 (3)	---
Not reported	24 (9)	7 (3)	5 (2)	2 (1)	3 (2)
N° Injected last month	N=231	N=191	N=191	N=206	N=174
Places injected last month (%)*					
Own home	191 (83)	164 (86)	168 (92)	176 (88)	151 (88)
Friend's home	112 (48)	88 (46)	85 (47)	90 (45)	74 (43)
Dealer's home	51 (22)	28 (15)	39 (21)	32 (16)	35 (20)
Street, park, beach	43 (19)	34 (18)	28 (15)	45 (23)	34 (20)
Car	89 (39)	87 (46)	63 (35)	84 (42)	66 (38)
Public toilet	43 (19)	30 (16)	33 (18)	44 (22)	36 (21)
Commercial injecting room	2 (1)	1 (1)	---	1 (<1)	1 (1)
Squat	9 (4)	4 (2)	3 (2)	10 (5)	5 (3)
Use of new sterile needles & syringes last month (%)					
All injections	162 (70)	134 (70)	143 (75)	147 (71)	126 (72)
Most of the time	57 (25)	48 (25)	27 (14)	45 (22)	34 (20)
Half of the time	6 (3)	6 (3)	10 (5)	4 (2)	6 (3)
Some of the time	2 (1)	3 (2)	3 (2)	3 (1)	5 (3)
Not last month	1 (<1)	---	2 (1)	---	1 (1)
Not reported	3 (1)	---	6 (3)	7 (3)	2 (1)
Re-used another's used needle & syringe last month (%)					
None	181 (78)	163 (85)	157 (82)	166 (81)	138 (79)
Once	8 (3)	8 (4)	5 (3)	11 (5)	7 (4)
Twice	15 (7)	6 (3)	8 (4)	8 (4)	10 (6)
3-5 times	12 (5)	2 (1)	11 (6)	8 (4)	11 (6)
>5 times	11 (5)	4 (2)	5 (3)	4 (2)	2 (1)
Not reported	4 (2)	8 (4)	5 (3)	9 (4)	6 (3)
Number of people needle & syringe was re-used after last month (%)					
None	181 (79)	157 (82)	157 (82)	166 (81)	138 (79)
One	21 (9)	12 (6)	12 (6)	10 (5)	17 (10)
Two	3 (1)	1 (1)	5 (3)	5 (2)	3 (2)
Three to five	3 (1)	1 (1)	---	3 (1)	---
More than five	2 (1)	3 (2)	---	1 (<1)	---
Don't know	7 (3)	8 (4)	7 (4)	5 (2)	8 (5)
Not reported	14 (6)	9 (5)	10 (5)	16 (8)	8 (5)
Relationship to people needle & syringe was re-used after last month (%)*					
Regular sex partner	13 (6)	15 (8)	10 (5)	15 (7)	10 (6)
Casual sex partner	3 (1)	1 (<1)	2 (1)	4 (2)	---
Close friend	11 (5)	5 (3)	7 (4)	2 (1)	7 (4)
Acquaintance	6 (3)	3 (2)	4 (2)	1 (<1)	3 (2)
Other	4 (2)	---	3 (2)	2 (1)	4 (2)
Equipment used after someone else last month (%)*					
Spoon	59 (26)	35 (18)	35 (19)	47 (24)	25 (16)
Water	56 (24)	37 (19)	32 (17)	39 (20)	36 (23)
Filter	40 (17)	20 (10)	19 (10)	29 (15)	16 (10)
Drug mix	36 (16)	24 (13)	14 (8)	15 (8)	9 (6)
Tourniquet	38 (16)	30 (16)	16 (9)	30 (15)	17 (11)
None**	---	---	112 (60)	118 (60)	100 (63)
Injected by someone after that person injected themselves or others last month (%)					
No	184 (80)	150 (79)	146 (75)	167 (81)	143 (82)
Yes	39 (17)	32 (17)	36 (19)	30 (15)	24 (14)
Not reported	8 (3)	9 (5)	9 (5)	9 (4)	7 (4)

* More than one option could be selected

** New variable in 2006

South Australia

Table 152 Number (percentage) of respondents by treatment for drug use and year of survey

Treatment for drug use	2004	2005	2006	2007	2008
N ^o surveyed	N=255	N=211	N=200	N=220	N=196
Any treatment/therapy for drug use (%)					
No	51 (20)	72 (34)	69 (35)	60 (27)	66 (34)
Yes	162 (64)	136 (64)	127 (64)	158 (72)	123 (63)
Not reported	42 (16)	3 (1)	4 (2)	2 (1)	7 (4)
History of methadone maintenance treatment (%)					
Currently	47 (18)	45 (21)	25 (13)	51 (23)	39 (20)
Previously	41 (16)	48 (23)	64 (32)	57 (26)	40 (20)
Never	89 (35)	114 (54)	108 (54)	109 (50)	112 (57)
Not reported	78 (31)	4 (2)	3 (2)	3 (1)	5 (3)
History of buprenorphine (Subutex®) treatment (%)*					
Currently	--	--	--	--	26 (13)
Previously	--	--	--	--	33 (17)
Never	--	--	--	--	130 (66)
Not reported	--	--	--	--	7 (4)
History of buprenorphine-naloxone (Suboxone®) treatment (%)*					
Currently	--	--	--	--	7 (4)
Previously	--	--	--	--	21 (11)
Never	--	--	--	--	160 (82)
Not reported	--	--	--	--	8 (4)

* New variable in 2008

Table 153 Number (percentage) of respondents by site of needle and syringe acquisition last month and year of survey

Needle & Syringe acquisition	2004	2005	2006	2007*	2008
N ^o surveyed	N=255	N=211	N=200	--	N=196
From an NSP last month (%)					
Daily or almost daily	16 (6)	7 (3)	7 (4)	--	8 (4)
A couple of times each week	61 (24)	46 (22)	47 (24)	--	40 (20)
Less than weekly	90 (35)	68 (32)	54 (27)	--	55 (28)
Once last month	49 (19)	60 (28)	59 (30)	--	44 (22)
Not in the last month	30 (12)	27 (13)	28 (14)	--	42 (21)
Not reported	9 (4)	3 (1)	5 (3)	--	7 (4)
From a chemist last month (%)					
Daily or almost daily	6 (2)	5 (2)	5 (2)	--	---
A couple of times each week	24 (9)	11 (5)	19 (10)	--	9 (5)
Less than weekly	29 (11)	23 (11)	17 (9)	--	18 (9)
Once last month	59 (23)	43 (20)	41 (21)	--	41 (21)
Not in the last month	126 (49)	125 (59)	113 (57)	--	120 (61)
Not reported	11 (4)	4 (2)	5 (2)	--	8 (4)

* Not asked in this form in 2007

Table 154 Number (percentage) of respondents by injecting equipment use, re-use and cleaning last month

Use, re-use and cleaning of any item*	Used	Re-used	Cleaned**
N ^o surveyed ^{†***}	N=174	N=174	N=174
Yes	163 (94)	82 (47)	70 (40)
No	0 (0)	74 (43)	86 (49)
Not reported	11 (6)	18 (10)	18 (10)
Use, re-use and cleaning by item type#			
1ml	149 (86)	59 (34)	50 (29)
3 ml	29 (17)	10 (6)	12 (7)
5 ml	14 (8)	5 (3)	5 (3)
10 ml	15 (9)	5 (3)	4 (2)
20 ml	4 (2)	3 (2)	3 (2)
Detachable needle (tip)	27 (16)	4 (2)	4 (2)
Winged vein infusion set (butterfly)	19 (11)	7 (4)	5 (3)
Wheel filter	27 (16)	18 (10)	15 (9)

* New question in 2008

** Includes 3 respondents that reported cleaning but not re-use in the last month

More than one item could be selected

*** Excludes respondents that did not inject in the last month

Table 155 Number (percentage) of respondents by sexual behaviour in the month prior to survey and year of survey

Sexual behaviour	2004	2005	2006	2007	2008
N° surveyed	N=255	N=211	N=200	N=220	N=196
Sex with a regular partner last month (%) **					
No	--	98 (46)	88 (44)	88 (40)	81 (41)
Yes	--	107 (51)	111 (56)	122 (55)	107 (55)
Not reported	--	6 (3)	1 (<1)	10 (5)	8 (4)
Condom used with regular partner last month (%)**					
N° surveyed		N=107	N=111	N=122	N=107
Never	--	82 (77)	81 (73)	97 (80)	78 (73)
Sometimes	--	15 (14)	14 (13)	17 (14)	17 (16)
Every time	--	8 (7)	8 (7)	6 (5)	8 (7)
Not reported	--	2 (2)	8 (7)	2 (2)	4 (4)
Sex with other partner/s last month (%)**					
No	--	172 (82)	164 (82)	171 (78)	153 (78)
Yes	--	34 (16)	30 (15)	42 (19)	31 (16)
Not reported	--	5 (2)	6 (3)	7 (3)	12 (6)
Condom used with other partner/s last month (%)**					
N° surveyed		N=34	N=30	N=42	N=31
Never	--	7 (21)	9 (30)	21 (50)	5 (16)
Sometimes	--	9 (26)	7 (23)	6 (14)	12 (39)
Every time	--	17 (50)	12 (40)	14 (33)	14 (45)
Not reported	--	1 (3)	2 (7)	1 (2)	---
Sex work last month (%)					
No	221 (87)	195 (92)	182 (91)	194 (88)	170 (87)
Yes	19 (7)	10 (5)	12 (6)	21 (10)	13 (7)
Not reported	15 (6)	6 (3)	6 (3)	5 (2)	13 (7)
Condom used at last sex work last month (%)**					
Yes	17 (94)	24 (96)	8 (80)	13 (72)	11 (85)

* Percentages exclude missing data

** New variable format commenced in 2005

Table 156 Number (percentage) of respondents reporting previous testing for HIV and HCV infection and HCV treatment by year of survey

	2004	2005	2006	2007	2008
N° surveyed	N=255	N=211	N=200	N=220	N=196
Previous HIV test (%)					
Yes, last year	134 (53)	107 (51)	99 (50)	116 (53)	94 (48)
> 1 year ago	76 (30)	77 (36)	67 (34)	76 (35)	62 (32)
Never tested	31 (12)	26 (12)	34 (17)	27 (12)	30 (15)
Not reported	14 (5)	1 (<1)	---	1 (<1)	10 (5)
Previous HCV test (%)					
Yes, last year	138 (54)	113 (54)	117 (59)	123 (56)	104 (53)
> 1 year ago	75 (30)	70 (33)	51 (26)	73 (33)	57 (29)
Never tested	34 (13)	27 (13)	32 (16)	23 (10)	29 (15)
Not reported	8 (3)	1 (<1)	---	1 (<1)	6 (3)
Any treatment for HCV (%)					
Interferon	2 (2)	2 (3)	3 (4)	---	3 (5)
Interferon+Ribarvarin	1 (1)	1 (1)	2 (3)	2 (3)	4 (7)
Other	2 (2)	1 (1)	2 (3)	1 (2)	---
No treatment	77 (93)	65 (93)	53 (78)	53 (90)	50 (85)
Not reported	2 (2)	1 (1)	8 (12)	3 (5)	2 (3)
Current treatment for HCV					
Interferon/Interferon+Ribarvirin	N=2 1	N=2 1	N=3 2	N=2 2	N=1 1
Other	1	1	1	---	---

HIV antibody prevalence

Table 157 HIV antibody prevalence by gender and year of survey

Year of survey	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2004	145	0 (0.0)	80	1 (1.3)	229	1 (0.4)
2005	122	1 (0.8)	82	0 (0.0)	205	1 (0.5)
2006	112	1 (0.9)	85	0 (0.0)	197	1 (0.5)
2007	120	2 (1.7)	89	0 (0.0)	211	2 (1.0)
2008	96	0 (0.0)	92	0 (0.0)	189	0 (0.0)
χ^2 trend p value		0.553		<0.001		0.840

* Total includes people whose gender was not reported or reported as transgender

Table 158 HIV antibody prevalence by sexual identity, gender and year of survey

Sexual identity	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2004						
Heterosexual	131	0 (0.0)	52	1 (1.9)	184	1 (0.5)
Bisexual	7	0 (0.0)	22	0 (0.0)	30	0 (0.0)
Homosexual	4	0 (0.0)	3	0 (0.0)	7	0 (0.0)
p value		---		1.0		1.0
2005						
Heterosexual	107	0 (0.0)	55	0 (0.0)	162	0 (0.0)
Bisexual	5	0 (0.0)	21	0 (0.0)	26	0 (0.0)
Homosexual	5	1 (20.0)	2	0 (0.0)	8	1 (12.5)
p value		<0.001		---		<0.001
2006						
Heterosexual	99	1 (1.0)	59	0 (0.0)	158	1 (0.6)
Bisexual	4	0 (0.0)	13	0 (0.0)	17	0 (0.0)
Homosexual	2	0 (0.0)	8	0 (0.0)	10	0 (0.0)
p value		1.000		---		1.000
2007						
Heterosexual	103	0 (0.0)	64	0 (0.0)	167	0 (0.0)
Bisexual	5	1 (20.0)	16	0 (0.0)	22	1 (4.6)
Homosexual	8	1 (12.5)	6	0 (0.0)	15	1 (6.7)
p value		0.012		---		0.032
2008						
Heterosexual	84	0 (0.0)	57	0 (0.0)	141	0 (0.0)
Bisexual	6	0 (0.0)	23	0 (0.0)	29	0 (0.0)
Homosexual	3	0 (0.0)	10	0 (0.0)	13	0 (0.0)
p value		---		---		---

* Total includes people whose gender was not reported or reported as transgender

Table 159 HIV antibody prevalence by age group, gender and year of survey

Age group	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2004						
< 20 years	4	0 (0.0)	10	0 (0.0)	14	0 (0.0)
20 – 24	28	0 (0.0)	14	0 (0.0)	42	0 (0.0)
25 – 29	33	0 (0.0)	17	0 (0.0)	50	0 (0.0)
30 + years	79	0 (0.0)	39	1 (2.6)	120	1 (0.8)
p value		---		1.0		1.0
2005						
< 20 years	1	0 (0.0)	4	0 (0.0)	5	0 (0.0)
20 – 24	12	0 (0.0)	11	0 (0.0)	23	0 (0.0)
25 – 29	17	0 (0.0)	22	0 (0.0)	39	0 (0.0)
30 + years	92	1 (1.1)	45	0 (0.0)	138	1 (0.7)
p value		1.0		---		0.9
2006						
< 20 years	1	0 (0.0)	4	0 (0.0)		0 (0.0)
20 – 24	8	0 (0.0)	13	0 (0.0)		0 (0.0)
25 – 29	17	0 (0.0)	12	0 (0.0)		0 (0.0)
30 + years	85	1 (1.2)	56	0 (0.0)		1 (0.7)
p value		1.000		---		1.000
2007						
< 20 years	---	---	1	0 (0.0)	1	0 (0.0)
20 – 24	7	0 (0.0)	13	0 (0.0)	21	0 (0.0)
25 – 29	23	0 (0.0)	21	0 (0.0)	44	0 (0.0)
30 + years	89	2 (2.3)	53	0 (0.0)	143	2 (1.4)
p value		1.000		---		1.000
2008						
< 20 years	1	0 (0.0)	1	0 (0.0)	2	0 (0.0)
20 – 24	5	0 (0.0)	10	0 (0.0)	15	0 (0.0)
25 – 29	8	0 (0.0)	15	0 (0.0)	23	0 (0.0)
30 + years	82	0 (0.0)	66	0 (0.0)	149	0 (0.0)
p value		---		---		---

* Total includes people whose gender was not reported or reported as transgender

South Australia

Table 160 HIV antibody prevalence by duration of drug injection, gender and year of survey

Duration of drug injection	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2004						
<3 years	13	0 (0.0)	9	0 (0.0)	22	0 (0.0)
3 to 5 years	21	0 (0.0)	17	0 (0.0)	38	0 (0.0)
6 to 10 years	32	0 (0.0)	18	0 (0.0)	50	0 (0.0)
10 + years	71	0 (0.0)	34	1 (2.9)	107	1 (0.9)
p value		---		1.0		1.0
2005						
<3 years	8	1 (12.5)	8	0 (0.0)	16	1 (6.3)
3 to 5 years	11	0 (0.0)	11	0 (0.0)	23	0 (0.0)
6 to 10 years	9	0 (0.0)	16	0 (0.0)	25	0 (0.0)
10 + years	89	0 (0.0)	44	0 (0.0)	133	0 (0.0)
p value		<0.01		---		0.01
2006						
<3 years	5	0 (0.0)	9	0 (0.0)	14	0 (0.0)
3 to 5 years	9	0 (0.0)	9	0 (0.0)	18	0 (0.0)
6 to 10 years	22	0 (0.0)	22	0 (0.0)	44	0 (0.0)
10 + years	72	1 (1.4)	44	0 (0.0)	116	1 (0.9)
p value		1.000		---		1.000
2007						
<3 years	8	0 (0.0)	7	0 (0.0)	15	0 (0.0)
3 to 5 years	9	1 (11.1)	11	0 (0.0)	20	1 (5.0)
6 to 10 years	18	0 (0.0)	22	0 (0.0)	41	0 (0.0)
10 + years	82	1 (1.2)	47	0 (0.0)	130	1 (0.8)
p value		0.293		---		0.350
2008						
<3 years	5	0 (0.0)	7	0 (0.0)	12	0 (0.0)
3 to 5 years	4	0 (0.0)	5	0 (0.0)	9	0 (0.0)
6 to 10 years	13	0 (0.0)	20	0 (0.0)	33	0 (0.0)
10 + years	74	0 (0.0)	57	0 (0.0)	132	0 (0.0)
p value		---		---		---

* Total includes people whose gender was not reported or reported as transgender

Table 161 HIV antibody prevalence by last drug injected, gender and year of survey

Last drug injected	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2004						
Heroin	40	0 (0.0)	23	1 (4.4)	65	1 (1.5)
Meth/Amphetamine	48	0 (0.0)	43	0 (0.0)	91	0 (0.0)
More than one	10	0 (0.0)	4	0 (0.0)	14	0 (0.0)
Other/Not reported	47	0 (0.0)	10	0 (0.0)	59	0 (0.0)
p value		---		0.5		0.6
2005						
Heroin	39	0 (0.0)	38	0 (0.0)	77	0 (0.0)
Meth/Amphetamine	54	1 (1.9)	30	0 (0.0)	84	1 (1.2)
More than one	5	0 (0.0)	1	0 (0.0)	6	0 (0.0)
Other/Not reported	24	0 (0.0)	13	0 (0.0)	38	0 (0.0)
p value		0.8		---		0.7
2006						
Heroin	24	1 (4.2)	16	0 (0.0)	40	1 (2.5)
Meth/Amphetamine	52	0 (0.0)	47	0 (0.0)	99	0 (0.0)
More than one	2	0 (0.0)	1	0 (0.0)	3	0 (0.0)
Other/Not reported	34	0 (0.0)	21	0 (0.0)	55	0 (0.0)
p value		0.232		---		0.218
2007						
Heroin	37	0 (0.0)	23	0 (0.0)	60	0 (0.0)
Meth/Amphetamine	45	1 (2.2)	45	0 (0.0)	90	1 (1.1)
More than one	3	0 (0.0)	3	0 (0.0)	6	0 (0.0)
Other/Not reported	35	1 (8.9)	18	0 (0.0)	55	1 (1.8)
p value		0.767		---		0.756
2008						
Heroin	26	0 (0.0)	21	0 (0.0)	48	0 (0.0)
Meth/Amphetamine	42	0 (0.0)	53	0 (0.0)	95	0 (0.0)
More than one	2	0 (0.0)	18	0 (0.0)	2	0 (0.0)
Other/Not reported	26	0 (0.0)	92	0 (0.0)	44	0 (0.0)
p value		---		---		---

* Total includes people whose gender was not reported or reported as transgender

South Australia

Table 162 HIV antibody prevalence by frequency of drug injection last month, gender and year of survey

Frequency of drug injection	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2004						
Not last month	7	0 (0.0)	8	0 (0.0)	15	0 (0.0)
Less than weekly	19	0 (0.0)	10	0 (0.0)	29	0 (0.0)
Weekly not daily	42	0 (0.0)	17	1 (5.9)	59	1 (1.7)
Daily or more	74	0 (0.0)	43	0 (0.0)	119	0 (0.0)
p value						
2005						
Not last month	9	1 (11.1)	9	0 (0.0)	18	1 (5.6)
Less than weekly	22	0 (0.0)	18	0 (0.0)	40	0 (0.0)
Weekly not daily	34	0 (0.0)	16	0 (0.0)	50	0 (0.0)
Daily or more	56	0 (0.0)	38	0 (0.0)	95	0 (0.0)
p value						
2006						
Not last month	5	0 (0.0)	2	0 (0.0)	7	0 (0.0)
Less than weekly	16	0 (0.0)	20	0 (0.0)	36	0 (0.0)
Weekly not daily	31	1 (3.2)	26	0 (0.0)	57	1 (1.8)
Daily or more	60	0 (0.0)	35	0 (0.0)	95	0 (0.0)
p value		0.464		---		0.513
2007						
Not last month	5	1 (20)	7	0 (0.0)	12	1 (8.3)
Less than weekly	21	0 (0.0)	18	0 (0.0)	39	0 (0.0)
Weekly not daily	31	0 (0.0)	18	0 (0.0)	49	0 (0.0)
Daily or more	63	1 (1.6)	46	0 (0.0)	111	1 (0.9)
p value		0.111		---		0.197
2008						
Not last month	5	0 (0.0)	14	0 (0.0)	19	0 (0.0)
Less than weekly	16	0 (0.0)	14	0 (0.0)	30	0 (0.0)
Weekly not daily	27	0 (0.0)	20	0 (0.0)	47	0 (0.0)
Daily or more	48	0 (0.0)	42	0 (0.0)	91	0 (0.0)
p value		---		---		---

* Total includes people whose gender was not reported or reported as transgender

Table 163 HIV antibody prevalence by re-use of someone else's used needle and syringe last month, gender and year of survey

Re-used someone else's used needle & syringe last month	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2004						
No	99	0 (0.0)	59	1 (1.7)	160	1 (0.6)
Yes	32	0 (0.0)	12	0 (0.0)	44	0 (0.0)
p value		---		1.0		1.0
2005						
No	93	0 (0.0)	65	0 (0.0)	159	0 (0.0)
Yes	14	0 (0.0)	5	0 (0.0)	19	0 (0.0)
p value		---		---		---
2006						
No	83	0 (0.0)	71	0 (0.0)	154	0 (0.0)
Yes	21	1 (4.8)	8	0 (0.0)	29	1 (3.5)
p value		0.202		---		---
2007						
No	93	1 (1.1)	67	0 (0.0)	161	1 (0.6)
Yes	18	0 (0.0)	10	0 (0.0)	29	0 (0.0)
p value		1.000		---		1.000
2008						
No	71	0 (0.0)	64	0 (0.0)	135	0 (0.0)
Yes	16	0 (0.0)	12	0 (0.0)	29	0 (0.0)
p value		---		---		---

* Total includes people whose gender was not reported or reported as transgender

Table 164 HIV antibody prevalence by imprisonment last year, gender and year of survey

Imprisonment last year	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2004						
No	107	0 (0.0)	66	1 (1.5)	174	1 (0.6)
Yes	29	0 (0.0)	11	0 (0.0)	41	0 (0.0)
p value		---		1.0		1.0
2005						
No	97	1 (1.0)	76	0 (0.0)	174	1 (0.6)
Yes	17	0 (0.0)	6	0 (0.0)	23	0 (0.0)
p value		0.7		---		0.7
2006						
No	96	1 (1.0)	75	0 (0.0)	171	1 (0.6)
Yes	12	0 (0.0)	6	0 (0.0)	18	0 (0.0)
p value		1.000		---		1.000
2007						
No	89	2 (2.3)	75	0 (0.0)	165	2 (1.2)
Yes	23	0 (0.0)	9	0 (0.0)	32	0 (0.0)
p value		1.000		---		1.000
2008						
No	73	0 (0.0)	80	0 (0.0)	154	0 (0.0)
Yes	16	0 (0.0)	5	0 (0.0)	21	0 (0.0)
p value		---		---		---

* Total includes people whose gender was not reported or reported as transgender

South Australia

Table 165 HIV antibody prevalence by condom use at last sex, gender and year of survey

Condom use at last sex	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2004						
No	98	0 (0.0)	52	1 (1.9)	152	1 (0.7)
Yes	40	0 (0.0)	19	0 (0.0)	59	0 (0.0)
p value		---		1.000		1.000
2005**						
No	44	0 (0.0)	44	0 (0.0)	88	0 (0.0)
Yes	17	0 (0.0)	11	0 (0.0)	28	0 (0.0)
p value		---		---		---
2006						
No	52	1 (1.9)	41	0 (0.0)	93	1 (1.1)
Yes	2	0 (0.0)	6	0 (0.0)	8	0 (0.0)
p value		1.000		---		1.000
2007						
No	58	1 (1.7)	51	0 (0.0)	110	1 (0.9)
Yes	3	0 (0.0)	2	0 (0.0)	5	0 (0.0)
p value		1.000		---		1.000
2008						
No	43	0 (0.0)	52	0 (0.0)	95	0 (0.0)
Yes	4	0 (0.0)	4	0 (0.0)	8	0 (0.0)
p value		---		---		---

* Total includes people whose gender was not reported or reported as transgender

**Question changed to "condom use with regular partner in last month" in 2005 survey.

Table 166 HIV antibody prevalence by sex work last month, gender and year of survey

Sex work last month	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2004						
No	133	0 (0.0)	64	0 (0.0)	197	0 (0.0)
Yes	8	0 (0.0)	9	1 (11.0)	19	1 (5.3)
p value		---		0.1		0.09
2005						
No	116	0 (0.0)	72	0 (0.0)	189	0 (0.0)
Yes	2	0 (0.0)	8	0 (0.0)	10	0 (0.0)
p value		---		---		---
2006						
No	104	1 (1.0)	75	0 (0.0)	179	1 (0.6)
Yes	3	0 (0.0)	9	0 (0.0)	12	0 (0.0)
p value		1.000		---		1.000
2007						
No	109	2 (1.8)	75	0 (0.0)	185	2 (1.1)
Yes	9	0 (0.0)	11	0 (0.0)	21	0 (0.0)
p value		1.000		---		1.000
2008						
No	85	0 (0.0)	79	0 (0.0)	165	0 (0.0)
Yes	3	0 (0.0)	10	0 (0.0)	13	0 (0.0)
p value		---		---		---

* Total includes people whose gender was not reported or reported as transgender

Table 167 HIV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and year of survey

Aboriginal and Torres Strait Islander origin	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2004						
No	136	0 (0.0)	65	1 (1.5)	205	1 (0.5)
Yes	7	0 (0.0)	12	0 (0.0)	19	0 (0.0)
p value		---		1.0		1.0
2005**						
No	110	0 (0.0)	71	0 (0.0)	182	0 (0.0)
Yes	6	0 (0.0)	9	0 (0.0)	15	0 (0.0)
p value		---		---		---
2006						
No	99	1 (1.0)	74	0 (0.0)	173	1 (0.6)
Yes	8	0 (0.0)	10	0 (0.0)	18	0 (0.0)
p value		1.000		---		1.000
2007						
No	110	2 (1.8)	82	0 (0.0)	194	2 (1.0)
Yes	9	0 (0.0)	6	0 (0.0)	15	0 (0.0)
p value		1.000		---		1.000
2008						
No	76	0 (0.0)	78	0 (0.0)	155	0 (0.0)
Yes	17	0 (0.0)	9	0 (0.0)	26	0 (0.0)
p value		---		---		---

* Total includes people whose gender was not reported or reported as transgender

South Australia

Table 168 HIV antibody prevalence by region/country of birth, gender and year of survey

Region/Country of birth	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2004						
Australia	123	0 (0.0)	72	1 (1.4)	198	1 (0.5)
Other Oceania	---	0 (0.0)	---	0 (0.0)	---	---
Asia	5	0 (0.0)	---	0 (0.0)	5	0 (0.0)
UK & Ireland	1	0 (0.0)	---	0 (0.0)	1	0 (0.0)
Other	13	0 (0.0)	8	0 (0.0)	22	0 (0.0)
p value		---		0.7		1.0
2005						
Australia	103	1 (1.0)	73	0 (0.0)	177	1 (0.6)
Other Oceania	2	0 (0.0)	---	0 (0.0)	2	0 (0.0)
Asia	1	0 (0.0)	1	0 (0.0)	2	0 (0.0)
UK & Ireland	11	0 (0.0)	5	0 (0.0)	16	0 (0.0)
Other	5	0 (0.0)	2	0 (0.0)	7	0 (0.0)
p value		1.0		---		1.0
2006						
Australia	90	1 (1.1)	74	0 (0.0)	164	1 (0.6)
Other Oceania	1	0 (0.0)	---	0 (0.0)	1	0 (0.0)
Asia	4	0 (0.0)	1	0 (0.0)	5	0 (0.0)
UK & Ireland	11	0 (0.0)	7	0 (0.0)	18	0 (0.0)
Other	5	0 (0.0)	3	0 (0.0)	8	0 (0.0)
p value		1.000		---		1.000
2007						
Australia	102	1 (1.0)	73	0 (0.0)	177	1 (0.6)
Other Oceania	1	0 (0.0)	2	0 (0.0)	3	0 (0.0)
Asia	2	0 (0.0)	---	---	2	0 (0.0)
UK & Ireland	7	1 (14.3)	11	0 (0.0)	18	1 (5.6)
Other	6	0 (0.0)	2	0 (0.0)	8	0 (0.0)
p value		0.254		---		0.276
2008						
Australia	79	0 (0.0)	75	0 (0.0)	154	0 (0.0)
Other Oceania	2	0 (0.0)	2	0 (0.0)	4	0 (0.0)
Asia	2	0 (0.0)	3	0 (0.0)	5	0 (0.0)
UK & Ireland	8	0 (0.0)	8	0 (0.0)	17	0 (0.0)
Other	3	0 (0.0)	2	0 (0.0)	5	0 (0.0)
p value		---		---		---

* Total includes people whose gender was not reported or reported as transgender

Table 169 HIV antibody prevalence by main language spoken at home by parents, gender and year of survey

Main language spoken at home by parents	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2004						
English speaking	92	0 (0.0)	66	1 (1.5)	161	1 (0.6)
Non-English speaking	17	0 (0.0)	5	0 (0.0)	22	0 (0.0)
p value		---		0.8		0.7
2005						
English speaking	94	1 (1.1)	74	0 (0.0)	169	1 (0.6)
Non-English speaking	28	0 (0.0)	8	0 (0.0)	36	0 (0.0)
p value		0.6		---		0.6
2006						
English speaking	90	1 (1.1)	74	0 (0.0)	164	1 (0.6)
Non-English speaking	13	0 (0.0)	6	0 (0.0)	19	0 (0.0)
p value		1.000		---		1.000
2007						
English speaking	102	2 (2.0)	85	0 (0.0)	188	2 (1.1)
Non-English speaking	17	0 (0.0)	3	0 (0.0)	21	0 (0.0)
p value		1.000		---		1.000
2008						
English speaking	88	0 (0.0)	85	0 (0.0)	174	0 (0.0)
Non-English speaking	5	0 (0.0)	6	0 (0.0)	11	0 (0.0)
p value		---		---		---

* Total includes people whose gender was not reported or reported as transgender

HCV antibody prevalence

Table 170 HCV antibody prevalence by gender and year of survey

Year of survey	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004	147	67 (46)	80	39 (49)	231	108 (47)
2005	122	54 (44)	82	40 (49)	205	95 (46)
2006	112	49 (44)	85	35 (41)	197	84 (43)
2007	120	50 (42)	89	31 (35)	211	82 (39)
2008	95	30 (32)	90	24 (27)	186	54 (29)
χ^2 trend p value		0.050		<0.001		<0.001

* Total includes people whose gender was not reported or reported as transgender

Table 171 HCV antibody prevalence by sexual identity, gender and year of survey

Sexual identity	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Heterosexual	133	62 (47)	52	27 (52)	186	90 (48)
Bisexual	7	5 (71)	22	9 (41)	30	15 (50)
Homosexual	4	0 (0)	3	1 (33)	7	1 (14)
p value		0.08		0.6		0.2
2005						
Heterosexual	107	47 (44)	55	28 (51)	162	75 (46)
Bisexual	5	2 (40)	21	10 (48)	26	12 (46)
Homosexual	5	1 (20)	2	1 (50)	8	3 (38)
p value		0.6		1.0		0.9
2006						
Heterosexual	99	47 (47)	59	26 (44)	158	73 (46)
Bisexual	4	0 (0)	13	8 (62)	17	8 (47)
Homosexual	2	1 (50)	8	1 (13)	10	2 (20)
p value		0.164		0.089		0.316
2007						
Heterosexual	103	41 (40)	64	26 (41)	167	67 (40)
Bisexual	5	3 (60)	16	3 (19)	22	7 (32)
Homosexual	8	4 (50)	6	2 (33)	15	6 (40)
p value		0.542		0.304		0.759
2008						
Heterosexual	84	29(35)	55	17 (31)	139	46 (33)
Bisexual	5	1 (20)	23	4 (17)	28	5 (18)
Homosexual	3	0 (0.0)	10	3 (30)	13	3 (23)
p value		0.592		0.462		0.238

* Total includes people whose gender was not reported or reported as transgender

Table 172 HCV antibody prevalence by age group, gender and year of survey

Age group	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
< 20 years	4	0 (0)	10	5 (50)	14	5 (36)
20 – 24	29	6 (21)	14	5 (36)	43	11 (26)
25 – 29	33	15 (45)	17	7 (41)	50	22 (44)
30 + years	81	46 (57)	39	22 (56)	124	70 (56)
p value		0.02		0.5		0.04
2005						
< 20 years	1	0 (0)	4	1 (25)	5	1 (20)
20 – 24	12	3 (25)	11	4 (36)	23	7 (30)
25 – 29	17	4 (24)	22	7 (32)	39	11 (28)
30 + years	92	47 (51)	45	28 (62)	138	76 (55)
p value		0.06		0.06		0.004
2006						
< 20 years	1	0 (0)	4	0 (0)	5	0 (0)
20 – 24	8	0 (0)	13	2 (15)	21	2 (10)
25 – 29	17	6 (35)	12	7 (58)	29	13 (45)
30 + years	85	42 (49)	56	26 (46)	141	68 (48)
p value		0.016		0.035		0.001
2007						
< 20 years	---	---	1	0 (0.0)	1	0 (0.0)
20 – 24	7	4 (57)	13	4 (31)	21	9 (43)
25 – 29	23	9 (39)	21	7 (33)	44	16 (36)
30 + years	89	36 (40)	53	20 (38)	143	56 (39)
p value		0.709		0.906		0.939
2008						
< 20 years	1	0 (0.0)	1	0 (0.0)	2	0 (0.0)
20 – 24	5	0 (0.0)	10	2 (20)	15	2 (13)
25 – 29	8	2 (25)	15	1 (7)	23	3 (13)
30 + years	81	28 (35)	64	21 (33)	146	49 (34)
p value		0.376		0.152		0.080

* Total includes people whose gender was not reported or reported as transgender

South Australia

Table 173 HCV antibody prevalence by duration of drug injection, gender and year of survey

Duration of drug injection	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
<3 years	13	3 (23)	9	1 (11)	22	4 (18)
3 to 5 years	22	3 (14)	17	7 (41)	39	10 (26)
6 to 10 years	32	12 (38)	18	7 (39)	50	19 (38)
10 + years	72	47 (65)	34	22 (65)	108	71 (66)
p value		<0.001		0.02		<0.001
2005						
<3 years	12	1 (8)	8	1 (13)	20	2 (10)
3 to 5 years	11	0 (0)	11	3 (27)	23	4 (17)
6 to 10 years	9	2 (22)	16	6 (38)	25	8 (32)
10 + years	85	48 (56)	44	29 (66)	129	77 (60)
p value		<0.001		0.007		<0.001
2006						
<3 years	5	1 (20)	9	0 (0.0)	14	1 (7)
3 to 5 years	9	0 (0)	9	1 (11)	18	1 (6)
6 to 10 years	22	4 (18)	22	6 (28)	44	10 (23)
10 + years	72	41 (57)	44	28 (64)	116	69 (59)
p value		<0.001		<0.001		<0.001
2007						
<3 years	8	0 (0.0)	7	4 (57)	15	4 (27)
3 to 5 years	9	3 (33)	11	2 (18)	20	5 (25)
6 to 10 years	18	6 (33)	22	7 (32)	41	13 (32)
10 + years	82	39 (48)	47	17 (36)	130	57 (44)
p value		0.043		0.405		0.209
2008						
<3 years	5	0 (0.0)	7	1 (14)	12	1 (8)
3 to 5 years	4	0 (0.0)	5	1 (20)	9	1 (11)
6 to 10 years	12	4 (33)	19	2 (11)	31	6 (19)
10 + years	74	26 (35)	57	20 (35)	132	46 (35)
p value		0.279		0.146		0.060

* Total includes people whose gender was not reported or reported as transgender

Table 174 HCV antibody prevalence by last drug injected, duration of drug injection and year of survey

Last drug injected	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Heroin	5	3 (60)	59	38 (64)	65	42 (65)
Meth/Amphetamine	13	1 (8)	77	24 (31)	92	26 (28)
More than one	2	0 (0)	11	4 (36)	14	5 (36)
Other/Not reported	2	0 (0)	50	34 (68)	60	35 (58)
p value		0.08		<0.001		<0.001
2005						
Heroin	6	2 (33)	71	40 (56)	77	42 (55)
Meth/Amphetamine	12	0 (0)	72	27 (38)	84	27 (32)
More than one	-	-	6	5 (83)	6	5 (83)
Other/Not reported	2	0 (0)	36	21 (58)	38	21 (55)
p value						
2006						
Heroin	1	0 (0)	39	23 (59)	40	23 (58)
Meth/Amphetamine	8	0 (0)	89	22 (25)	99	22 (22)
More than one	---	---	3	0 (0)	3	0 (0)
Other/Not reported	5	1 (7)	47	35 (74)	55	39 (71)
p value		0.429		0.0		0.0
2007						
Heroin	3	2 (67)	57	29 (51)	60	31 (52)
Meth/Amphetamine	9	1 (11)	78	19 (24)	90	23 (26)
More than one	1	0 (0.0)	5	1 (20)	6	1 (17)
Other/Not reported	2	1 (50)	51	26 (51)	55	27 (49)
p value		0.169		0.002		0.002
2008						
Heroin	3	1 (33)	45	22 (49)	48	23 (48)
Meth/Amphetamine	7	0 (0.0)	85	12 (14)	92	12 (13)
More than one	---	---	2	2 (100)	2	2 (100)
Other/Not reported	2	0 (0.0)	40	17 (43)	44	17 (39)
p value		0.417		<0.001		<0.001

* Total includes people who did not report duration of drug injection

South Australia

Table 175 HCV antibody prevalence by frequency of injection last month, duration of drug injection and year of survey

Frequency of drug injection last month	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Less than daily	7	1 (14)	80	35 (44)	90	37 (41)
Daily or more	13	3 (23)	103	60 (58)	119	66 (55)
p value		1.0		0.05		0.04
2005						
Less than daily	15	2 (13)	92	48 (52)	110	51 (46)
Daily or more	5	0 (0)	85	41 (48)	95	44 (46)
p value		0.4		0.6		>0.9
2006						
Less than daily	9	1 (11)	84	36 (43)	93	37 (40)
Daily or more	3	0 (0)	89	43 (48)	95	45 (47)
p value		1.000		0.542		0.307
2007						
Less than daily	10	1 (10)	77	33 (43)	88	35 (40)
Daily or more	4	2 (50)	103	40 (39)	111	44 (40)
p value		0.176		0.646		1.000
2008						
Less than daily	6	0 (0.0)	68	19 (28)	74	19 (26)
Daily or more	4	1 (25)	87	30(34)	91	31 (34)
p value		0.400		0.487		0.307

* Total includes people who did not report duration of drug injection

Table 176 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and year of survey

Re-used someone else's used needle & syringe last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
No	12	2 (17)	143	70 (49)	161	76 (47)
Yes	7	2 (29)	37	23 (62)	44	25 (57)
p value		0.6		0.2		0.3
2005						
No	13	2 (15)	139	67 (48)	159	72 (45)
Yes	2	0 (0)	17	11 (65)	19	11 (58)
p value		0.6		0.2		0.3
2006						
No	10	0 (0)	141	61 (43)	154	63 (41)
Yes	1	0 (0)	28	14 (50)	29	14 (48)
p value		---		0.538		0.540
2007						
No	13	2 (15)	145	61 (42)	161	64 (40)
Yes	1	1 (100)	27	9 (33)	29	11 (38)
p value		0.214		0.523		1.000
2008						
No	7	0 (0.0)	125	40 (32)	132	40 (30)
Yes	3	1 (33)	26	8 (31)	29	9 (31)
p value		0.300		1.000		1.000

* Total includes people who did not report duration of drug injection

Table 177 HCV antibody prevalence by imprisonment last year, duration of drug injection and year of survey

Imprisonment last year	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
No	19	4 (21)	149	68 (46)	176	75 (43)
Yes	2	0 (0)	39	25 (64)	41	25 (61)
p value		1.0		0.04		0.03
2005						
No	18	2 (11)	151	72 (48)	174	75 (43)
Yes	1	0 (0)	20	11 (55)	23	13 (57)
p value		0.7		0.5		0.2
2006						
No	14	0 (0)	153	67 (44)	171	70 (41)
Yes	---	---	17	8 (47)	18	9 (50)
p value		---		0.803		0.464
2007						
No	12	3 (25)	150	51 (34)	165	55 (33)
Yes	1	0 (0.0)	30	20 (67)	32	21 (66)
p value		1.000		0.002		0.001
2008						
No	11	1 (9)	139	42 (30)	151	43 (28)
Yes	---	---	21	8 (38)	21	8 (38)
p value		---		0.460		0.445

* Total includes people who did not report duration of drug injection

Table 178 HCV antibody prevalence by sex work last month, duration of drug injection and year of survey

Sex work last month	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
No	18	4 (22)	171	84 (49)	199	92 (46)
Yes	2	0 (0)	17	11 (65)	19	11 (58)
p value		1.0		0.2		0.3
2005						
No	19	2 (11)	163	84 (52)	189	89 (47)
Yes	-	-	9	5 (56)	10	6 (60)
p value				0.8		0.4
2006						
No	12	1 (8)	163	72 (44)	179	75 (42)
Yes	2	0 (0)	10	6 (60)	12	6 (50)
p value		1.000		0.349		0.764
2007						
No	12	3 (25)	169	70 (41)	185	75 (41)
Yes	2	0 (0.0)	18	4 (22)	21	5 (24)
p value		1.000		0.134		0.161
2008						
No	11	1 (9)	150	48 (32)	162	49 (30)
Yes	---	---	13	5 (38)	13	5 (38)
p value		---		0.759		0.543

* Total includes people who did not report duration of drug injection

South Australia

Table 179 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and year of survey

Aboriginal and Torres Strait Islander origin	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
No	138	61 (44)	65	30 (46)	207	93 (45)
Yes	7	5 (71)	12	8 (67)	19	13 (68)
p value		0.2		0.2		0.05
2005						
No	110	45 (41)	71	34 (48)	182	80 (44)
Yes	6	5 (83)	9	5 (56)	15	10 (67)
p value		0.04		0.7		0.09
2006						
No	99	40 (40)	74	30 (41)	173	70 (41)
Yes	8	6 (75)	10	4 (40)	18	10 (56)
p value		0.072		1.000		0.315
2007						
No	110	43 (39)	82	29 (35)	194	73 (38)
Yes	9	6 (67)	6	2 (33)	15	8 (53)
p value		0.159		1.000		0.275
2008						
No	75	23 (31)	77	23 (30)	153	46 (30)
Yes	17	6 (35)	8	0 (0.0)	25	6 (24)
p value		0.775		0.101		0.640

* Total includes people whose gender was not reported or reported as transgender

Table 180 HCV antibody prevalence by region/country of birth, gender and year of survey

Region/Country of birth	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Australia	124	56 (45)	72	33 (46)	199	91 (46)
Other Oceania	---	---	---	---	---	---
Asia	5	4 (80)	---	---	5	4 (80)
UK & Ireland	1	1 (100)	---	---	1	1 (100)
Other	14	4 (29)	9	4 (44)	23	10 (43)
p value		0.2		0.1		0.3
2005						
Australia	103	48 (47)	73	34 (47)	177	83 (47)
Other Oceania	2	0 (0)	---	---	2	0 (0)
Asia	1	1 (100)	1	1 (100)	2	2 (100)
UK & Ireland	11	4 (36)	5	4 (80)	16	8 (50)
Other	5	1 (20)	2	1 (50)	7	2 (29)
p value		0.3		0.4		0.3
2006						
Australia	90	37 (41)	74	29 (39)	164	66 (41)
Other Oceania	1	0 (0)	---	---	1	0 (0)
Asia	4	1 (25)	1	0 (0)	5	1 (20)
UK & Ireland	11	7 (64)	7	4 (57)	18	11 (61)
Other	5	3 (60)	3	2 (67)	8	5 (63)
p value		0.442		0.601		0.170
2007						
Australia	102	41 (40)	73	23 (32)	177	65 (37)
Other Oceania	1	0 (0.0)	2	0 (0.0)	3	0 (0.0)
Asia	2	2 (100)	---	---	2	2 (100)
UK & Ireland	7	4 (57)	11	7 (64)	18	11 (61)
Other	6	3 (50)	2	1 (50)	8	4 (50)
p value		0.361		0.087		0.041
2008						
Australia	79	24 (30)	73	15 (21)	152	39 (26)
Other Oceania	2	1 (50)	2	0 (0.0)	4	1 (25)
Asia	2	2 (100)	3	2 (67)	5	4 (80)
UK & Ireland	7	1 (14)	8	4 (50)	16	5 (31)
Other	3	2 (67)	2	2 (100)	5	4 (80)
p value		0.091		0.010		0.009

* Total includes people whose gender was not reported or reported as transgender

South Australia

Table 181 HCV antibody prevalence by main language spoken at home by parents, gender and year of survey

Main language spoken at home by parents	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
English speaking	93	46 (49)	66	32 (48)	162	79 (49)
Non-English speaking	17	5 (29)	5	3 (60)	22	8 (36)
p value		0.1		0.6		0.3
2005						
English speaking	94	40 (43)	74	35 (47)	169	76 (45)
Non-English speaking	28	14 (50)	8	5 (63)	36	19 (53)
p value		0.5		0.4		0.4
2006						
English speaking	90	39 (43)	74	33 (45)	164	72 (44)
Non-English speaking	13	5 (38)	6	1 (17)	19	6 (32)
p value		1.000		0.233		0.338
2007						
English speaking	102	40 (39)	85	30 (35)	188	70 (37)
Non-English speaking	17	9 (53)	3	1 (33)	21	11 (52)
p value		0.301		1.000		0.237
2008						
English speaking	87	26 (30)	83	21 (25)	171	47 (27)
Non-English speaking	5	4 (80)	6	2 (33)	11	6 (55)
p value		0.037		0.646		0.083

* Total includes people whose gender was not reported or reported as transgender

Tasmania
2004 - 2008

Table 182 Number (percentage) of respondents by demographic characteristics and year of survey

Demographic characteristics	2004	2005	2006	2007	2008
Number of sites	3	3	2	5	4
N ^o surveyed	N=107	N=137	N=150	N=168	N=57
Response (%)	85		50	45	25
Gender (%)					
Male	66 (62)	86 (63)	94 (63)	111 (66)	33 (58)
Female	40 (37)	51 (37)	56 (37)	57 (34)	24 (42)
Transgender	---	---	---	---	---
Not reported	1 (1)	---	---	---	---
Sexual identity (%)					
Heterosexual	94 (88)	124 (91)	130 (87)	138 (82)	46 (81)
Bisexual	5 (5)	5 (4)	14 (9)	12 (7)	6 (11)
Homosexual	---	1 (1)	---	13 (8)	3 (5)
Not reported	8 (7)	7 (5)	6 (4)	5 (3)	2 (4)
Age and duration of injection (years)					
<i>Median age</i>	32	31	33	34	36
<i>Age range</i>	17 – 57	18-53	16-60	15-57	21-58
Age group (%)					
<25 years	13 (12)	23 (17)	21 (14)	26 (10)	3 (5)
25+ years	93 (87)	114 (83)	129 (86)	152 (90)	54 (95)
Not reported	1 (1)	---	---	---	---
<i>Median age 1st IDU</i>	19	19	18	18	18
<i>Age range</i>	9 – 46	11-49	11-47	10-44	11-38
Not reported	4	7	---	3	1
<i>Median years IDU</i>	12	11	12	14	16.5
<i>Range</i>	<1–35	<1-34	<1-40	<1-40	1-41
Duration of drug injection (%)					
<3 years	8 (7)	7 (5)	9 (6)	10 (6)	1 (2)
3+ years	95 (89)	122 (89)	137 (91)	155 (92)	55 (96)
Not reported	4 (4)	8 (6)	4 (3)	3 (2)	1 (2)
Aboriginal and Torres Strait Islander origin (%)					
No	96 (90)	121 (88)	121 (81)	141 (84)	50 (88)
Yes	8 (7)	12 (9)	25 (17)	25 (15)	5 (9)
Not reported	3 (3)	4 (3)	4 (3)	2 (1)	2 (4)
Region/Country of birth (%)					
Australia	95 (89)	138 (82)	138 (92)	159 (95)	48 (84)
Other Oceania	2 (2)	---	1 (<1)	3 (2)	---
Asia	---	---	---	---	---
UK & Ireland	3 (3)	139 (82)	6 (4)	3 (2)	6 (11)
Other	4 (3)	140 (82)	2 (1)	---	---
Not reported	3 (3)	141 (82)	3 (2)	3 (2)	3 (5)
Main language spoken at home by parents (%)					
English speaking	71 (66)	115 (84)	136 (91)	165 (98)	55 (96)
Non-English speaking	3 (3)	22 (16)	2 (1)	3 (2)	2 (4)
Not reported	33 (31)	---	12 (8)	---	---
Imprisonment last year (%)					
No	91 (85)	113 (82)	126 (84)	139 (83)	45 (79)
Yes	14 (13)	18 (13)	19 (13)	25 (15)	7 (12)
Not reported	2 (2)	6 (4)	5 (3)	4 (2)	5 (9)
Injected in prison (%)					
Yes	N=14 10 (71)	N=18 89 (61)	N=19 3 (16)	N=25 11 (44)	N=7 3 (43)
Frequency of injection last month (%)					
Not last month	3 (3)	6 (4)	4 (3)	6 (4)	2 (4)
Less than weekly	20 (19)	31 (23)	31 (21)	48 (29)	8 (14)
Weekly not daily	38 (35)	46 (34)	41 (27)	55 (33)	23 (40)
Daily or more	45 (42)	54 (39)	73 (49)	58 (35)	24 (42)
Not reported	1 (1)	---	1 (<1)	1 (<1)	---

Tasmania

Table 183 Number (percentage) of respondents by last drug injected, injecting behaviour in the month prior to survey and year of survey

Injecting behaviour	2004	2005	2006	2007	2008
Last drug injected (%)	N=107	N=137	N=150	N=168	N=57
Anabolic steroids	1 (1)	1 (<1)	1 (<1)	---	---
Cocaine	---	---	1 (<1)	---	---
Heroin	---	2 (1)	3 (2)	3 (2)	4 (7)
Methadone	41 (38)	30 (22)	35 (23)	54 (32)	24 (42)
Meth/Amphetamine	33 (31)	64 (47)	73 (49)	50 (30)	13 (23)
Morphine/Other Opioids	20 (19)	27 (20)	24 (16)	43 (26)	12 (21)
Subutex/Buprenorphine	1 (1)	1 (<1)	--	1 (<1)	1 (2)
More than one	9 (8)	6 (4)	6 (4)	5 (3)	1 (2)
Other	---	2 (1)	--	9 (5)	1 (2)
Not reported	2 (2)	4 (3)	5 (3)	3 (2)	1 (2)
N° Injected last month	N=103	N=131	N=145	N=161	N=55
Places injected last month (%)*					
Own home	87 (85)	115 (88)	121 (86)	147 (91)	50 (94)
Friend's home	35 (34)	51 (39)	52 (37)	72 (45)	13 (25)
Dealer's home	7 (7)	11 (8)	11 (8)	17 (11)	6 (11)
Street, park, beach	6 (6)	10 (8)	13 (9)	18 (11)	4 (8)
Car	22 (21)	36 (27)	52 (37)	51 (32)	15 (28)
Public toilet	14 (14)	18 (14)	19 (13)	24 (15)	9 (17)
Commercial injecting room	---	---	---	1 (<1)	---
Squat	1 (1)	---	1 (<1)	5 (3)	---
Use of new sterile needles & syringes last month (%)					
All injections	88 (85)	112 (86)	114 (79)	131 (81)	40 (73)
Most of the time	10 (10)	19 (15)	26 (18)	27 (17)	13 (24)
Half of the time	---	---	1 (<1)	---	---
Some of the time	1 (1)	---	1 (<1)	1 (<1)	---
Not last month	---	---	---	---	---
Not reported	4 (4)	---	3 (2)	2 (1)	2 (4)
Re-used another's used needle & syringe last month (%)					
None	86 (83)	121 (92)	127 (88)	132 (82)	44 (80)
One	4 (4)	3 (2)	4 (3)	8 (5)	2 (4)
Twice	5 (5)	2 (2)	5 (3)	3 (2)	2 (4)
3-5 times	2 (2)	2 (2)	---	6 (4)	3 (5)
>5 times	1 (1)	---	2 (1)	2 (1)	2 (4)
Not reported	5 (5)	---	7 (5)	10 (6)	2 (4)
Number of people needle & syringe was re-used after last month (%)					
None	86 (83)	114 (87)	127 (88)	132 (82)	44 (80)
One	5 (5)	7 (5)	5 (3)	6 (4)	3 (5)
Two	---	---	---	---	---
Three to five	1 (1)	---	1 (<1)	---	1 (2)
More than five	1 (1)	1 (1)	---	1 (<1)	---
Don't know	2 (2)	5 (4)	1 (<1)	4 (2)	1 (2)
Not reported	8 (8)	4 (3)	11 (8)	18 (11)	6 (11)
Relationship to people needle & syringe was re-used after last month (%)*					
Regular sex partner	5 (5)	5 (4)	5 (3)	7 (4)	4 (7)
Casual sex partner	---	---	1 (<1)	1 (<1)	---
Close friend	3 (3)	4 (3)	2 (1)	2 (1)	2 (4)
Acquaintance	---	1 (1)	1 (<1)	2 (1)	---
Other	1 (1)	2 (2)	---	---	---
Equipment used after someone else last month (%)*					
Spoon	6 (6)	9 (7)	11 (8)	16 (11)	4 (9)
Water	10 (10)	18 (14)	15 (11)	17 (11)	5 (11)
Filter	4 (4)	9 (7)	3 (2)	10 (7)	---
Drug mix	4 (4)	11 (8)	6 (4)	5 (3)	1 (2)
Tourniquet	8 (8)	12 (9)	12 (8)	12 (8)	7 (16)
None**	---	---	98 (69)	112 (75)	36 (82)
Injected by someone after that person injected themselves or others last month (%)					
No	86 (83)	110 (84)	111 (77)	130 (81)	47 (85)
Yes	11 (11)	14 (11)	27 (19)	21 (13)	4 (7)
Not reported	6 (6)	7 (5)	7 (5)	10 (6)	4 (7)

* More than one option could be selected

** New variable in 2006

Table 184 Number (percentage) of respondents by treatment for drug use and year of survey

Treatment for drug use	2004	2005	2006	2007	2008
N° surveyed	N=107	N=137	N=150	N=168	N=57
Any treatment/therapy for drug use (%)					
No	34 (32)	50 (37)	51 (34)	46 (27)	13 (23)
Yes	73 (68)	85 (62)	95 (63)	120 (71)	43 (75)
Not reported	---	2 (1)	4 (3)	2 (1)	1 (2)
History of methadone maintenance treatment (%)					
Currently	48 (45)	49 (36)	52 (35)	66 (39)	24 (42)
Previously	15 (14)	19 (14)	24 (16)	41 (24)	12 (21)
Never	43 (40)	67 (49)	70 (47)	61 (36)	21 (37)
Not reported	1 (1)	2 (1)	4 (3)	---	---
History of buprenorphine (Subutex®) treatment (%)*					
Currently	--	--	--	--	4 (7)
Previously	--	--	--	--	10 (18)
Never	--	--	--	--	39 (68)
Not reported	--	--	--	--	4 (7)
History of buprenorphine-naloxone (Suboxone®) treatment (%)*					
Currently	--	--	--	--	2 (4)
Previously	--	--	--	--	2 (4)
Never	--	--	--	--	48 (84)
Not reported	--	--	--	--	5 (9)

* New variable in 2008

Table 185 Number (percentage) of respondents by site of needle and syringe acquisition last month and year of survey

Needle & Syringe acquisition	2004	2005	2006	2007*	2008
N° surveyed	N=107	N=137	N=150	--	N=57
From an NSP last month (%)					
Daily or almost daily	10 (9)	12 (9)	19 (13)	--	7 (12)
A couple of times each week	45 (42)	39 (28)	64 (43)	--	29 (51)
Less than weekly	26 (24)	45 (33)	27 (18)	--	16 (28)
Once last month	19 (18)	28 (20)	22 (15)	--	3 (5)
Not in the last month	5 (5)	11 (8)	16 (11)	--	1 (2)
Not reported	2 (2)	2 (1)	2 (1)	--	1 (2)
From a chemist last month (%)					
Daily or almost daily	4 (4)	3 (2)	8 (5)	--	3 (5)
A couple of times each week	5 (5)	15 (11)	23 (15)	--	8 (14)
Less than weekly	5 (5)	14 (10)	23 (15)	--	1 (2)
Once last month	13 (12)	19 (14)	19 (13)	--	3 (5)
Not in the last month	73 (68)	79 (58)	72 (48)	--	40 (70)
Not reported	7 (6)	7 (5)	5 (3)	--	2 (4)

* Not asked in this form in 2007

Table 186 Number (percentage) of respondents by injecting equipment use, re-use and cleaning last month

Use, re-use and cleaning of any item*	Used	Re-used	Cleaned**
N° surveyed***	N=55	N=55	N=55
Yes	51 (93)	28 (51)	26 (47)
No	2 (4)	24 (44)	25 (45)
Not reported	2 (4)	3 (5)	4 (7)
Use, re-use and cleaning by item type#			
1ml	17 (31)	7 (13)	6 (11)
3 ml	13 (24)	6 (11)	6 (11)
5 ml	8 (15)	3 (5)	3 (5)
10 ml	12 (22)	2 (4)	4 (7)
20 ml	24 (44)	11 (20)	8 (15)
Detachable needle (tip)	18 (33)	2 (4)	2 (4)
Winged vein infusion set (butterfly)	32 (58)	15 (27)	13 (24)
Wheel filter	17 (31)	2 (4)	0 (0)

* New question in 2008

** Includes 1 respondent that reported cleaning but not re-use in the last month

More than one item could be selected

*** Excludes respondents that did not inject in the last month

Tasmania

Table 187 Number (percentage) of respondents by sexual behaviour in the month prior to survey and year of survey

Sexual behaviour	2004	2005	2006	2007	2008
N° surveyed	N=107	N=137	N=150	N=168	N=57
Sex with a regular partner last month (%) **					
No	--	45 (33)	55 (37)	63 (38)	23 (40)
Yes	--	88 (64)	91 (61)	103 (61)	34 (60)
Not reported	--	4 (3)	4 (3)	2 (1)	---
Condom used with regular partner last month (%)**					
N° surveyed		N=88	N=91	N=103	N=34
Never	--	67 (76)	70 (77)	74 (72)	21 (62)
Sometimes	--	9 (10)	9 (10)	15 (15)	5 (15)
Every time	--	3 (3)	8 (9)	9 (9)	7 (21)
Not reported	--	9 (10)	4 (4)	5 (5)	1 (3)
Sex with other partner/s last month (%)**					
No	--	113 (82)	132 (88)	145 (86)	48 (84)
Yes	--	21 (15)	9 (6)	16 (10)	7 (12)
Not reported	--	3 (2)	9 (6)	7 (4)	2 (4)
Condom used with other partner/s last month (%)**					
N° surveyed		N=21	N=9	N=16	N=7
Never	--	7 (33)	4 (44)	7 (44)	2 (29)
Sometimes	--	6 (29)	3 (33)	5 (31)	2 (29)
Every time	--	7 (33)	2 (22)	3 (19)	3 (43)
Not reported	--	1 (5)	---	1 (6)	---
Sex work last month (%)					
No	93 (87)	129 (94)	134 (89)	157 (93)	54 (95)
Yes	10 (9)	4 (3)	5 (3)	3 (2)	2 (4)
Not reported	4 (4)	4 (3)	11 (7)	8 (5)	1 (2)
Condom used at last sex work last month (%)*					
Yes	5 (56)	---	4 (80)	3 (100)	1 (100)

* Percentages exclude missing data

** New variable format commenced in 2005

Table 188 Number (percentage) of respondents reporting previous testing for HIV and HCV infection and HCV treatment by year of survey

	2004	2005	2006	2007	2008
N° surveyed	N=107	N=137	N=150	N=168	N=57
Previous HIV test (%)					
Yes, last year	58 (54)	61 (45)	71 (47)	92 (55)	35 (61)
> 1 year ago	28 (26)	49 (36)	50 (33)	54 (32)	16 (28)
Never tested	18 (17)	25 (18)	25 (17)	22 (13)	5 (9)
Not reported	3 (3)	2 (1)	4 (3)	---	1 (2)
Previous HCV test (%)					
Yes, last year	65 (61)	70 (51)	81 (54)	99 (59)	37 (65)
> 1 year ago	23 (21)	43 (31)	44 (29)	53 (32)	17 (30)
Never tested	17 (16)	23 (17)	22 (15)	16 (10)	3 (5)
Not reported	2 (2)	1 (1)	3 (2)	---	---
Any treatment for HCV (%)					
Interferon	1 (100)	1 (50)	3 (60)	---	---
Interferon+Ribarvarin	---	---	2 (40)	---	1 (3)
Other	---	1 (50)	---	---	29 (94)
No treatment	---	---	---	---	---
Not reported	---	---	---	---	1 (3)
Current treatment for HCV	N=0	N=0	N=0	N=0	N=0

HIV antibody prevalence

Table 189 HIV antibody prevalence by gender and year of survey

Year of survey	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2004	65	0 (0.0)	39	0 (0.0)	105	0 (0.0)
2005	86	0 (0.0)	51	0 (0.0)	137	0 (0.0)
2006	94	0 (0.0)	56	0 (0.0)	150	0 (0.0)
2007	110	0 (0.0)	56	0 (0.0)	166	0 (0.0)
2008	33	0 (0.0)	24	0 (0.0)	57	0 (0.0)
χ^2 trend p value		---		---		---

* Total includes people whose gender was not reported or reported as transgender

HCV antibody prevalence

Table 190 HCV antibody prevalence by gender and year of survey

Year of survey	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004	66	30 (45)	39	20 (51)	106	50 (47)
2005	86	51 (59)	51	30 (59)	137	81 (59)
2006	93	53 (57)	55	32 (58)	148	85 (57)
2007	91	52 (57)	43	30 (70)	134	82 (61)
2008	32	26 (81)	24	19 (79)	56	45 (80)
χ^2 trend p value		0.012		0.016		<0.001

* Total includes people whose gender was not reported or reported as transgender

Table 191 HCV antibody prevalence by sexual identity, gender and year of survey

Sexual identity	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Heterosexual	59	28 (47)	34	17 (50)	93	45 (48)
Bisexual	1	1 (100)	4	3 (75)	5	4 (80)
Homosexual	-	-	-	-	-	-
P value		0.3		0.2		0.2
2005						
Heterosexual	82	48 (59)	42	26 (62)	124	74 (60)
Bisexual	3	2 (67)	2	0 (0)	5	2 (40)
Homosexual		---	1	1 (100)	1	1 (100)
2006						
Heterosexual	86	51 (59)	43	23 (53)	129	74 (57)
Bisexual	5	2 (40)	8	7 (88)	13	9 (69)
Homosexual		---		---		---
p value		0.646		0.119		0.558
2007						
Heterosexual	83	46 (55)	28	18 (64)	111	64 (58)
Bisexual	3	2 (67)	9	7 (78)	12	9 (75)
Homosexual	5	4 (80)	4	4 (100)	9	8 (89)
p value		0.626		0.432		
2008						
Heterosexual	31	25 (81)	14	11 (79)	45	36 (80)
Bisexual		---	6	5 (83)	6	5 (83)
Homosexual	1	1 (100)	2	2 (100)	3	3 (100)
p value		1.000		1.000		1.000

* Total includes people whose gender was not reported or reported as transgender

Tasmania

Table 192 HCV antibody prevalence by age group, gender and year of survey

Age group	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
< 20 years	1	0 (0)	4	0 (0)	5	0 (0)
20 – 24	6	2 (33)	2	2 (100)	8	4 (50)
25 – 29	13	7 (54)	9	4 (44)	22	11 (50)
30 + years	46	21 (46)	24	14 (58)	71	35 (49)
p value		0.02		0.5		0.04
2005						
< 20 years	-	-	2	0 (0)	2	0 (0)
20 – 24	12	6 (50)	9	4 (44)	21	10 (48)
25 – 29	19	10 (53)	10	7 (70)	29	17 (59)
30 + years	55	35 (64)	30	19 (63)	85	54 (64)
p value		0.5		0.2		0.2
2006						
< 20 years	---	---	3	1 (33)	3	1 (33)
20 – 24	8	2 (25)	9	4 (44)	17	6 (35)
25 – 29	24	13 (54)	11	6 (55)	35	19 (54)
30 + years	61	38 (62)	32	21 (66)	93	59 (63)
p value		0.137		0.534		0.111
2007						
< 20 years	1	1 (100)	3	0 (0.0)	4	1 (25)
20 – 24	2	2 (100)	4	3 (75)	6	5 (83)
25 – 29	20	11 (55)	13	9 (69)	33	20 (61)
30 + years	68	38 (56)	23	18 (78)	91	56 (62)
p value		0.720		0.063		0.368
2008						
< 20 years	---	---	---	---	---	---
20 – 24	2	2 (100)	1	1 (100)	3	3 (100)
25 – 29	3	3 (100)	7	6 (86)	10	9 (90)
30 + years	27	21 (78)	16	12 (75)	43	33 (77)
p value		1.000		1.000		0.698

* Total includes people whose gender was not reported or reported as transgender

Table 193 HCV antibody prevalence by duration of drug injection, gender and year of survey

Duration of drug injection	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
<3 years	5	1 (20)	6	1 (17)	12	2 (17)
3 to 5 years	6	1 (17)	6	2 (33)	12	3 (25)
6 to 10 years	9	4 (44)	8	6 (75)	17	10 (59)
10 + years	45	24 (53)	17	10 (59)	62	34 (55)
p value		<0.001		0.02		<0.001
2005						
<3 years	12	2 (17)	2	1 (50)	14	3 (21)
3 to 5 years	12	5 (42)	12	3 (25)	24	8 (33)
6 to 10 years	9	4 (44)	5	3 (60)	14	7 (50)
10 + years	48	37 (77)	29	21 (72)	77	58 (75)
p value		0.001		0.05		<0.001
2006						
<3 years	4	1 (25)	4	1 (25)	8	2 (25)
3 to 5 years	2	1 (50)	11	3 (28)	13	4 (31)
6 to 10 years	24	12 (50)	16	10 (63)	40	22 (55)
10 + years	60	37 (62)	23	18 (78)	83	55 (66)
p value		0.399		0.014		0.018
2007						
<3 years	5	1 (20)	2	0 (0.0)	7	1 (14)
3 to 5 years	3	1 (33)	5	1 (20)	8	2 (25)
6 to 10 years	17	10 (59)	8	5 (63)	25	15 (60)
10 + years	65	39 (60)	26	22 (85)	91	61 (67)
p value		0.322		0.003		0.007
2008						
<3 years	1	1 (100)	---	---	1	1 (100)
3 to 5 years	2	2 (100)	---	---	2	2 (100)
6 to 10 years	3	3 (100)	8	6 (75)	11	9 (82)
10 + years	26	20 (77)	15	12 (80)	41	32 (78)
p value		1.000		1.000		1.000

* Total includes people whose gender was not reported or reported as transgender

Tasmania

Table 194 HCV antibody prevalence by last drug injected, duration of drug injection and year of survey

Last drug injected	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Heroin	-	-	-	-	-	-
Meth/Amphetamine	5	0 (0)	26	8 (31)	32	8 (25)
More than one	2	0 (0)	7	3 (43)	9	3 (33)
Other/Not reported	5	2 (40)	58	36 (62)	65	39 (60)
p value		0.08		<0.001		<0.001
2005						
Heroin	-	-	2	1 (50)	2	1 (2)
Meth/Amphetamine	9	1 (11)	55	29 (53)	64	30 (47)
More than one	1	1 (100)	5	5 (100)	6	6 (100)
Other/Not reported	4	1 (25)	61	43 (70)	65	44 (68)
p value		0.225		0.043		0.008
2006						
Heroin	---	---	3	2 (67)	3	2 (67)
Meth/Amphetamine	6	0 (0)	65	28 (43)	72	28 (39)
More than one	---	---	6	3 (50)	6	3 (50)
Other/Not reported	2	2 (100)	62	48 (77)	67	52 (78)
p value		0.036		<0.001		<0.001
2007						
Heroin	---	---	1	1 (100)	2	2 (100)
Meth/Amphetamine	4	0 (0.0)	33	15 (45)	38	16 (42)
More than one	---	---	8	5 (63)	8	5 (63)
Other/Not reported	3	1 (33)	82	57 (70)	86	59 (69)
p value		0.429		0.070		0.023
2008						
Heroin	---	---	4	4 (100)	4	4 (100)
Meth/Amphetamine	---	---	12	11 (92)	12	11 (92)
More than one	1	1 (100)	---	---	1	1 (100)
Other/Not reported	---	---	38	28 (74)	39	29 (74)
p value		---		0.377		0.547

* Total includes people who did not report duration of drug injection

Table 195 HCV antibody prevalence by frequency of injection last month, duration of drug injection and year of survey

Frequency of drug injection last month	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Less than daily	8	2 (25)	52	28 (54)	61	31 (51)
Daily or more	3	0 (0)	39	19 (49)	44	19 (43)
p value		0.3		0.6		0.4
2005						
Less than daily	10	2 (20)	68	41 (60)	83	46 (55)
Daily or more	4	1 (25)	47	32 (68)	54	35 (65)
p value		0.8		0.4		0.3
2006						
Less than daily	4	1 (25)	66	37 (56)	71	39 (55)
Daily or more	4	1 (25)	65	41 (63)	72	43 (60)
p value		1.000		0.478		0.614
2007						
Less than daily	3	1 (33)	80	53 (66)	84	55 (65)
Daily or more	3	0 (0.0)	41	25 (61)	45	26 (58)
p value		1.000		0.689		0.446
2008						
Less than daily	---	---	30	23 (77)	31	24 (77)
Daily or more	1	1 (100)	22	19 (86)	23	20 (87)
p value		---		0.488		0.489

* Total includes people who did not report duration of drug injection

Table 196 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and year of survey

Re-used someone else's used needle & syringe last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
No	10	2 (20)	73	37 (51)	86	40 (47)
Yes	1	0 (0)	10	6 (60)	11	6 (55)
p value		0.6		0.6		0.6
2005						
No	14	3 (21)	101	64 (63)	121	71 (59)
Yes	-	-	6	3 (50)	7	4 (57)
p value		-		0.9		0.5
2006						
No	8	2 (25)	113	67 (59)	125	71 (57)
Yes	---	---	11	8 (73)	11	8 (73)
p value		---		0.524		0.358
2007						
No	5	1 (20)	98	67 (68)	104	69 (66)
Yes	---	---	15	6 (40)	16	7 (44)
p value		---		0.043		0.098
2008						
No	1	1 (100)	42	34 (81)	43	35 (81)
Yes	---	---	8	8 (100)	9	9 (100)
p value		---		0.324		0.323

* Total includes people who did not report duration of drug injection

Tasmania

Table 197 HCV antibody prevalence by imprisonment last year, duration of drug injection and year of survey

Imprisonment last year	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
No	9	1 (11)	78	38 (49)	90	40 (44)
Yes	2	1 (50)	12	8 (67)	14	9 (64)
p value		0.2		0.2		0.2
2005						
No	12	2 (17)	96	60 (63)	113	64 (57)
Yes	1	1 (100)	15	10 (67)	18	13 (72)
p value		0.06		0.8		0.2
2006						
No	7	1 (14)	113	62 (55)	124	65 (52)
Yes	1	1 (100)	18	15 (83)	19	16 (84)
p value		0.250		0.037		0.012
2007						
No	7	1 (14)	100	60 (60)	110	64 (58)
Yes	---	---	20	15 (75)	20	15 (75)
p value		---		0.312		0.214
2008						
No	1	1 (100)	43	33 (77)	44	34 (77)
Yes	---	---	6	6 (100)	7	7 (100)
p value		---		0.324		0.320

* Total includes people who did not report duration of drug injection

Table 198 HCV antibody prevalence by sex work last month, duration of drug injection and year of survey

Sex work last month	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
No	11	2 (18)	78	41 (53)	92	44 (48)
Yes	-	-	10	4 (40)	10	4 (40)
p value		1.0		0.2		0.3
2005						
No	13	3 (13)	109	67 (61)	129	75 (58)
Yes	-	-	3	3 (100)	4	3 (75)
p value				0.2		0.5
2006						
No	6	2 (33)	123	71 (58)	133	75 (56)
Yes	1	0 (0)	4	2 (50)	5	2 (40)
p value		1.000		1.000		0.655
2007						
No	7	1 (14)	115	73 (63)	125	77 (62)
Yes	---	---	2	2 (100)	2	2 (100)
p value		---		0.536		0.526
2008						
No	1	1 (100)	51	40 (78)	53	42 (79)
Yes	---	---	2	2 (100)	2	2 (100)
p value		---		1.000		1.000

* Total includes people who did not report duration of drug injection

Table 199 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and year of survey

Aboriginal and Torres Strait Islander origin	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
No	58	27 (47)	36	20 (56)	95	47 (49)
Yes	6	3 (50)	2	0 (0)	8	3 (38)
p value		0.9		0.1		0.5
2005						
No	74	45 (61)	47	26 (55)	121	71 (59)
Yes	8	5 (63)	4	4 (100)	12	9 (75)
p value		0.9		0.1		0.3
2006						
No	73	39 (53)	48	28 (58)	121	67 (55)
Yes	17	11 (65)	6	3 (50)	23	14 (61)
p value		0.432		1.000		0.655
2007						
No	78	44 (56)	35	24 (69)	113	68 (60)
Yes	12	8 (67)	7	5 (71)	19	13 (68)
p value		0.550		1.000		0.614
2008						
No	29	23 (79)	20	16 (80)	49	39 (80)
Yes	3	3 (100)	2	1 (50)	5	4 (80)
p value		1.000		0.411		1.000

* Total includes people whose gender was not reported or reported as transgender

Tasmania

Table 200 HCV antibody prevalence by region/country of birth, gender and year of survey

Region/Country of birth	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Australia	59	25 (42)	35	16 (46)	95	41 (43)
Other Oceania	---	---	---	---	---	---
Asia	---	---	---	---	---	---
UK & Ireland	---	---	---	---	---	---
Other	5	4 (80)	4	4 (100)	9	8 (89)
p value		0.1		0.04		0.009
2005						
Australia	79	45 (57)	47	27 (57)	126	72 (57)
Other Oceania	---	---	---	---	---	---
Asia	---	---	---	---	---	---
UK & Ireland	4	4 (100)	2	1 (50)	6	5 (83)
Other	2	2 (100)	1	1 (100)	3	3 (100)
p value		0.1		0.7		0.2
2006						
Australia	86	47 (55)	50	30 (60)	136	77 (57)
Other Oceania	---	---	1	0 (0)	1	0 (0)
Asia	---	---	---	---	---	---
UK & Ireland	3	2 (67)	3	2 (67)	6	4 (67)
Other	1	1 (100)	1	0 (0)	2	1 (50)
p value		1.000		0.533		0.769
2007						
Australia	86	48 (56)	39	26 (67)	125	74 (59)
Other Oceania	2	2 (100)	1	1 (100)	3	3 (100)
Asia	---	---	---	---	---	---
UK & Ireland	2	1 (50)	1	1 (100)	3	2 (67)
Other	---	---	---	---	---	---
p value		0.754		1.000		0.557
2008						
Australia	30	24 (80)	17	13 (76)	47	37 (79)
Other Oceania	---	---	---	---	---	---
Asia	---	---	---	---	---	---
UK & Ireland	1	1 (100)	5	4 (80)	6	5 (83)
Other	---	---	1	1 (100)	1	1 (100)
p value		1.000		1.000		1.000

* Total includes people whose gender was not reported or reported as transgender

Table 201 HCV antibody prevalence by main language spoken at home by parents, gender and year of survey

Main language spoken at home by parents	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
English speaking	39	18 (46)	31	15 (48)	71	33 (46)
Non-English speaking	2	1 (50)	1	1 (100)	3	2 (67)
p value		0.9		0.3		0.5
2005						
English speaking	70	40 (57)	45	27 (60)	115	67 (58)
Non-English speaking	16	11 (69)	6	3 (50)	22	14 (64)
p value		0.6		0.4		0.6
2006						
English speaking	81	45 (56)	53	32 (60)	134	77 (57)
Non-English speaking	2	1 (50)	---	---	2	1 (50)
p value		1.000		---		1.000
2007						
English speaking	88	50 (57)	43	30 (70)	131	80 (91)
Non-English speaking	3	2 (67)	---	---	3	2 (67)
p value		1.000		---		1.000
2008						
English speaking	32	26 (81)	22	17 (77)	54	43 (80)
Non-English speaking	---	---	2	2 (100)	2	2 (100)
p value		---		1.000		1.000

* Total includes people whose gender was not reported or reported as transgender

Victoria
2004 - 2008

Table 202 Number (percentage) of respondents by demographic characteristics and year of survey

Demographic characteristics	2004	2005	2006	2007	2008
Number of sites	5	5	4	7	6
N° surveyed	N=228	N=194	N=195	N=243	N=308
Response (%)	42	44	20	33	36
Gender (%)					
Male	152 (67)	116 (60)	126 (65)	166 (68)	206 (67)
Female	74 (32)	78 (40)	68 (35)	76 (31)	102 (33)
Transgender	---	---	---	1 (<1)	---
Not reported	2 (1)	---	1 (<1)	---	---
Sexual identity (%)					
Heterosexual	182 (80)	151 (78)	165 (85)	192 (79)	258 (84)
Bisexual	23 (10)	19 (10)	18 (9)	37 (15)	22 (7)
Homosexual	12 (5)	12 (6)	4 (2)	8 (3)	7 (2)
Not reported	11 (5)	12 (6)	8 (4)	6 (2)	21 (7)
Age and duration of injection (years)					
<i>Median age</i>	30	32	32	33	34
Age range	16-58	16-53	15-54	14-62	16-65
<i>Age group (%)</i>					
<25 years	51 (22)	33 (17)	27 (14)	19 (8)	19 (6)
25+ years	176 (77)	161 (83)	167 (86)	224 (92)	289 (94)
Not reported	1 (<1)	--	1 (<1)	---	---
<i>Median age 1st IDU</i>	18	18	18	17	18
Age range	8-42	11-35	10-41	10-42	10-45
Not reported	5	7	1	6	9
<i>Median years IDU</i>	10	12	13	13	15
Range	<1-44	<1-37	<1-35	<1-46	<1-40
<i>Duration of drug injection (%)</i>					
<3 years	19 (8)	11 (6)	7 (6)	12 (5)	19 (6)
3+ years	204 (90)	172 (89)	174 (89)	225 (93)	280 (91)
Not reported	5 (2)	11 (6)	14 (7)	6 (2)	9 (3)
Aboriginal and Torres Strait Islander origin (%)					
No	212 (93)	178 (92)	170 (87)	217 (89)	266 (86)
Yes	9 (4)	9 (5)	14 (7)	14 (6)	28 (9)
Not reported	7 (3)	7 (4)	11 (6)	12 (5)	14 (5)
Region/Country of birth (%)					
Australia	185 (81)	156 (80)	160 (82)	202 (83)	259 (84)
Other Oceania	5 (2)	9 (5)	4 (2)	5 (2)	5 (2)
Asia	9 (4)	3 (2)	2 (1)	7 (3)	10 (3)
UK & Ireland	11 (5)	11 (6)	15 (8)	12 (5)	20 (6)
Other	15 (7)	15 (8)	8 (4)	10 (4)	8 (3)
Not reported	3 (1)	---	6 (3)	7 (3)	6 (2)
Main language spoken at home by parents (%)					
English speaking	154 (67)	158 (81)	171 (88)	221 (91)	270 (88)
Non-English speaking	31 (14)	36 (19)	10 (5)	17 (7)	32 (10)
Not reported	43 (19)	---	14 (7)	5 (2)	6 (2)
Imprisonment last year (%)					
No	185 (81)	162 (84)	161 (83)	195 (80)	241 (78)
Yes	42 (18)	22 (11)	20 (10)	30 (12)	40 (13)
Not reported	1 (<1)	10 (5)	14 (7)	18 (7)	27 (9)
Injected in prison (%)	N=42	N=22	N=20	N=30	N=40
Yes	22 (52)	10 (45)	5 (25)	9 (30)	12 (30)
Frequency of injection last month (%)					
Not last month	13 (6)	12 (6)	10 (5)	11 (5)	21 (7)
Less than weekly	27 (12)	31 (16)	31 (16)	30 (12)	53 (17)
Weekly not daily	68 (30)	41 (21)	47 (24)	53 (22)	61 (20)
Daily or more	118 (52)	110 (57)	106 (54)	143 (59)	167 (54)
Not reported	2 (<1)	--	1 (<1)	6 (2)	6 (2)

Table 203 Number (percentage) of respondents by last drug injected, injecting behaviour in the month prior to survey and year of survey

Injecting behaviour	2004	2005	2006	2007	2008
Last drug injected (%)	N=228	N=194	N=195	N=243	N=308
Anabolic steroids	4 (2)	---	1 (<1)	1 (<1)	3 (1)
Cocaine	1 (<1)	5 (3)	4 (2)	---	2 (1)
Heroin	134 (59)	96 (49)	71 (36)	131 (54)	180 (58)
Methadone	---	3 (2)	3 (2)	6 (2)	8 (3)
Meth/Amphetamine	37 (16)	47 (24)	69 (35)	51 (21)	55 (18)
Morphine/Other Opioids	7 (3)	7 (4)	10 (5)	8 (3)	22 (7)
Subutex/Buprenorphine	18 (8)	19 (10)	22 (11)	27 (11)	21 (7)
More than one	20 (9)	4 (2)	9 (5)	8 (3)	6 (2)
Other	1 (<1)	2 (1)	1 (<1)	6 (2)	2 (1)
Not reported	3 (1)	7 (4)	3 (2)	5 (2)	9 (3)
N^o Injected last month	N=213	N=182	N=184	N=226	N=281
Places injected last month (%)*					
Own home	181 (85)	145 (80)	155 (89)	187 (85)	231 (84)
Friend's home	104 (49)	77 (42)	80 (46)	100 (46)	112 (41)
Dealer's home	52 (24)	20 (11)	30 (17)	35 (16)	65 (24)
Street, park, beach	92 (43)	54 (30)	56 (32)	82 (37)	91 (33)
Car	114 (54)	67 (37)	82 (47)	81 (37)	107 (39)
Public toilet	80 (38)	61 (34)	63 (36)	77 (35)	106 (39)
Commercial injecting room	1 (<1)	--	2 (1)	2 (1)	3 (1)
Squat	23 (11)	11 (6)	14 (8)	21 (10)	30 (11)
Use of new sterile needles & syringes last month (%)					
All injections	141 (66)	131 (72)	117 (64)	150 (66)	186 (66)
Most of the time	57 (27)	47 (26)	48 (26)	64 (28)	76 (27)
Half of the time	8 (4)	3 (2)	8 (4)	3 (1)	7 (2)
Some of the time	2 (1)	--	5 (3)	2 (1)	6 (2)
Not last month	1 (<1)	1 (1)	2 (1)	---	---
Not reported	4 (2)	--	4 (2)	7 (3)	6 (2)
Re-used another's used needle & syringe last month (%)					
None	163 (77)	147 (81)	142 (77)	172 (76)	226 (80)
Once	15 (7)	5 (3)	8 (4)	14 (6)	11 (4)
Twice	13 (6)	7 (4)	9 (5)	9 (4)	19 (7)
3-5 times	9 (4)	5 (3)	10 (5)	9 (4)	11 (4)
>5 times	7 (3)	6 (3)	7 (4)	10 (4)	7 (2)
Not reported	6 (3)	12 (7)	8 (4)	12 (5)	7 (2)
Number of people needle & syringe was re-used after last month (%)					
None	163 (76)	139 (76)	142 (77)	172 (76)	226 (80)
One	23 (11)	20 (11)	19 (10)	24 (11)	27 (10)
Two	4 (2)	2 (1)	2 (1)	2 (1)	2 (1)
Three to five	2 (1)	1 (1)	---	3 (1)	1 (<1)
More than five	2 (1)	---	3 (2)	2 (1)	---
Don't know	2 (1)	5 (3)	5 (3)	8 (4)	13 (5)
Not reported	17 (8)	15 (8)	13 (7)	15 (7)	12 (4)
Relationship to people needle & syringe was re-used after last month (%)*					
Regular sex partner	16 (8)	18 (10)	16 (9)	21 (9)	19 (7)
Casual sex partner	4 (2)	---	1 (<1)	2 (1)	---
Close friend	10 (5)	6 (3)	9 (5)	10 (4)	13 (5)
Acquaintance	1 (<1)	5 (3)	3 (2)	6 (3)	2 (1)
Other	2 (1)	2 (1)	1 (<1)	3 (1)	3 (1)
Equipment used after someone else last month (%)*					
Spoon	82 (39)	52 (29)	63 (36)	70 (34)	96 (36)
Water	63 (30)	42 (23)	34 (19)	43 (21)	56 (21)
Filter	55 (26)	35 (19)	32 (18)	36 (17)	45 (17)
Drug mix	47 (22)	31 (17)	15 (9)	21 (10)	31 (12)
Tourniquet	25 (12)	24 (13)	18 (10)	16 (8)	20 (8)
None**	---	---	96 (55)	118 (57)	151 (57)
Injected by someone after that person injected themselves or others last month (%)					
No	178 (84)	147 (81)	155 (84)	182 (81)	234 (83)
Yes	28 (13)	23 (13)	23 (13)	29 (13)	37 (13)
Not reported	7 (3)	12 (7)	6 (3)	15 (7)	10 (4)

* More than one option could be selected

** New variable in 2006

Victoria

Table 204 Number (percentage) of respondents by treatment for drug use and year of survey

Treatment for drug use	2004	2005	2006	2007	2008
N ^o surveyed	N=228	N=194	N=195	N=243	N=308
Any treatment/therapy for drug use (%)					
No	29 (13)	22 (11)	22 (11)	23 (9)	34 (11)
Yes	197 (86)	172 (89)	169 (87)	215 (88)	272 (88)
Not reported	2 (1)	--	4 (2)	5 (2)	2 (1)
History of methadone maintenance treatment (%)					
Currently	58 (25)	56 (29)	58 (30)	78 (32)	100 (32)
Previously	86 (38)	66 (34)	66 (34)	81 (33)	104 (34)
Never	78 (34)	72 (37)	67 (34)	79 (33)	99 (32)
Not reported	6 (3)	--	4 (2)	5 (2)	5 (2)
History of buprenorphine (Subutex®) treatment (%)*					
Currently	--	--	--	--	40 (13)
Previously	--	--	--	--	121 (39)
Never	--	--	--	--	141 (46)
Not reported	--	--	--	--	6 (2)
History of buprenorphine-naloxone (Suboxone®) treatment (%)*					
Currently	--	--	--	--	38 (12)
Previously	--	--	--	--	69 (22)
Never	--	--	--	--	196 (64)
Not reported	--	--	--	--	5 (2)

* New variable in 2008

Table 205 Number (percentage) of respondents by site of needle and syringe acquisition last month and year of survey

Needle & Syringe acquisition	2004	2005	2006	2007*	2008
N ^o surveyed	N=228	N=194	N=195	--	N=308
From an NSP last month (%)					
Daily or almost daily	35 (15)	42 (22)	49 (25)	--	87 (28)
A couple of times each week	81 (36)	63 (32)	51 (26)	--	91 (30)
Less than weekly	67 (29)	46 (24)	52 (26)	--	55 (18)
Once last month	23 (10)	25 (13)	21 (11)	--	41 (13)
Not in the last month	17 (8)	17 (9)	18 (9)	--	29 (9)
Not reported	5 (2)	1 (1)	4 (2)	--	5 (2)
From a chemist last month (%)					
Daily or almost daily	5 (2)	10 (5)	9 (5)	--	13 (4)
A couple of times each week	23 (10)	11 (6)	12 (6)	--	24 (8)
Less than weekly	44 (19)	23 (12)	20 (10)	--	28 (9)
Once last month	39 (17)	27 (14)	34 (17)	--	53 (17)
Not in the last month	113 (50)	121 (62)	112 (57)	--	182 (59)
Not reported	4 (2)	2 (1)	8 (4)	--	8 (3)

* Not asked in this form in 2007

Table 206 Number (percentage) of respondents by injecting equipment use, re-use and cleaning last month

Use, re-use and cleaning of any item*	Used	Re-used	Cleaned**
N ^o surveyed ^{†***}	N=281	N=281	N=281
Yes	253 (90)	145 (52)	128 (46)
No	8 (3)	108 (38)	127 (45)
Not reported	20 (7)	28 (10)	26 (9)
Use, re-use and cleaning by item type#			
1ml	237 (84)	120 (43)	111 (40)
3 ml	13 (24)	17 (6)	13 (5)
5 ml	12 (4)	4 (1)	2 (<1)
10 ml	14 (5)	6 (2)	5 (2)
20 ml	3 (1)	1 (<1)	0 (0)
Detachable needle (tip)	29 (10)	5 (2)	5 (2)
Winged vein infusion set (butterfly)	12 (4)	9 (3)	6 (2)
Wheel filter	24 (8)	14 (5)	5 (2)

* New question in 2008

** Includes 6 respondents that reported cleaning but not re-use in the last month

More than one item could be selected

*** Excludes respondents that did not inject in the last month

Table 207 Number (percentage) of respondents by sexual behaviour in the month prior to survey and year of survey

Sexual behaviour	2004	2005	2006	2007	2008
N° surveyed	N=228	N=194	N=195	N=243	N=308
Sex with a regular partner last month (%) **					
No	--	86 (44)	85 (44)	115 (47)	146 (47)
Yes	--	107 (55)	101 (52)	114 (47)	153 (50)
Not reported	--	1 (1)	9 (5)	14 (6)	9 (3)
Condom used with regular partner last month (%)**					
N° surveyed		N=107	N=101	N=114	N=153
Never	--	69 (64)	68 (67)	82 (72)	101 (66)
Sometimes	--	21 (20)	17 (17)	20 (18)	22 (14)
Every time	--	12 (11)	12 (12)	7 (6)	19 (12)
Not reported	--	5 (5)	4 (4)	5 (4)	11 (7)
Sex with other partner/s last month (%)**					
No	--	156 (80)	158 (81)	194 (80)	259 (84)
Yes	--	37 (19)	22 (11)	36 (15)	35 (11)
Not reported	--	1 (1)	15 (8)	13 (5)	14 (5)
Condom used with other partner/s last month (%)**					
N° surveyed		N=37	N=22	N=36	N=35
Never	--	7 (19)	6 (27)	8 (22)	9 (26)
Sometimes	--	5 (14)	6 (27)	13 (36)	14 (40)
Every time	--	23 (62)	8 (36)	14 (39)	10 (29)
Not reported	--	2 (5)	2 (9)	1 (3)	2 (6)
Sex work last month (%)					
No	201 (88)	168 (87)	169 (67)	218 (90)	266 (86)
Yes	25 (11)	24 (12)	12 (6)	15 (6)	17 (6)
Not reported	2 (1)	2 (1)	14 (7)	10 (4)	25 (8)
Condom used at last sex work last month (%)*					
Yes	22 (88)	47 (98)	10 (83)	12 (86)	11 (73)

* Percentages exclude missing data

** New variable format commenced in 2005

Table 208 Number and (percentage) of respondents reporting previous testing for HIV and HCV infection and HCV treatment by year of survey

	2004	2005	2006	2007	2008
N° surveyed	N=228	N=194	N=195	N=243	N=308
Previous HIV test (%)					
Yes, last year	124 (54)	121 (62)	104 (53)	151 (62)	151 (49)
> 1 year ago	77 (34)	55 (28)	66 (34)	65 (27)	109 (35)
Never tested	24 (11)	16 (8)	18 (9)	19 (8)	34 (11)
Not reported	3 (1)	2 (1)	7 (4)	8 (3)	14 (5)
Previous HCV test (%)					
Yes, last year	131 (57)	127 (65)	114 (58)	154 (63)	176 (57)
> 1 year ago	81 (36)	50 (26)	58 (30)	78 (32)	98 (32)
Never tested	13 (6)	15 (8)	15 (8)	6 (2)	20 (6)
Not reported	3 (1)	2 (1)	8 (4)	5 (2)	14 (5)
Any treatment for HCV (%)					
Interferon	4 (3)	2 (2)	3 (3)	6 (4)	10 (5)
Interferon+Ribarvarin	4 (3)	2 (2)	1 (1)	2 (1)	5 (3)
Other	4 (3)	4 (4)	3 (3)	3 (2)	6 (3)
No treatment	110 (88)	95 (92)	92 (91)	122 (87)	158 (85)
Not reported	4 (3)	--	2 (2)	8 (6)	6 (3)
Current treatment for HCV					
Interferon/Interferon+Ribarvirin	N=2	N=5	N=3	N=3	N=5
Other	1	1	2	2	3
	1	4	1	1	2

HIV antibody prevalence

Table 209 HIV antibody prevalence by gender and year of survey

Year of survey	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2004	122	1 (0.8)	65	0 (0.0)	189	1 (0.5)
2005	102	1 (1.0)	76	0 (0.0)	178	1 (0.6)
2006	122	1 (0.8)	68	0 (0.0)	191	1 (0.5)
2007	163	0 (0.0)	76	0 (0.0)	240	0 (0.0)
2008	199	2 (1.0)	93	0 (0.0)	292	2 (0.7)
χ^2 trend p value		0.872		---		0.943

* Total includes people whose gender was not reported or reported as transgender

Table 210 HIV antibody prevalence by sexual identity, gender and year of survey

Sexual identity	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2004						
Heterosexual	101	0 (0.0)	48	0 (0.0)	150	0 (0.0)
Bisexual	8	0 (0.0)	11	0 (0.0)	19	0 (0.0)
Homosexual	7	0 (0.0)	4	0 (0.0)	11	0 (0.0)
p value		---		---		---
2005						
Heterosexual	84	0 (0.0)	53	0 (0.0)	137	0 (0.0)
Bisexual	6	0 (0.0)	13	0 (0.0)	19	0 (0.0)
Homosexual	6	1 (16.7)	5	0 (0.0)	11	1 (9.1)
p value		0.001		---		0.001
2006						
Heterosexual	105	0 (0.0)	55	0 (0.0)	161	0 (0.0)
Bisexual	8	1 (12.5)	10	0 (0.0)	18	1 (5.6)
Homosexual	1	0 (0.0)	3	0 (0.0)	4	0 (0.0)
p value		0.079		---		0.120
2007						
Heterosexual	144	0 (0.0)	45	0 (0.0)	189	0 (0.0)
Bisexual	10	0 (0.0)	27	0 (0.0)	37	0 (0.0)
Homosexual	5	0 (0.0)	2	0 (0.0)	8	0 (0.0)
p value		---		---		---
2008						
Heterosexual	175	0 (0.0)	69	0 (0.0)	244	0 (0.0)
Bisexual	6	0 (0.0)	16	0 (0.0)	22	0 (0.0)
Homosexual	4	2 (50)	3	0 (0.0)	7	2 (29)
p value		<0.001		---		0.001

* Total includes people whose gender was not reported or reported as transgender

Table 211 HIV antibody prevalence by age group, gender and year of survey

Age group	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2004						
< 20 years	2	0 (0.0)	3	0 (0.0)	6	0 (0.0)
20 – 24	21	1 (4.8)	15	0 (0.0)	36	1 (2.8)
25 – 29	30	0 (0.0)	14	0 (0.0)	44	0 (0.0)
30 + years	69	0 (0.0)	33	0 (0.0)	102	0 (0.0)
p value		0.2		---		0.2
2005						
< 20 years	5	0 (0.0)	5	0 (0.0)	10	0 (0.0)
20 – 24	9	0 (0.0)	14	0 (0.0)	23	0 (0.0)
25 – 29	24	0 (0.0)	16	0 (0.0)	40	0 (0.0)
30 + years	64	1 (1.6)	41	0 (0.0)	105	1 (1.0)
p value		0.9		---		0.9
2006						
< 20 years	1	0 (0.0)	2	0 (0.0)	3	0 (0.0)
20 – 24	9	0 (0.0)	13	0 (0.0)	22	0 (0.0)
25 – 29	31	0 (0.0)	15	0 (0.0)	46	0 (0.0)
30 + years	80	1 (1.3)	38	0 (0.0)	119	1 (0.8)
p value		1.000		---		1.000
2007						
< 20 years	5	0 (0.0)	2	0 (0.0)	7	0 (0.0)
20 – 24	5	0 (0.0)	7	0 (0.0)	12	0 (0.0)
25 – 29	34	0 (0.0)	24	0 (0.0)	58	0 (0.0)
30 + years	119	0 (0.0)	43	0 (0.0)	163	0 (0.0)
p value		---		---		---
2008						
< 20 years	2	0 (0.0)	3	0 (0.0)	5	0 (0.0)
20 – 24	7	0 (0.0)	6	0 (0.0)	13	0 (0.0)
25 – 29	38	0 (0.0)	29	0 (0.0)	67	0 (0.0)
30 + years	152	2 (1.3)	55	0 (0.0)	207	2 (1.0)
p value		1.000		---		1.000

* Total includes people whose gender was not reported or reported as transgender

Victoria

Table 212 HIV antibody prevalence by duration of drug injection, gender and year of survey

Duration of drug injection	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2004						
<3 years	7	0 (0.0)	7	0 (0.0)	14	0 (0.0)
3 to 5 years	11	1 (9.1)	11	0 (0.0)	23	1 (4.4)
6 to 10 years	34	0 (0.0)	19	0 (0.0)	53	0 (0.0)
10 + years	68	0 (0.0)	28	0 (0.0)	96	0 (0.0)
p value		0.2		---		0.2
2005						
<3 years	5	0 (0.0)	5	0 (0.0)	10	0 (0.0)
3 to 5 years	11	0 (0.0)	9	0 (0.0)	20	0 (0.0)
6 to 10 years	13	0 (0.0)	13	0 (0.0)	26	0 (0.0)
10 + years	70	1 (1.4)	42	0 (0.0)	112	1 (0.9)
p value		0.9		---		0.9
2006						
<3 years	4	0 (0.0)	2	0 (0.0)	6	0 (0.0)
3 to 5 years	5	0 (0.0)	7	0 (0.0)	12	0 (0.0)
6 to 10 years	28	0 (0.0)	8	0 (0.0)	46	0 (0.0)
10 + years	75	1 (1.3)	38	0 (0.0)	114	1 (0.9)
p value		1.000		---		1.000
2007						
<3 years	7	0 (0.0)	5	0 (0.0)	12	0 (0.0)
3 to 5 years	4	0 (0.0)	4	0 (0.0)	8	0 (0.0)
6 to 10 years	29	0 (0.0)	23	0 (0.0)	53	0 (0.0)
10 + years	118	0 (0.0)	43	0 (0.0)	161	0 (0.0)
p value		---		---		---
2008						
<3 years	9	1 (11.1)	9	0 (0.0)	18	1 (5.6)
3 to 5 years	10	0 (0.0)	9	0 (0.0)	19	0 (0.0)
6 to 10 years	29	0 (0.0)	12	0 (0.0)	41	0 (0.0)
10 + years	145	0 (0.0)	60	0 (0.0)	205	0 (0.0)
p value		0.047		---		0.064

* Total includes people whose gender was not reported or reported as transgender

Table 213 HIV antibody prevalence by last drug injected, gender and year of survey

Last drug injected	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2004						
Heroin	71	0 (0.0)	41	0 (0.0)	113	0 (0.0)
Meth/Amphetamine	16	0 (0.0)	12	0 (0.0)	28	0 (0.0)
More than one	11	0 (0.0)	5	0 (0.0)	16	0 (0.0)
Other/Not reported	24	1 (4.2)	7	0 (0.0)	32	1 (3.1)
p value		0.4		---		0.4
2005						
Heroin	44	0 (0.0)	45	0 (0.0)	89	0 (0.0)
Meth/Amphetamine	24	0 (0.0)	18	0 (0.0)	42	0 (0.0)
More than one	3	0 (0.0)	1	0 (0.0)	4	0 (0.0)
Other/Not reported	32	1 (3.1)	13	0 (0.0)	45	1 (2.2)
p value		0.4		---		0.2
2006						
Heroin	46	0 (0.0)	23	0 (0.0)	70	0 (0.0)
Meth/Amphetamine	40	1 (2.5)	26	0 (0.0)	66	1 (1.5)
More than one	6	0 (0.0)	3	0 (0.0)	9	0 (0.0)
Other/Not reported	30	0 (0.0)	16	0 (0.0)	46	0 (0.0)
p value		0.623		---		0.634
2007						
Heroin	77	0 (0.0)	51	0 (0.0)	129	0 (0.0)
Meth/Amphetamine	38	0 (0.0)	12	0 (0.0)	50	0 (0.0)
More than one	5	0 (0.0)	1	0 (0.0)	6	0 (0.0)
Other/Not reported	43	0 (0.0)	12	0 (0.0)	55	0 (0.0)
p value		---		---		---
2008						
Heroin	121	1 (0.8)	48	0 (0.0)	169	1 (0.6)
Meth/Amphetamine	30	1 (3.3)	23	0 (0.0)	53	1 (1.9)
More than one	5	0 (0.0)	1	0 (0.0)	6	0 (0.0)
Other/Not reported	43	0 (0.0)	21	0 (0.0)	64	0 (0.0)
p value		0.367		---		0.411

* Total includes people whose gender was not reported or reported as transgender

Victoria

Table 214 HIV antibody prevalence by frequency of drug injection last month, gender and year of survey

Frequency of drug injection	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2004						
Not last month	7	0 (0.0)	2	0 (0.0)	9	0 (0.0)
Less than weekly	12	0 (0.0)	8	0 (0.0)	20	0 (0.0)
Weekly not daily	41	1 (2.4)	17	0 (0.0)	58	1 (1.7)
Daily or more	62	0 (0.0)	38	0 (0.0)	101	0 (0.0)
p value		0.5		---		0.5
2005						
Not last month	62	1 (1.6)	40	0 (0.0)	102	1 (1.0)
Less than weekly	21	0 (0.0)	18	0 (0.0)	39	0 (0.0)
Weekly not daily	13	0 (0.0)	13	0 (0.0)	26	0 (0.0)
Daily or more	6	0 (0.0)	5	0 (0.0)	11	0 (0.0)
p value		0.9		---		0.9
2006						
Not last month	5	0 (0.0)	4	0 (0.0)	10	0 (0.0)
Less than weekly	16	0 (0.0)	43	0 (0.0)	29	0 (0.0)
Weekly not daily	28	1 (3.6)	18	0 (0.0)	46	1 (2.2)
Daily or more	72	0 (0.0)	33	0 (0.0)	105	0 (0.0)
p value		0.405		---		0.447
2007						
Not last month	7	0 (0.0)	4	0 (0.0)	11	0 (0.0)
Less than weekly	18	0 (0.0)	12	0 (0.0)	30	0 (0.0)
Weekly not daily	34	0 (0.0)	16	0 (0.0)	50	0 (0.0)
Daily or more	101	0 (0.0)	41	0 (0.0)	143	0 (0.0)
p value		---		---		---
2008						
Not last month	17	0 (0.0)	3	0 (0.0)	20	0 (0.0)
Less than weekly	38	1 (2.6)	14	0 (0.0)	52	1 (1.9)
Weekly not daily	34	1 (2.9)	26	0 (0.0)	60	1 (1.7)
Daily or more	106	0 (0.0)	48	0 (0.0)	154	0 (0.0)
p value		0.207		---		0.288

* Total includes people whose gender was not reported or reported as transgender

Table 215 HIV antibody prevalence by re-use of someone else's used needle and syringe last month, gender and year of survey

Re-used someone else's used needle & syringe last month	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2004						
No	89	1 (1.1)	49	0 (0.0)	139	1 (0.7)
Yes	23	0 (0.0)	13	0 (0.0)	36	0 (0.0)
p value		1.0		---		1.0
2005						
No	71	1 (1.4)	63	0 (0.0)	134	1 (0.8)
Yes	15	0 (0.0)	6	0 (0.0)	21	0 (0.0)
p value		0.6		---		0.7
2006						
No	86	1 (1.2)	53	0 (0.0)	139	1 (0.7)
Yes	24	0 (0.0)	9	0 (0.0)	33	0 (0.0)
p value		1.000		---		1.000
2007						
No	115	0 (0.0)	55	0 (0.0)	170	0 (0.0)
Yes	28	0 (0.0)	12	0 (0.0)	41	0 (0.0)
p value		---		---		---
2008						
No	144	2 (1.4)	72	0 (0.0)	216	2 (0.9)
Yes	28	0 (0.0)	16	0 (0.0)	44	0 (0.0)
p value		1.000		---		1.000

* Total includes people whose gender was not reported or reported as transgender

Table 216 HIV antibody prevalence by imprisonment last year, gender and year of survey

Imprisonment last year	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2004						
No	99	1 (1.0)	55	0 (0.0)	155	1 (0.7)
Yes	23	0 (0.0)	10	0 (0.0)	33	0 (0.0)
p value		1.0		---		1.0
2005						
No	82	1 (1.2)	66	0 (0.0)	148	1 (0.7)
Yes	15	0 (0.0)	5	0 (0.0)	20	0 (0.0)
p value		0.7		---		0.7
2006						
No	100	1 (1)	57	0 (0.0)	158	1 (0.6)
Yes	13	0 (0.0)	7	0 (0.0)	20	0 (0.0)
p value		1.000		---		1.000
2007						
No	125	0 (0.0)	67	0 (0.0)	193	0 (0.0)
Yes	24	0 (0.0)	6	0 (0.0)	30	0 (0.0)
p value		---		---		---
2008						
No	147	2 (1.4)	82	0 (0.0)	229	2 (0.9)
Yes	33	0 (0.0)	5	0 (0.0)	38	0 (0.0)
p value		1.000		---		1.000

* Total includes people whose gender was not reported or reported as transgender

Victoria

Table 217 HIV antibody prevalence by condom use at last sex, gender and year of survey

Condom use at last sex	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2004						
No	97	1 (1.0)	46	0 (0.0)	143	1 (0.7)
Yes	25	0 (0.0)	18	0 (0.0)	44	0 (0.0)
p value		1.0		---		1.0
2005**						
No	33	0 (0.0)	38	0 (0.0)	71	0 (0.0)
Yes	20	1 (5.0)	15	0 (0.0)	35	1 (2.9)
p value				---		0.2
2006						
No	51	0 (0.0)	34	0 (0.0)	85	0 (0.0)
Yes	10	1 (10)	1	0 (0.0)	11	1 (9.1)
p value		0.164		---		0.115
2007						
No	54	0 (0.0)	46	0 (0.0)	100	0 (0.0)
Yes	7	0 (0.0)	0	0 (0.0)	7	0 (0.0)
p value		---		---		---
2008						
No	66	0 (0.0)	48	0 (0.0)	114	0 (0.0)
Yes	14	1 (7.1)	5	0 (0.0)	19	1 (5.3)
p value		0.175		---		0.143

* Total includes people whose gender was not reported or reported as transgender

** Question changed to "condom use with regular partner in last month" in 2005.

Table 218 HIV antibody prevalence by sex work last month, gender and year of survey

Sex work last month	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2004						
No	113	0 (0.0)	50	0 (0.0)	163	0 (0.0)
Yes	8	1 (12.5)	15	0 (0.0)	24	1 (4.2)
p value		0.07		---		0.1
2005						
No	98	1 (1.0)	56	0 (0.0)	154	1 (0.7)
Yes	3	0 (0.0)	19	0 (0.0)	22	0 (0.0)
p value		0.9		---		0.7
2006						
No	109	1 (0.9)	55	0 (0.0)	165	1 (0.6)
Yes	3	0 (0.0)	9	0 (0.0)	12	0 (0.0)
p value		1.000		---		1.000
2007						
No	152	0 (0.0)	62	0 (0.0)	215	0 (0.0)
Yes	4	0 (0.0)	11	0 (0.0)	15	0 (0.0)
p value		---		---		---
2008						
No	172	2 (1.2)	78	0 (0.0)	250	2 (0.8)
Yes	8	0 (0.0)	9	0 (0.0)	17	0 (0.0)
p value		1.000		---		1.000

* Total includes people whose gender was not reported or reported as transgender

Table 219 HIV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and year of survey

Aboriginal and Torres Strait Islander origin	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2004						
No	117	1 (0.9)	59	0 (0.0)	178	1 (0.6)
Yes	3	0 (0.0)	3	0 (0.0)	6	0 (0.0)
p value		0.9				0.9
2005						
No	94	1 (1.1)	70	0 (0.0)	164	1 (0.6)
Yes	5	0 (0.0)	4	0 (0.0)	9	0 (0.0)
p value		0.8				0.8
2006						
No	106	1 (0.9)	59	0 (0.0)	166	1 (0.6)
Yes	7	0 (0.0)	7	0 (0.0)	14	0 (0.0)
p value		1.000		---		1.000
2007						
No	144	0 (0.0)	69	0 (0.0)	214	0 (0.0)
Yes	11	0 (0.0)	3	0 (0.0)	14	0 (0.0)
p value		---		---		---
2008						
No	174	1 (0.6)	79	0 (0.0)	253	1 (0.4)
Yes	17	1 (5.9)	10	0 (0.0)	27	1 (3.7)
p value		0.171		---		0.184

* Total includes people whose gender was not reported or reported as transgender

Victoria

Table 220 HIV antibody prevalence by region/country of birth, gender and year of survey

Region/Country of birth	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2004						
Australia	99	1 (1.0)	54	0 (0.0)	155	1 (0.7)
Other Oceania	---	0 (0.0)	---	0 (0.0)	---	0 (0.0)
Asia	---	0 (0.0)	2	0 (0.0)	2	0 (0.0)
UK & Ireland	2	0 (0.0)	---	0 (0.0)	2	0 (0.0)
Other	20	0 (0.0)	9	0 (0.0)	29	0 (0.0)
p value		0.9		---		1.0
2005						
Australia	80	1 (1.3)	64	0 (0.0)	144	1 (0.7)
Other Oceania	3	0 (0.0)	5	0 (0.0)	8	0 (0.0)
Asia	2	0 (0.0)	1	0 (0.0)	3	0 (0.0)
UK & Ireland	8	0 (0.0)	2	0 (0.0)	10	0 (0.0)
Other	9	0 (0.0)	4	0 (0.0)	13	0 (0.0)
p value		1.0		---		1.0
2006						
Australia	97	1 (1.0)	58	0 (0.0)	156	1 (0.6)
Other Oceania	4	0 (0.0)	---	---	4	0 (0.0)
Asia	---	---	2	0 (0.0)	2	0 (0.0)
UK & Ireland	10	0 (0.0)	5	0 (0.0)	1	0 (0.0)
Other	6	0 (0.0)	2	0 (0.0)	8	0 (0.0)
p value		1.000		---		1.000
2007						
Australia	133	0 (0.0)	65	0 (0.0)	199	0 (0.0)
Other Oceania	3	0 (0.0)	2	0 (0.0)	5	0 (0.0)
Asia	5	0 (0.0)	2	0 (0.0)	7	0 (0.0)
UK & Ireland	10	0 (0.0)	2	0 (0.0)	12	0 (0.0)
Other	6	0 (0.0)	4	0 (0.0)	10	0 (0.0)
p value		---		---		---
2008						
Australia	167	1 (0.6)	78	0 (0.0)	245	1 (0.4)
Other Oceania	2	0 (0.0)	2	0 (0.0)	4	0 (0.0)
Asia	7	1 (14.3)	2	0 (0.0)	9	1 (11.1)
UK & Ireland	11	0 (0.0)	8	0 (0.0)	19	0 (0.0)
Other	9	0 (0.0)	3	0 (0.0)	12	0 (0.0)
p value		0.100		---		0.099

* Total includes people whose gender was not reported or reported as transgender

Table 221 HIV antibody prevalence by main language spoken at home by parents, gender and year of survey

Main language spoken at home by parents	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2004						
English speaking	77	1 (1.3)	53	0 (0.0)	132	1 (0.8)
Non-English speaking	19	0 (0.0)	6	0 (0.0)	25	0 (0.0)
p value		0.6		---		0.7
2005						
English speaking	81	1 (1.2)	64	0 (0.0)	145	1 (0.7)
Non-English speaking	21	0 (0.0)	12	0 (0.0)	33	0 (0.0)
p value		0.6		---		0.6
2006						
English speaking	105	1 (1.0)	62	0 (0.0)	168	1 (0.6)
Non-English speaking	6	0 (0.0)	3	0 (0.0)	9	0 (0.0)
p value		1.000		---		1.000
2007						
English speaking	147	0 (0.0)	70	0 (0.0)	218	0 (0.0)
Non-English speaking	12	0 (0.0)	5	0 (0.0)	17	0 (0.0)
p value		---		---		---
2008						
English speaking	168	2 (1.2)	87	0 (0.0)	255	2 (0.8)
Non-English speaking	25	0 (0.0)	6	0 (0.0)	31	0 (0.0)
p value		1.000		---		1.000

* Total includes people whose gender was not reported or reported as transgender

HCV antibody prevalence

Table 222 HCV antibody prevalence by gender and year of survey

Year of survey	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004	122	82 (67)	65	48 (74)	189	130 (69)
2005	101	64 (63)	76	55 (72)	177	119 (67)
2006	121	84 (69)	67	50 (75)	189	135 (71)
2007	139	100 (72)	65	48 (74)	205	149 (73)
2008	188	141 (75)	90	58 (64)	278	199 (72)
χ^2 trend p value		0.050		0.233		0.289

* Total includes people whose gender was not reported or reported as transgender

Table 223 HCV antibody prevalence by sexual identity, gender and year of survey

Sexual identity	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Heterosexual	101	67 (66)	48	32 (67)	150	99 (66)
Bisexual	8	6 (75)	11	10 (91)	19	16 (84)
Homosexual	7	4 (57)	4	4 (100)	11	8 (73)
p value		0.8		0.2		0.3
2005						
Heterosexual	83	53 (64)	53	37 (70)	136	90 (66)
Bisexual	6	4 (67)	13	9 (69)	19	13 (68)
Homosexual	6	3 (50)	5	5 (100)	11	8 (73)
p value						
2006						
Heterosexual	105	74 (70)	54	38 (70)	160	113 (71)
Bisexual	8	3 (38)	10	9 (90)	18	12 (67)
Homosexual	1	1 (100)	3	3 (100)	4	4 (100)
p value		0.107		0.311		0.590
2007						
Heterosexual	124	91 (73)	37	30 (81)	161	121 (75)
Bisexual	9	5 (56)	24	16 (67)	33	21 (64)
Homosexual	3	2 (67)	2	1 (50)	6	4 (67)
p value		0.470		0.229		0.289
2008						
Heterosexual	165	122 (74)	67	44 (66)	232	166 (72)
Bisexual	5	4 (80)	16	9 (56)	21	13 (62)
Homosexual	4	3 (75)	3	3 (100)	7	6 (86)
p value		1.000		0.435		0.481

* Total includes people whose gender was not reported or reported as transgender

Table 224 HCV antibody prevalence by age group, gender and year of survey

Age group	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
< 20 years	2	0 (0.0)	3	1 (33)	6	1 (17)
20 – 24	21	13 (62)	15	11 (73)	36	24 (67)
25 – 29	30	22 (73)	14	11 (79)	44	33 (75)
30 + years	69	47 (68)	33	25 (76)	102	72 (71)
p value		0.2		0.5		0.05
2005						
< 20 years	5	2 (40)	5	5 (100)	10	7 (70)
20 – 24	9	3 (33)	14	8 (57)	23	11 (48)
25 – 29	24	15 (63)	16	12 (75)	40	27 (68)
30 + years	63	44 (70)	41	30 (73)	104	74 (71)
p value		0.1		0.3		0.2
2006						
< 20 years	1	0 (0)	2	0 (0.0)	3	0 (0.0)
20 – 24	9	7 (78)	13	9 (69)	22	16 (73)
25 – 29	31	20 (65)	15	12 (80)	46	32 (70)
30 + years	79	56 (71)	37	29 (78)	117	86 (74)
p value		0.472		0.132		0.078
2007						
< 20 years	5	0 (0.0)	2	1 (50)	7	1 (14)
20 – 24	4	2 (50)	6	3 (50)	10	5 (50)
25 – 29	29	18 (62)	21	16 (76)	50	34 (68)
30 + years	101	80 (79)	36	28 (78)	138	109 (79)
p value		<0.001		0.346		0.001
2008						
< 20 years	2	0 (0.0)	3	0 (0.0)	5	0 (0.0)
20 – 24	7	3 (43)	6	1 (17)	13	4 (31)
25 – 29	34	22 (65)	29	18 (62)	63	40 (63)
30 + years	145	116 (80)	52	39 (75)	197	155 (79)
p value		0.004		0.002		<0.001

* Total includes people whose gender was not reported or reported as transgender

Victoria

Table 225 HCV antibody prevalence by duration of drug injection, gender and year of survey

Duration of drug injection	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
<3 years	7	0 (0)	7	2 (29)	14	2 (14)
3 to 5 years	11	5 (45)	11	7 (64)	23	12 (52)
6 to 10 years	34	23 (68)	19	15 (79)	53	38 (72)
10 + years	68	52 (76)	28	24 (86)	96	76 (79)
p value		<0.001		0.02		<0.001
2005						
<3 years	10	5 (50)	7	6 (86)	17	11 (65)
3 to 5 years	11	5 (45)	9	5 (56)	20	10 (50)
6 to 10 years	13	8 (62)	13	10 (77)	26	18 (69)
10 + years	64	44 (69)	40	29 (73)	104	73 (70)
p value		0.3		0.6		0.4
2006						
<3 years	4	1 (25)	2	1 (50)	6	2 (33)
3 to 5 years	5	3 (60)	7	1 (14)	12	4 (33)
6 to 10 years	28	16 (57)	17	13 (76)	45	29 (64)
10 + years	75	57 (76)	38	32 (84)	114	90 (79)
p value		0.044		0.001		0.001
2007						
<3 years	7	1 (14)	5	1 (20)	12	2 (17)
3 to 5 years	4	0 (0.0)	4	2 (50)	8	2 (25)
6 to 10 years	26	14 (54)	20	17 (85)	47	32 (68)
10 + years	97	81 (84)	35	27 (77)	132	108 (82)
p value		<0.001		0.018		<0.001
2008						
<3 years	8	2 (25)	9	4 (44)	17	6 (35)
3 to 5 years	10	1 (10)	9	2 (22)	19	3 (16)
6 to 10 years	25	18 (72)	12	8 (67)	37	26 (70)
10 + years	139	115 (83)	57	43 (75)	196	158 (81)
p value		<0.001		0.007		<0.001

* Total includes people whose gender was not reported or reported as transgender

Table 226 HCV antibody prevalence by last drug injected, duration of drug injection and year of survey

Last drug injected	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Heroin	7	1 (14)	106	81 (76)	113	82 (73)
Meth/Amphetamine	4	0 (0)	23	13 (57)	28	14 (50)
More than one	1	1 (100)	15	9 (60)	16	10 (63)
Other/Not reported	2	0 (0)	28	23 (82)	32	24 (75)
p value		0.2		0.1		0.1
2005						
Heroin	5	4 (80)	84	60 (71)	89	64 (72)
Meth/Amphetamine	5	2 (40)	37	21 (57)	42	23 (55)
More than one	---	---	4	2 (50)	4	2 (50)
Other/Not reported	7	5 (71)	37	27 (73)	44	32 (73)
p value		0.548		0.283		0.150
2006						
Heroin	2	1 (50)	67	54 (81)	70	55 (79)
Meth/Amphetamine	3	1 (33)	58	37 (64)	66	42 (64)
More than one	---	---	7	5 (71)	8	6 (75)
Other/Not reported	1	0 (0)	39	27 (69)	45	32 (71)
p value		1.000		0.184		0.289
2007						
Heroin	4	2 (50)	101	78 (77)	106	81 (76)
Meth/Amphetamine	4	0 (0.0)	36	25 (69)	42	27 (64)
More than one	---	---	5	4 (80)	6	4 (67)
Other/Not reported	4	0 (0.0)	45	35 (78)	51	37 (73)
p value		0.273		0.816		0.458
2008						
Heroin	6	3 (50)	151	114 (76)	161	120 (75)
Meth/Amphetamine	7	3 (43)	42	29 (69)	50	32 (64)
More than one	---	---	6	5 (83)	6	5 (83)
Other/Not reported	4	0 (0.0)	53	39 (74)	61	42 (69)
p value		0.304		0.807		0.450

* Total includes people who did not report duration of drug injection

Victoria

Table 227 HCV antibody prevalence by frequency of injection last month, duration of drug injection and year of survey

Frequency of drug injection last month	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Less than daily	5	1 (20)	74	51 (69)	87	58 (67)
Daily or more	11	3 (27)	87	66 (76)	101	72 (71)
p value		0.8		0.3		0.5
2005						
Less than daily	6	2 (33)	67	47 (70)	76	51 (67)
Daily or more	11	9 (82)	83	54 (65)	101	68 (67)
p value		0.5		0.05		>0.9
2006						
Less than daily	3	1 (33)	68	48 (71)	74	52 (70)
Daily or more	3	1 (33)	92	69 (75)	104	77 (74)
p value		1.000		0.590		0.612
2007						
Less than daily	4	0 (0.0)	59	45 (76)	66	48 (73)
Daily or more	7	1 (14)	115	88 (77)	124	91 (73)
p value		1.000		1.000		1.000
2008						
Less than daily	8	3 (38)	96	74 (77)	108	79 (73)
Daily or more	5	2 (40)	137	101 (74)	147	107 (73)
p value		1.000		0.645		1.000

* Total includes people who did not report duration of drug injection

Table 228 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and year of survey

Re-used someone else's used needle & syringe last month	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
No	13	3 (23)	119	86 (72)	139	95 (68)
Yes	3	1 (33)	31	25 (81)	36	28 (78)
p value		0.7		0.3		0.3
2005						
No	13	10 (77)	112	77 (69)	133	93 (70)
Yes	3	1 (33)	16	8 (50)	21	10 (48)
p value		0.1		0.1		0.04
2006						
No	4	1 (25)	127	89 (70)	138	95 (69)
Yes	2	1 (50)	28	24 (86)	33	28 (85)
p value		1.000		0.105		0.084
2007						
No	8	0 (0.0)	129	97 (75)	140	100 (71)
Yes	2	1 (50)	36	28 (78)	39	30 (77)
p value		0.200		0.829		0.549
2008						
No	13	5 (38)	188	140 (74)	209	150 (72)
Yes	---	---	40	32 (80)	41	33 (80)
p value		---		0.547		0.335

* Total includes people who did not report duration of drug injection

Table 229 HCV antibody prevalence by imprisonment last year, duration of drug injection and year of survey

Imprisonment last year	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
No	155	103 (66)	13	2 (15)	155	103 (66)
Yes	33	27 (82)	3	2 (67)	33	27 (82)
p value		0.08		0.06		0.01
2005						
No	14	8 (57)	127	83 (65)	147	95 (65)
Yes	2	2 (100)	14	13 (93)	20	18 (90)
p value		0.2		0.04		0.02
2006						
No	6	2 (33)	142	98 (69)	158	108 (68)
Yes	---	---	17	14 (82)	18	15 (83)
p value		---		0.399		0.279
2007						
No	10	1 (10)	149	111 (75)	163	115 (71)
Yes	1	1 (100)	26	20 (77)	28	22 (79)
p value		0.182		1.000		0.498
2008						
No	15	6 (40)	198	141 (71)	220	152 (69)
Yes	1	0 (0.0)	33	27 (82)	35	27 (77)
p value		1.000		0.291		0.427

* Total includes people who did not report duration of drug injection

Table 230 HCV antibody prevalence by sex work last month, duration of drug injection and year of survey

Sex work last month	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
No	15	3 (20)	137	97 (71)	163	109 (67)
Yes	1	1 (100)	23	20 (87)	24	21 (88)
p value		0.07		0.1		0.04
2005						
No	16	10 (63)	130	83 (64)	153	98 (64)
Yes	1	1 (100)	18	16 (89)	22	19 (86)
p value		0.4		0.03		0.04
2006						
No	6	2 (33)	146	102 (70)	163	113 (69)
Yes	---	---	12	10 (83)	12	10 (83)
p value		---		0.511		0.514
2007						
No	9	0 (0.0)	170	129 (76)	183	133 (73)
Yes	2	1 (100)	11	8 (73)	13	10 (77)
p value		0.018		0.730		1.000
2008						
No	15	6 (40)	219	164 (75)	241	175 (73)
Yes	---	---	14	11 (79)	15	11 (73)
p value		---		1.000		1.000

* Total includes people who did not report duration of drug injection

Victoria

Table 231 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and year of survey

Aboriginal and Torres Strait Islander origin	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
No	117	80 (68)	59	43 (73)	178	123 (69)
Yes	3	2 (67)	3	3 (100)	6	5 (83)
p value		1.0		0.3		0.5
2005						
No	93	57 (61)	70	50 (71)	163	107 (66)
Yes	5	4 (80)	4	3 (75)	9	7 (78)
p value		0.4		0.9		0.5
2006						
No	105	72 (69)	59	45 (76)	165	118 (72)
Yes	7	6 (86)	6	4 (67)	13	10 (77)
p value		0.673		0.631		1.000
2007						
No	123	87 (71)	60	46 (77)	184	134 (73)
Yes	9	9 (100)	3	0 (0.0)	12	12 (75)
p value		0.113		0.017		1.000
2008						
No	165	121 (73)	77	50 (65)	242	171 (71)
Yes	16	14 (88)	10	6 (60)	26	20 (77)
p value		0.366		0.739		0.650

* Total includes people whose gender was not reported or reported as transgender

Table 232 HCV antibody prevalence by region/country of birth, gender and year of survey

Region/Country of birth	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Australia	99	67 (68)	54	39 (72)	155	106 (68)
Other Oceania	---	---	---	---	---	---
Asia	---	---	2	2 (100)	2	2 (100)
UK & Ireland	2	2 (100)	---	---	2	2 (100)
Other	20	13 (65)	9	7 (78)	29	20 (69)
p value		0.6		0.7		0.6
2005						
Australia	79	46 (58)	64	47 (73)	143	93 (65)
Other Oceania	3	2 (67)	5	2 (40)	8	4 (50)
Asia	2	0 (0)	1	0 (0)	3	0 (0)
UK & Ireland	8	7 (88)	2	2 (100)	10	9 (90)
Other	9	9 (100)	4	4 (100)	13	13 (100)
p value		0.02		0.1		0.03
2006						
Australia	96	67 (70)	57	42 (74)	154	110 (71)
Other Oceania	4	2 (50)	---	---	4	2 (50)
Asia	---	---	2	2 (100)	2	2 (100)
UK & Ireland	10	8 (80)	5	4 (80)	15	12 (80)
Other	6	3 (50)	2	1 (50)	8	4 (50)
p value		0.516		0.885		0.406
2007						
Australia	114	85 (75)	56	40 (71)	171	126 (74)
Other Oceania	2	2 (100)	1	0 (0.0)	3	2 (67)
Asia	4	3 (75)	1	1 (100)	5	4 (80)
UK & Ireland	9	6 (67)	2	2 (100)	11	8 (73)
Other	5	1 (20)	4	4 (100)	9	5 (56)
p value		0.092		0.371		0.753
2008						
Australia	159	120 (75)	76	47 (62)	235	167 (71)
Other Oceania	2	0 (0.0)	2	1 (50)	4	1 (25)
Asia	5	4 (80)	1	1 (100)	6	5 (83)
UK & Ireland	11	7 (64)	8	8 (100)	19	15 (79)
Other	9	8 (89)	3	1 (33)	12	9 (75)
p value		0.142		0.068		0.311

* Total includes people whose gender was not reported or reported as transgender

Victoria

Table 233 HCV antibody prevalence by main language spoken at home by parents, gender and year of survey

Main language spoken at home by parents	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
English speaking	77	53 (69)	53	38 (72)	132	91 (69)
Non-English speaking	19	12 (63)	6	4 (67)	25	16 (64)
p value		0.6		1.0		0.6
2005						
English speaking	80	51 (64)	64	45 (70)	144	96 (67)
Non-English speaking	21	13 (62)	12	10 (83)	33	23 (70)
p value		0.9		0.4		0.7
2006						
English speaking	104	72 (69)	62	45 (73)	167	118 (71)
Non-English speaking	6	3 (50)	3	3 (100)	9	6 (67)
p value		0.380		0.561		0.725
2007						
English speaking	126	92 (73)	60	43 (72)	187	136 (73)
Non-English speaking	10	7 (70)	4	4 (100)	14	11 (79)
p value		1.000		0.566		0.763
2008						
English speaking	162	120 (74)	85	57 (67)	247	177 (72)
Non-English speaking	21	17 (81)	5	1 (20)	26	18 (69)
p value		0.601		0.052		0.821

* Total includes people whose gender was not reported or reported as transgender

Western Australia 2004 - 2008

Table 234 Number (percentage) of respondents by demographic characteristics and year of survey

Demographic characteristics	2004	2005	2006	2007	2008
Number of sites	3	3	3	2	2
N° surveyed	N=161	N=169	N=160	N=110	N=196
Response (%)	65	48	53	51	73
Gender (%)					
Male	99 (62)	110 (65)	104 (65)	71 (65)	123 (63)
Female	61 (38)	59 (35)	55 (34)	39 (35)	73 (37)
Transgender	---	---	1 (<1)	---	---
Not reported	1 (1)	---	---	---	---
Sexual identity (%)					
Heterosexual	133 (83)	137 (81)	135 (84)	93 (85)	158 (81)
Bisexual	11 (7)	14 (8)	14 (9)	8 (7)	22 (11)
Homosexual	8 (5)	8 (5)	7 (4)	7 (6)	7 (4)
Not reported	9 (5)	10 (6)	4 (3)	2 (2)	9 (5)
Age and duration of injection (years)					
<i>Median age</i>	35	36	35	36.5	35
<i>Age range</i>	16-60	17-57	16-68	16-55	17-65
Age group (%)					
<25 years	30 (19)	30 (18)	18 (11)	10 (9)	12 (6)
25+ years	130 (81)	139 (82)	142 (89)	100 (91)	183 (93)
Not reported	1 (<1)	---	---	---	1 (1)
<i>Median age 1st IDU</i>	17	18	18	18	18
<i>Age range</i>	5 - 40	12-40	12-46	12-49	11-47
Not reported	5	3	---	2	5
<i>Median years IDU</i>	13	15	15	15	15
<i>Range</i>	<1 - 46	<1-37	<1-41	<1-37	<1-42
Duration of drug injection (%)					
<3 years	8 (5)	5 (3)	5 (3)	8 (7)	3 (2)
3+ years	148 (92)	154 (91)	153 (96)	100 (91)	188 (96)
Not reported	5 (3)	10 (6)	2 (1)	2 (2)	5 (3)
Aboriginal and Torres Strait Islander origin (%)					
No	146 (91)	156 (93)	153 (96)	102 (93)	179 (91)
Yes	9 (5)	10 (6)	4 (3)	5 (5)	9 (5)
Not reported	6 (4)	2 (1)	3 (2)	3 (3)	8 (4)
Region/Country of birth (%)					
Australia	123 (76)	138 (82)	130 (81)	90 (82)	149 (76)
Other Oceania	6 (4)	6 (4)	3 (2)	1 (1)	16 (8)
Asia	5 (3)	2 (1)	---	1 (1)	2 (1)
UK & Ireland	17 (11)	16 (9)	12 (8)	9 (8)	18 (9)
Other	7 (4)	6 (4)	11 (7)	5 (5)	7 (4)
Not reported	3 (2)	1 (1)	4 (3)	4 (4)	4 (2)
Main language spoken at home by parents (%)					
English speaking	113 (70)	143 (85)	144 (90)	105 (95)	186 (95)
Non-English speaking	15 (9)	26 (15)	6 (4)	2 (2)	10 (5)
Not reported	33 (21)	---	10 (6)	3 (3)	---
Imprisonment last year (%)					
No	127 (79)	146 (86)	130 (81)	85 (77)	168 (86)
Yes	32 (20)	18 (11)	21 (13)	18 (16)	21 (11)
Not reported	2 (1)	6 (4)	9 (6)	7 (6)	7 (4)
Injected in prison (%)					
Yes	N=32 17 (53)	N=18 11 (61)	N=21 7 (33)	N=18 6 (33)	N=21 8 (38)
Frequency of injection last month (%)					
Not last month	12 (7)	7 (4)	5 (3)	6 (5)	7 (4)
Less than weekly	18 (11)	18 (11)	20 (13)	9 (8)	15 (8)
Weekly not daily	42 (26)	38 (22)	42 (26)	21 (19)	49 (25)
Daily or more	83 (52)	106 (63)	92 (58)	73 (66)	124 (63)
Not reported	6 (4)	---	1 (<1)	1 (1)	1 (1)

Western Australia

Table 235 Number (percentage) of respondents by last drug injected, injecting behaviour in the month prior to survey and year of survey

Injecting behaviour	2004	2005	2006	2007	2008
Last drug injected (%)	N = 161	N=170	N=160	N=110	N=196
Anabolic steroids	---	---	2 (1)	---	---
Cocaine	1 (1)	---	---	---	---
Heroin	31 (19)	48 (28)	30 (19)	28 (25)	62 (32)
Methadone	3 (2)	6 (4)	9 (6)	4 (4)	5 (3)
Meth/Amphetamine	74 (46)	57 (34)	72 (45)	34 (31)	54 (28)
Morphine/Other Opioids	18 (11)	24 (14)	22 (14)	23 (21)	42 (21)
Subutex/Buprenorphine	4 (2)	19 (11)	16 (10)	7 (6)	18 (9)
More than one	21 (13)	3 (2)	4 (3)	5 (5)	10 (5)
Other	---	5 (3)	1 (<1)	6 (6)	---
Not reported	8 (5)	7 (4)	1 (<1)	3 (3)	5 (3)
N° Injected last month	N = 143	N=162	N=154	N=103	N=188
Places injected last month (%)*					
Own home	118 (83)	129 (80)	142 (96)	91 (93)	171 (92)
Friend's home	68 (48)	57 (35)	73 (49)	48 (49)	100 (54)
Dealer's home	30 (21)	28 (17)	32 (22)	31 (32)	56 (30)
Street, park, beach	37 (26)	25 (15)	27 (18)	23 (23)	55 (30)
Car	46 (32)	49 (30)	57 (39)	41 (42)	80 (43)
Public toilet	34 (24)	23 (14)	26 (18)	19 (19)	45 (24)
Commercial injecting room	---	---	1 (<1)	---	2 (1)
Squat	13 (9)	2 (1)	2 (1)	8 (8)	18 (10)
Use of new sterile needles & syringes last month (%)					
All injections	91 (64)	103 (64)	102 (66)	58 (56)	119 (63)
Most of the time	37 (26)	44 (27)	40 (26)	29 (28)	56 (30)
Half of the time	8 (5)	5 (3)	6 (4)	6 (6)	5 (3)
Some of the time	6 (4)	4 (2)	3 (2)	7 (7)	3 (2)
Not last month	---	1 (1)	1 (<1)	---	3 (2)
Not reported	1 (1)	6 (3)	2 (1)	3 (3)	2 (1)
Re-used another's needle & syringe last month (%)					
None	110 (77)	124 (78)	127 (82)	75 (73)	150 (80)
One	10 (7)	7 (4)	8 (5)	10 (10)	11 (6)
Twice	11 (8)	9 (6)	4 (3)	1 (1)	10 (5)
3-5 times	7 (5)	8 (5)	5 (3)	11 (11)	8 (4)
>5 times	4 (3)	3 (2)	6 (4)	3 (3)	8 (4)
Not reported	1 (<1)	9 (5)	4 (3)	3 (3)	1 (1)
Number of people needle & syringe was re-used after last month (%)					
None	110 (77)	119 (73)	127 (82)	75 (73)	150 (80)
One	12 (8)	17 (10)	14 (9)	13 (13)	16 (9)
Two	5 (4)	3 (2)	---	1 (1)	2 (1)
Three to five	1 (1)	1 (1)	1 (<1)	1 (1)	1 (1)
More than five	-	2 (1)	3 (2)	1 (1)	---
Don't know	9 (6)	5 (3)	4 (3)	4 (4)	8 (4)
Not reported	6 (4)	16 (9)	5 (3)	9 (9)	11 (6)
Relationship to people needle & syringe was re-used after last month (%)*					
Regular sex partner	10 (7)	15 (9)	9 (6)	12 (12)	16 (9)
Casual sex partner	2 (1)	2 (1)	---	1 (1)	3 (2)
Close friend	12 (8)	11 (7)	9 (6)	7 (7)	8 (4)
Acquaintance	1 (1)	4 (2)	1 (<1)	---	3 (2)
Other	2 (1)	3 (1)	---	1 (1)	2 (1)
Equipment used after someone else last month (%)*					
Spoon	32 (22)	31 (19)	25 (16)	22 (22)	37 (23)
Water	28 (20)	31 (19)	27 (18)	14 (14)	29 (18)
Filter	23 (16)	25 (16)	23 (15)	13 (13)	20 (12)
Drug mix	17 (12)	16 (10)	17 (11)	12 (12)	20 (12)
Tourniquet	20 (14)	20 (12)	22 (14)	17 (17)	23 (14)
None**	---	---	97 (63)	63 (64)	100 (61)
Injected by someone after that person injected themselves or others last month (%)					
No	122 (85)	126 (78)	129 (84)	83 (81)	150 (80)
Yes	20 (14)	24 (15)	22 (14)	16 (16)	30 (16)
Not reported	1 (1)	13 (7)	3 (2)	4 (4)	8 (4)

* More than one option could be selected

** New variable in 2006

Table 236 Number (percentage) of respondents by treatment for drug use and year of survey

Treatment for drug use	2004	2005	2006	2007	2008
N° surveyed	N=161	N=169	N=160	N=110	N=196
Any treatment/therapy for drug use (%)					
No	39 (24)	40 (24)	41 (26)	31 (28)	54 (28)
Yes	121 (75)	125 (74)	113 (71)	76 (69)	139 (71)
Not reported	1 (1)	5 (2)	6 (4)	3 (3)	3 (2)
History of methadone maintenance treatment (%)					
Currently	28 (17)	50 (30)	30 (19)	21 (19)	39 (20)
Previously	43 (27)	34 (20)	43 (27)	27 (25)	55 (28)
Never	89 (55)	82 (49)	84 (53)	60 (55)	99 (51)
Not reported	1 (1)	4 (2)	3 (2)	2 (2)	3 (2)
History of buprenorphine (Subutex®) treatment (%)*					
Currently	--	--	--	--	21 (11)
Previously	--	--	--	--	59 (30)
Never	--	--	--	--	111 (57)
Not reported	--	--	--	--	5 (3)
History of buprenorphine-naloxone (Suboxone®) treatment (%)*					
Currently	--	--	--	--	18 (9)
Previously	--	--	--	--	24 (12)
Never	--	--	--	--	149 (76)
Not reported	--	--	--	--	5 (3)

* New variable in 2008

Table 237 Number (percentage) of respondents by site of needle and syringe acquisition last month and year of survey

Needle & Syringe acquisition	2004	2005	2006	2007*	2008
N° surveyed	N=161	N=169	N=160	--	N=196
From an NSP last month (%)					
Daily or almost daily	20 (13)	12 (7)	7 (4)	--	11 (6)
A couple of times each week	42 (26)	39 (23)	52 (32)	--	36 (18)
Less than weekly	45 (28)	50 (30)	44 (28)	--	56 (29)
Once last month	29 (18)	49 (29)	42 (26)	--	59 (30)
Not in the last month	23 (14)	17 (10)	14 (9)	--	25 (13)
Not reported	2 (1)	1 (1)	1 (<1)	--	9 (5)
From a chemist last month (%)					
Daily or almost daily	9 (6)	4 (2)	5 (3)	--	3 (2)
A couple of times each week	16 (10)	11 (7)	17 (11)	--	30 (15)
Less than weekly	18 (11)	22 (13)	28 (18)	--	25 (13)
Once last month	29 (18)	28 (17)	29 (18)	--	39 (20)
Not in the last month	84 (52)	100 (59)	78 (49)	--	96 (49)
Not reported	5 (3)	4 (2)	3 (2)	--	3 (2)

* Not asked in this form in 2007

Table 238 Number (percentage) of respondents by injecting equipment use, re-use and cleaning last month

Use, re-use and cleaning of any item*	Used	Re-used	Cleaned**
N° surveyed***	N=188	N=188	N=188
Yes	177 (94)	105 (56)	88 (47)
No	1 (<1)	68 (36)	83 (44)
Not reported	10 (5)	15 (8)	17 (9)
Use, re-use and cleaning by item type#			
1ml	152 (81)	75 (40)	68 (36)
3 ml	49 (26)	19 (10)	19 (10)
5 ml	14 (7)	7 (4)	3 (2)
10 ml	17 (9)	8 (4)	9 (5)
20 ml	7 (4)	3 (2)	4 (2)
Detachable needle (tip)	21 (11)	8 (4)	12 (6)
Winged vein infusion set (butterfly)	20 (11)	6 (3)	7 (4)
Wheel filter	25 (13)	15 (8)	11 (6)

* New question in 2008

** Includes 8 respondents that reported cleaning but not re-use in the last month

More than one item could be selected

*** Excludes respondents that did not inject in the last month

Western Australia

Table 239 Number (percentage) of respondents by sexual behaviour in the month prior to survey and year of survey

Sexual behaviour	2004	2005	2006	2007	2008
N ^o surveyed	N=161	N=169	N=160	N=110	N=196
Sex with a regular partner last month (%) **					
No	--	86 (51)	77 (48)	42 (38)	81 (41)
Yes	--	82 (49)	77 (48)	66 (60)	113 (58)
Not reported	--	2 (1)	6 (4)	2 (2)	2 (1)
Condom used with regular partner last month (%)**					
N ^o surveyed		N=82	N=77	N=66	N=113
Never	--	59 (72)	57 (74)	46 (70)	80 (71)
Sometimes	--	8 (10)	9 (12)	8 (12)	12 (11)
Every time	--	11 (13)	5 (6)	8 (12)	14 (12)
Not reported	--	5 (5)	6 (8)	4 (6)	7 (6)
Sex with other partner/s last month (%)**					
No	--	133 (79)	124 (78)	97 (88)	164 (84)
Yes	--	32 (19)	29 (18)	11 (10)	29 (15)
Not reported	--	4 (2)	7 (4)	2 (2)	3 (2)
Condom used with other partner/s last month (%)**					
N ^o surveyed		N=32	N=29	N=11	N=29
Never	--	8 (25)	10 (34)	2 (18)	6 (21)
Sometimes	--	10 (31)	3 (10)	4 (36)	14 (48)
Every time	--	13 (41)	14 (48)	5 (45)	7 (24)
Not reported	--	1 (3)	2 (7)	---	2 (7)
Sex work last month (%)					
No	141 (88)	159 (94)	145 (91)	99 (90)	177 (90)
Yes	16 (10)	8 (5)	10 (6)	4 (4)	11 (6)
Not reported	4 (2)	2 (1)	5 (3)	7 (6)	8 (4)
Condom used at last sex work last month (%)*					
Yes	13 (81)	12 (92)	7 (88)	4 (100)	9 (82)

* Percentages exclude missing data

** New variable format commenced in 2005

Table 240 Number (percentage) of respondents reporting previous testing for HIV and HCV infection and HCV treatment by year of survey

	2004	2005	2006	2007	2008
N ^o surveyed	N=161	N=170	N=160	N=110	N=196
Previous HIV test (%)					
Yes, last year	100 (62)	96 (56)	83 (52)	58 (53)	99 (51)
> 1 year ago	39 (24)	48 (28)	61 (38)	38 (35)	75 (38)
Never tested	21 (13)	25 (15)	12 (8)	12 (11)	14 (7)
Not reported	1 (1)	1 (1)	4 (3)	2 (2)	8 (4)
Previous HCV test (%)					
Yes, last year	106 (66)	103 (61)	94 (59)	62 (56)	108 (55)
> 1 year ago	30 (19)	45 (27)	52 (33)	34 (31)	65 (33)
Never tested	23 (14)	19 (11)	11 (7)	11 (10)	15 (8)
Not reported	2 (1)	2 (1)	3 (2)	3 (3)	8 (4)
Any treatment for HCV (%)	N=62	N=66	N=65	N=31	N=90
Interferon	5 (8)	1 (2)	3 (5)	2 (6)	5 (6)
Interferon+Ribarvarin	3 (5)	2 (3)	2 (3)	---	4 (4)
Other	---	1 (2)	2 (3)	1 (3)	4 (4)
No treatment	54 (87)	62 (94)	54 (83)	27 (87)	75 (83)
Not reported	---	---	4 (6)	1 (3)	2 (2)
Current treatment for HCV	N=3	N=2	N=2	N=1	N=5
Interferon/Interferon+Ribarvirin	3	2	1	1	3
Other	---	---	1	---	2

HIV antibody prevalence

Table 241 HIV antibody prevalence by gender and year of survey

Year of survey	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2004	69	0 (0.0)	43	0 (0.0)	113	0 (0.0)
2005	100	3 (3.0)	55	0 (0.0)	156	3 (1.9)
2006	82	1 (1.2)	49	0 (0.0)	132	1 (0.8)
2007	54	1 (1.9)	31	0 (0.0)	85	1 (1.2)
2008	106	2 (1.9)	62	0 (0.0)	168	2 (1.2)
χ^2 trend p value		0.698		---		0.686

* Total includes people whose gender was not reported or reported as transgender

Table 242 HIV antibody prevalence by sexual identity and year of survey

Sexual identity	N° tested	N° with HIV (%)
2004		
Heterosexual	---	0 (0.0)
Bisexual	---	0 (0.0)
Homosexual	---	0 (0.0)
2005		
Heterosexual	126	2 (1.6)
Bisexual	14	0 (0.0)
Homosexual	7	1 (14.3)
2006		
Heterosexual	109	0 (0.0)
Bisexual	13	0 (0.0)
Homosexual	6	1 (16.7)
2007		
Heterosexual	73	0 (0.0)
Bisexual	5	0 (0.0)
Homosexual	6	1 (16.7)
2008		
Heterosexual	136	0 (0.0)
Bisexual	20	1 (5.0)
Homosexual	7	1 (14.3)
p value		0.012

Table 243 HIV antibody prevalence by age group and year of survey

Age group	N° tested	N° with HIV (%)
2004		
< 20 years	---	0 (0.0)
20 – 24	---	0 (0.0)
25 – 29	---	0 (0.0)
30 + years	---	0 (0.0)
2005		
< 20 years	3	0 (0.0)
20 – 24	22	0 (0.0)
25 – 29	17	0 (0.0)
30 + years	114	3 (2.7)
2006		
< 20 years	3	0 (0.0)
20 – 24	9	0 (0.0)
25 – 29	23	0 (0.0)
30 + years	97	1 (1.0)
2007		
< 20 years	3	0 (0.0)
20 – 24	6	0 (0.0)
25 – 29	15	0 (0.0)
30 + years	61	1 (1.6)
2008		
< 20 years	2	0 (0.0)
20 – 24	8	0 (0.0)
25 – 29	25	0 (0.0)
30 + years	132	2 (1.5)
p value		1.000

Western Australia

Table 244 HIV antibody prevalence by duration of drug injection and year of survey

Duration of drug injection	N° tested	N° with HIV (%)
2004		
<3 years	---	0 (0.0)
3 to 5 years	---	0 (0.0)
6 to 10 years	---	0 (0.0)
10 + years	---	0 (0.0)
2005		
<3 years	5	0 (0.0)
3 to 5 years	10	0 (0.0)
6 to 10 years	17	0 (0.0)
10 + years	114	3 (2.6)
2006		
<3 years	2	0 (0.0)
3 to 5 years	10	0 (0.0)
6 to 10 years	8	0 (0.0)
10 + years	90	1 (1.1)
2007		
<3 years	7	0 (0.0)
3 to 5 years	7	0 (0.0)
6 to 10 years	20	1 (5.0)
10 + years	50	0 (0.0)
2008		
<3 years	2	0 (0.0)
3 to 5 years	15	0 (0.0)
6 to 10 years	25	1 (4.0)
10 + years	122	1 (0.8)
p value		0.448

Table 245 HIV antibody prevalence by last drug injected and year of survey

Last drug injected	N° tested	N° with HIV (%)
2004		
Heroin	---	0 (0.0)
Meth/Amphetamine	---	0 (0.0)
More than one	---	0 (0.0)
Other/Not reported	---	0 (0.0)
2005		
Heroin	47	1 (2.1)
Meth/Amphetamine	49	0 (0.0)
More than one	3	0 (0.0)
Other/Not reported	57	2 (3.5)
2006		
Heroin	27	0 (0.0)
Meth/Amphetamine	60	1 (1.7)
More than one	3	0 (0.0)
Other/Not reported	42	0 (0.0)
2007		
Heroin	23	0 (0.0)
Meth/Amphetamine	26	1 (3.9)
More than one	4	0 (0.0)
Other/Not reported	32	0 (0.0)
2008		
Heroin	55	0 (0.0)
Meth/Amphetamine	43	1 (2.3)
More than one	9	0 (0.0)
Other/Not reported	61	1 (1.6)
p value		0.761

Table 246 HIV antibody prevalence by frequency of drug injection last month and year of survey

Frequency of drug injection	N° tested	N° with HIV (%)
2004		
Not last month	---	0 (0.0)
Less than weekly	---	0 (0.0)
Weekly not daily	---	0 (0.0)
Daily or more	---	0 (0.0)
2005		
Not last month	6	0 (0.0)
Less than weekly	15	0 (0.0)
Weekly not daily	36	2 (5.6)
Daily or more	99	1 (1.0)
2006		
Not last month	5	0 (0.0)
Less than weekly	17	0 (0.0)
Weekly not daily	34	0 (0.0)
Daily or more	75	1 (1.3)
2007		
Not last month	5	0 (0.0)
Less than weekly	7	0 (0.0)
Weekly not daily	18	0 (0.0)
Daily or more	54	1 (1.9)
2008		
Not last month	5	1 (20)
Less than weekly	12	0 (0.0)
Weekly not daily	41	0 (0.0)
Daily or more	110	1 (0.9)
p value		0.099

Table 247 HIV antibody prevalence by re-use of someone else's used needle and syringe last month and year of survey

Re-used someone else's used needle & syringe last month	N° tested	N° with HIV (%)
2004		
No	---	0 (0.0)
Yes	---	0 (0.0)
2005		
No	114	2 (1.8)
Yes	26	1 (3.8)
2006		
No	106	1 (0.9)
Yes	17	0 (0.0)
2007		
No	61	1 (1.6)
Yes	15	0 (0.0)
2008		
No	132	1 (0.8)
Yes	30	0 (0.0)
p value		1.00

Table 248 HIV antibody prevalence by imprisonment last year and year of survey

Imprisonment last year	N° tested	N° with HIV (%)
2004		
No	---	0 (0.0)
Yes	---	0 (0.0)
2005		
No	80	3 (3.8)
Yes	74	0 (0.0)
2006		
No	107	1 (0.9)
Yes	18	0 (0.0)
2007		
No	66	1 (1.5)
Yes	15	0 (0.0)
2008		
No	146	2 (1.4)
Yes	19	0 (0.0)
p value		1.000

Table 250 HIV antibody prevalence by sex work last month and year of survey

Sex work last month	N° tested	N° with HIV (%)
2004		
No	---	0 (0.0)
Yes	---	0 (0.0)
2005		
No	141	3 (2.1)
Yes	8	0 (0.0)
2006		
No	121	1 (0.8)
Yes	7	0 (0.0)
2007		
No	75	0 (0.0)
Yes	4	0 (0.0)
2008		
No	153	2 (1.3)
Yes	10	0 (0.0)
p value		1.000

Table 249 HIV antibody prevalence by condom use at last sex and year of survey

Condom use at last sex	N° tested	N° with HIV (%)
2004		
No	---	0 (0.0)
Yes	---	0 (0.0)
2005*		
No	66	0 (0.0)
Yes	8	0 (0.0)
2006*		
No	57	0 (0.0)
Yes	3	0 (0.0)
2007*		
No	43	0 (0.0)
Yes	6	0 (0.0)
2008*		
No	79	1 (1.3)
Yes	12	1 (8.3)
p value		0.248

* Question changed to "condom use with regular partner in last month" in 2005 survey.

Table 251 HIV antibody prevalence by Aboriginal and Torres Strait Islander origin status and year of survey

Aboriginal and Torres Strait Islander origin	N° tested	N° with HIV (%)
2004		
No	---	0 (0.0)
Yes	---	0 (0.0)
2005		
No	140	3 (2.1)
Yes	10	0 (0.0)
2006		
No	128	1 (0.8)
Yes	2	0 (0.0)
2007		
No	79	1 (1.3)
Yes	5	0 (0.0)
2008		
No	153	2 (1.3)
Yes	8	0 (0.0)
p value		1.000

Western Australia

Table 252 HIV antibody prevalence by region/country of birth and year of survey

Region/Country of birth	N° tested	N° with HIV (%)
2004		
Australia	---	---
Other Oceania	---	---
Asia	---	---
UK & Ireland	---	---
Other	---	---
2005		
Australia	128	3 (2.3)
Other Oceania	5	0 (0.0)
Asia	2	0 (0.0)
UK & Ireland	16	0 (0.0)
Other	4	0 (0.0)
2006		
Australia		
Other Oceania	104	1 (1.0)
Asia	3	0 (0.0)
UK & Ireland	---	0 (0.0)
Other	11	0 (0.0)
2007		
Australia	69	1 (1.5)
Other Oceania	---	---
Asia	1	0 (0.0)
UK & Ireland	9	0 (0.0)
Other	5	0 (0.0)
2008		
Australia	127	2 (1.6)
Other Oceania	13	0 (0.0)
Asia	2	0 (0.0)
UK & Ireland	13	0 (0.0)
Other	12	0 (0.0)
p value		1.000

Table 253 HIV antibody prevalence by main language spoken at home by parents and year of survey

Main language spoken at home by parents	N° tested	N° with HIV (%)
2004		
English speaking	---	0 (0.0)
Non-English speaking	---	0 (0.0)
2005		
English speaking	133	3 (2.3)
Non-English speaking	22	0 (0.0)
2006		
English speaking	118	1 (0.9)
Non-English speaking	6	0 (0.0)
2007		
English speaking	82	1 (1.2)
Non-English speaking	2	0 (0.0)
2008		
English speaking	160	2 (1.3)
Non-English speaking	8	0 (0.0)
p value		1.000

HCV antibody prevalence

Table 254 HCV antibody prevalence by gender and year of survey

Year of survey	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004	69	42 (61)	43	22 (51)	113	65 (58)
2005	101	59 (58)	55	31 (56)	156	90 (58)
2006	82	46 (56)	49	30 (61)	132	76 (58)
2007	54	23 (43)	31	14 (45)	85	37 (44)
2008	101	59 (58)	59	32 (54)	160	91 (57)
χ^2 trend p value		0.420		0.903		0.447

* Total includes people whose gender was not reported or reported as transgender

Table 255 HCV antibody prevalence by sexual identity, gender and year of survey

Sexual identity	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Heterosexual	61	38 (62)	35	17 (49)	96	55 (57)
Bisexual	4	2 (50)	5	3 (60)	5	3 (60)
Homosexual	65	40 (62)	3	2 (67)	7	4 (57)
P value		0.6		0.8		0.9
2005						
Heterosexual	89	56 (63)	37	21 (57)	126	77 (61)
Bisexual	4	0 (0)	10	5 (50)	14	5 (36)
Homosexual	4	1 (25)	3	1 (33)	7	2 (29)
p value		0.02		0.7		0.06
2006						
Heterosexual	73	43 (59)	36	22 (61)	109	65 (60)
Bisexual	4	2 (50)	8	6 (75)	13	8 (62)
Homosexual	1	0 (0.0)	5	2 (40)	6	2 (33)
p value		0.601		0.497		0.465
2007						
Heterosexual	50	23 (46)	23	11 (48)	73	34 (47)
Bisexual	1	0 (0.0)	4	1 (25)	5	1 (20)
Homosexual	3	0 (0.0)	3	1 (33)	6	1 (17)
p value		0.253		0.828		0.257
2008						
Heterosexual	91	53 (58)	39	19 (49)	130	72 (55)
Bisexual	4	2 (50)	14	10 (71)	18	12 (67)
Homosexual	3	1 (33)	4	2 (50)	7	3 (43)
p value		0.707		0.332		0.509

* Total includes people whose gender was not reported or reported as transgender

Western Australia

Table 256 HCV antibody prevalence by age group, gender and year of survey

Age group	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
< 20 years	1	0 (0)	-	-	1	0 (0)
20 – 24	9	2 (22)	7	1 (14)	16	3 (19)
25 – 29	7	4 (57)	8	2 (25)	15	6 (40)
30 + years	52	36 (69)	28	19 (68)	81	56 (69)
p value		0.02		0.5		0.04
2005						
< 20 years	1	0 (0)	2	1 (50)	3	1 (33)
20 – 24	13	5 (38)	9	3 (33)	22	8 (36)
25 – 29	10	6 (60)	7	1 (14)	17	7 (41)
30 + years	77	48 (62)	37	26 (70)	114	74 (65)
p value		0.03		0.01		0.001
2006						
< 20 years	2	0 (0.0)	1	1 (100)	3	1 (33)
20 – 24	6	5 (83)	3	2 (67)	9	7 (78)
25 – 29	15	7 (47)	8	5 (63)	23	12 (52)
30 + years	59	34 (58)	37	22 (60)	97	56 (58)
p value		0.202		1.000		0.492
2007						
< 20 years	2	0 (0.0)	1	0 (0.0)	3	0 (0.0)
20 – 24	4	2 (50)	2	0 (0.0)	6	2 (33)
25 – 29	7	1 (14)	8	4 (50)	15	5 (33)
30 + years	41	20 (49)	20	10 (50)	61	30 (49)
p value		0.211		0.643		0.309
2008						
< 20 years	1	0 (0.0)	1	0 (0.0)	2	0 (0.0)
20 – 24	4	1 (25)	4	0 (0.0)	8	1 (13)
25 – 29	11	4 (36)	14	9 (64)	25	13 (52)
30 + years	84	53 (63)	40	23 (58)	124	76 (61)
p value		0.079		0.059		0.011

* Total includes people whose gender was not reported or reported as transgender

Table 257 HCV antibody prevalence by duration of drug injection, gender and year of survey

Duration of drug injection	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
<3 years	4	2 (50)	-	-	5	3 (60)
3 to 5 years	4	1 (25)	2	0 (0)	6	1 (17)
6 to 10 years	13	5 (38)	9	2 (22)	22	7 (32)
10 + years	45	33 (73)	29	19 (66)	74	52 (70)
p value		<0.001		0.02		<0.001
2005						
<3 years	5	1 (20)	2	0 (0)	5	1 (20)
3 to 5 years	10	5 (50)	4	1 (25)	10	5 (50)
6 to 10 years	17	5 (29)	8	4 (50)	17	5 (29)
10 + years	114	74 (65)	80	50 (63)	114	74 (65)
p value		0.1		0.01		0.01
2006						
<3 years	1	0 (0.0)	---	---	2	0 (0.0)
3 to 5 years	5	2 (40)	5	2 (40)	10	4 (40)
6 to 10 years	18	9 (50)	10	5 (50)	28	14 (50)
10 + years	57	35 (61)	33	22 (67)	90	57 (63)
p value		0.419		0.418		0.111
2007						
<3 years	4	0 (0.0)	3	0 (0.0)	7	0 (0.0)
3 to 5 years	4	2 (50)	3	1 (33)	7	3 (43)
6 to 10 years	12	2 (17)	8	1 (13)	20	3 (15)
10 + years	33	18 (55)	17	12 (71)	50	30 (60)
p value		0.036		0.006		<0.001
2008						
<3 years	---	---	2	1 (50)	2	1 (50)
3 to 5 years	10	2 (20)	5	1 (20)	15	3 (20)
6 to 10 years	13	6 (46)	12	4 (33)	25	10 (40)
10 + years	74	48 (65)	40	26 (65)	114	74 (65)
p value		0.019		0.078		0.001

* Total includes people whose gender was not reported or reported as transgender

Western Australia

Table 258 HCV antibody prevalence by last drug injected, duration of drug injection and year of survey

Last drug injected	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Heroin	---	---	26	20 (77)	28	21 (75)
Meth/Amphetamine	3	1 (33)	42	14 (33)	48	15 (31)
More than one	---	---	14	12 (86)	14	12 (86)
Other/Not reported	2	2 (100)	20	14 (70)	23	17 (74)
p value		0.1		<0.001		<0.001
2005						
Heroin	1	1 (100)	46	30 (65)	47	31 (66)
Meth/Amphetamine	3	0 (0)	47	22 (47)	50	22 (44)
More than one	---	---	3	2 (67)	3	2 (67)
Other/Not reported	1	0 (0)	55	35 (64)	56	35 (63)
p value		0.400		0.232		0.106
2006						
Heroin	1	0 (0.0)	26	20 (77)	27	20 (74)
Meth/Amphetamine	---	---	59	29 (49)	60	30 (50)
More than one	---	---	3	2 (67)	3	2 (67)
Other/Not reported	1	0 (0.0)	40	24 (60)	42	24 (57)
p value		---		0.093		0.185
2007						
Heroin	--	---	22	17 (77)	23	18 (78)
Meth/Amphetamine	4	0 (0.0)	22	5 (23)	26	5 (19)
More than one	1	0 (0.0)	3	1 (33)	4	1 (25)
Other/Not reported	2	0 (0.0)	30	13 (43)	32	13 (41)
p value		---		0.002		<0.001
2008						
Heroin	1	1 (100)	49	34 (69)	52	37 (71)
Meth/Amphetamine	1	0 (0.0)	40	13 (14)	42	13 (31)
More than one	---	---	8	6 (75)	8	6 (75)
Other/Not reported	---	---	57	34 (60)	58	35 (60)
p value		1.000		0.003		0.001

* Total includes people who did not report duration of drug injection

Table 259 HCV antibody prevalence by frequency of injection last month, duration of drug injection and year of survey

Frequency of drug injection last month	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Less than daily	2	1 (50)	47	20 (43)	50	22 (44)
Daily or more	2	1 (50)	55	40 (73)	61	42 (69)
p value		0.01		>0.9		0.01
2005						
Less than daily	2	0 (0)	52	29 (56)	57	30 (53)
Daily or more	3	1 (33)	89	55 (62)	99	60 (61)
p value		0.4		0.5		0.3
2006						
Less than daily	2	0 (0.0)	48	27 (56)	51	27 (53)
Daily or more	---	---	74	45 (61)	75	46 (61)
p value		---		0.707		0.364
2007						
Less than daily	5	0 (0.0)	20	7 (35)	25	7 (28)
Daily or more	2	0 (0.0)	51	26 (51)	54	27 (50)
p value		---		0.293		0.088
2008						
Less than daily	1	0 (0.0)	50	27 (52)	52	27 (52)
Daily or more	1	1 (100)	100	59 (59)	104	63 (61)
p value		1.000		0.602		0.309

* Total includes people who did not report duration of drug injection

Table 260 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and year of survey

Re-used someone else's used needle & syringe last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
No	3	1 (33)	69	41 (59)	75	43 (57)
Yes	1	1 (100)	24	15 (63)	26	16 (62)
p value		0.3		0.8		0.7
2005						
No	3	1 (33)	103	59 (57)	115	64 (56)
Yes	1	0 (0)	23	17 (74)	25	18 (72)
p value		0.5		0.1		0.1
2006						
No	1	0 (0.0)	103	56 (54)	106	57 (54)
Yes	1	0 (0.0)	16	13 (81)	17	13 (76)
p value		---		0.057		0.113
2007						
No	5	0 (0.0)	55	26 (47)	61	27 (44)
Yes	2	0 (0.0)	13	6 (46)	15	6 (40)
p value		---		1.000		1.000
2008						
No	2	1 (50)	121	70 (58)	127	74 (58)
Yes	---	---	28	16 (57)	28	16 (57)
p value		---		1.000		1.000

* Total includes people who did not report duration of drug injection

Western Australia

Table 261 HCV antibody prevalence by imprisonment last year, duration of drug injection and year of survey

Imprisonment last year	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
No	4	2 (50)	81	41 (51)	91	45 (49)
Yes	---	---	20	18 (90)	20	18 (90)
p value				0.001		0.001
2005						
No	5	1 (20)	120	67 (56)	133	71 (53)
Yes	---	---	15	13 (87)	17	15 (88)
p value				0.02		0.001
2006						
No	2	0 (0.0)	104	55 (53)	107	56 (52)
Yes	---	---	17	14 (82)	18	14 (78)
p value				0.033		0.070
2007						
No	7	0 (0.0)	59	27 (46)	66	27 (41)
Yes	---	---	14	7 (50)	15	8 (53)
p value				1.000		0.402
2008						
No	2	1 (50)	133	74 (56)	139	78 (56)
Yes	---	---	18	12 (67)	18	12 (67)
p value				0.453		0.456

* Total includes people who did not report duration of drug injection

Table 262 HCV antibody prevalence by sex work last month, duration of drug injection and year of survey

Sex work last month	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
No	3	1 (33)	91	52 (57)	99	55 (56)
Yes	1	1 (100)	10	7 (70)	11	8 (73)
p value		0.2		0.4		0.3
2005						
No	5	1(20)	131	78 (60)	146	84 (58)
Yes	-	-	8	4 (50)	8	4 (50)
p value				0.1		0.3
2006						
No	2	0 (0.0)	117	67 (57)	121	68 (56)
Yes	---	---	7	5 (71)	7	5 (71)
p value				0.698		0.698
2007						
No	5	0 (0.0)	69	32 (46)	75	33 (44)
Yes	1	0 (0.0)	3	1 (33)	4	1 (25)
p value				1.000		0.630
2008						
No	2	1 (50)	140	79 (56)	146	83 (57)
Yes	---	---	9	4 (44)	9	4 (44)
p value				0.510		0.507

* Total includes people who did not report duration of drug injection

Table 263 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and year of survey

Aboriginal and Torres Strait Islander origin	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
No	60	37 (62)	40	20 (50)	101	58 (57)
Yes	5	3 (60)	2	1 (50)	7	4 (57)
p value		0.9		1.0		1.0
2005						
No	93	53 (57)	51	29 (57)	144	82 (57)
Yes	6	4 (67)	4	2 (50)	10	6 (60)
p value		0.6		0.8		0.8
2006						
No	81	45 (56)	46	27 (59)	128	72 (56)
Yes	1	1 (100)	1	1 (100)	2	2 (100)
p value		1.000		1.000		0.506
2007						
No	51	21 (41)	28	12 (43)	79	33 (42)
Yes	2	1 (50)	3	2 (67)	5	3 (60)
p value		1.000		0.576		0.647
2008						
No	93	54 (58)	53	31 (58)	146	85 (58)
Yes	4	1 (25)	4	1 (25)	8	2 (25)
p value		0.313		0.309		0.079

* Total includes people who did not report duration of drug injection

Western Australia

Table 264 HCV antibody prevalence by region/country of birth, gender and year of survey

Region/Country of birth	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Australia	54	32 (59)	32	17 (53)	87	50 (57)
Other Oceania	---	---	---	---	---	---
Asia	2	0 (0)	---	---	2	0 (0)
UK & Ireland	2	1 (50)	2	0 (0)	4	1 (25)
Other	9	7 (78)	2	1 (50)	18	12 (67)
p value		0.2		0.3		0.1
2005						
Australia	84	48 (57)	43	25 (58)	127	73 (57)
Other Oceania	4	1 (25)	1	0 (0)	5	1 (20)
Asia	1	0 (0)	1	0 (0)	2	0 (0)
UK & Ireland	8	7 (88)	8	5 (63)	16	12 (75)
Other	3	2 (67)	2	1 (50)	5	3 (60)
p value		0.2		0.6		0.1
2006						
Australia	68	37 (54)	36	24 (67)	104	61 (59)
Other Oceania	---	---	3	1 (33)	3	1 (33)
Asia	---	---	---	---	---	---
UK & Ireland	6	3 (50)	4	3 (75)	11	6 (55)
Other	7	5 (71)	4	0 (0.0)	11	5 (45)
p value		0.670		0.034		0.733
2007						
Australia	43	18 (42)	26	13 (50)	69	31 (45)
Other Oceania	---	---	---	---	---	---
Asia	1	1 (100)	---	---	1	1 (100)
UK & Ireland	6	1 (17)	3	1 (33)	9	2 (22)
Other	3	2 (67)	2	0 (0.0)	5	2 (40)
p value		0.230		0.607		0.397
2008						
Australia	77	44 (57)	43	24 (56)	120	68 (57)
Other Oceania	6	1 (17)	7	2 (29)	13	3 (23)
Asia	2	2 (100)	---	---	2	2 (100)
UK & Ireland	8	6 (75)	5	4 (80)	13	10 (77)
Other	7	5 (71)	4	2 (50)	11	7 (64)
p value		0.139		0.374		0.042

* Total includes people whose gender was not reported or reported as transgender

Table 265 HCV antibody prevalence by main language spoken at home by parents, gender and year of survey

Main language spoken at home by parents	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
English speaking	52	32 (62)	29	15 (52)	82	48 (59)
Non-English speaking	4	2 (50)	5	3 (60)	9	5 (56)
p value		0.7		0.6		0.9
2005						
English speaking	84	48 (57)	50	28 (56)	134	76 (57)
Non-English speaking	17	11 (65)	5	3 (60)	22	14 (64)
p value		0.6		0.9		0.5
2006						
English speaking	71	41 (58)	46	28 (61)	118	69 (58)
Non-English speaking	5	3 (60)	1	0 (0)	6	3 (50)
p value		1.000		0.404		0.695
2007						
English speaking	52	22 (42)	30	14 (47)	82	36 (44)
Non-English speaking	1	0 (0.0)	1	0 (0.0)	2	0 (0.0)
p value		1.000		1.000		0.504
2008						
English speaking	95	55 (58)	58	32 (55)	153	87 (57)
Non-English speaking	6	4 (67)	1	0 (0.0)	7	4 (57)
p value		1.000		0.458		1.000

* Total includes people whose gender was not reported or reported as transgender

Methodological Notes

All clients attending selected Needle and Syringe Program (NSP) sites during the 15th to 21st October 2007 were asked to complete a brief, self-administered questionnaire and to provide a capillary blood sample for HIV and hepatitis C antibody testing. In 2007 the survey period was extended from 15th to 26th October at some rural and regional low volume NSP sites. The survey was also conducted at ten additional (non-sentinel) NSP sites in Queensland in 2007. Data from the 298 participants at these non-sentinel sites were not included in this report.

NSP sites were initially selected on the basis of volume of syringes distributed, coverage of all Australian jurisdictions and willingness to participate, with subsequent expansion based on size, geographic coverage and sub-populations targeted. NSP staff recorded sex, age group and survey participation for all clients at the NSP during the survey week to assess response rate and representativeness of the survey sample. Some clients visited the site more than once during the survey week. Consequently, it was also necessary to record whether each attendance at the NSP was the first that week for each client so that only one attendance per person was included in the response rate denominator. Ethical approval for the survey was obtained from ethics committees associated with the investigators and participating sites, and verbal rather than written informed consent was obtained to assure the anonymity of participants.

Demographic characteristics and behavioural data, including information on injecting drug use, injecting risk behaviours, needle and syringe acquisition, pharmacotherapy treatment for drug use, sexual behaviour, tattooing and body piercing, and HIV and hepatitis B and C testing history, were captured using a brief, self-administered, anonymous questionnaire.

In 2007 there was a change to the coding system used for last drug injected. The previously used category "morphine" was changed to "morphine/other opioids". This was done to accommodate the increasing numbers of participants reporting non-morphine narcotic analgesics as the last drug injected. In previous years, non-morphine narcotic analgesics were classified under the category "other". These are now classified under the category "morphine/other opioids". Tables reporting last drug injected, including results from previous years, have been updated accordingly.

Capillary blood was obtained by finger-prick using disposable lancets and cotton-fibre blotting paper. Dried blood samples were kept at room temperature at the survey sites and couriered to a central laboratory every second or third day. HIV antibody was detected using Genetic Systems HIV-1 ELISA tests. Repeatedly reactive specimens were subjected to Western blot confirmatory testing (Bio-Rad New LAV blot 1, France).

A modified third generation enzyme immunoassay (Monolisa anti-HCV Plus Version 2 EIA, Biorad, France) was used to test for HCV antibody. A modified cut off value for optical density was calculated to capture greater than 95% of the seronegative population. Specimens were considered positive for HCV antibody if the optical density to cut off ratio was greater than or equal to one on initial and subsequent testing.

Data were analysed using the Stata, Version 10 (Stata Corporation, College Station TX). Changes for HIV and HCV antibody prevalence overtime were assessed using the χ^2 test for linear trends. Associations between demographic, behavioural variables, syringe use, and HIV/HCV antibody prevalence were assessed using the χ^2 test or Fisher's exact test where expected frequencies were less than five. Percentage values may not add to 100 due to rounding.

Further information is available in:

Topp L, Iversen JL, Wand H, Day CA, Kaldor JM, Maher L. Representativeness of injecting drug users who participate in HIV surveillance: Results from Australia's Needle and Syringe Program Survey. *Journal of Acquired Immune Deficiency Syndrome* 2008; 47:632-638.

Topp L, Iversen JL, Conroy A, Salmon A, Maher L. Prevalence and predictors of injecting-related injury and disease among clients of Australia's Needle and Syringe Programs. *Australian and New Zealand Journal of Public Health* 2008; 32:34-37.

Day CA, Topp L, Iversen J, Maher L. Collaboration of Australian NSPs. Blood-borne virus prevalence and risk among steroid injectors: results from the Australian Needle and Syringe Program Survey. *Drug Alcohol Review* 2008;27:559-561

Falster K, Kaldor JM, Maher L, on behalf of the collaboration of Australian Needle and Syringe Programs. Hepatitis C virus acquisition among injecting drug users: a cohort analysis of a national repeated cross-sectional survey of needle and syringe program attendees in Australia, 1995-2004. *J Urban Health* 2008;86:106-118

National Centre in HIV Epidemiology and Clinical Research. *HIV/AIDS, viral hepatitis and sexually transmissible infections in Australia Annual Surveillance Report 2008*. National Centre in HIV Epidemiology and Clinical Research, The University of New South Wales, Sydney, NSW. 2008.

MacDonald MA, Wodak AD, Dolan KA, et al. Hepatitis C virus antibody prevalence among injecting drug users at selected needle and syringe programs in Australia, 1995-1997. *Medical Journal of Australia* 2000;172(2): 57-61.

MacDonald M, Wodak A, Ali R, et al. HIV prevalence and risk behaviour in needle exchange attenders: a national study. *Medical Journal of Australia* 1997; 166: 237-240.

Australian NSP Survey 2008

Thank you for your help.

This is a national study, endorsed by the Australian Injecting & Illicit Drug Users League (AIVL) and local user groups.

BLOOD SPOTS

When you have finished the questionnaire, please supply a blood spot.

QUESTIONNAIRE

Fill in this questionnaire and return it to the open (non-sealed) section of the plastic bag.

Shade bubbles like this:

Not like this:

You may use a pencil or blue/black pen.



1. Are you Male
 Female
 Transgender
2. Do you identify as Heterosexual
 Bisexual
 Gay/lesbian
3. How old are you? _____
4. How old were you when you first injected drugs? _____
5. What was the **LAST drug you INJECTED?**
(MARK ONE ONLY)
 Heroin
 Meth/Amphetamine (Speed, Base, Ice)
 Cocaine
 Methadone
 Morphine
 Anabolic steroids
 Subutex/Buprenorphine
 Other (please specify)

6. How often did you inject **last month**?
 More than 3 times most days
 2 to 3 times most days
 Once a day
 More than weekly, not daily
 Less than weekly (on 1 to 5 days)
 Not in the last month **➔ Go to Q10**

If you **did NOT inject last month**, skip the next section and go to Q10. If you did inject last month, please continue.

- 6a. Mark all the places where you injected **last month**.
 Own home
 Friend's home
 Dealer's home
 Street, park or beach
 Car
 Public toilet
 Commercial "shooting" room
 MSIC (KX injecting centre)
 Squat
 Other (please specify)

- 6b. How often did you use a **NEW** sterile needle and syringe **last month**?
 All injections
 Most of the time
 Half of the time
 Some of the time
 Not last month

- 6c. Mark any equipment that you used after anyone else **last month**.
 Spoon Tourniquet
 Water Drug solution/mix
 Filter Did not share any of the above last month

- 6d. How many **TIMES last month** did someone else inject you after injecting themselves or others?
 More than 5 times 3 to 5 times
 Once or twice None

7. How many **TIMES in the last month** did you re-use a needle and syringe **after** someone else had used it, including your sex partner (even if it was cleaned)?
- More than 5 times 3 to 5 times
 Twice Once
 None ◀ **Go to Q8**
- 7a. How many different people (including your sex partner) have used a needle before you in the last month (even if cleaned)?
- More than 5 people
 3 to 5 people
 2 people
 1 person
 Don't know how many
- 7b. Who were these people?
- Regular sex partner
 Other sex partners
 Close friend
 Acquaintance
 Other (please specify) _____
8. What items of injecting equipment have you **used** in the **last month**? (**MARK ALL THAT APPLY**)
- 1 ml needle and syringe
 3 ml syringe (barrel)
 5 ml syringe (barrel)
 10 ml syringe (barrel)
 20 ml syringe (barrel)
 detachable needle (tip)
 winged vein infusion set (butterfly)
 wheel filter
 none of the above ◀ **Go to Q9**
- 8a. What items have you **re-used** in the **last month**? Mark all items that had been previously used by either you or someone else. (**MARK ALL THAT APPLY**)
- 1 ml needle and syringe
 3 ml syringe (barrel)
 5 ml syringe (barrel)
- 10 ml syringe (barrel)
 20 ml syringe (barrel)
 detachable needle (tip)
 winged vein infusion set (butterfly)
 wheel filter
 none of the above ◀ **Go to Q9**
- 8b. What items have you **cleaned** in the **last month**? (**MARK ALL THAT APPLY**)
- 1 ml needle and syringe
 3 ml syringe (barrel)
 5 ml syringe (barrel)
 10 ml syringe (barrel)
 20 ml syringe (barrel)
 detachable needle (tip)
 winged vein infusion set (butterfly)
 wheel filter
 none of the above
9. What was the **last item** you cleaned? (**MARK ONLY ONE**)
- 1 ml needle and syringe
 3 ml syringe (barrel)
 5 ml syringe (barrel)
 10 ml syringe (barrel)
 20 ml syringe (barrel)
 detachable needle (tip)
 winged vein infusion set (butterfly)
 wheel filter
 none of the above ◀ **Go to Q10**
- 9a. Who had used this item before you cleaned it?
- Me only Someone else
 Me and someone else
- 9b. What cleaning substance did you use for this item? (**MARK ALL THAT APPLY**)
- Hot water
 Cold water
 Boiling water
 Bleach
 Soap/detergent
 Swabs
 Other (please specify) _____

- 9c.** What cleaning method did you use for this item? (**MARK ALL THAT APPLY**)
- Rinse/flush once
 - Rinse/flush more than once
 - Wipe
 - Soak
 - Other (please specify) _____
- 9d.** Approximately how many times would you normally clean and re-use this item before replacing it?
- none
 - once
 - 2 to 5 times
 - 6 to 10 times
 - more than 10 times
- 10.** Have you **EVER** been in prison?
- Yes
 - No ◀ **Go to Q11**
- 10a.** If **YES**, were you in prison last year? (the calendar year January to December)
- Yes
 - No ◀ **Go to Q11**
- 10b.** If **YES**, did you inject drugs in prison?
- Yes
 - No
- 11.** Have you had sex with a regular partner in the **last month**?
- Yes
 - No ◀ **Go to Q12**
- 11a.** If **YES**, how often did you use a condom?
- Never
 - Sometimes
 - Every time
- 12.** Have you had sex with other partners in the **last month**?
- Yes
 - No ◀ **Go to Q13**
- 12a.** If **YES**, how often did you use a condom?
- Never
 - Sometimes
 - Every time
- 13.** Have you been paid for sex in the **last month**?
- Yes
 - No ◀ **Go to Q14**
- 13a.** If **YES**, did you use condoms the **last time** you were paid for sex?
- Yes
 - No
- 14.** Have you ever been tested for HIV?
- Yes, in the last year
 - Yes, more than a year ago
 - Never tested ◀ **Go to Q15**
- 14a.** If **YES**, what was the result of your last HIV test?
- Did not have HIV ◀ **Go to Q15**
 - I have HIV infection
 - Don't know result ◀ **Go to Q15**
- 14b.** What year did you find out you had HIV?
- _____
- 15.** Have you been tested for hepatitis C?
- Yes, in the last year
 - Yes, more than a year ago
 - Never tested ◀ **Go to Q16**
- 15a.** Have you ever been told that you have hepatitis C infection?
- Yes
 - No ◀ **Go to Q16**
- 15b.** If **YES**, what is your current hepatitis C status?
- I have hepatitis C
 - I cleared the virus spontaneously
 - I cleared the virus with treatment
 - Don't know
- 15c.** What year did you find out you had hep C?
- _____
- 15d.** Have you **EVER** had any treatment for your hep C?
- No treatment ◀ **Go to Q16**
 - Yes, interferon
 - Yes, interferon + ribavirin
 - Other, specify _____

- 15e.** If **YES**, are you on any treatment for your hep C **NOW**?
- No treatment Yes, interferon
 Yes, interferon + ribavirin
 Other, specify _____
- 16.** Have you ever been prescribed methadone?
- Yes, am on it now
 Yes, in the past
 No, never
- 16a.** Have you ever been prescribed Buprenorphine or Subutex?
- Yes, am on it now
 Yes, in the past
 No, never
- 16b.** Have you ever been prescribed Suboxone?
- Yes, am on it now
 Yes, in the past
 No, never
- 16c.** Have you ever had any other treatment or therapy for drug use? e.g. detox, rehab, counselling, NA?
- Yes, am on it now
 Yes, in the past
 No, never
- 17.** What was the main language spoken at home by your parents?
- English
 Other (please specify)

- 18.** In which country were you born?
- Australia
 Other (please specify)

- 19.** When were you born? _____ / _____
 month year
- 20.** Are you
- Aboriginal Torres Strait Islander
 Both Neither
- 21.** How many **TIMES last month** did you get needles & syringes from a **pharmacy**?
- Daily or almost daily
 A couple of times each week
 Less than weekly (2 to 5 times)
 Once last month
 Not in the last month
- 22.** How many **TIMES last month** did you get needles & syringes at a **Needle and Syringe Program**?
- Daily or almost daily
 A couple of times each week
 Less than weekly (2 to 5 times)
 Once last month
 Not in the last month
- 23.** Have you been in this survey before?
- Yes No
- 24.** What are the first two letters of your **FIRST** name? _____
- 24a.** What are the first two letters of your **LAST** name? _____
- 25.** Who completed the questionnaire?
- Self
 Assisted by NSP staff
 Assisted by other (please specify)

All questions are voluntary. The name code (Q24) is used to see how drug use changes over time. We cannot identify you from the code. If you have been in the survey before, please use the same code. If you use initials other than your own, please use code you will remember for next time.

Place the completed questionnaire in the open (non-sealable) section of the plastic bag. Please complete the blood spot now.

Participating NSP sites

Year		04	05	06	07	08
Number of NSP sites		42	52	45	52	52
Australian Capital Territory						
Canberra	Directions ACT	✓	✓	✓	✓	✓
New South Wales						
Albury	Albury Community Health Centre, GSAHS	✓	✓		✓	✓
Ballina/Byron	Harm Reduction Services, NCAHS	✓	✓	✓	✓	✓
Bankstown, Cabramatta & Liverpool	Indo-Chinese Outreach Network (ICON)	✓				
Blacktown	HIV/Hepatitis C Prevention Service, SWAHS	✓	✓	✓	✓	✓
Coffs Harbour/Grafton	Harm Reduction Services, NCAHS					✓
Canterbury	Resource and Education Program for IDUs (REPIDU)	✓	✓	✓	✓	✓
Gosford	Gosford Needle Syringe Program, NSCCAHS				✓	✓
Liverpool	Health ConneXions, SSWAHS		✓	✓	✓	✓
Long Jetty	Long Jetty Needle Syringe Program, NSCCAHS				✓	✓
Kings Cross	K2 Health Service, SEIAHS	✓	✓	✓	✓	✓
Kings Cross	Kirketon Road Centre, SEIAHS	✓	✓	✓	✓	✓
Kogarah	St. George NSP, SEIAHS	✓		✓	✓	✓
Merrylands	HIV/Hepatitis C Prevention Service, SWAHS		✓	✓		
Mt Druitt	Kelly Close Needle Syringe Program, SWAHS	✓	✓		✓	✓
Murwillumbah/Tweed	Harm Reduction Services, NCAHS	✓	✓	✓	✓	✓
Nepean	South Court Primary Care NSP, SWAHS	✓	✓	✓	✓	✓
Newcastle	Hunter Harm Reduction Services, HNEAHS		✓	✓	✓	✓
Newcastle	AIDS Council of NSW (ACON)		✓	✓	✓	✓
Nimbin/Lismore	Harm Reduction Services, NCAHS	✓	✓	✓	✓	✓
North Sydney	Responsive User Services in Health (RUSH), NSCCAHS – Ryde, Manly and Clinic 16, RNSH St Leonards	✓	✓	✓	✓	✓
Parramatta	HIV/Hepatitis C Prevention Service, SWAHS	✓	✓	✓	✓	✓
Illawarra	First Step Program, SEIAHS – Port Kembla and Nowra	✓	✓	✓	✓	✓
Redfern	Resource and Education Program for IDUs (REPIDU), SSWAHS	✓	✓	✓	✓	✓
Surry Hills	AIDS Council of New South Wales (ACON)		✓			
Surry Hills	NSW Users and AIDS Association (NUAA)		✓	✓	✓	✓
Northern Territory						
Alice Springs	Northern Territory AIDS Council – Alice Springs		✓		✓	✓
Darwin	Northern Territory AIDS Council – Darwin/Palmerston	✓	✓	✓	✓	✓

Participating NSP sites continued

		04	05	06	07	08
Queensland						
Brisbane	Biala Community Alcohol and Drug Services	✓	✓	✓	✓	✓
Brisbane	Queensland Injectors Health Network (QuiHN)	✓	✓	✓	✓	✓
Cairns	Cairns ATODS NSP	✓	✓	✓	✓	✓
Gold Coast	Queensland Injectors Health Network (QuiHN)	✓	✓	✓	✓	✓
Ipswich	West Moreton Sexual Health Service	✓	✓	✓	✓	✓
Sunshine Coast	Queensland Injectors Health Network (QuiHN)	✓	✓	✓	✓	✓
Toowoomba	Kobi House	✓	✓	✓	✓	✓
Townsville	Townsville ATODS NSP					✓
South Australia						
Adelaide	South Australia Voice for Intravenous Education (SAVIVE) AIDS Council -Norwood	✓	✓	✓	✓	✓
Adelaide	SAVIVE, Parks Community Health Service	✓	✓	✓	✓	✓
Adelaide	Noarlunga Community Health Service		✓	✓	✓	✓
Adelaide	Nunkuwarrin Yunti Community Health Centre	✓	✓		✓	✓
Hindmarsh	Hindmarsh Centre	✓	✓	✓	✓	✓
Port Adelaide	SAVIVE, Port Adelaide Community Health Service		✓	✓	✓	✓
Salisbury	SAVIVE, Northern Metropolitan Community Health Service NSP and Shopfront	✓	✓	✓	✓	✓
Tasmania						
Clarence	Clarence Community Health Centre				✓	✓
Devonport	Devonport Community Health Centre	✓	✓			
Glenorchy	Tasmanian Council on AIDS, Hepatitis and Related Diseases (TasCAHRD)	✓	✓	✓	✓	✓
Hobart	Tasmanian Council on AIDS, Hepatitis and Related Diseases (TasCAHRD)	✓	✓	✓	✓	✓
Hobart	The Link - Youth Health Service				✓	
Launceston	Salvation Army Launceston				✓	✓
Victoria						
Barwon	Barwon Health Drug and Alcohol Services				✓	✓
Bendigo	Bendigo NSP Services				✓	
Collingwood	InnerSpace NSP (formerly MINE)	✓	✓	✓	✓	✓
Dandenong	South East Alcohol and Drug Service	✓	✓	✓		
Footscray	Health Works	✓	✓			
Frankston	Southern Hepatitis/HIV/AIDS Resource and Prevention Service	✓	✓	✓	✓	✓
North Richmond	North Richmond NSP Services				✓	✓
Northcote	Northcote NSP Services				✓	✓
St Kilda	St Kilda NSP	✓	✓	✓	✓	✓
Western Australia						
Bunbury	Western Australia Substance Users Association (WASUA)	✓	✓	✓		
Northbridge	Western Australia Substance Users Association (WASUA)	✓	✓	✓	✓	✓
Perth	WA AIDS Council Mobile Exchange	✓	✓	✓	✓	✓

List of Tables

National

Table 2	Number (percentage) of respondents by demographic characteristics and year of survey	9
Table 3	Number (percentage) of respondents by last drug injected, injecting behaviour in the month prior to survey and year of survey	10
Table 4	Number (percentage) of respondents by treatment for drug use and year of survey	11
Table 5	Number (percentage) of respondents by source of needle and syringe acquisition last month and year of survey	11
Table 6	Number (percentage) of respondents by injecting equipment use, re-use and cleaning last month	11
Table 7	Number (percentage) of respondents by sexual behaviour in the month prior to survey and year of survey	12
Table 8	Number (percentage) of respondents reporting previous testing for HIV and HCV infection and HCV treatment by year of survey	12
Table 9	HIV antibody prevalence by gender and year of survey	13
Table 10	HIV antibody prevalence by sexual identity, gender and year of survey	13
Table 11	HIV antibody prevalence by age group, gender and year of survey	14
Table 12	HIV antibody prevalence by duration of drug injection, gender and year of survey	15
Table 13	HIV antibody prevalence by last drug injected, gender and year of survey	16
Table 14	HIV antibody prevalence by frequency of drug injection last month, gender and year of survey	17
Table 15	HIV antibody prevalence by re-use of someone else's used needle and syringe last month, gender and year of survey	18
Table 16	HIV antibody prevalence by imprisonment last year, gender and year of survey	18
Table 17	HIV antibody prevalence by condom use at last sex with regular partner, gender and year of survey	19
Table 18	HIV antibody prevalence by sex work last month, gender and year of survey	19
Table 19	HIV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and year of survey	20
Table 20	HIV antibody prevalence by region/country of birth, gender and year of survey	21
Table 21	HIV antibody prevalence by main language spoken at home by parents, gender and year of survey	22
Table 22	HCV antibody prevalence by gender and year of survey	23
Table 23	HCV antibody prevalence by sexual identity, gender and year of survey	23
Table 24	HCV antibody prevalence by age group, gender and year of survey	24
Table 25	HCV antibody prevalence by duration of drug injection, gender and year of survey	25
Table 26	HCV antibody prevalence by last drug injected, duration of drug injection and year of survey	26
Table 27	HCV antibody prevalence by frequency of injection last month, duration of drug injection and year of survey	27
Table 28	HCV antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and year of survey	27
Table 29	HCV antibody prevalence by imprisonment last year, duration of drug injection and year of survey	28
Table 30	HCV antibody prevalence by sex work last month, duration of drug injection and year of survey	28
Table 31	HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and year of survey	29
Table 32	HCV antibody prevalence by region/country of birth, gender and year of survey	30
Table 33	HCV antibody prevalence by main language spoken at home by parents, gender and year of survey	31

Australian Capital Territory

Table 34	Number (percentage) of respondents by demographic characteristics and year of survey.....	32
Table 35	Number (percentage) of respondents by last drug injected, injecting behaviour in the month prior to survey and year of survey	33
Table 36	Number (percentage) of respondents by treatment for drug use and year of survey	34
Table 37	Number (percentage) of respondents by site of needle and syringe acquisition last month and year of survey	34
Table 38	Number (percentage) of respondents by injecting equipment use, re-use and cleaning last month	34
Table 39	Number (percentage) of respondents by sexual behaviour in the month prior to survey and year of survey	35
Table 40	Number (percentage) of respondents reporting previous testing for HIV, HBV and HCV infection, HBV vaccination and HCV treatment by year of survey	35
Table 41	HIV antibody prevalence by gender and year of survey	36
Table 42	HCV antibody prevalence by gender and year of survey	36
Table 43	HCV antibody prevalence by sexual identity, gender and year of survey	36
Table 44	HCV antibody prevalence by age group, gender and year of survey	37
Table 45	HCV antibody prevalence by duration of drug injection, gender and year of survey	38
Table 46	HCV antibody prevalence by last drug injected, duration of drug injection and year of survey	39
Table 47	HCV antibody prevalence by frequency of injection last month, duration of drug injection and year of survey	40
Table 48	HCV antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and year of survey	40
Table 49	HCV antibody prevalence by imprisonment last year, duration of drug injection and year of survey	41
Table 50	HCV antibody prevalence by sex work last month, duration of drug injection and year of survey	41
Table 51	HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and year of survey	42
Table 52	HCV antibody prevalence by region/country of birth, gender and year of survey	43
Table 53	HCV antibody prevalence by main language spoken at home by parents, gender and year of survey	44

New South Wales

Table 54	Number (percentage) of respondents by demographic characteristics and year of survey	45
Table 55	Number (percentage) of respondents by last drug injected, injecting behaviour in the month prior to survey and year of survey	46
Table 56	Number (percentage) of respondents by treatment for drug use and year of survey.....	47
Table 57	Number (percentage) of respondents by site of needle and syringe acquisition last month and year of survey.....	47
Table 58	Number (percentage) of respondents by injecting equipment use, re-use and cleaning last month.....	47
Table 59	Number (percentage) of respondents by sexual behaviour in the month prior to survey and year of survey.....	48
Table 60	Number (percentage) of respondents reporting previous testing for HIV, HBV and HCV infection, HBV vaccination and HCV treatment by year of survey	48
Table 61	HIV antibody prevalence by gender and year of survey	49
Table 62	HIV antibody prevalence by sexual identity, gender and year of survey	49
Table 63	HIV antibody prevalence by age group, gender and year of survey	50
Table 64	HIV antibody prevalence by duration of drug injection, gender and year of survey	51
Table 65	HIV antibody prevalence by last drug injected, gender and year of survey	52
Table 66	HIV antibody prevalence by frequency of drug injection last month, gender and year of survey	53
Table 67	HIV antibody prevalence by re-use of someone else's used needle & syringe last month, gender and year of survey.....	54
Table 68	HIV antibody prevalence by imprisonment last year, gender and year of survey.....	54
Table 69	HIV antibody prevalence by condom use at last sex, gender and year of survey.....	55
Table 70	HIV antibody prevalence by sex work last month, gender and year of survey.....	55
Table 71	HIV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and year of survey.....	56
Table 72	HIV antibody prevalence by region/country of birth, gender and year of survey	57
Table 73	HIV antibody prevalence by main language spoken at home by parents, gender and year of survey	58
Table 74	HCV antibody prevalence by gender and year of survey.....	59
Table 75	HCV antibody prevalence by sexual identity, gender and year of survey	59
Table 76	HCV antibody prevalence by age group, gender and year of survey	60
Table 77	HCV antibody prevalence by duration of drug injection, gender and year of survey.....	61
Table 78	HCV antibody prevalence by last drug injected, duration of drug injection and year of survey	62
Table 79	HCV antibody prevalence by frequency of injection last month, duration of drug injection and year of survey.....	63
Table 80	HCV antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and year of survey.....	63
Table 81	HCV antibody prevalence by imprisonment last year, duration of drug injection and year of survey	64
Table 82	HCV antibody prevalence by sex work last month, duration of drug injection and year of survey	64
Table 83	HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and year of survey.....	65
Table 84	HCV antibody prevalence by region/country of birth, gender and year of survey.....	66
Table 85	HCV antibody prevalence by main language spoken at home by parents, gender and year of survey	67

Northern Territory

Table 86	Number (percentage) of respondents by graphic characteristics and year of survey	68
Table 87	Number (percentage) of respondents by last drug injected, injecting behaviour in the month prior to survey and year of survey	69
Table 88	Number (percentage) of respondents by treatment for drug use and year of survey	70
Table 89	Number (percentage) of respondents by site of needle and syringe acquisition last month and year of survey	70
Table 90	Number (percentage) of respondents by injecting equipment use, re-use and cleaning last month	70
Table 91	Number (percentage) of respondents by sexual behaviour in the month prior to survey and year of survey	71
Table 92	Number (percentage) of respondents reporting previous testing for HIV, HBV and HCV infection, HBV vaccination, HCV treatment by year of survey	71
Table 93	HIV antibody prevalence by gender and year of survey	72
Table 94	HIV antibody prevalence by sexual identity and year of survey	72
Table 95	HIV antibody prevalence by age group and year of survey	72
Table 96	HIV antibody prevalence by duration of drug injection and year of survey	73
Table 97	HIV antibody prevalence by last drug injected and year of survey	73
Table 98	HIV antibody prevalence by frequency of drug injection last month and year of survey	74
Table 99	HIV antibody prevalence by re-use of someone else's used needle and syringe last month and year of survey	74
Table 100	HIV antibody prevalence by imprisonment last year and year of survey.....	75
Table 101	HIV antibody prevalence by condom use at last sex and year of survey.....	75
Table 102	HIV antibody prevalence by sex work last month and year of survey.....	76
Table 103	HIV antibody prevalence by Aboriginal and Torres Strait Islander origin status and year of survey	76
Table 104	HIV antibody prevalence by region/country of birth and year of survey	77
Table 105	HIV antibody prevalence by main language spoken at home by parents and year of survey	77
Table 106	HCV antibody prevalence by gender and year of survey	78
Table 107	HCV antibody prevalence by sexual identity, gender and year of survey	78
Table 108	HCV antibody prevalence by age group, gender and year of survey	79
Table 109	HCV antibody prevalence by duration of drug injection, gender and year of survey	80
Table 110	HCV antibody prevalence by last drug injected, duration of drug injection and year of survey	81
Table 111	HCV antibody prevalence by frequency of injection last month, duration of drug injection and year of survey	82
Table 112	HCV antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and year of survey	82
Table 113	HCV antibody prevalence by imprisonment last year, duration of drug injection and year of survey	83
Table 114	HCV antibody prevalence by sex work last month, duration of drug injection and year of survey	83
Table 115	HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and year of survey	84
Table 116	HCV antibody prevalence by region/country of birth, gender and year of survey	85
Table 117	HCV antibody prevalence by main language spoken at home by parents, gender and year of survey	86

Queensland

Table 118	Number (percentage) of respondents by demographic characteristics and year of survey	87
Table 119	Number (percentage) of respondents by last drug injected, injecting behaviour in the month prior to survey and year of survey	88
Table 120	Number (percentage) of respondents by treatment for drug use and year of survey	89
Table 121	Number (percentage) of respondents by site of needle and syringe acquisition last month and year of survey	89
Table 122	Number (percentage) of respondents by injecting equipment use, re-use and cleaning last month	89
Table 123	Number (percentage) of respondents by sexual behaviour in the month prior to survey and year of survey	90
Table 124	Number (percentage) of respondents reporting previous testing for HIV, HBV and HCV infection, HBV vaccination, HCV treatment by year of survey	90
Table 125	HIV antibody prevalence by gender and year of survey	91
Table 126	HIV antibody prevalence by sexual identity, gender and year of survey	91
Table 127	HIV antibody prevalence by age group, gender and year of survey	92
Table 128	HIV antibody prevalence by duration of drug injection, gender and year of survey	93
Table 129	HIV antibody prevalence by last drug injected, gender and year of survey	94
Table 130	HIV antibody prevalence by frequency of drug injection last month, gender and year of survey	95
Table 131	HIV antibody prevalence by re-use of someone else's used needle and syringe last month, gender and year of survey	96
Table 132	HIV antibody prevalence by imprisonment last year, gender and year of survey	96
Table 133	HIV antibody prevalence by condom use at last sex, gender and year of survey	97
Table 134	HIV antibody prevalence by sex work last month, gender and year of survey	97
Table 135	HIV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and year of survey	98
Table 136	HIV antibody prevalence by region/country of birth, gender and year of survey	99
Table 137	HIV antibody prevalence by main language spoken at home by parents, gender and year of survey	100
Table 138	HCV antibody prevalence by gender and year of survey	101
Table 139	HCV antibody prevalence by sexual identity, gender and year of survey	101
Table 140	HCV antibody prevalence by age group, gender and year of survey	102
Table 141	HCV antibody prevalence by duration of drug injection, gender and year of survey	103
Table 142	HCV antibody prevalence by last drug injected, duration of drug injection and year of survey	104
Table 143	HCV antibody prevalence by frequency of injection last month, duration of drug injection and year of survey	105
Table 144	HCV antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and year of survey	105
Table 145	HCV antibody prevalence by imprisonment last year, duration of drug injection and year of survey	106
Table 146	HCV antibody prevalence by sex work last month, duration of drug injection and year of survey	106
Table 147	HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and year of survey	107
Table 148	HCV antibody prevalence by region/country of birth, gender and year of survey	108
Table 149	HCV antibody prevalence by main language spoken at home by parents, gender and year of survey	109

South Australia

Table 150	Number (percentage) of respondents by demographic characteristics and year of survey.....	110
Table 151	Number (percentage) of respondents by last drug injected, injecting behaviour in the month prior to survey and year of survey	111
Table 152	Number (percentage) of respondents by treatment for drug use and year of survey	112
Table 153	Number (percentage) of respondents by site of needle and syringe acquisition last month and year of survey	112
Table 154	Number (percentage) of respondents by injecting equipment use, re-use and cleaning last month	112
Table 155	Number (percentage) of respondents by sexual behaviour in the month prior to survey and year of survey	113
Table 156	Number (percentage) of respondents reporting previous testing for HIV, HBV and HCV infection, HBV vaccination, HCV treatment by year of survey	113
Table 157	HIV antibody prevalence by gender and year of survey	114
Table 158	HIV antibody prevalence by sexual identity, gender and year of survey.....	114
Table 159	HIV antibody prevalence by age group, gender and year of survey	115
Table 160	HIV antibody prevalence by duration of drug injection, gender and year of survey	116
Table 161	HIV antibody prevalence by last drug injected, gender and year of survey.....	117
Table 162	HIV antibody prevalence by frequency of drug injection last month, gender and year of survey	118
Table 163	HIV antibody prevalence by re-use of someone else's used needle and syringe last month, gender and year of survey	119
Table 164	HIV antibody prevalence by imprisonment last year, gender and year of survey.....	119
Table 165	HIV antibody prevalence by condom use at last sex, gender and year of survey	120
Table 166	HIV antibody prevalence by sex work last month, gender and year of survey	120
Table 167	HIV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and year of survey	121
Table 168	HIV antibody prevalence by region/country of birth, gender and year of survey	122
Table 169	HIV antibody prevalence by main language spoken at home by parents, gender and year of survey	123
Table 170	HCV antibody prevalence by gender and year of survey	124
Table 171	HCV antibody prevalence by sexual identity, gender and year of survey	124
Table 172	HCV antibody prevalence by age group, gender and year of survey	125
Table 173	HCV antibody prevalence by duration of drug injection, gender and year of survey	126
Table 174	HCV antibody prevalence by last drug injected, duration of drug injection and year of survey	127
Table 175	HCV antibody prevalence by frequency of injection last month, duration of drug injection and year of survey	128
Table 176	HCV antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and year of survey	128
Table 177	HCV antibody prevalence by imprisonment last year, duration of drug injection and year of survey	129
Table 178	HCV antibody prevalence by sex work last month, duration of drug injection and year of survey	129
Table 179	HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and year of survey.....	130
Table 180	HCV antibody prevalence by region/country of birth, gender and year of survey.....	131
Table 181	HCV antibody prevalence by main language spoken at home by parents, gender and year of survey.....	132

Tasmania

Table 182	Number (percentage) of respondents by demographic characteristics and year of survey	133
Table 183	Number (percentage) of respondents by last drug injected, injecting behaviour in the month prior to survey and year of survey	134
Table 184	Number (percentage) of respondents by treatment for drug use and year of survey	135
Table 185	Number (percentage) of respondents by site of needle and syringe acquisition last month and year of survey	135
Table 186	Number (percentage) of respondents by injecting equipment use, re-use and cleaning last month	135
Table 187	Number (percentage) of respondents by sexual behaviour in the month prior to survey and year of survey	136
Table 188	Number (percentage) of respondents reporting previous testing for HIV, HBV and HCV infection, HBV vaccination, HCV treatment by year of survey	136
Table 189	HIV antibody prevalence by gender and year of survey	137
Table 190	HCV antibody prevalence by gender and year of survey	137
Table 191	HCV antibody prevalence by sexual identity, gender and year of survey	137
Table 192	HCV antibody prevalence by age group, gender and year of survey	138
Table 193	HCV antibody prevalence by duration of drug injection, gender and year of survey	139
Table 194	HCV antibody prevalence by last drug injected, duration of drug injection and year of survey	140
Table 195	HCV antibody prevalence by frequency of injection last month, duration of drug injection and year of survey	141
Table 196	HCV antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and year of survey	141
Table 197	HCV antibody prevalence by imprisonment last year, duration of drug injection and year of survey	142
Table 198	HCV antibody prevalence by sex work last month, duration of drug injection and year of survey	142
Table 199	HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and year of survey	143
Table 200	HCV antibody prevalence by region/country of birth, gender and year of survey	144
Table 201	HCV antibody prevalence by main language spoken at home by parents, gender and year of survey	145

Victoria

Table 202	Number (percentage) of respondents by demographic characteristics and year of survey.....	146
Table 203	Number (percentage) of respondents by last drug injected, injecting behaviour in the month prior to survey and year of survey	147
Table 204	Number (percentage) of respondents by treatment for drug use and year of survey	148
Table 205	Number (percentage) of respondents by site of needle and syringe acquisition last month and year of survey	148
Table 206	Number (percentage) of respondents by injecting equipment use, re-use and cleaning last month	148
Table 207	Number (percentage) of respondents by sexual behaviour in the month prior to survey and year of survey	149
Table 208	Number and (percentage) of respondents reporting previous testing for HIV, HBV and HCV infection, HBV vaccination, HCV treatment by year of survey.....	149
Table 209	HIV antibody prevalence by gender and year of survey	150
Table 210	HIV antibody prevalence by sexual identity, gender and year of survey.....	150
Table 211	HIV antibody prevalence by age group, gender and year of survey.....	151
Table 212	HIV antibody prevalence by duration of drug injection, gender and year of survey	152
Table 213	HIV antibody prevalence by last drug injected, gender and year of survey.....	153
Table 214	HIV antibody prevalence by frequency of drug injection last month, gender and year of survey	154
Table 215	HIV antibody prevalence by re-use of someone else's used needle and syringe last month, gender and year of survey	155
Table 216	HIV antibody prevalence by imprisonment last year, gender and year of survey.....	155
Table 217	HIV antibody prevalence by condom use at last sex, gender and year of survey	156
Table 218	HIV antibody prevalence by sex work last month, gender and year of survey	156
Table 219	HIV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and year of survey	157
Table 220	HIV antibody prevalence by region/country of birth, gender and year of survey	158
Table 221	HIV antibody prevalence by main language spoken at home by parents, gender and year of survey	159
Table 222	HCV antibody prevalence by gender and year of survey	160
Table 223	HCV antibody prevalence by sexual identity, gender and year of survey	160
Table 224	HCV antibody prevalence by age group, gender and year of survey	161
Table 225	HCV antibody prevalence by duration of drug injection, gender and year of survey	162
Table 226	HCV antibody prevalence by last drug injected, duration of drug injection and year of survey	163
Table 227	HCV antibody prevalence by frequency of injection last month, duration of drug injection and year of survey	164
Table 228	HCV antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and year of survey	164
Table 229	HCV antibody prevalence by imprisonment last year, duration of drug injection and year of survey	165
Table 230	HCV antibody prevalence by sex work last month, duration of drug injection and year of survey	165
Table 231	HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and year of survey	166
Table 232	HCV antibody prevalence by region/country of birth, gender and year of survey.....	167
Table 233	HCV antibody prevalence by main language spoken at home by parents, gender and year of survey.....	168

Western Australia

Table 234	Number (percentage) of respondents by demographic characteristics and year of survey	169
Table 235	Number (percentage) of respondents by last drug injected, injecting behaviour in the month prior to survey and year of survey	170
Table 236	Number (percentage) of respondents by treatment for drug use and year of survey	171
Table 237	Number (percentage) of respondents by site of needle and syringe acquisition last month and year of survey	171
Table 238	Number (percentage) of respondents by injecting equipment use, re-use and cleaning last month	171
Table 239	Number (percentage) of respondents by sexual behaviour in the month prior to survey and year of survey	172
Table 240	Number (percentage) of respondents reporting previous testing for HIV, HBV and HCV infection, HBV vaccination, HCV treatment by year of survey	172
Table 241	HIV antibody prevalence by gender and year of survey	173
Table 242	HIV antibody prevalence by sexual identity and year of survey	173
Table 243	HIV antibody prevalence by age group and year of survey	173
Table 244	HIV antibody prevalence by duration of drug injection and year of survey	174
Table 245	HIV antibody prevalence by last drug injected and year of survey	174
Table 246	HIV antibody prevalence by frequency of drug injection last month and year of survey	174
Table 247	HIV antibody prevalence by re-use of someone else's used needle and syringe last month and year of survey	174
Table 248	HIV antibody prevalence by imprisonment last year and year of survey	175
Table 249	HIV antibody prevalence by condom use at last sex and year of survey	175
Table 250	HIV antibody prevalence by sex work last month and year of survey	175
Table 251	HIV antibody prevalence by Aboriginal and Torres Strait Islander origin status and year of survey	175
Table 252	HIV antibody prevalence by region/country of birth and year of survey	176
Table 253	HIV antibody prevalence by main language spoken at home by parents and year of survey	176
Table 254	HCV antibody prevalence by gender and year of survey	177
Table 255	HCV antibody prevalence by sexual identity, gender and year of survey	177
Table 256	HCV antibody prevalence by age group, gender and year of survey	178
Table 257	HCV antibody prevalence by duration of drug injection, gender and year of survey	179
Table 258	HCV antibody prevalence by last drug injected, duration of drug injection and year of survey	180
Table 259	HCV antibody prevalence by frequency of injection last month, duration of drug injection and year of survey	181
Table 260	HCV antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and year of survey	181
Table 261	HCV antibody prevalence by imprisonment last year, duration of drug injection and year of survey	182
Table 262	HCV antibody prevalence by sex work last month, duration of drug injection and year of survey	182
Table 263	HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and year of survey	183
Table 264	HCV antibody prevalence by region/country of birth, gender and year of survey	184
Table 265	HCV antibody prevalence by main language spoken at home by parents, gender and year of survey	185

Harbour/Grafton. HIV/Hepatitis C Prevention Services, Blacktown, Parramatta, Redfern. NSW Users and AIDS Association (NUAA). Northern Territory AIDS Council, Alice Springs, Darwin, Palmerston
Education Program for IDUs (REPIDU), Canterbury, Redfern. Gosford
Health Connexions, Liverpool. Kirketon Road Centre, K2, Kings Cross
Responsive User Services in Health (RUSH), Ryde, St Leonards, Manly, First Step
Northern Territory AIDS Council, Alice Springs, Darwin, Palmerston
Brisbane, Gold Coast, Sunshine Coast. West Moreton Sexual Health
Norwood, Parks, Port Adelaide, Northern Metropolitan, Shopfront. Hill
Community Health Centre, Clarence Community Health Centre, The
Drug and Alcohol Services, Bendigo NSP, InnerSpace, Southern Hepa
ces, Northcote NSP, Darebin Community Health Centre, St Kilda NSP
WA AIDS Council Mobile NSP, Directions ACT, Albury Community
Murwillumbah/Tweed Coffs Harbour/Grafton. HIV/Hepatitis C Preven
NSP, Nepean, Resource and Education Program for IDUs (REPIDU
Needle and Syringe Program, Health Connexions, Liverpool, Kirketon
Services, ACON Hunter, Responsive User Services in Health (RUSH),
and AIDS Association (NUAA), Northern Territory AIDS Council, Alice
Townsville ATODS, QUIHN Brisbane, Gold Coast, Sunshine Coast,
Kobi House, Toowoomba, SAVIVE, Norwood, Parks, Port Adelaide, North
Community Health Centre, Noarlunga Community Health Centre, Clare
Army Launceston, Barwon Health Drug and Alcohol Services, Bendigo
(SHARPS), North Richmond NSP Services, Northcote NSP, Darebin Co
Association (WASUA), Northbridge. WA AIDS Council Mobile NSP,
Services Ballina/Byron, Nimbin/Lismore, Murwillumbah/Tweed Coffs Harb
Mt Druitt, South Court Primary Care NSP, Nepean, Resource and Ed
and Syringe Program, Long Jetty Needle and Syringe Program, Health
NSP, Hunter Harm Reduction Services, ACON Hunter, Responsive Us
Illawarra, Nowra, NSW Users and AIDS Association (NUAA), Northern
nity Alcohol and Drug Services, Townsville ATODS, QUIHN Brisbane
Cairns Base Hospital, Kobi House, Toowoomba, SAVIVE, Norwood, Park
Nunkuwarrin Yunti Community Health Centre, Noarlunga Community
Glenorchy, Salvation Army Launceston, Barwon Health Drug and Al
Source Prevention (SHARPS), North Richmond NSP Services, North
Tralla Substance Users Association (WASUA), Northbridge. WA AIDS
Harm Reduction Services Ballina/Byron, Nimbin/Lismore, Murwillumbah
Blacktown, Parramatta, Mt Druitt, South Court Primary Care NSP, The
Redfern, Gosford Needle and Syringe Program, Long Jetty Needle and
Kings Cross, St George NSP, Hunter Harm Reduction Services, ACCO
Manly, First Step Program Illawarra, Nowra, NSW Users and AIDS Ass
Palmerston, Biala Community Alcohol and Drug Services, Townsville
Sexual Health Service, Ipswich, Cairns Base Hospital, Kobi House, To
Shopfront, Hindmarsh Centre, Nunkuwarrin Yunti Community Health
Health Centre, TASCHARD Hobart, Glenorchy, Salvation Army Launceston